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Abbreviations 
Abbreviation Definition 
ADCC Antibody-dependent cellular cytotoxicity 
AMPK AMP-activated protein kinase 
ATF4 Activating transcription factor 4 
ATF6 Activating transcription factor 6 
ATRA All-trans retinoic acid 
Breg regulatory B cells 
CAFs Cancer-associated fibroblasts 
CCL2/MCP-1 Chemokine (C-C motif) ligand 2, monocyte chemoattractant protein-1 
CCL5/RANTES Chemokine (C-C motif) ligand 5 
CCL19 Chemokine (C-C motif) ligand 19 
CCL20/ MIP-3 Chemokine (C-C motif) ligand 20, macrophage inflammatory protein 3 alpha 
CHOP (C/EBP) homologous protein 
CRC Colorectal cancer 
CREB cAMP response-element binding 
CTGF Connective tissue growth factor 
CTL-4 Cytotoxic T-lymphocyte-associated Protein 4 
CXCL1 (C-X-C motif) ligand 1, GRO-α 
CXCL2 (C-X-C motif) ligand 2, MIP2-α 
CXCL3 (C-X-C motif) ligand 3, GRO-γ 
CXCL5 (C-X-C motif) ligand 5, epithelial-derived neutrophil-activating peptide 78 (ENA78) 
CXCL 12 (C-X-C motif) ligand 12 
CXCR 1/2 C-X-C motif chemokine receptor 1 
DC Dendritic cells 
DISC Death inducing signal complex 
DR4 TRAIL receptor 1, death receptor 4 
DR5 TRAIL receptor 2, death receptor 5 
DTT Dithiothreitol 
ECM Extracellular matrix 
EGFR Epidermal growth factor receptor 
eIF2 Eukaryotic initiation factor 2 
EMT Epithelial-mesenchymal transition 
FADD Fas-associated death domain 
Fru Fructose 
GADD34 DNA-damage-inducible 34 
GCN2 General control non‐derepressible 2 
Glc Glucose 
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GlcNAc N-Acetylglucosamine 
Gln Glutamine 
HBP Hexosamine biosynthetic pathway 
HBSS Hank´s Balanced Salt Solution 
HRI Heme‐regulated eIF2α kinase 
IKK IκB kinase 
IL-6 Interleukin-6 
IL-8 Interneukin-8 
IL-11 Interleukin-11 
IFN γ Interferon γ 
IRE1 Inositol requiring kinase 1 
ISR Integrated stress response 
JNK c-Jun N-terminal Kinase 
KRAS Kirsten Rat Sarcoma 
LKB1 Liver Kinase B1 
MAMs Mitochondria associated membranes 
MAPK Mitogen-activated protein kinase 
MCS-F/(CSF-1) Macrophage colony-stimulating factor, co-stimulatory factor 1 
MDSC Myeloid-derived suppressor cells 
Me-Pyr Methyl-pyruvate 
miRNA Micro RNA 
mTOR Mammalian target of rapamycin 
mTORC 1/2 Mammalian target of rapamycin complex 1/2 
NK cells Natural killer cells 
NRF2 Nuclear factor erythroid 2-related factor 
NSCLC Non-small-cell lung carcinoma 
PARP poly (ADP-ribose) polymerase 
PBMCs Peripheral blood mononuclear cells 
PD-L1 Programmed death ligand 1 
PDAC Pancreatic ductal adenocarcinoma 
PDGF Platelet-derived growth factor 
PERK RNA-activated (PKR)-like endoplasmic reticulum kinase 
PI Propidium Iodide 
PI3K Phosphoinositide 3-kinase 
PKR Double‐stranded RNA‐dependent protein kinase 
PMA Phorbol 12-Myristate 13-Acetate 
PTEN Phosphatase and tensin homolog 
RIDD Regulated IRE1-dependent decay 
ROS Reactive oxygen species 
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siRNA Small interfering RNA 
SIRT1 Sirtuin 1 
SPARC Secreted Protein Acidic and Rich in Cysteine 
TAMs Tumor-associated macrophages 
TANs Tumor associated neutrophils 
Tg Thapsigargin 
TILs Tumor-infiltrating lymphocytes 
TLR Toll like receptor 
TNF Tumor necrosis factor  
TNFR TNF receptor family receptors 
TRAF2 Tumour-necrosis factor-α (TNF-α)-receptor-associated factor 2 
Treg Regulatory T cells 
tRNase Transfer RNases 
TSC2 Tuberin, Tuberous Sclerosis Complex 2 
TSGs Tumor suppressor genes 
uORFs upstream open reading frames 
XBP1 X-box binding protein 
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1. Summary 
The reprograming of the cancer metabolism is considered as one of the hallmarks of cancer. 
Regarding that, new lines of research evolved in the last years which not only address the 
metabolism of cancer cells but also investigate the impact of the rewired cancer metabolism on 
the tumor microenvironment (TME). The TME is a heterogenic tissue, which consist not only 
of cancer cells but also of resident or infiltrating non-cancerous cells including for instance 
fibroblasts, cells of the vasculature and immune cells.  
Metabolic alterations are primarily caused by oncogenic mutations in cancer cells, which 
modify the expression of metabolic enzymes and key regulatory proteins of biochemical 
reactions. Therefore, cancer cells use aerobic glycolysis instead of OXPHOS in the presence of 
oxygen, a phenomenon known as the ´´Warburg effect´´. The Warburg effect allows cancer 
cells to generate larger quantities of cellular building blocks such as proteins, nucleic acids and 
lipids, which are required for proliferation and cell growth. Moreover, cancerous cells are more 
dependent on glucose compared to non-transformed tissue, which in turn sensitises them to low 
glucose availability and makes cells more prone to cell death upon glucose deprivation. This 
opens up the door to new anti-cancer strategies based on the sensitivity of cancer cells to 
nutrient supply. In the last years new anti-metabolic drugs entered clinical trials, targeting the 
uptake and utilization of nutrients. In order to make these drugs more efficient and applicable 
in the clinic, it is necessary to fully investigate the cancer cell metabolism, especially how 
cancer cells die upon glucose deprivation and more importantly, the consequences on the 
surrounding tissue when modifying or interfering with the cancer metabolism.  
The unfolded protein response (UPR) is an intracellular stress response that is known to be 
induced upon glucose deprivation in cancer cells. Cancer cells, which are exposed to glucose 
deprivation, fail to post translationally modify de novo synthesized proteins properly, which is 
possibly due to impaired glycosylation. Misfolded proteins are recognized by the ER intrinsic 
sensor proteins which induce the three UPR pathways: inositol requiring kinase 1 (IRE1), the 
activating transcription factor 6 (ATF6) and the protein kinase RNA-activated (PKR)-like 
endoplasmic reticulum kinase (PERK). The activation of the three branches of the UPR 
facilitates pro-survival responses mainly through the reduction of protein synthesis and through 
the upregulation of alternative metabolic pathways. However, chronic exposure to intra- or 
extracellular stresses result in a switch towards a pro-death UPR response, which goes along 
with the upregulation of the cell death machinery. The UPR is also described to be involved in 
pro-inflammatory responses based on the induction of cytokines and chemokines in several cell 
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lines. Therefore, the release of cytokines upon glucose deprivation could facilitate the 
infiltration or exclusion of specific immune cells. 
This thesis aims to investigate how cancer cells die upon glucose deprivation and what are the 
adaptive responses cancer cells induce for survival. In detail, we hypothesized that the UPR, 
and other signaling pathways such as NF-B and mTOR, which are modulated by glucose 
deprivation in cancer cells, promote the induction of cell death as well as the upregulation and 
secretion of cytokines. We further hypothesized that secreted cytokines promote the infiltration 
of immune cells from the surrounding tissue. 
We found that HeLa cells, exposed to glucose deprivation, died in a TRAIL receptor 1- (DR4) 
and 2- (DR5) dependent manner. We also confirmed that HeLa cells undergo cell death in an 
UPR-dependent manner facilitated by the activating transcription factor 4 (ATF4). Moreover, 
ATF4 mediated the upregulation of the cell death receptor DR5 upon glucose deprivation in 
HeLa cells. 
Furthermore, we found the release of pro-tumorigenic cytokines such as interleukin-8 (IL-8), 
interleukin-6 (IL-6) and the leukemia inhibitory factor (LIF) from glucose-deprived cancer 
cells. We also found that glutamine deprivation and the treatment with anti-metabolic drugs 
such as metformin promoted the release of IL-8 and IL-6, whereas the application of 
2-deoxyglucose (2-DG) promoted the release of IL-8, IL-6 and LIF in several cancer cell lines.  
Investigating the regulation of cytokine induction upon glucose deprivation, we found that IL-6 
and IL-8 but not LIF were regulated in an ATF4-dependent manner. We also investigated the 
role of the mTOR signaling pathway in cytokine induction by using the chemical inhibitors, 
rapamycin and Torin1. We found that rapamycin and Torin1 reduced IL-8 release upon glucose 
deprivation, whereas LIF release was only slightly reduced by rapamycin. Furthermore, we 
found that p65, the transcription factor of the NF-B pathway, regulated the release of IL-8 and 
IL-6 as well as the mRNA of several other tested cytokines. However, LIF was not regulated 
in a p65-dependent manner upon glucose deprivation in HeLa and A549 cells. Moreover, the 
conditioned media of glucose-deprived A549 promoted the migration of macrophage-like 
THP-1 cells as well as of B cells and neutrophils isolated from human blood. 
In conclusion, we found that nutrient deprivation as well as the application of anti-metabolic 
drugs induced the release of cytokines and chemokines from cancer cells. Moreover, 
conditioned media of starved A549 cells promoted the migration of some immune cells, which 
could have immunosuppressive functions in the TME. These findings are important, since 
interfering with the cancer metabolism by using anti-metabolic drugs could suppress their anti-
tumorigenic effects by promoting more substantial pro-tumorigenic responses. 
                Introduction 
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2. Introduction 
Cancer is classically defined by the six hallmarks of cancer, which were acquired by oncogenic 
transformations and distinguishes them from non-cancerous cells. These hallmarks include, 
sustaining proliferation, resistance to cell death, evading growth suppressors, replicative 
immortality, and the ability to promote angiogenesis, invasion and metastasis (Figure 1) 
(Hanahan and Weinberg, 2011a). In general, cancer evolves due to genetic predeterminations 
or due to oncogenic mutations induced by environmental factors such as pollution or the 
exposure to toxins and ultraviolet (UV) light. Other causes are unhealthy life styles, poor diets 
and the lack of exercise, which are associated with obesity and in some cases predisposes to 
cancer (Stone et al., 2018). Other risk factors include smoking, which is associated with lung 
cancer (Hecht, 2002). 
 
Figure 1 Hallmarks of cancer 
Cancer is classified by six hallmarks including sustained proliferation, evading growth 
suppressors, activating invasion and metastasis, enabling replicative immortality, inducing 
angiogenesis and cell death resistance (Hanahan and Weinberg, 2011a). 
The investigation of cancer and the development of new therapies are progressing rapidly in 
the last decades. However, common treatments like chemotherapy often fail and are insufficient 
due to the development of resistance or the relapse of patients years later. To overcome these 
drawbacks, there is a high demand for new strategies in order to improve patient survival. 
Currently, a new area in cancer research emerged, which gained strong interest in the last years, 
which is the personalized therapy. This form of therapy allows medical doctors to treat patients 
with adequate drugs according to their specific cancer type, based on mutational burdens and 
other patient specific characteristics. Another field is immunotherapy which focuses on the 
investigation of tumor-intrinsic immune cells and on the development of drugs that promote 
anti-tumorigenic responses. Regarding that, tumors are often considered as immunosuppressed 
Introduction 
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or as ‘cold’, meaning that anti-tumorigenic immune cells are inactivated or excluded from the 
tumor tissue. Hence, it is necessary to conduct further studies of the overall intra-tumoral 
interactions between cancer cells and immune cells.  
Furthermore, the tumor tissue is also characterized by a hostile tumor microenvironment 
(TME), including regions of hypoxia, low nutrient supply as well as acidity. Tumor-intrinsic 
cell populations cope differently with these conditions, which promotes a variety of biological 
responses, such as migration, cytokine secretion or cell death. Moreover, these environmental 
alterations also affect the efficiency of chemotherapeutic drugs and influence patient responses 
to specific therapies. Cancer cells are more resistant to hostile environments compared to other 
cell populations, due to their oncogenic mutations. Oncogenic mutations allow cells to rewire 
their metabolism, which was first described by Otto Warburg (Warburg, 1956). Moreover, 
cancer cells are also able to induce cell-intrinsic stress signaling pathways, such as the unfolded 
protein response (UPR) upon perturbations in the endoplasmic reticulum (ER), to ensure 
survival. These adaptations give cancer cells advantages in terms of growth and survival 
compared to other tumor-intrinsic cell populations, such as immune cells. In this sense, many 
recent reports claim that in particular the adapted metabolism of cancer cells is associated with 
tumor immunosuppression (Chang et al., 2015). 
Keeping this in mind, it is of high importance to understand how immune cells and cancer cells 
interact among each other under metabolic stress. Therefore, this thesis deals with the 
investigation of how cancer cells respond towards environments low in glucose with focus on 
the induction of the UPR and possible subsequent effects on cells of the immune system.  
2.1 Cell metabolism 
Anabolic biochemical reactions require energy and are utilized by the cell to synthesize 
complex macromolecules from smaller building blocks (Sullivan et al., 2016). Cells use 
catabolic biochemical reactions to produce energy by breaking down complex macromolecules 
into smaller units. Smaller units are metabolized and converted to adenosine triphosphate 
(ATP), which is the intracellular energy-unit. In order to fuel catabolic reactions, nutrients are 
uptaken from the extracellular environment in form of glucose, lipids or amino acids. These 
macromolecules are catabolized by the cell by various biochemical reactions to generate energy 
in form of ATP (Arnim McLaughlin, 2011). 
In general, untransformed proliferating cells use glycolysis in the presence of oxygen to convert 
glucose to pyruvate, which is followed by oxidative phosphorylation (OXPHOS) in the 
mitochondria. Intermediate products derived from glycolysis and OXPHOS can be utilized for 
                Introduction 
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anabolic biochemical reactions such as amino acid- and fatty acid- synthesis and de novo 
nucleic acid synthesis by the pentose phosphate pathway (PPP).  
The balance between catabolic and anabolic pathways allow cells to convert extracellular 
nutrients into energy and to build up proteins, membranes as well as DNA and RNA for 
sustained proliferation and tissue growth. (Caro-Maldonado and Muñoz-Pinedo, 2011; Muñoz-
Pinedo et al., 2012) 
2.2 Glucose metabolism 
Glycolysis, followed by OXPHOS, is the conventional biochemical pathway to produce ATP 
in the presence of oxygen in proliferating cells (Figure 2). Glucose uptake is facilitated by 
glucose transporters (GLUT), which are located in the cell membrane. Once uptaken, glucose 
is phosphorylated by the hexokinase (HK) to glucose-6-phosphate (G6P) in the cytoplasm of 
the cell. The glucose-6-phosphophate isomerase (GPI) converts G6P to fructose-6-phospate 
(F6P), which is further metabolized to two molecules of pyruvate, two molecules of ATP and 
two molecules of nicotinamide adenine dinucleotide (NADH). This pathway is known as 
glycolysis. In a next step is pyruvate, derived from glycolysis, converted by the pyruvate 
dehydrogenase complex (PDC) to acetyl-Coenzyme A (acetyl-CoA) that enters the 
tricarboxylic acid (TCA) cycle in the mitochondria, also known as Krebs cycle or citric acid 
cycle. In detail, acetyl-CoA enters the TCA cycle and is converted to various intermediate 
products as well as to three molecules of NADH and one molecule of reduced flavin adenine 
dinucleotide (FADH2). Citrate is an intermediate products of the TCA cycle and can be exported 
from the mitochondria to the cytosol and converted to acetyl-CoA for lipid and amino acid 
synthesis (Levine and Puzio-Kuter, 2010). 
During OXPHOS, protons (H+) are pumped into the intermembrane space of the mitochondria, 
which is facilitated by the oxidation of NADH to NAD+ at the electron transport chain 
complexes I-IV. Electrons are accepted by oxygen (O2) and protons are pumped back into the 
mitochondrial matrix through ATP synthase channels, using the concentration gradient of H+, 
which catalyse the synthesis of ATP out of adenosine monophosphate (ADP) and phosphate. 
This process produces energy in form of 36 ATP molecules generated from one molecule of 
glucose. In the absence of oxygen pyruvate does not fuel the Krebs cycle but gets reduced to 
lactate by the lactate dehydrogenase (LDH) in the cytoplasm. This process is named anaerobic 
glycolysis, which yields lactate but only two molecules of ATP. However, this metabolic 
pathway is favoured by many cancer cells even in the presence of oxygen, known as the 
´´Warburg Effect´´. (Cairns et al., 2011a; Ngo et al., 2015) 
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Another way to metabolize glucose is the hexosamine biosynthetic pathway (HBP). In a first 
step is F6P and glutamine converted to glucosamine-6-phosphate (GlcN-6P) and glutamate 
(Glu), which is catalysed by the fructose-6-phosphate transaminase (GFAT) (Chiaradonna et 
al., 2018). The final product of the HBP is UDP-N-acetylglucosamine (UDP-N-GlcNAc). 
UDP-N-GlcNAc is transferred by O-GlcNAc transferases (OGT) to proteins, which is 
important for protein glycosylation. (Chiaradonna et al., 2018; Kim et al., 2018) 
The PPP is a parallel biochemical pathway to glycolysis and needed for nucleic acid synthesis 
and the generation of nicotinamide adenine dinucleotide phosphate (NADPH). NADPH is a 
reducing molecule and needed for other cellular biosynthetic reactions such as fatty acids, 
cholesterol, nucleotides and amino acid synthesis. Glucose is converted to ribose-5-phosphate 
(R5P), which is a pentose sugar used for nucleic acid synthesis. (Laurence Cole, 2016)  
In summary, glucose is uptaken from the cell and converted to intermediate products which fuel 
the TCA cycle for energy production in form of ATP, the HBP for post translational 
modifications of proteins and lipids, whereas the PPP is mainly used for nucleic acid synthesis. 
(Figure 2) 
 
  
Figure 2 Glucose Metabolism 
Glucose uptake is facilitated by glucose transporters (GLUT) in the cell membrane. During 
glycolysis in the cytoplasm is glucose converted to glucose-6-phosphate (G6P) by hexokinases 
(HK), and further converted to fructose-6-P (F6P) by the glucose-6-P isomerase (GPI). F6P is 
further metabolized to pyruvate including several intermediate steps. During the Warburg effect 
(aerobic glycolysis) pyruvate is reduced to lactate by the lactate dehydrogenase (LDH). 
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Pyruvate is converted to acetyl-CoA by the pyruvate dehydrogenase complex (PDC), which 
enters the tricarboxylic acid (TCA) cycle in the mitochondria. The TCA cycle produces various 
intermediate products and the generation of NADH. During OXPHOS at the mitochondrial 
respiratory chain complex is NADH oxidized to NAD+ and protons are pumped in the 
intermembrane space of the mitochondria. Protons are transported back by the ATP synthase I 
the mitochondrial matrix, generating adenosine triphosphate (ATP). Citrate, a TCA cycle 
intermediate product is exported to the cytosol where it is used for lipid, nucleic and amino acid 
synthesis. The hexosamine biosynthetic pathway (HBP) converts F6P and glutamine to 
glucosamine-6-phosphate, catalysed by the fructose-6-phosphate transaminase (GFAT). 
Glucosamine-6-phosphate is converted to UDP-N-GlcNAc, which is used for protein 
glycosylation. Glucose fuels the pentose phosphate pathway (PPP) parallel to glycolysis for the 
generation of nucleotides and nicotinamide adenine dinucleotide phosphate (NADPH). Glucose 
is converted to ribose-5-phosphate (R5P) by oxidation of NADH+ to NADPH. 
2.3 Cancer metabolism 
Tumor-associated alterations of the metabolism were announced as a hallmark of cancer 
(Hanahan and Weinberg, 2011b; Luo et al., 2009). Altered metabolic pathways allow cancer 
cells to adapt to their increased energetic needs in order to maintain fast proliferation rates.   
The most important metabolic alteration is the increased uptake of nutrients, such as glucose 
and glutamine. These nutrients fuel anabolic biochemical reactions to produce cellular building 
blocks for instance for lipid membrane generation. (Deberardinis et al.; Heiden et al., 2009) 
Furthermore, metabolic alterations also lead to alterations in intracellular stress signaling 
pathways (Panieri and Santoro, 2016). Cancer cells acquired an altered metabolism mostly due 
to evolutionary induced oncogenic mutations, which promotes their competitiveness in hostile 
regions of the TME. These regions are marked by low oxygen and nutrient supply as well as by 
pH changes. One of the major oncogenic mutations that promote a rewiring of the metabolism, 
are mutations in the KRAS (Kirsten rat sarcoma) gene, which is a proto oncogene that belongs 
to the RAS family of GTPases. In its active state it binds guanosine triphosphate (GTP) and 
activates several downstream pathways like the mitogen activated kinase-like protein (MAPK) 
or the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathway. Its mutation occurs in 
cancers like colorectal cancer (CRC), pancreatic ductal cell carcinoma (PDCA) and most 
frequently in non-small cell lung cancer (NSCLC) (Kawada et al., 2017). One third of lung 
adenocarcinomas contain a KRAS mutation, which promotes proliferation, suppression of 
apoptosis and most importantly metabolic reprogramming (Pylayeva-Gupta et al., 2011; 
Rajalingam et al., 2007). With focus on lung cancer, it is described that homozygous 
KrasG12D/G12D;p53-/- tumors increase the expression of glycolytic genes (Kerr et al., 2016). This 
is accompanied by enhanced nutrient uptake, increased autophagy and higher energetic and 
anabolic needs (Pylayeva-Gupta et al., 2011).  
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Another oncogenic mutation is the deletion of phosphatase and tensin homolog (PTEN), which 
is a tumor suppressor and inhibitor of the PI3K pathway. A constitutively active PI3K pathway 
promotes increased tumor growth. The AKT serine/threonine kinase 1 (AKT) is the main 
downstream effector of PI3K and promotes glycolysis through the expression and the transport 
of glucose transporters to the membrane. (Elstrom et al., 2004) The downstream effector of 
AKT is the mTOR pathway, which regulates protein synthesis. AKT inactivates the negative 
regulator tuberous sclerosis complex 2 (TSC2), which results in a hyperactivation of the 
mammalian target of rapamycin (mTOR) signaling pathway and subsequently to increased 
protein and lipid synthesis (Cairns et al., 2011b; Robey and Hay, 2009) 
2.3.1 The Warburg Effect 
Proliferation and the energy metabolism of untransformed cells is controlled by growth and 
survival factors. Only when stimulated cells take up nutrients from the extracellular 
environment. In contrary to untransformed cells, cancer cells take up continuously high 
amounts of nutrients such as glucose (Hay, 2016) and glutamine (Altman et al., 2016) even 
without stimulation by growth factors.  
The oncogenic mutations discussed before, and many others, are responsible for the altered 
metabolism and increased glucose uptake. Glucose is utilized as one of the main sources for 
energy production in tumor tissue, which allows cancer cells to increase their proliferation rates 
and fasten tumor growth. Differentiated non-tumorigenic tissue converts glucose to pyruvate 
by glycolysis which fuels the TCA cycle in the mitochondria, and which is finally oxidized by 
OXPHOS to CO2 yielding 36 mol of ATP per mol glucose. This reaction needs oxygen as 
electron acceptor during OXPHOS. If oxygen is not available cells undergo anaerobic 
glycolysis in which pyruvate does not fuel the TCA cycle in the mitochondria but is redirected 
for the conversion into lactate by glycolysis. This reaction yields two molar equivalents of ATP 
per mol glucose and is therefore less energy producing.  
Otto Warburg discovered in the 1920s that the metabolism of tumor cells mainly consists of 
aerobic glycolysis. That means that cancer cells convert glucose to pyruvate followed by the 
conversion to lactate by glycolysis even in the presence of oxygen. This metabolic reaction is 
called aerobic glycolysis or the ´´Warburg effect´´ (Figure 3). (Warburg, 1956; Warburg et al., 
1927) First it was assumed that this was to be due to impaired mitochondrial functions, which 
was disproved in the last years. Nowadays the mitochondria is awarded with many important 
functions involved in cancer progression (Porporato et al., 2018). 
                Introduction 
25 
 
In patients, the high glycolytic tumor activity can be visualized by 18F-deoxyglucose positron 
emission tomography (FDG-PET). It is based on a radioactive fluorine-labelled glucose  
analogue, which is uptaken by the tumor tissue. Afterwards, radioactivity of certain tissue can 
be visualized. Nowadays this technique is an important clinical tool for cancer monitoring. 
(Almuhaideb et al., 2011) 
The Warburg effect allows cancer cells to utilize nutrients for anabolic biosynthetic pathways 
by reducing the generation of energy in form of ATP. This is beneficial for the cells since 
consequentially cells produce higher amounts of macromolecules, which fuel cell growth and 
proliferation. Today’s assumption is that the Warburg effect, along with a reprogrammed 
metabolism, is based on oncogenic transformation accompanied by loss-of-function of certain 
tumor suppressor genes, as well as altered growth factor signaling. (Vaupel et al., 2019) 
2.4 AMPK and mTOR signaling 
The altered metabolism of cancer cells goes along with an increased glucose dependency 
compared to untransformed tissue. Hence, glucose plays a crucial role in tumor progression and 
Figure 3 Schematic representation of metabolic differences between 
differentiated tissue and tumor tissue 
Oxidative phosphorylation (OXPHOS): In the presence of oxygen, differentiated tissue 
converts glucose to pyruvate by glycolysis, which is further oxidized in the mitochondria to 
CO2. OXPHOS requires O2 as final electron acceptor. This results in the generation of energy 
in form of 36 mol ATP per metabolized mol glucose. 
Anaerobic glycolysis: In the absence of oxygen in differentiated tissue glucose is metabolized 
in the cytoplasm to pyruvate, which is enzymatically converted to lactate by glycolysis. The 
conversion of pyruvate to lactate instead of its oxidation by OXPHOS yields only in two mol 
of ATP per mol glucose. 
Warburg effect (aerobic glycolysis): Tumor tissue and proliferating tissue uses only small 
portions for OXPHOS and favour lactate generation by glycolysis independent of oxygen 
availability (Vander Heiden et al., 2009) 
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if glucose is limited in the extracellular environment, cells undergo cell cycle arrest and stop 
growing. When glucose deprivation is sustained, cell death promoting pathways are upregulated 
and cells undergo cell death. (El Mjiyad et al., 2011) However, cancer cells developed 
mechanisms which allow them to survive periods of low glucose availability mainly by the 
upregulation of alternative metabolic pathways for energy production. In order to sense low 
glucose level, cells possess glucose-sensing mechanisms. One of them is the activation of the 
AMP-activated protein kinase (AMPK) and subsequent inhibition of mTOR signaling. 
(Figure 4) A major consequence of low glucose availability is an ATP drop in the cell due to 
reduced OXPHOS, which is sensed by AMPK. Low glucose availability changes the adenosine 
monophosphate (AMP)/ATP ratio, which functions as a metabolic checkpoint. If the AMP/ATP 
ratio is increased AMPK is phosphorylated and activates downstream signaling pathways 
resulting in growth inhibition. (Gowans and Hardie, 2014) Moreover, recently it was shown 
that a cellular decrease in Fructose-1,6-bisphosphate (FBP), a glycolytic intermediate product, 
promotes AMPK activation independently of ATP (Lin and Hardie, 2018; Zhang et al., 2017a). 
The liver kinase B1 (LKB1), which is frequently deleted in non-small-lung cancer (NSCLC) 
(Ji et al., 2007), is an activator of AMPK. AMPK phosphorylation induces a metabolic switch 
in nutrient utilization, favouring fatty acid oxidation and catabolic processes such as autophagy 
(Hardie, 2007; Jeon, 2016; Salt et al., 1998). Interestingly, in cancer cells several oncogenic 
mutations suppress AMPK signaling, which promote cell growth even in nutrient poor 
environments (Lin and Grahame Hardie, 2018).  
AMPK is also an inhibitor of the mTOR pathway, which is another key sensor of cellular 
nutrient availability and involved in the regulation of protein synthesis (Tokunaga et al., 2004). 
mTOR is the catalytic subunit of the functional distinct complexes mTORC1 and mTORC2. 
mTORC1 is activated by growth factors, energy level or amino acids, whereas mTORC2 is 
regulated by growth factors. Activated mTORC1 phosphorylates the p70 ribosomal protein S6 
Kinase (p70S6K), which subsequently phosphorylates ribosomal protein S6 (S6). Furthermore, 
mTORC1 also phosphorylates the elongation initiation factor (EIF)-4E Binding Protein 1 
(4EBP-1). Dephosphorylation of these proteins results in decreased protein, nucleotide and lipid 
synthesis as well as cellular growth arrest. (Figure 4)  mTORC2 activates among others protein 
kinase B (AKT) as well as Protein-Kinase C (PKC) and controls cell structure. (Conciatori et 
al., 2018) 
The mTOR pathway is constitutively active in proliferating cells, promoting protein synthesis 
and cell growth. However, activation of AMPK by glucose deprivation leads to an inactivation 
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of mTOR and subsequently an attenuation of protein synthesis to restore energy. (El Mjiyad et 
al., 2011)  
Inhibition of mTOR signaling is a potent anti-cancer target and several mTOR inhibitors were 
developed in the last years. Among them is rapamycin (Sirolimus) a macrocyclic antibiotic, that 
is described to specifically inhibit mTORC1 (Ballou and Lin, 2008), whereas Torin1, an ATP-
competitive inhibitor, blocks both mTOR complex 1 and 2 (Thoreen et al., 2009). 
 
Figure 4 Schematic presentation of AMPK/mTOR signaling 
Growth factors promote phosphatidylinositol 3-kinase (PI3K) signaling through AKT, that 
inactivates the tuberous sclerosis complex 1 and 2 (TSC1) and (TSC2). TSC1 and 2 inhibit the 
mammalian target-of-rapamycin (mTOR), which is present in the mTOR complex 1 and 2. 
Activation of mTORC1 leads to the phosphorylation of S6K and subsequently S6 as well as 
4EBP-1 and promotes protein synthesis. Phosphorylation of mTORC2 regulates migration, 
survival and cytoskeleton remodelling. 
The AMP-activated protein kinase (AMPK) is activated by low glucose level sensed by an ATP 
drop. Phosphorylated AMPK activates TSC1 und 2 and inhibits mTOR signaling. Rapamycin 
is a mTOR inhibitor which blocks mTORC1 whereas Torin1 blocks mTORC1 and 2. 
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2.5 The impact of glucose deprivation on cancer cells 
Cancer cells are highly dependent on glucose and their metabolic requirements makes them 
more susceptible towards glucose deprivation compared to untransformed cells. Several 
pathological scenarios within the body tissues or in a tumor result in nutrient and glucose 
deprivation. Among them are vessel occlusions, which result in transient ischemia and fast 
tumor growth, which results in poor vascularisation and therefore in low nutrient supply of 
certain regions of the tumor. Moreover, the application of anti-angiogenic or anti-metabolic 
drugs, which either inhibit the formation of vessels or the uptake and metabolization of nutrients 
also promote starvation in the tumor tissue. 
Glucose availability is not only essential for proper metabolic functions and macromolecule 
generation, but it is also involved in epigenetic gen regulation. Glucose is converted to acetyl-
CoA from citrate, a mitochondrial intermediate product from the TCA cycle, which is involved 
in acetylating histones in the nucleus and therefore in gene regulation (Wellen et al., 2009). 
Acetyl-CoA and other metabolites also function as co-factors for epigenetic enzymes, which 
regulate DNA-methylation (Donohoe and Bultman, 2012). This could be a regulatory 
mechanism in order to reduce gene expression upon nutrient limitation to reduce the energy 
expenditure of the cell. 
Furthermore, low glucose level result in a drop in the ATP level of some cells, which is a 
consequence of reduced OXPHOS. Reduced ATP level result in AMPK activation and mTOR 
inhibition as described before, to reduce the energetic needs of the cell. Moreover, glucose 
deprivation leads to an impaired glycosylation, which is an important posttranslational 
modification of many proteins.  This is due to a reduced HBP which is not sufficiently fuelled 
by glucose. The HBP converts glucose in UDP-GlcNAc, a substrate for intracellular O-linked-
glycosylation as well as for extracellular glycoconjugates (Vasconcelos-dos-Santos et al., 
2015). Impaired N-linked glycosylation at the ER leads to an accumulation of glycosylated 
proteins in the ER, which promotes the induction of the UPR. 
Taken together, glucose deprivation has severe effects on the homeostasis of metabolic 
pathways as well as on the regulation of gene transcription and on qualitative protein folding 
that promotes, upon sustained starvation, cell death. However, cancer cells upregulate adaptive 
signaling pathways to cope and resolve the cellular stress induced by glucose deprivation.  
Regarding that, one of the most important stress signaling pathways, which is induced upon 
glucose deprivation, is the UPR.  
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2.6 Anti-metabolic drugs 
Since glucose and other nutrients play an essential role in proliferation and growth, targeting 
the cancer metabolism is seen as a promising anti-cancer therapy. Anti-metabolic drugs are in 
development based on the Warburg effect and the increased glycolytic activity of cancer cells.  
Amongst them is 2-deoxyglucose (2-DG), an anti-glycolytic drug that is uptaken by the cell 
and promotes the inhibition of the glycolytic enzymes HK and GPI (WICK et al., 1957) 
(Figure 2). Hence, 2-DG treatment results in an ATP drop (Karczmar et al., 1992) and in the 
inhibition of glycosylation. Several forms of protein glycosylation are described in the 
literature; however, the two most important forms are O-linked-glycosylation and N-linked 
glycosylation. O-linked-glycosylation is the form by which an O-linked N-acetylglucosamine 
(GlcNAc), derived from the HBP modification is transferred to a serine or threonine protein 
residue.  UDP-GlcNAc is the product of the HBP. N-linked glycosylation is mostly carried out 
at the ER by the transfer of oligosaccharides to asparagine residues. N-linked glycosylation is 
prevented by tunicamycin treatment, a known UPR inducer and is thought to be the most 
vulnerable glycosylation form, that is impaired by glucose deprivation (Kang and Hwang, 
2006). 2-DG blocks N-linked glycosylation and consequently, non-glycosylated proteins 
accumulate in the ER and facilitate the induction of the UPR (León-Annicchiarico et al., 2015a), 
as well as the sensitization of tumors cells towards cell death (Muñoz-Pinedo et al., 2003) 
Another anti-metabolic drug is metformin which is commonly used for treatment of patients 
with type II diabetes; however, it gained strong interest in the last years as an anti-cancer drug 
(Libby et al., 2009) especially for NSCLC (Levy and Doyen, 2018) and pancreatic cancer (Zhou 
et al., 2017). Metformin inhibits complex I of the respiratory chain in the mitochondria during 
OXPHOS (Owen et al., 2000), which results in an ATP drop . An increased ADP/ATP ration 
activates AMPK, which subsequently inhibits mTOR signaling and cell growth (Zhou et al., 
2001). There are many more modes of actions described for metformin both systemically as 
well as at cellular level including the activation of the UPR, which will be described in the 
following chapter. However, impacts at cellular level are cell type and concentration dependent. 
However, the detailed mechanism of its anti-cancer effect is not completely understood yet.  
(Rena et al., 2017) 
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2.7 The Unfolded Protein Response 
The UPR is a stress response induced in the ER due to an overload of misfolded or unfolded 
proteins. The UPR triggers the transcriptional machinery, promoting the induction of target 
proteins, which are involved in the resolution of the stress. These proteins promote, among 
others, the upregulation of alternative metabolic signaling pathways or the Endoplasmic-
reticulum-associated protein degradation (ERAD) to reduce the protein load and to restore cell 
homeostasis. Furthermore, a sustained activation of the UPR promotes the induction of pro-
apoptotic proteins, promoting to cell death.  
In general, the UPR is induced due to intrinsic or extrinsic perturbations of the cell. Intrinsic 
perturbations include oncogenic mutations, which promote sustained cell growth, proliferation 
and differentiation. This is accompanied by increased protein synthesis that leads to a protein 
overload of the ER and can induce the UPR.  
Extrinsic perturbations include microenvironmental stresses such as non-physiological 
temperatures, alterations in pH and acidification and reactive oxygen species (ROS) production. 
The application of drugs and toxins are also described to function as ER stressors. In detail, 
microenvironmental perturbations occur in a tumor due to its rapid tumor growth, which is 
accompanied by nutrient and oxygen depletion, causing local microenvironmental stress 
including hypoxia, starvation and acidosis. Another extrinsic perturbation is ROS. The ER 
lumen is under normal conditions highly oxidized compared to the cytoplasm in order to 
facilitate the formation of disulphide bounds for proper protein folding. Moreover, an oxidized 
environment prevents the accumulation of unfolded protein aggregates in the ER lumen 
(Almanza et al., 2019; Zeeshan et al., 2016a). Therefore, high ROS level disturb cellular 
signaling pathways and functions and promote the UPR. Other extrinsic perturbations of the 
cell include drugs such as tunicamycin or thapsigargin. Thapsigargin targets the Sarco/ER Ca2+ 
-ATPase (SERCA) which pumps Ca2+ in the ER for proper protein folding. Thapsigargin 
treatment results in a Ca2+ decrease in the ER lumen and subsequently in the accumulation of 
unfolded proteins. Tunicamycin blocks the N-linked glycosylation by inhibiting the GlcNAc 
phosphotransferase (GPT). As a consequence, oligosaccharides cannot be transferred to nascent 
polypeptides, which results in impaired protein glycosylation at the ER. Proteins are recognized 
as misfolded or unfolded and induce the UPR. (Hemming, 1985) 2-DG, which is an anti-
glycolytic drug (see also chapter 3.7), blocks glycosylation due to its interference with the 
glucose metabolism (Simons et al., 2009). Other UPR inducing drugs are Dithiothreitol (DTT), 
which inhibits protein disulphide bond formation (Cleland, 1964) and Brefeldin A, which 
prevents the trafficking of proteins from the ER to the Golgi apparatus (Liu et al., 1992). 
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Intrinsic and extrinsic perturbations lead to a protein overload or an accumulation of misfolded 
or unfolded proteins in the ER. If the accumulation of un- and misfolded proteins in the ER 
exceeds the threshold, the UPR sensors are activated. These sensors induce transcriptional or 
translational genes and proteins, which are involved in the clearance of the unfolded/misfolded 
proteins from the ER. Furthermore, the induction of the UPR also increases the capacity of the 
ER to fold proteins correctly in order to regain cell homeostasis (Almanza, Püschel et al., 2019).  
The major sensor for un- and/or misfolded proteins in the ER lumen is the ER resident 
chaperone, heat shock protein A5 (heat shock protein family A (Hsp70) member 5) also known 
as glucose-regulated protein 78 (GRP78) or binding immunoglobulin protein (BiP). Under 
unstressed conditions BiP is bound by the luminal domains of the three key transmembrane ER 
stress sensors: inositol requiring kinase 1 (IRE1), the activating transcription factor 6 (ATF6) 
and the protein kinase RNA-activated (PKR)-like endoplasmic reticulum kinase (PERK) 
(Figure 5). If there is an accumulation of unfolded or misfolded proteins in the ER, BiP binds 
to these proteins and dissociates from the luminal domain of IRE1, ATF6 and PERK. IRE1 
activation can further be regulated by the ER luminal co-chaperone ERdj4/DNAJB9, which 
represses IRE1 activation by promoting a complex between the luminal domain of IRE1 and 
BiP (Amin-Wetzel et al., 2017).  
To sum it up, dissociation of BiP from the UPR key stress sensor proteins elicits the UPR 
response by activating the three UPR branches of the UPRosome, which will be explained in 
detail below. (reviewed in Almanza, Püschel et al., 2019)  
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Figure 5 The Unfolded Protein Response 
The UPR is induced upon accumulation of unfolded proteins in the ER lumen. BiP dissociates 
from the UPR stress sensors: IRE1, PERK and ATF6. IRE1 oligomerizes and auto-
phosphorylates to activate the cytosolic RNase domain. The RNase domain cleaves dual stem 
loops within the XBP1 mRNA. Spliced XBP1 (XBP1s) translocates to the nucleus and 
functions as transcription factor for chaperons, genes involved in ERAD and lipid synthesis. 
The RNase activity of IRE1 degrades other mRNAs through the regulated IRE1-dependent 
decay (RIDD). ATF6 translocates to the Golgi apparatus upon activation where it is cleaved. 
Cleaved ATF6 translocates to the nucleus where it functions as a transcription factor for 
chaperones and genes involved in lipid synthesis. PERK autophosphorylates upon activation 
and phosphorylates eIF2, that leads to an attenuation of protein synthesis. However, ATF4 is 
selectively  induced and leads to the induction of genes involved in amino acid metabolism, 
redox homeostasis and apoptosis. (Janssens et al., 2014) 
2.7.1 ATF6 signaling 
ATF6 is a leucine zipper protein and can be encoded in humans by ATF6 A for ATF6α or ATF6 
B for ATF6β. After dissociation from BiP, ATF6 gets translocated from the ER membrane to 
the Golgi apparatus where it is cleaved by the Golgi-resident protease membrane bound 
transcription factor peptidase, site-1 (MBTPS1) and site-2 (MBTPS2). A ~400 amino acid long 
fragment gets released, which corresponds to the ATF6 cytosolic N-terminal portion (ATF6N). 
ATF6N contains a transcription activation domain (TAD), a bZIP domain, a DNA-binding 
domain and a nuclear localization signal. In the nucleus it functions as a transcription factor, 
involved in the expression of its target genes (Figure 5). Moreover, ATF6 can also induce the 
transcription of XBP1 and CHOP to enhance UPR signaling (Yoshida et al., 2001).  
2.7.2 IRE1 signaling 
The IRE1 branch is the most conserved arm of the UPR and plays crucial roles in many 
processes including development, immunity, inflammation and metabolism. In humans two 
paralogues exist for IRE1 (IRE1 α and β) encoded by endoplasmic reticulum to nucleus 
signaling 1 and 2 (ERN1 and ERN2) genes. IRE1α is expressed in all tissues however, IRE1β 
expression is restricted to the gastrointestinal tract and the pulmonary mucosal epithelium. 
IRE1 activation results in its oligomerization at the luminal sensor domain and the activation 
of the cytosolic effector domains, which contain the kinase and RNase subdomains. 
Oligomerization facilitates the trans-autophosphorylation in the activation loop of the kinase 
domain, specifically at the Ser724, Ser726 and Ser729. Phosphorylation is necessary to activate 
the cytosolic RNase domain, as well as for the recruitment of the TNF receptor-associated factor 
2 (TRAF2) and for the activation of the c-Jun N-terminal Kinase (JNK) pathway (Urano, 2000).  
The RNase domain catalyses the splicing of a 26-nucleotide intron from unspliced mammalian 
X-box binding protein 1 (XBP1) mRNA. The splicing of the 26 base intron from the XBP1 
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mRNA produces spliced XBP1 (XBP1s), which functions as a transcription factor (Sidrauski 
and Walter, 1997). XBP1s is a basic leucin zipper (bZIP) transcription factor. The unspliced 
form of XBP1 (XBP1u) is not able to function as a transcription factor due to the lack of a 
transactivation domain. The XBP1u C-terminal region contains a P (proline), E (glutamic acid), 
S (serine) and T (threonine) motif, which is responsible for the destabilization and short half-life 
of the protein. The N-terminal domain of XBP1u also contains a hydrophobic region that targets 
XBP1u to the ER membrane and a domain that promotes efficient XBP1 splicing and cleavage 
by preventing XBP1 translation (Yanagitani et al., 2009). XBP1 promotes the transcription of 
chaperones, foldases and components of ERAD (Figure 5). Moreover, XBP1 can interact with 
other transcription factors like AP1, oestrogen receptor α (ERα), cAMP response element-
binding protein (CREB)/ATF and the hypoxia inducible factor 1 α subunit (HIF1α). XBP1s is 
also involved in the regulation of metabolic pathways such as lipid biosynthesis, glucose 
metabolism, DNA repair, differentiation and development.  
The RNase activity of IRE1 also targets other mRNA transcripts promoting their degradation 
through the regulated  IRE1-dependent decay (RIDD), which as a consequence reduces protein 
synthesis (Hollien et al., 2009). Thereby, IRE1 cleaves mRNA transcripts containing the 
consensus sequence (CUGCAG) accompanied by a stem-loop structure. The cleaved RNA 
fragments are rapidly degraded by cellular endoribonucleases. (Almanza, Püschel et al., 2019) 
2.7.3 PERK signaling 
The third branch of the UPR is the PERK signaling pathway. PERK is ubiquitously expressed 
in the body and contains a cytosolic kinase domain and an ER luminal sensor domain. PERK 
is activated due to BiP dissociation from its luminal domain, oligomerization and trans-
autophosphorylation and the subsequent phosphorylation on Ser51 of the eukaryotic initiation 
factor  (eIF2α). eIF2α is a subunit of the eIF2 heterotrimer, which regulates the initiation step 
of protein synthesis. It promotes the binding of the initiator tRNA to the 40S ribosomal subunits. 
However, phosphorylated eIF2α (peIF2α) inhibits the eukaryotic translation initiation factor 2B 
(eIF2B) activity and thereby attenuates protein synthesis and reduces protein load in the ER. 
However, transcripts containing short upstream open reading frames (uORFs), like the 
activating transcription factor 4 (ATF4), which is a member of the cAMP response-element 
binding (CREB) family of transcription factors, are translated (Figure 5). Under normal 
conditions these transcripts are inefficiently translated from the protein coding AUG sequence. 
However, attenuation of translation from uORFs shifts translation initiation towards the protein 
coding AUG, leading to a more efficient synthesis of selectively ATF4 (Harding et al., 2000). 
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ATF4 is the major transcription factor of the CAAT/enhancer-binding protein (C/EBP) 
homologous protein (CHOP)/GADD153 by binding to the C/EBP-ATF site in its promotor 
(Kato and Nishitoh, 2015). The induction of genes induced by ATF4 and CHOP can result in 
ATP depletion, oxidative stress and cell death (Han et al., 2013). Growth arrest and DNA-
damage-inducible 34 (GADD34) is a negative regulator of eIF2α. GADD34 interacts with the 
catalytic subunit of type 1 protein serine/threonine phosphatase (PP1), which dephosphorylates 
eIF2α. GADD34 is transcriptionally induced by ATF4 and CHOP and facilitates a negative 
feedback loop that antagonizes p-eIF2α-dependent translation inhibition and restores protein 
synthesis. Protein translation attenuation serves the cell to restore protein load in the ER and to 
save energy (Kato and Nishitoh, 2015). ATF4 translation further promotes gene transcription 
involved in amino acid transport and metabolism, protection from oxidative stress, protein 
homeostasis and autophagy. 
ATF4 can also be induced by one of the four integrated stress response (ISR) family members: 
PERK, double‐stranded RNA‐dependent protein kinase (PKR), heme‐regulated eIF2α kinase 
(HRI), and general control nonderepressible 2 (GCN2). The kinases catalytic domains of the 
four regulators are homolog and promote in the phosphorylation of eIF2α as described before. 
However, their activation domains are distinctive and so are the activation stimuli. GCN2 is 
mainly activated by amino acid deprivation. However, recent reports also suggest that glucose 
deprivation elicits the same response. Though, this could be mediated by a higher amino acid 
consumption as a secondary effect of glucose deprivation (Ye et al., 2010).  In detail, GCN2 
binds to deacylated transfer RNases (tRNAs) via a histidyl‐tRNA synthetase‐related domain 
(Vazquez de Aldana et al., 2015), which facilitates its activation. PKR, is activated by double-
stranded RNA (dsRNA) upon viral infections (Clemens and Elia, 2009). HRI is mainly 
expressed in erythroid cells, regulating differentiation, and protects cells against accumulation 
of toxic globin aggregates (Han et al., 2001). (Pakos‐Zebrucka et al., 2016) 
Mild ER stress activates signaling pathways to resolve the stress. However, if the stress is 
chronic and irreversible, the primary adaptive UPR response switches towards an pro-death 
response (Oakes, 2017). The phosphorylation status of eIF2α possibly codetermines the pro-
survival and pro-death switch. A delayed negative feedback loop through GADD34, ATF4 and 
CHOP signaling promotes the transcription of genes involved in the cell death response. 
(Almanza, Püschel et al, FEBS Journal, 2019) 
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2.8 Cell death 
Cells induce alternative metabolic pathways and adaptive stress signaling pathways when 
lacking nutrients, as described before. However, if nutrient deprivation is sustained, cell cycle 
arrest is induced followed by the upregulation of pro-death proteins (Sun and Lee, 2008). 
Under physiological conditions cell death is an important cellular mechanism, which aims at 
maintaining tissue homeostasis. Under pathological conditions cells undergo cell death to 
eliminate infected, transformed or defective cells.  
After the first description of cell death in 1960 several cell death forms have been described. 
The two main cell death forms are known as necrosis and apoptosis and have been classified 
by their morphological and biochemical criteria. (Favaloro et al., 2012)  
Apoptosis, also called ‘programmed cell death’, is a highly regulated and energy dependent cell 
death mechanism, which was first described by Kerr, Wyllie and Currie in 1972 as an active, 
inherently programmed phenomenon (J. F. R. KERR*, 1972). If the cell receives apoptosis 
inducing signals, for instance through cytokines or cell death promoting proteins, the cell 
induces the condensation of the chromatin, cytoplasmic shrinking and the blebbing of the 
membrane (Chen and Lai, 2009). In contrast to necrosis, apoptosis is not induced by mechanic 
damage of the cell, but by cellular signaling factors that activate the intrinsic (mitochondria-
mediated) or extrinsic (death receptor mediated) apoptotic pathway.  
The extrinsic apoptotic pathway is mediated by cell death receptors including: tumor necrosis 
factor receptor (TNFR), Fas (APO-1, CD95) or the Tumor necrosis factor-related apoptosis-
inducing ligand receptor (TRAIL/Apo-2) (Wang and El-Deiry, 2003). The TRAIL receptor is 
a type II transmembrane protein and in human exist four homologous receptors including 
TRAIL receptor 1/DR4 and TRAIL receptor2/DR5 (Pan et al., 1997). Reports proved that the 
TRAIL ligand has the potent ability to induce apoptosis in tumor cells but not most of 
untransformed cells (Ashkenazi et al., 1999). Once cell death receptors are activated by their 
ligand or by ligand independent mechanism, the death inducing signal complex (DISC) is 
formed at the cytoplasmic membrane. DISC consist of the Fas-associated death domain 
(FADD) and the procaspase-8 and -10, which interact with FADD. Caspases are a family of 
proteases that use their proteolytic activity in order to coordinate cell death (Earnshaw et al., 
1999). Oligomerization of procaspase-8 induces its autoproteolytic cleavage and facilitates 
cleavage and activation of caspase-3 (Galluzzi et al., 2018). 
The intrinsic apoptotic pathway is regulated by BCL-2 family proteins like Bax and Bak. Bim, 
NOXA and Puma are the major BH3-only proteins that interact with Bax and Bak. Bax and 
Bak form pores in the outer mitochondrial membrane that promotes mitochondrial outer 
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membrane permeabilization (MOMP) followed by cytochrome C release. Cytochrome C 
interacts with Apaf-1 and procaspase-9 forming the apoptosome. The apoptosome formation is 
followed by caspase-3 and caspase-7 activation and the induction of proteins involved in the 
execution of cell death (Elmore, 2007). 
2.8.1 UPR-mediated cell death induction upon glucose deprivation 
If the cell is exposed to chronic and severe ER stress, cells induce pro-death signaling pathways 
(Figure 6). It is described that the UPR regulates the pro-apoptotic BH3-only proteins PUMA, 
NOXA and BIM, which are involved in the intrinsic apoptotic pathway. ER stress induced by 
thapsigargin or tunicamycin facilitates the upregulation of DR5 mRNA and protein in cancer 
cell lines, mediated by the transcription factor CHOP (Figure 6) (Lu et al., 2014; Yamaguchi 
and Wang, 2004; Zinszner et al., 1998). Furthermore, the PERK-ATF4-CHOP axis was shown 
to induce the induction and activation of DR5 in an ligand independent manner which results 
in caspase-8 activation (Lu et al., 2014; Martín-Pérez et al., 2012).  
Regarding the mitochondrial apoptotic pathway it is reported that CHOP induces Bim 
(Puthalakath et al., 2007). Furthermore, NOXA is known to be involved in starvation induced 
cell death (Ramírez-Peinado et al., 2011). Our group also proved that ATF4 mediates necrosis 
in rhabdomyosarcoma cells upon glucose deprivation (León-Annicchiarico et al., 2015b). 
Though, how glucose deprivation induces apoptosis in an UPR dependent manner was still not 
completely understood and will be the first objective of this thesis. (Iurlaro and Munoz-Pinedo, 
2016)  
 
 
Figure 6 Endoplasmic reticulum stress induced cell death 
Left: UPR induction activates and phosphorylates PERK and its downstream target eIF2. 
ATF4 is selectively translated and induces CHOP and NOXA, which results in apoptosis. 
CHOP induces Bim and inhibits anti-apoptotic Bcl-2 proteins. It is still under investigation how 
p53 induction upon ER stress facilitates induction of NOXA and Puma. IRE1 induction 
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mediates TRAF2 recruitment and mediates ASK1 and subsequently JNK induction. JNK can 
promote apoptosis by inhibiting Bcl-2 and Bcl-XL proteins. Right: Sustained ER stress 
activates PERK, which promotes ATF4 and CHOP induction. CHOP can bind the promotor of 
DR5 and DR4 and upregulate their expression. This promotes caspase-8 activation, DISC 
formation and cell death. (modified from Iurlaro and Muñoz-Pinedo, 2016) 
2.9 Tumor heterogeneity 
The tumor microenvironment (TME) consist not only of cancer cells but also of other cell types 
including cancer-associated fibroblasts (CAFs) and myofibroblasts, which form the tumor 
stroma. Other cell population include cells of the lymphatic and vascular network, blood cells, 
adipose cells and immune cells. Furthermore, the extracellular matrix (ECM), which is the 
extracellular space between cells, consists of extracellular components like collagen, 
fibronectin and Secreted Protein Acidic and Rich in Cysteine (SPARC), growth factors, 
cytokines and hormones, which together build an environment that facilitates tumor growth 
(Kim et al., 2011). The distinct cell populations, together with the ECM, form the tumor tissue. 
Each of these cell populations have their specific functions in order to maintain tumor growth, 
which will be explained in detail in the following chapter. Furthermore, cells communicate 
among each other through cell-cell interactions, mediated by soluble secreted factors in form 
of cytokines, chemokines or metabolites, as well as through membrane interactions. (Wu and 
Dai, 2017) 
High numbers of CAFs are associated with poor patient outcome in breast, lung and pancreatic 
cancer (Räsänen and Vaheri, 2010). These cells express high levels of chemokines including 
CXC motif ligand (CXCL)12 (Orimo et al., 2005), chemokine CC motif ligand (CCL)2 or 
CCL8. Secretion of these chemokines promotes the infiltration of inflammatory cells in the 
tumor microenvironment. (Chen et al., 2015)  
Cells of the tumor vasculature are responsible for the supply of oxygen and nutrients in the 
tumor. Unequally distributed vasculature or more distant regions from the vasculature generate 
distinct TME regions in terms of nutrient and oxygen supply. Cancer cells in different regions 
in the tumor tissue adapt to these changes through alterations in gene expression, which induce 
alternative metabolic pathways and the secretion of cytokines such as the platelet-derived 
growth factor (PDGF), transforming growth factor α (TNFα) or VEGF, which promote the re-
vascularization of the tumor tissue. Moreover, cancer cells also secrete inflammatory cytokines, 
which promote the infiltration of immune cells in the tumor tissue. Tumor-intrinsic immune 
cells become ‘reprogrammed’ and release cytokines which provide a pro-tumorigenic 
environment and promote tumor growth and metastasis (Atretkhany et al., 2016b). (Figure 7) 
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Figure 7 Schematic presentation of tumor-induced inflammation 
Tumorigenesis is initiated by oncogenic mutations with impacts on proliferation, apoptosis and 
other pro-tumorigenic processes. (2) Oncogenic mutations promote altered cytokine and 
chemokine expression, increased proliferation and survival. Secreted pro-inflammatory 
cytokines from cancer cells activate in an autocrine manner transcription factor such as NF-κB, 
STAT3, AP1 families of transcription factors. Cytokines also function in a paracrine manner 
through stimulating distant tissue. This results in increased vascular endothelium permeability 
and the upregulation of adhesion molecules. The release of chemokines favours immune cell 
infiltration. (3) Tumor-infiltrating immune cells and stromal cells are possibly ´reprogrammed´ 
by the tumor cells and release cytokines which provide a pro-tumorigenic environment, which 
stimulates tumor growth and anti-immune responses. Tumor cells release proinflammatory 
cytokines, chemokines, ROS and nitrogen oxide, which amplify the inflammatory response. (4) 
Infiltrating myeloid cells produce metalloproteases, which are needed for tumor niche 
remodelling including: angiogenesis, acquisition of invasive properties of tumor cells and 
metastasis. Epithelial-mesenchymal transition (EMT) is promoted through activation of E-
cadherin repressors: SNAIL, TWIST and Zeb transcription factors. Transcription factors like 
NFκB, HIF, Notch, Wnt/β-catenin are also promoting EMT an metastasis. (5) In the last step 
of tumor progression, tumor cells release exosomes and chemokines to metastasize towards 
distal sites. (Atretkhany et al., 2016a) 
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2.9.1 Immune cell composition in cancer 
In general, immune cells can be classified in innate immune cells, including macrophages, 
neutrophils, dendritic cells (DC), myeloid-derived suppressor cells (MDSC) and natural killer 
(NK) cells and in cells from the adaptive immune system, including T and B cells.  
Immune cells were primary thought to be anti-tumorigenic in order to prevent malignancy 
by recognition of antigens at the cell surface of cancer cells. However, the tumor-immune 
environment is rather characterized by ‘limited antigen recognition` and ´immune suppression´. 
One reason is that cancer cells are highly impacted by their mutational load, which favours the 
expression of oncogenes and tumor suppressor genes (TSGs). Regarding that, epidermal growth 
factor receptor (EGFR) mutated lung tumors are associates with high expression levels of  the 
programmed death ligand (PD-L1), which is associated with immune escape (Tung et al., 2018).  
Recent findings confirm that cells of the innate immune response, such as macrophages and 
neutrophils, promote cancer cell growth. In detail, MDSC are derived from myeloid origin and 
include myeloid progenitor cells and immature -macrophages, -dendritic cells, or monocytes. 
These cells secret cytokines and chemokines with immunosuppressive functions and are 
therefore considered as pro-tumorigenic (L.J. et al., 2012). Moreover, some myeloid cells are 
known to have immunosuppressive effects on T cells. These cells release factors such as VEGF, 
which promotes the re-vascularization of the tumor. (Motz and Coukos, 2011; Stockmann et 
al., 2008) Furthermore, MDSC migrate towards the tumor from the circulating blood and 
differentiate into type II tumor-associated macrophages (TAMs). TAMs promote tumor growth 
through secretion of cytokines like interleukin-6 (IL-6), which promotes tumor growth, chemo-
resistance and is protective against cell death in several cancers (Bollrath et al., 2009; 
Grivennikov et al., 2009; Ruffell and Coussens, 2015). Furthermore, TAMs can prevent the 
immune attack from natural killer (NK) cells, which are described to be anti-tumorigenic due 
to their ability in killing cancer cells (Marcus et al., 2014; Noy and Pollard, 2014). TAMs can 
be classified into M1 and M2 subpopulations. Class M1 macrophages are activated by 
interferon γ (INF γ), which is released by Th1 subcellular populations. M1 cells are 
characterized by expression of the major histocompatibility complex (MHC) class II, secretion 
of interleukin-12 (IL-12) and TNFα. M2 macrophages induce differentiation upon stimulation 
with cytokines such as IL-4 and IL-13. (Qian and Pollard, 2010) The M2 phenotype is described 
to promote tumorigenesis due to the secretion of immune suppressive cytokines. However, the 
classification of M1 and M2 macrophages is controversially discussed. It is rather seen as a 
‘functionally diverse group’ than a ‘unique activation state’ (Metchnikoff, 2015).  
Introduction 
40 
 
Tumor associated neutrophils (TANs) are associated with poor patient prognosis in several 
cancers (Gentles et al., 2015). The major chemokines promoting neutrophil migration are: 
CXCL1 (GRO-α), CXCL3 (GRO-γ), CXCL5 (ENA-78) and IL-8, which are released by other 
immune cells as well as by cancer cells themselves (Atretkhany et al., 2016a). Neutrophil 
recruitment is associated with poor prognosis in patients due to their T cell suppressive effects. 
(Templeton et al., 2014). After being recruited to the tumor tissue, cells secrete cytokines and 
factors that promote tumor growth, including IL-6, VEGF and reactive oxygen species (ROS) 
(Coffelt et al., 2016). 
B cells occur in all stages of tumor development. Up to date their role in tumor progression is 
still under investigation and controversial (Tsou et al., 2016). However, some studies have 
shown that patients with a high number of follicular B cells and tumor infiltrating plasma cells 
have a better long-term survival in NSCLC. This is mediated by secreted antibodies and 
immunoglobulins which are associated with tumor lysis through antibody-dependent cellular 
cytotoxicity (ADCC) (Germain et al., 2014; Lohr et al., 2013; Wang et al., 2018). Moreover, 
B cell infiltration is also associated with activation and formation as well as with memory 
formation of T cells, promoting anti-tumorigenic effects.  On the other hand, it is reported that 
B cells promote de novo carcinogenesis by promoting innate immune cell infiltration (De Visser 
et al., 2005). Other reports show that regulatory B cells (Breg) secrete factors like IL-10 and 
TGFβ, which are associated with immunosuppression. Moreover, B cells can also upregulate 
ligands like PD-L1 and the cytotoxic T-lymphocyte-associated Protein 4 (CTL-4), which inhibit 
T and NK cells response and promote the tumor responses mediated by regulatory T cells 
(Tregs), MDSCs and TAMs (Wang et al., 2018; Zhang et al., 2015). 
2.9.2 Tumor-intrinsic immune cells in lung cancer 
Lung tumors contain approximately 2/3 of tumor-infiltrating lymphocytes (TILs) and 1/3 of 
TAMs (Kataki et al., 2002). CD4+, CD8+ and CD20+ lymphocytes are associated with good 
prognosis in lung cancer patients (Bremnes et al., 2016). In contrary Th2, Th17 and Foxp3+ 
Treg cells are associated with poor prognosis (Marshall et al., 2016). In approximately 35 % of 
lung cancer incidences proliferating B cells are observed, which could have an impact on the 
patient outcome (Gottlin et al., 2011). In NSCLC, neutrophils are the pre-dominant immune 
cell population. However, the immune cell composition differs between adenocarcinoma and 
squamous carcinomas. Squamous carcinomas have a reduced macrophage but a higher 
neutrophil content compared to adenocarcinomas (Kargl et al., 2017). 
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2.9.3 Immune cell metabolism in the tumor microenvironment 
The decreased pH in some regions of the tumor environment results among other factors from 
increased lactate secretion. This creates together with hypoxia and nutrient starvation a hostile 
tumor microenvironment (Reznik et al., 2018). The flexibility of malignant cells, which 
involves the ability to adapt to hostile environments through oncogenic mutations and TSGs, 
gives cancer cells an advantage to other cell populations in the TME (Vander Heiden and 
DeBerardinis, 2017). Alterations of cancer cell-intrinsic signaling pathways promote for 
instance cytokine and metabolite release from cancer cells. Subsequently this also affects the 
metabolism of non-malignant cells in the stroma. Regarding that, cancer cells can adapt their 
metabolism and deplete the tumor environment of nutrients like glucose (Busk et al., 2011; 
Chang et al., 2015), which leads to immunosuppression of some immune cells (Badur and 
Metallo, 2018). For instance, low glucose level in the TME promote T cell inactivation due to 
their high glycolytic needs and results in the downregulation of key signaling pathways like 
Nuclear factor of activated T-cell (NFAT) signaling (Ho et al., 2015). Furthermore, glucose 
deprivation also affects B cells which are described to be dependent on glucose in order to 
proliferate and differentiate towards antibody producing cells. B cells have on the one hand 
anti-tumorigenic effects but also promote an immunosuppressive milieu due to their various 
subtypes. (Caro-Maldonado et al., 2014; Singer et al., 2018; Wang et al., 2018) 
Some cancer cells secrete high amounts of lactate based on their increased aerobic 
glycolytic activity. Lactate in the extracellular milieu can have immunosuppressive effects on 
infiltrated immune cells. For instance, lactate inhibits the cytotoxic activity of CD8+ T cell, 
which are considered as anti-tumorigenic (Fischer et al., 2007). Moreover, lactate blocks the 
production of IFN of tumor-infiltrating NK cells, which is associated with loss of 
immunosurveillance (Brand et al., 2016). Lactate also affects macrophages of the innate 
immune system by inducing an M2-like phenotype (Colegio et al., 2014). Furthermore, 
increased acidity is associated with negative effects on cells of the innate and adaptive immune 
response due to the downregulation of cytokines and therefore lactate inhibits the cytotoxic 
effector function of several immune cells. (Fischer et al., 2000; Singer et al., 2018) 
Keeping this in mind, glucose deprivation does not only affect cancer cells but also the activity 
of tumor-associated immune cells.  
2.9.4 The role of the UPR in the tumor microenvironment 
The UPR is not only a stress response in non-malignant cells in order to regain cell homeostasis 
upon extra- or intracellular perturbations, but also displays a pro-tumorigenic role in some 
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cancers. This is associated with cancer cell survival, as well as with drug resistance (Almanza 
et al., 2019). Moreover, several reports indicate that the UPR is involved in  immunosuppression 
and an important regulator of the inflammatory response (Grootjans et al., 2016). The induction 
of the UPR results in cytokine secretion and modulation of immune cells within the TME, which 
promotes tumor growth (Cubillos-Ruiz et al., 2017; Mogilenko et al., 2019). Regarding that, it 
was recently published that IRE1 is responsible for myeloid recruitment in glioblastoma (Obacz 
et al.,2019). Moreover, it is described that pharmacological induction of ER stress promoted 
distinct macrophage populations (Zhang, et al, 2019) as well as cancer cells (Logue et al., 2018) 
to release inflammatory cytokines with pro-tumorigenic functions. 
To sum it up, glucose deprivation induces the UPR and this could promote the secretion of pro-
inflammatory cytokines in an UPR-dependent manner, impacting the TME. 
2.10 Cytokines and chemokines in the tumor microenvironment  
Distinct cell populations in the TME communicate with each other through cell-cell 
interactions, mediated by soluble signaling proteins. Depending on the cell type, these factors 
are cell type-specific and function in autocrine or paracrine manners. Secreted factors can be 
metabolites, such as lactate or pyruvate, as well as cytokines. Cytokines are small proteins 
(5-20 kDa), which are secreted mainly by immune cells in order to facilitate inflammatory 
responses. These signaling molecules have paracrine or autocrine functions and bind through 
receptor-ligand interactions to their corresponding receptor at the cell surface. Cytokines can 
be further subclassified in chemokines, which promote infiltration of immune cells from the 
circulating blood towards an inflamed tissue, based on a concentration gradient. (Lee and 
Margolin, 2011; M.D. et al., 2014) 
2.10.1 The involvement of NF-κB signaling in cytokine induction 
The Nuclear Factor-kappa B (NF-κB) pathway is involved in cell survival, proliferation, 
angiogenesis and the inflammatory response. Furthermore, it is the major signaling pathway for 
the induction of pro-inflammatory cytokines and chemokines, which is well described for many 
diseases (Liu et al., 2017). This pathway can be induced, among others, downstream of 
interleukin-1 (IL-1), by the TNFR or by the Toll-like microbial pattern recognition receptors 
(TLRs). In detail, inactive IκB is bound to the transcription factor p65/RelA.  IκB gets 
activated upon phosphorylation by a multi-subunit IκB kinase (IKK) complex that results in its 
proteasomal degradation. Therefore, p65 can translocate to the nucleus and induce the 
transcription of pro-inflammatory cytokines (Liu et al., 2017).  
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With regard to the UPR, it is described that NF-κB can be induced downstream of the UPR 
through the formation of an IRE1-TRAF2 complex, interacting with IKK, which results in IκB 
phosphorylation. Moreover, phosphorylation of eIF2α results in a global attenuation of protein 
synthesis, which also prevents de novo IκB synthesis. As a consequence, p65 translocate to 
the nucleus and induces transcriptionally cytokine genes (Figure 8). (Schmitz et al., 2018; 
Zhang and Kaufman, 2008a) 
In cancer, the NF-κB pathway is activated by many chemotherapeutic drugs or ionic radiation, 
which in some cases promotes drug resistance (Wolf et al., 2014). Furthermore, NF-κB 
signaling promotes tumor development in a murine mouse adenocarcinoma model KrasLSL-
G12D;Trp53f/f promoting a pro-inflammatory TME  (Meylan et al., 2009). 
 
Figure 8 Schematic presentation of UPR-mediated NF-B activation 
Activation of PERK results in eIF2α phosphorylation, which mediates protein translation 
attenuation. IκB has a shorter half-life than p65, which results in a shift towards higher p65 
protein level. Free p65 can translocate to the nucleus. The cytoplasmic domain of IRE1α can 
recruit TRAF2. The complex IRE1α-TRAF2 complex can interact with IKK or JNK promoting 
its activation. Activated JNK phosphorylates activator protein 1 (AP1), which can also mediate 
transcription of inflammatory genes. Activated IKK mediates the degradation of IκB and 
subsequently p65 can translocation to the nucleus, inducing inflammatory gene 
transcription.(Zhang and Kaufman, 2008b) 
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2.11 Cancer-associated cytokines 
Focusing on cancer, recent findings award cytokines important functions in tumor progression. 
Cancer related cytokines can be subclassified in pro- or anti-tumorigenic, depending on their 
functions. For instance, chemokines like CXCL1/2/3 are known chemoattractants for 
neutrophils, macrophages and MDSCs in the TME, which are associated with poor prognosis. 
Other cytokines are associated with immunomodulatory functions, angiogenesis or tumor 
growth. An overview of the cytokines which were examined in this thesis and examples of their 
general and tumorigenic functions are summarized in Table 1. 
Within this thesis we will focus on the regulation of mainly three pro-tumorigenic cytokines: 
IL-8, IL-6 and the leukaemia inhibitory factor (LIF) since these cytokines are well described to 
have pro-tumorigenic functions in several cancers and are associated with poor patient survival. 
Table 1 Cancer-associated cytokines and their functions 
Cytokine Function 
CXCL1 Neutrophil recruitment, metastasis (Sawant et al., 2016) 
CXCL2 Chemoattractant for myeloid cells (Massagué et al., 2012)  
CXCL3 Leukocyte recruitment (Gui et al., 2016) 
CXCL5 Tumor progression, neutrophil recruitment and angiogenesis (Hu et al., 2018) 
CCL2  Monocyte attractant (Yoshimura, 2018), tumor growth (Zhang et al., 2010) 
CCL19 T and B cell migration, pro-tumorigenic in cervical cancer (Zhang et al., 2017b) 
CCL20 
Chemoattractant for lymphocytes (Hieshima et al., 1997), pro-tumorigenic (Samaniego et 
al., 2018) 
IL-6 
Proliferation and activation of T cells, regulation of acute phase response (Hunter and 
Jones, 2015), proliferation, metastasis and angiogenesis (Kumari et al., 2016; Lee and 
Margolin, 2011) 
IL-8 
Chemoattractant for neutrophils, angiogenesis, tumor progression (Lee and Margolin, 
2011) 
LIF 
Self-renewal of cancer-initiating cells (Peñuelas et al., 2009), expansion and activation of 
MDSCs (Won et al., 2017), infiltration of TAMs (Mónica Pascual-García et al., 2019) 
MCS-F 
Proliferation and differentiation of monocytes and macrophages, recruitment of TAMs 
(Chockalingam and Ghosh, 2014) 
 
2.11.1 Interleukin-8 
IL-8 is a proinflammatory cytokine, which was initially described to attract neutrophils to 
the site of inflammation (Baggiolini et al., 1989). Many reports associate IL-8 serum level of 
patients with poor prognosis and several reports link its chemotactic functions to neutrophil, 
monocytes and MSDC infiltration in tumors (Alfaro et al., 2016) as well as with angiogenesis 
in cancer. In NSCLC, IL-8 promotes proliferation in an EGFR dependent manner by promoting 
the activation of MAPK p42/44 (ERK1/2). Other studies prove that the IL-8 mRNA expression 
in lung tumors versus non-malignant lung tissue is associates with a shorter overall survival, 
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relapse and tumor progression (Yuan et al., 2000). Furthermore, increased IL-8 serum level 
after PD1/PD-L1 therapy are associated with worse response towards therapy (Sanmamed et 
al., 2017). IL-8 and IL-6 serum level in patients are in coherence with poor patient survival in 
stage I lung cancer patients. Moreover, IL-8 promotes the formation of neutrophil extracellular 
traps (NETs) of MSDCs (Alfaro et al., 2016). NETs consist out of DNA and DNA binding 
proteins, which have bacteriostatic properties. Binding of IL-8 at the CXCR1 or CXCR2 
receptors activates among others PI3K, PKC and MARK signaling cascades. (Raghuwanshi et 
al., 2012)  
2.11.2 Interleukin-6 
IL-6 is a glycosylated polypeptide chain with a size of 25 kDa. It was first discovered as a 
cytokine involved in B cell maturation towards antibody producing plasma cells (Kishimoto, 
2003). Nowadays it is considered as a pleiotropic cytokine involved in inflammation, immune 
response, and haematopoiesis (Tanaka et al., 2014). IL-6 is not exclusively release  from 
immune cells but also from stromal and cancer cells in the TME. (Kumari et al., 2016) 
In a tumor setting IL-6 is described to promote differentiation and proliferation of tumor cells, 
which correlates with the aggressiveness of the tumor. Regarding that, clinical studies found 
that IL-6 is increased in the patient serum of many cancers, including lung tumors, which is  
associated with poor prognosis and poor response to therapy (Chang et al., 2013). IL-6 can also 
induce HIF1α and activate neutrophils. Furthermore, IL-6, secreted from stromal cells, 
stimulates the secretion of VEGF from multiple myeloma cells (Dankbar et al., 2000). IL-6 also 
has an important role in cell metabolism. Mice that lack IL-6 are intolerant to glucose and 
insulin resistant (Wunderlich et al., 2010). In muscle cells it was shown that IL-6 promotes 
increased fatty acid oxidation, glucose uptake, translocation of glucose transporters to the cell 
membrane, as well as the increased activation of AMPK (Carey et al., 2006). Targeting IL-6 
with receptor-tyrosine inhibitors (TKIs) is seen as a promising approach to prevent IL-6 
paracrine signaling networks in cancer (Lin et al., 2002). 
2.11.3 Leukemia inhibitor factor 
The leukemia inhibitory factor (LIF) belongs to the IL-6 superfamily. LIF is a glycosylated 
monomeric protein with a size of 20-25 kDa. It binds to the Leukemia inhibitory factor receptor 
(LIFR) followed by the recruitment of the gp130 receptor, which forms together with LIFR a 
heterogenic complex. Dimerization induces several signaling pathways including JAK/STAT3, 
PI3K/AKT, ERK1/2 and mTOR signaling (Li et al., 2014).  
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LIF is a pleiotropic cytokine, involved in several physiological processes including 
embryonal implantation, neuronal development, stem cell self-renewal and in the regulation of 
the immune system. (Janssens et al., 2015; Metcalfe, 2011; Taga and Kishimoto, 1997; 2015) 
Furthermore, LIF also has some metabolic implications. Regarding that it is reported that LIF 
promotes the glucose uptake in skeletal muscle cells (O’Neill et al., 2015) and it alternates the 
energy metabolism of cardiomyocytes (Odegaard et al., 2005). 
With focus on cancer, LIF is involved in the proliferation of breast, kidney, ovarian as well as 
prostate cancer cells (Kellokumpu-Lehtinen et al., 1996a; McLean et al., 2018). LIF promotes 
the invasion of fibroblasts and creates an invasive tumor environment, which can result in 
primary metastasis (Albrengues et al., 2014). With regard to tumor resident immune cells, LIF 
is involved in the differentiation of murine M1 myeloid leukemia cell and macrophages 
(Gearing et al., 1987), as well as in the prevention of CD8+ T cell tumor-infiltration and 
promotes the infiltration of TAMs (Pascual-García et al.,2019). Therefore,  high LIF level 
predict poor prognosis of patient. (Kellokumpu-Lehtinen et al., 1996b; Won et al., 2017; Zeng 
et al., 2016) 
To sum it up, cytokines released from cancer or other tumor-resident cells can regulate a broad 
range of functions in autocrine and paracrine manners. Through ligand-receptor interactions 
cytokines induce several downstream signaling pathways, ranging from STAT, NF-κB, PI3K 
or MAPK signaling to cell death signaling. Therefore, the investigation of the tumor-intrinsic 
events promoting their secretion and of the regulatory mechanisms behind regulating their 
release, is important to develop effective anti-cancer drugs. 
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3. Hypothesis and objectives 
Since cancer cells are highly dependent on glucose and mainly use aerobic glycolysis for energy 
production, known as the Warburg effect, targeting the glucose metabolism is a promising anti-
cancer approach. However, to develop functional drugs it is important to understand in detail 
the adaptive survival mechanism induced by cancer cells upon glucose deprivation as well as 
the mechanisms promoting cell death. Due to the discovery that the TME plays a significant 
role in tumor progression, it is also necessary to investigate the impacts of glucose-deprived 
cancer cells on the surrounding tissue. 
Regarding that, it is known that glucose deprivation induces the UPR, which is not only a pro-
death but also a pro-survival response. We hypothesize that sustained glucose deprivation 
induces among other stress signaling pathways the UPR, which mediates apoptosis in a TRAIL 
death receptor dependent manner. Moreover, we further hypothesize that cancer cells induce in 
an earlier response adaptive mechanism, which allow them to escape nutrient stress in order to 
regain cell homeostasis. We suggest that one of the adaptive responses is the secretion of 
cytokines and chemokines with functional roles in migration, cell death and immune cell 
infiltration.  
In detail, we want to investigate how cancer cells die in an UPR-dependent manner upon 
glucose deprivation and whether secreted cytokines from glucose-deprived cancer cells 
promote the migration of macrophages, neutrophils and lymphocytes. Experiments will be 
performed in different lung cancer cell lines including adenocarcinoma and squamous 
carcinoma cells as well as in a cervical cancer cell line.  
1. Investigation of cell death induction upon glucose deprivation in cancer cells 
− Uncovering the cell death mechanism induced by cancer cells upon glucose deprivation.  
− Revealing the mechanistical pathway involved in glucose deprivation-induced cell 
death. 
2. Investigation of cytokine release upon glucose deprivation from cancer cells and functional 
analysis  
− Identification of cytokines released from starved cancer cells and from cancer cells 
treated with anti-metabolic drugs. 
− Revealing the regulatory mechanism of cytokine release upon glucose deprivation with 
a focus on the UPR, NF-κB signaling and the mTOR pathway. 
− Functional analysis of the effect of conditioned media derived from glucose-deprived 
cancer cells on cancer cells, THP-1 cells and primary immune cells isolated from human 
blood. 
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4. Material 
 Table 2 Products and reagents 
Products/Reagents Manufactures Cat. Number 
Blocking Buffer ODDYSSEY LI-COR 927-40000 
Bovine Serum Albumin SIGMA A7030 
Boyden 3.0 μm Transparent PET Membrane (24-well) 
 
Millipore PITP01250 
Boyden 8.0 μm Transparent PET Membrane (24 well) Falcon 353097 
Crystal Violet Sigma 61135 
D-(−)-Fructose Sigma F0127 
D-(+)-Glucose Sigma G7021 
D-(+)-Mannose Sigma M6020 
Dextran  Sigma 31392-50G 
Dharmafect Fisher W9945D 
Dimethyl sulfoxide (DMSO) SIGMA D2650 
DMEM, high glucose Life Technologies 41965-062 
DMEM, no glucose Life Technologies 11966-025 
DMEM, no L-glutamine Life Technologies 11960044 
 
dNTP Mixes Fermentas R1121 
Dulbecco's Phosphate Buffered Saline 10X w/o 
Calcium w/o Magnesium (PBS) 
Biowest X0515-500 
ECL Western Blotting Substrate Promega W1001 
EDTA SIGMA E5134 
ELISA 96-well Plates Sigma M9410-1CS 
Ethanol Alcoholes Gual 47000ER 
Fast EvaGreen Master Mix for qPCR (500rxn) Biogen Cientifica S.L. 31003-1 
FBS  Life Technologies 10270106 
Ficoll (Lymphocytes isolation solution, 1.077 g/ml) Rafer LN0250 
Film Curix RP2 Plus Medical X-Ray film 100 NIF 18 
x 24 
Agfa ENKMV 
Glycine SIGMA 161-0718 
HBSS Gibco 24020083 
HBSS (w/o Magnesium and Calcium) Sigma H9394-500ML 
Immobilon-FL PVDF (fluorescence) Merck Millipore IPFL00010 
Immobilon-PSQ Membrane, PVDF Millipore ISEQ00010 
L-Glutamine Life Technologies 25030-024 
Methanol Alcoholes Gual S.A. UN1230 
MicroAmp® Optical 96-Well Reaction Plate Life Technologies N8010560G 
Nitrocellulose Membrane Bio-rad 162-0112 
Paraformaldehyde VWR 1.04005.1000 
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Percoll Sigma P4937-100ML 
PfuTurbo Hotstart DNA Polymerase Agilent Tech 600320 
Ponceau S. SIGMA P3504 
Potassium chloride SIGMA P9541 
Precision Plus Protein™ Dual Colour Bio-rad 161-0394SP 
Propidium iodide SIGMA 81845 
Protein Concentrator PES, 3K MWCO, 2-6 mL 
 
Thermo Fisher Scientific 88515 
Protein Concentrator PES, 3K MWCO, 5-20 mL Thermo Fisher Scientific 88526 
Recombinant Human IL-8 R&D System 208-IL-010 
Recombinant Human LIF R&D System 7734-LF-025 
Recombinant Human TNF  Peprotech 300-01A 
RIPA Lysis and Extraction Buffer Thermoscientific 89900 
RPMI Thermo Fisher 21875034 
Sodium bicarbonate SIGMA S5761 
TaqMan® Gene Expression Master Mix Applied biosystems 4369016 
TaqMan® Gene Expression Master Mix Applied Biosystems 4369016 
TEMED SIGMA T7024 
Triton® X-100 VWR 108603 
Trypan Blue solution SIGMA 93595 
Trypsin-EDTA (0.05 %), phenol red Life Technologies 25300-062 
Tween® 20 SIGMA P1379 
 
 Table 3 Commercial kits 
Kit Manufacture Cat. Number 
ELISA Ancillary Reagent Kit 2 R&D System DY008 
ELISA CCL20 NOVUS 
NBP2-31049-1 
KIT 
ELISA DuoSet Human CXCL1 R&D System DY275-05 
ELISA DuoSet Human CXCL5 R&D System DY254-05 
ELISA Duoset Human IL-6 R&D System DY206-05 
ELISA Duoset Human IL-8 R&D System DY208-05 
ELISA DuoSet Human LIF  R&D System DY7734-05 
ELISA DuoSet Human M-CSF  R&D System DMC00B 
ELISA Duoset Human TNFα R&D System DY210-05 
High Capacity cDNA Reverse Transcription Kit Applied Biosystems 4368814 
Pierce™ BCA Protein Assay Kit Thermo Scientific 23225 
Proteome Profiler Human Chemokine Array R&D System ARY017 
Proteome Profiler Human XL Cytokine Array R&D System ARY005 
RNeasy MINI KIT QIAGEN 74104 
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5. Methods 
5.1 Cell lines and human derived primary cultures 
Human blood samples (buffy coats) were obtained from the Banc de Sang i Teixits - BST 
(Blood and Tissue Banc). Experiments were approved by the Clinical Research Ethical 
Committee from the Hospital of Bellvitge (Comitè d'Ètica d'Investigació Clínica - CEIC). 
Isolation of peripheral blood mononuclear cells (PBMCs) and neutrophils was performed 
immediately after arrival of buffy coats, and primary cultures did not exceed 24 h including 
experiments. Primary cells were cultured in pyruvate-free Dulbecco’s Modified Eagle’s 
Medium (DMEM) containing 25 mM glucose, complemented with 10 % FBS (heated at 57ºC 
for 30 min) and 2 mM fresh L-glutamine at 37ºC and 5 % CO2 atmosphere. 
Different cancer cell lines (lung: A549, H1299, H460, H520, SW900; cervix: HeLa; and 
leukemia: HL60) were cultured in the same DMEM supplemented as for primary cells. Cells 
were maintained at 37ºC and 5 % CO2 atmosphere and adherent cells were splitted twice a week 
when reached 90 % confluence using a 0.05 % trypsin EDTA solution. THP-1 (leukemia) cells 
were grown in RPMI supplemented with 10 % FBS and 2 mM L-glutamine and diluted once a 
week with fresh RPMI in a ration of 1:20. All cells were grown in antibiotic-free medium. 
(Table 4) 
 Table 4 Cell lines 
Cell Lines Source Cat. Number 
HeLa Douglas Green Lab N/A 
HeLa Joan Gil Lab ECACC 
A549 Maria Molina Lab ATCC-CCL-185 
H1299 Ana Montes N/A 
H460 Laboratory of Vanessa Soto Cerrato N/A 
H520 Laboratory of Vanessa Soto Cerrato N/A 
THP-1 Laboratory of Isabel Fabregat N/A 
HL60 Esteban BallestarLab N/A 
 
5.2 Cell treatments 
5.2.1 Dialyzing FBS 
For FBS dialysis, the dialyzing membrane was washed according to manufacturer 
recommendations and filled with 100 mL of heat-inactivated FBS. The pipe was washed twice 
for 1 h and once overnight (O/N) in 1 L of PBS at 4ºC while stirring. Dialyzed FBS (dFBS) was 
sterile filtered using a 22 µm syringe filter. (Püschel and Muñoz-Pinedo, 2019) 
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5.2.2 Glucose and glutamine deprivation, total starvation  
Treatment was performed by plating 300.000 (6-well plate) or 150.000 (12-well plate) cells 
24 h prior to treatment. At a confluence of 80 % cells were washed twice with pyruvate-free 
DMEM, 0 mM glucose and 0 % FBS. Cells were treated with pyruvate-free DMEM containing 
0 mM glucose, 10 % dFBS and 1 % L-glutamine, while the control cells were supplemented 
with 25 mM glucose or at concentrations indicated in the figures. (Püschel and Muñoz-Pinedo, 
2019) 
5.2.3 Drug treatment 
For other treatments, cells were incubated in pyruvate-free DMEM with 25 mM glucose, 10 % 
FBS and 2 mM L-glutamine, unless indicated differently. Specifically, cells were treated with 
drugs summarized in Table 5. For glutamine free treatments, cells were washed twice with 
glutamine- and pyruvate-free DMEM containing 10 % FBS and incubated with this medium. 
For HBSS (Hank's Balanced Salt Solution) treatments, cells were washed twice with HBSS 
(with calcium, magnesium and 5.55 mM glucose) and incubated in HBSS. Control cells were 
incubated in regular culture media. 
Table 5 Drugs 
Drugs CTreatment Manufacture  Cat.Nº Function 
2-Deoxyglucose  5-25 mM Sigma D6134 Glycolysis Inhibitor 
AMG PERK 44 1-2 µM TOCRIS 5517 PERK Inhibitor 
DTT 1 mM Sigma D9779 UPR stressor 
GSK2656157 0.5-1 µM Chemigen HY-13820 PERK Inhibitor 
ISRIB 0.1-0.25 µM Sigma SML0843 eIF2α Inhibitor 
Metformin 10-50 mM Sigma D150959 Metabolic drug 
PMA 100 nM Sigma P1585 THP-1 Differentiation 
Rapamycin 10-100 nM Calbiochem 53123-88-9 mTOR inhibitor 
Torin1 0.1-1 µM Selleckchem S2827 mTOR inhibitor 
Thapsigargin 4 µM Sigma T9033 UPR stressor 
QVD 10 µM Sigma A1901 Caspase Inhibitor 
Ac-Y-VAD-cmk 10 µM apeXbio SML0429 Caspase-1 Inhibitor 
Z-VAD 20 µM apeXbio A1902 Caspase Inhibitor 
MKC-8866 10 µM 
Fosun Orinove 
PharmaTech Inc 
Eric Chevet 
Lab 
IRE1 inhibitor 
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5.3 Secreted chemokine and cytokine arrays 
For the cytokine array, A549 cells were treated for 24 h with pyruvate-free DMEM containing 
25 mM or 0 mM glucose, 10 % dFBS and 2 mM L-glutamine as described before. After 24 h, 
the supernatant was collected and centrifuged for 5 min at 3000 g at 4ºC. The supernatants of 
three independent experiments were combined and the Proteome Profiler Human XL Cytokine 
Array Kit (Table 3) was performed according to manufacture instruction. For the chemokine 
array (Table 3), A549 cells were transfected for 40 h with siRNA against a non-targeting 
sequence (C) or against ATF4 (sequence #1) (Table 6). Cells were trypsinized and plated at 
confluences of 40 % (Glc+) and 60 % (Glc-) so that confluences were the same at the day of 
supernatant collection. The following day cells were treated with glucose deprivation for 24 h 
as described before. The supernatants were collected and centrifuged for 5 min at 3000 g at 4ºC. 
The supernatants of three independent experiments were combined and the Human Chemokine 
Antibody Array was performed according to manufacturer instructions. Membranes were 
developed by chemiluminescence (ECL) reaction using freshly prepared ECL reagent and 
ChemiDoc® development. Mean density of spots were analysed by quantification with ImageJ. 
Fold induction is shown by normalization of the mean intensity of the control (Glc+) versus the 
intensity of the Glc- treatment.  
5.4 Transfection with small interfering (si)RNAs 
Cells were plated in 6-well plates at a concentration of 450.000 cells/well (50 % confluence) in 
2 mL fresh culture medium. Cells were transfected 5 h later, when adhered. Transfection 
solution (150 uL culture DMEM without supplements per well) was preincubated with 1 uL/mL 
DharmaFECT for 5 min. A final concentration of 50 nM siRNA (Table 6) was added and 
incubated for another 20 min. Complete transfection solution was added to cells. 40 h post-
transfection medium was replaced with treatment media as described before. 
 Table 6 siRNA sequences 
Target Sequence 5’-3’ 
ATF4#1 CCAGAUCAUUCCUUUAGUUUA 
ATF4#2 GCCUAGGUCUCUUAGAUGA 
XBP1#1 GGAAGCCAUUAAUGAACUA 
XBP1#2 AGAAGGCUCGAAUGAGUG 
p65#1 GAUUGAGGAGAAACGUAAA 
p65#2 GCCCUAUCCCUUUACGUCA 
IL8#1 ACCACCGGAAGGAACCAUC 
IL8#2 GCCAAGGAGUGCUAAAGAA 
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IL8#3 CCAAGGAGUGCUAAAGAACUUAGAU 
LIF#1 GGUCUUGGCGGCAGGAGUU 
ATF6 GGCAGGACUACGAAGUGAUGATT 
 
IRE1 GCGUCUUUUACUACGUAAUCU 
DR4 CACCAAUGCUUCCAACAAU 
DR5 GCUGUGGAGGAGACGGUGAUU 
5.5 Western blot 
Supernatants were removed and cells were scraped on ice using RIPA lysis buffer supplemented 
with protease inhibitor (Roche) and phosphatase inhibitors (Roche) and stored at -20ºC. Cell 
lysates were sonicated, and quantification was carried out by Pierce BCA Protein Assay Kit©. 
The standard curve was prepared by using 2 mg/mL bovine serum albumin (BSA). The optical 
density was measured at an absorbance of 562 nm by BioTek’s PowerWave XS microplate 
spectrophotometer. For gel electrophoresis 40 μg protein of each sample was loaded in a final 
volume of 40 μL 4X Laemmli Buffer (Table 8). Samples were denaturated at 95ºC for 10 min 
prior to loading the gel. Proteins were separated by Sodium Dodecyl Sulphate Polyacrylamide 
Gel Electrophoresis (SDS-PAGE). 
The percentage of the polyacrylamide gel was chosen according to the size of the protein of 
interest: 7 % resolving gel was prepared for proteins with the size of 80-180 kDa and 12 % 
resolving gel for proteins between 15-60 kDa. Gel preparation is shown in Table 7.  
Table 7 Gel preparation 
Percent 
Gel [%] 
dest. H2O [mL] Acrylamide [mL] 
Gel buffer 
[mL] 
10 % SDS 
[mL] 
APS 
[mL] 
TEMED 
[μL] 
Stacking  6.425 0.975 2.5 0.1 0.1 0.01 
7 5.675 1.725 2.5 0.1 0.1 0.01 
12 4.4 3 2.5 0.1 0.1 0.01 
15 3.65 3.75 2.5 0.1 0.1 0.01 
 
The gel chamber was filled with 500 mL running buffer (Table 8). Proteins were transferred to 
a nitrocellulose membrane for 1 h, 100 V at RT by using 1 L of transfer buffer (Table 8). 
Membranes were blocked in 5 % non-fat dry milk and TBS-T for 1 h at RT.  
Table 8: Western blot buffer and solutions 
Buffer Concentrations 
Ammonium persulphate (APS) 0.1 g/ml in H20 
Laemmli (4X) Loading Buffer 
63 mM Tris-HCl; 10 % glycerol; 2 % SDS; 0.01 % 
bromophenol; 5 % β-mercaptoethanol; in dest. H20 
Ponceau Staining Solution 1.31 mM Ponceau; 5 % acetic acid; in dest. H20 
Resolving Buffer 
1.5 M Tris; SDS 0.4 % in dest. H20 pH 8.8 
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RIPA Buffer 
25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1 % NP-40, 1 % 
sodium deoxycholate, 0.1 % SDS 
Running Buffer 10X 
0.249 M Tris-Base; 1.92 M glycine; 1 % SDS in dest. 
H20; pH 8.3 
Stacking Buffer 0.5 M Tris ;0.4 % SDS 
TBS 10X 0.1 M Tris-HCl; 1.5 M NaCl; in dest. H20; pH 7.5. 
Transfer Buffer 10X 
25 mM Tris-HCl; 0.2 M glycine; 3.46 mM SDS; 20 % 
methanol; in dest. H20 
TBS-T 0.1 % Tween in TBS (1X). 
 
Membranes were incubated with the primary antibody, see Table 9, overnight at 4ºC in 
blocking buffer (5 % BSA in TBS-T), and washed afterwards three times for 10 min in TBS-T. 
The secondary antibodies are listed in Table 10.  We used either a horseradish peroxidase 
(HRP) or a fluorescent secondary antibody (Li-COR Biosciences). The first was diluted 1:5000 
in TBS-T and the latter 1:15-20.0000 in (1:1) TBS:Odyssey blocking buffer (Li-COR 
Biosciences) and incubated with the membrane for 1 h at RT. Membranes were washed 3 times 
for 10 min each in TBS-T and signal was obtained by chemiluminescence (ECL) reaction using 
freshly prepared ECL reagent and ChemiDoc® development. When fluorescent secondary 
antibodies were used the third wash was performed with TBS and the membrane was developed 
with the Odyssey Infrared Imaging System. 
 
 Table 9 Primary antibodies 
 
Primary antibody Dilution 
Produced 
in 
MW 
(kDa) 
Manufacture 
Cat. 
Number 
Actin 1:2000 mouse 42 Merck Millipore MAB1501R 
ATF4/Creb2 1:1000 rabbit 49 Cell Signaling 11815 
Caspase-3 (full length 
and cleaved) 
1:1000 rabbit 17, 35 Cell Signaling 9662 
CHOP/GADD153 1:500 mouse 30 Cell Signaling 2895 
4EBP-1 total 1:1000 rabbit 15-20 Cell Signaling 9452 
AMPK–phospho 
(Thr172) 
1:1000 rabbit 62 Cell Signaling 2535 
PARP 1:1000 mouse 116 Cell Signaling 9542 
PARP Cleaved 1:1000 rabbit 89 Cell Signaling 9541 
Phospho-eIF2α(Ser51) 1:1000 rabbit 38 Cell Signaling 1673398S 
eIF2α 1:1000 rabbit 36 cell signaling 1675324S 
S6 (Phospho) Ser235/236 1:1000 rabbit 32 Cell Signaling 2211 
p65 (C-20) 1:1000 rabbit 65 Cell Signaling D14E12 
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Table 10 Secondary antibody 
Secondary antibody Conjungated with Manufacture Cat. Number 
rabbit HRP Zymax 81-6120 
mouse HRP Zymax 81-6520 
rabbit IRDye 800CW LI-COR Biosciences 926-32213 
mouse IRDye 680CW LI-COR Biosciences 926-68022 
5.6 ELISA 
Cells were treated in a 6-well plate with 2 mL treatment media or in a 12-well plate with 1 mL 
treatment media. Supernatants were collected and centrifuged at 3000 g at 4°C to remove dead 
cells and cell debris and stored at -80ºC. Supernatants were diluted when necessary to be in the 
optimal optical range and analysed by ELISA using the DuoSet ELISA Development Systems© 
(Table 3) according to manufacturer’s instructions. Optical densities were measured at a 
BioTek’sPowerWave XS microplate spectrophotometer at 450 and 540 nm. Final cytokine 
concentrations (pg/mL) were normalized to the protein concentration of each sample, measured 
as described before for WB and is displayed as pg/mg of protein in the final figures. Protein 
from a 6-well plate was lysed using 50 µL RIPA Buffer (12-well plate, 25 µL RIPA Buffer). 
5.7 Gene expression analysis by RT-PCR and qPCR 
Cells were washed once with PBS and trypsinized using a 0.05 % trypsin EDTA Solution. Cells 
were pelleted at RT, 450 g for 5 min. Cell pellet was washed once with PBS, centrifuged again 
at 450 g for 5 min, and lysed in 350 µL RLT buffer (Quiagen) completed with 
β-mercapthoethanol (10 µL/mL) of the RNeasy MINI KIT© (Quiagen). Cell lysate was mixed 
with 350 µL 70 % ethanol and transferred to a mini spin column placed in a 2 mL collection 
tube. RNA extraction was performed according to manufacturer instructions. Total RNA was 
quantified at the NanoDrop and 1 µg per condition of total RNA was retro-transcribed to cDNA 
using the High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher) (Table 11 and 12).  
 Table 11 Reverse transcription 
Reagent Volume [L] 
Buffer 10X 2 
25X dNTP Mix (100 mM) 0.8 
10X RT Random Primers 2 
MultiScribe RNase 1 
RNase Inhibitor 1 
RNase-free water 3.2 
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Table 12 Reverse transcription cycle 
 Step 1 Step 2 Step 3 Step 4 
Temperature (ºC) 25 37 85 4 
Time (min) 10 120 5 ∞ 
5.7.1 qPCR 
For qPCR 10 ng of cDNA, 1 µM of primer (Table 13) and the Syber-Green Mastermix (Thermo 
Fisher) was used per reaction. Amplification was performed in a 384-well plate using the Light 
Cycler480© according to the following protocol: denaturation 1 cycle at 95ºC; amplification: 
45 cycles: 95ºC 4s, 62ºC 30s, 72ºC 30s, see also Table 14. For the analysis, the ΔCp of the 
mRNA of interest was calculated by using L32 as the housekeeping gene. The fold increase of 
2^(-ΔΔCq) was calculated by normalization to the control sample of cells cultured in the 
presence of glucose at indicated time points. 
Table 13 pPCR primer 
 
Primer sequence 5’-3’ 
Forward  Reverse 
CCL2 CAGCCAGATGCAATCAATGC GCACTGAGATCTTCCTATTGGTGAA 
CCL20 CCAAGAGTTTGCTCCTGGCT  TGCTTGCTGCTTCTGATTCG 
CCL19 CCAGCCCCAACTCTGAGTG  ATCCTTGATGAGAAGGTAGTGGA 
CHOP AAGGCACTGAGCGTATCATGT TGAAGATACACTTCCTTCTTGAACA 
CXCL1 ACTGAACTGCGCTGCCAGTG GGCATGTTGCAGGCTCCTCA 
CXCL2 CACACTCAAGAATGGGCAGA CTTCAGGAACAGCCACCAAT 
CXCL3 TCCCCCATGGTTCAGAAAATC GGTGCTCCCCTTGTTCAGTATCT 
CXCL5 TGGACGGTGGAAACAAGG CTTCCCTGGGTTCAGAGAC 
CXCL8 ATACTCCAAACCTTTCCACCC TCTGCACCCAGTTTTCCTTG 
CTGF TTGGCCCAGACCCAACTA GCA GGA GGCGTTGTCATT 
MCS-F GTTTGTAGACCAGGAACAGTTGAA CGCATGGTGTCCTCCATTAT 
IL6 CAACCTGAACCTTCCAAAGATG ACCTCAAACTCCAAAAGACCAG 
TNFα ACTTTGGAGTGATCGGCC GCTTGAGGGTTTGCTACAAC 
Erdj4 TGGTGGTTCCAGTAGACAAAGG CTTCGTTGACTGACAGTCCTGC 
Herpud1 ACTTGCTTCCAAAGCAGGAA CTCTTGTGCACTTGGTGGTG 
 
Table 14 qPCR cycle program 
Steps Cycle n Temperature ºC 
Pre-incubation 1 95 
Amplification 45 95,62, 72 
Melting Curve 1 95 
Cooling 1 ∞ 
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5.7.2 RT-PCR 
For RT-PCR cells were collected, and RNA was extracted and retro-transcribed as described in 
chapter 6.7. Amplification of cDNA, using the primers in Table 15, was performed in a 
Thermal Cycler according to the following protocol: 95ºC 5 min, 95ºC 1 min, 55ºC 1 min, 72ºC 
1 min for 34 cycles, 72ºC 1 min, 72ºC 5 min, see Table 16. Samples were separated using an 
acrylamide gel and subsequent ethidium bromide (EtBr) staining. Separation was visualized 
using a ChemiDoc. 
Table 15 RT-PCR primer 
 Primer sequence 5’-3’ 
Forward Reverse 
XBP1 TTACGAGAGAAAACTCATGGCC GGGTCCAAGTTGTCCAGAATGC 
 
Table 16 RT-PCR cycle Program 
 Cycle n Temperature ºC 
Pre-incubation 1 95 
Amplification 34 95, 55, 72 
Melting Curve 1 72 
Cooling 1 ∞ 
 
5.8 Cell death analysis by propidium iodide incorporation and FACS 
analysis 
Supernatant were collected and cells were collected by trypsinization using a 0.05 % trypsin 
EDTA solution at RT. Cells and supernatant were combined and centrifuged for 5 min at 350 g 
at RT. Cell pellet was resuspended in 300 µL PBS containing 0.5 µL/mL propidium iodide (PI). 
Samples were analysed with the Gallios Flow Cytometer Beckman Coulter©. The 
quantification was done using the FlowJo software by gating PI positive population.  (Püschel 
and Muñoz-Pinedo, 2019) 
5.9 Preparation of conditioned medium from cancer cells 
A549 and H460 cells were treated with DMEM containing 25 mM or 0 mM glucose, 2 mM 
L-glutamine and 0 % dFBS (A549) or 2 % dFBS (H460). After 24 h, supernatants were 
collected and centrifuged for 5 min at 3000 g at 4°C to remove remaining dead cells and cell 
debris.  
1. Conditioned media of A549 cells was prepared by concentrating supernatants 5X using 
protein concentrator with a cut-off of 3 kDa by centrifugation at 3000 g. Aliquots were 
stored at -80ºC (yellow). The filtrate was kept at -80ºC likewise (blue).  
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2. Conditioned washed media was prepared by concentrating supernatants 20X, using protein 
concentrators with a cut-off of 3 kDa and centrifugation at 3000 g and 4°C. The 20X 
concentrated conditioned media was refilled with fresh dFBS- and glucose-free DMEM and 
once again concentrated 20X. Concentrated conditioned media was diluted with fresh 
dFBS- and glucose-free DMEM to a final 5X concentration of the initial volume of the 
supernatant and stored at -80ºC. 25 mM glucose (+) was added for experiments when 
indicated. 
 
Schematic representation of conditioned media preparation. 
5.10 Purification of PBMC from human blood 
Cells were purified from whole blood buffy coats. Buffy coats (ca. 10 mL) were diluted in a 
1:1 ratio in 1X PBS and layered on top of 15 mL Ficoll in a 50 mL tube. After centrifugation 
for 30 min at 750 g the layer containing PBMCs was transferred into a new 50 mL tube. Cells 
were washed twice in 50 mL 1X PBS by centrifugation at 250 g, 6 min and RT. Cells were 
resuspended in pyruvate-free DMEM containing 25 mM glucose, 0 % FBS and 2 mM 
L-glutamine. 
5.11 Purification of primary neutrophils 
Cells were purified from whole blood buffy coats. Buffy coats were diluted 1:4 in 0.9 %-NaCL 
before adding a 3 % Dextran-0.9 % NaCl solution in a ratio of 1:1. After sedimentation for 
30-40 min the upper layer, which contained the cells of interest, was centrifuged for 6 min at 
250 g without breaks and resuspended in calcium- and magnesium-free HBSS containing 
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0.25 % BSA (HBSS-BSA). The percoll gradient consisted out of a 42 % (top) layer and a 51 % 
(down) layer of a 90 %-percoll solution in HBSS-BSA. The cell suspension was layered on top 
and centrifuged for 10 min at 250 g and RT without breaks. The layer between the 51 % and 
42 % percoll gradient was removed and washed twice in HBSS-BSA at 250 g and RT for 5 min. 
Cells were resuspended in pyruvate-free DMEM containing 25 mM glucose, 0 % dFBS and 2 
mM L-glutamine. 
5.12 Differentiation of THP-1 and HL60 cells 
Undifferentiated THP-1 cells were incubated for 48 h with 100 nM Phorbol 12-Myristate 13-
Acetate (PMA) in culture media until adherent and allowed to recover for 24 h in fresh culture 
media before using differentiated THP-1 cells for experimental analysis. 
Undifferentiated HL60 cells were incubated with 1.25 % DMSO and trans-retinoic acid 
(ATRA). After 3 days cells were diluted 1:1 with fresh culture media containing 1.25 % DMSO 
and were incubated for another 4 days before using differentiated HL60 cells for experimental 
analysis. 
5.13 Chemotactic assay 
A549 and differentiated THP-1 cells (50.000 cells) were plated on top of an 8 µm Falcon® 
boyden insert (200 µl) in a 24-well plate and conditioned media (500 µl) was placed in the 
bottom chamber and cells were allowed to migrate for 20 h. For analysis boyden inserts were 
removed and washed 2 times with PBS 1X and cells, which were attached to the membrane of 
the boyden, were stained for 3 h with crystal violet. Remaining crystal violet was removed using 
a cotton swap and 5 pictures of each boyden were taken using an inverted microscope. Cells 
were counted using ImageJ and average cell number was calculated. 
PBMCs (500.000 cells) were plated on top of a 3 µm Millicell® boyden insert (200 µl) and 
indicated conditioned media (500 µl) was placed in the bottom chamber with a re-addition of 
1 % dFBS. Cells migrated for 20 h. Migrated cells were collected and centrifuged at 250 g for 
5 min at RT and were resuspended in 100 µL 1X PBS containing markers for CD56, CD3 and 
CD19, listed in Table 14. After 20 min at RT, 1 mL of PBS was added to the cell suspension 
and centrifuged for 5 min, 250 g at RT. Cells were resuspended in 300 µL PBS and analysed 
by FACS. Analysis was performed by FlowJo. 
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Table 14 Primary antibodies immune cells 
 
Neutrophils and HL60 cells (500.000 cells) were plated on top of a 3 µm Millicell® boyden 
insert (200 µl) in a 24-well plate. The bottom chamber contained the conditioned media (500 
µl) with 0 % (for neutrophils) and 2 % (for HL60 cells) dFBS. Cells migrated for 2 h and were 
counted using a Neubauer chamber. 
5.14 Statistical analysis 
The significance of the data was calculated using the two-tailed, paired Student’s T-test unless 
indicated differently. Two-way ANOVA followed by Sidak’s multiple comparison test was 
performed using Prism Graph/Pad. Error bars represent the standard error of the mean (SEM). 
The significance was indicated as following: p< 0.05 one (*) asterisk; p< 0.01 two (**) asterisk; 
p< 0.001 three (***) asterisks. N.S means not significant. 
 
 
 
Primary antibody Conjugated with Manufacture Cat. Number 
CD3 APC Becton Dickinson 345767 
CD19 PE-Cy™7 BD Pharmingen™ 552854 
CD56 AF488 BD Pharmingen 557699 
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6. Results - Part I 
6.1 Glucose deprivation induces cell death in a TRAIL receptor 1 (DR4) 
and receptor 2 (DR5) dependent manner mediated by ATF4  
Cancer cells are highly dependent on glucose and sustained low level of glucose promote cell 
death. In a tumor, environmental low glucose level emerges due to several scenarios such as 
fast tumor growth, which is associated with transient ischemia due to insufficient 
vascularization or by the application of anti-angiogenic or -metabolic drugs. The former 
prevents vessel formation and therefore the nutrient flux in the tumor and the latter prevents 
nutrient uptake or its metabolization. However, very little was known about the regulatory 
mechanisms that induce cell death upon glucose deprivation.  
Therefore, the first result chapter of this thesis examines the mechanistic pathways which 
promote cell death upon glucose deprivation in cancer cells. The experiments were performed 
in cooperation with Raffaella Iurlaro (Iurlaro, 2015) and recently published (Iurlaro, Püschel et 
al., 2017)  
 
First, we examined if HeLa cells undergo cell death in an apoptotic manner upon glucose 
deprivation. Therefore, HeLa cells were treated between 24 and 72 h with the pan-caspase 
inhibitors QVD and Z-VAD, as well as with the caspase-1 inhibitor Y-VAD in combination 
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Figure 9 Glucose deprivation induces apoptosis in HeLa cells  
A) HeLa cells were treated between 24 and 72 h with 0 mM glucose (Glc-) or Glc- in 
combination with Y-VAD (10 µM), QVD (10 µM) and Z-VAD (20 µM) and cell death was 
detected by propidium iodide (PI) incorporation and FACS analysis. Data represent mean 
SEM (n=6-8). Asterisks denote significant differences versus control cells (Glc-) for each time 
point. 
B) A representative western blot of PARP and Caspase-3 cleavage after treatment of HeLa cells 
with 25 mM (Glc+) or with 0 mM (Glc-) glucose and QVD (10 M) between 24 and 72 h is 
shown. WB was taken from doctoral thesis of Raffaella Iurlaro (Iurlaro, 2015) and (Iurlaro, 
Püschel et al., 2017) 
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with glucose deprivation. QVD and Z-VAD but not Y-VAD protected significantly from cell 
death after 48 and 72 h of glucose deprivation, indicating that cells die in an apoptotic manner 
(Figure 9A). This result was further confirmed PARP and caspase-3 cleavage after 48 and 72 h 
of glucose deprivation, which are downstream effectors of the apoptotic pathway. Moreover, 
cleavage of PARP and caspase-3 was prevented when treated in combination with QVD, see 
Figure 9B. 
Apoptosis is carried out by the intrinsic- or extrinsic-apoptotic pathway. Examination of the 
extrinsic-apoptotic pathway showed that glucose deprivation promotes the protein expression 
of the cell death receptors DR4 and DR5 respectively, in a time dependent manner, starting at 
24 h. (Figure 10A). To verify if these receptors are involved in cell death induction, DR4 and 
DR5 were silenced using siRNA (Figure 10B-C) and cell death was measured by PI 
incorporation and FACS analysis. We found that HeLa cells are significantly protected from 
cell death upon glucose deprivation when DR4 and DR5 were silenced. Double knockdown of 
DR4 and DR5 did not synergistically increase cell death protection (Figure 10D). 
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Figure 10 HeLa cells die in an DR4 and DR5 dependent manner.  
A) HeLa cells were treated between 24 and 72 h with 25 mM (Glc+) or with 0 mM (Glc-) 
glucose in the presence or absence of QVD (10 µM). A representative western of DR4 and DR5 
protein expression is shown. (L) long; (S) short. Western blot taken from doctoral thesis of 
Rafaella Iurlaro and (Iurlaro, Püschel et al., 2017) 
B-C) HeLa cells were transfected for 24 h with control siRNA (labeled as ‘’siControl’’) or with 
siRNA for DR4 (labeled as ‘‘siDR4 (1)’’) and DR5 (labeled as ‘’siDR5 (1)’’). Cells were 
treated for 48 h post transfection with 0 mM glucose. A representative western blot for DR4 
(B) and DR5 (C) knockdown is shown. 
D) HeLa cells were transfected as described in B. and treated for 48 h with 0 mM glucose. Cell 
death was measured by PI incorporation and FACS analysis. Data represent mean SEM (n=4). 
Asterisks denote significant differences versus the control siRNA. 
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Several studies before linked the induction of DR4 and DR5 to the UPR (Iurlaro and Munoz-
Pinedo, 2016). Taking this into consideration, we examined if the UPR is induced upon glucose 
deprivation in HeLa cells. Therefore, we analysed ATF4 and CHOP protein expression as 
downstream effectors of the PERK branch of the UPR. We found that ATF4 and CHOP are 
upregulated on protein level upon 24 h of glucose deprivation (Figure 11A-B). Knockdown of 
ATF4 using siRNA prevented DR5 but not DR4 protein induction upon glucose deprivation. 
Surprisingly, knockdown of CHOP did not affect DR5 protein expression as described before 
by other stimuli (Lu et al., 2014). However, DR4 protein expression was slightly regulated by  
CHOP (Figure 11A-B). 
Moreover, knocking down ATF4 with two different siRNA sequences (A#1 and A#2) 
prevented cell death induction, whereas CHOP knockdown only protected minor from cell 
death. (Figure 12A-D).  
To sum it up, we found that HeLa cells undergo cell death upon glucose deprivation in an 
apoptotic manner, which is mediated by the induction of DR4 and DR5. We also found that 
ATF4 but not CHOP regulates DR5 protein expression. These results were further confirmed 
in DR4, DR5 and CHOP deficient cells (see also Appendix (Iurlaro, Püschel et al., 2017b)) 
 
Figure 11 ATF4 but not CHOP regulates DR5 protein expression   
A, B) HeLa cells were transfected for 24 h with control siRNA (labelled as ‘’Control’’), siRNA 
for CHOP and ATF4 (labelled as ‘’ATF4#2’’ and ‘’CHOP#2’’ and treated post transfection 
for indicated times with 25 mM (+) or 0 mM (Glc-) glucose. A representative western blot of 
protein level of CHOP, DR5, DR4 and ATF4 is shown. (L) long; (S) short. (A and B are taken 
from doctoral thesis of Raffaela Iurlaro and (Iurlaro, Püschel et al., 2017) 
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Figure 12 ATF4 mediates cell death upon glucose deprivation 
A,B,C,D) Cells were transfected for 24 h with control siRNA (labelled as ‘Control’ or ‘C’) and 
with siRNA against CHOP (labelled as ‘CHOP’ or ‘C#1’ for sequence 1 and ‘‘CHOP’’ or ‘C#2’ 
for sequence 2) and against ATF4 (labelled as ‘A#1’ and ‘A#2’). Cells were treated for indicated 
times with 0 mM (Glc-) or with 25 mM (Glc+) glucose when indicated. Cell death was analysed 
by PI incorporation and FACS analysis. Data represent mean SEM (n=7). Asterisks denote 
significant differences against the control siRNA of each time point. 
C) HeLa cells were transfected as described in A. Representative western blot of ATF4 
induction upon glucose deprivation (Glc-) or in the presence of glucose (Glc+) are shown.  
D) HeLa cells were transfected as described in A. Representative western blot of CHOP 
induction after 48 h of glucose deprivation. 
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 7. Results - Part II 
7.1 Starvation and anti-metabolic drugs induce the secretion of cytokines 
and chemokines 
In the previous section we showed that cancer cells, under sustained glucose deprivation, 
undergo apoptotic cell death. However, we also hypothesized that cancer cells induce an 
adaptive response, which allows cells to regain homeostasis when exposed to nutrient stress. 
Concerning that, it is described that hypoxia, which can result among others from fast tumor 
growth and its poor vascularization, promotes the secretion of cytokines like VEGF (Forsythe 
et al., 1996). VEGF is a cytokine that induces angiogenesis and therefore promotes the re-
vascularisation of the tumor (Carmeliet, 2005). Furthermore, transient ischemia, which involves 
nutrient and oxygen deprivation, is associated with increased inflammation (Lee et al., 2000). 
This suggests that cancer cells induce cytokine release upon nutrient stress, which promote cell-
cell interaction in the tumor for survival.   
Regarding that it is not only important to understand how cells undergo cell death upon glucose 
deprivation but also how cells adapt to nutrient limitations and how this affects the overall 
survival of the tumor in order to discover suitable therapies for patients.  
Therefore, the second part of the results presented in this thesis address the question of how 
cancer cells adapt to nutrient deprivation and what are the underlying mechanisms and 
consequences for the tumor and its surrounding tissue. We specifically investigated if cancer 
cells release cytokines upon starvation and which were the functional consequences of these 
cytokines for cancer as well as for immune cells. 
7.1.1 Glucose deprivation promotes the secretion of cytokines 
In the first chapter, we demonstrated that glucose deprivation promotes cell death. Cell death 
has been linked to cytokine release and inflammation. The most prominent cell death form that 
induces inflammation is necrosis. One of the consequences of necrotic cell death is the release 
of cellular contents, which contain ´danger signals´, promoting the activation of the immune 
system (Matzinger et al., 2002). However, also apoptosis is associated with inflammation since 
dying cells, which are not immediately cleared by immune cells, release cellular contents by a 
process named ´secondary necrosis´. In this process the cell membrane becomes permeable for 
macromolecules and inflammation is triggered due to released cell contents (Kono and Rock, 
2008). This is an important defence reaction of the body against pathogens or to induce wound 
healing and tissue repair upon damage. However, not only released cellular contents promote 
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inflammation but also the release of cytokines. Regarding that it is reported that IL-8 is released 
upon TNFα treatment and Fas-ligation mediating apoptosis (Hagimoto et al., 1999). 
In our experimental settings we wanted to exclude cell death involvement in cytokine induction 
upon glucose deprivation. Therefore, cell death was analysed in several cancer cell lines from 
different origins: NSCLC adenocarcinoma cells: A549 and H1299, squamous lung carcinoma 
cells: SW900 and H520 and large cell lung cancer cells: H460. We found that none of the tested 
cell lines underwent cell death at 24 h of glucose deprivation (Figure 13A-E). Cell death 
occurred after 48 h of glucose deprivation in A549, H460, H1299, SW900 and HeLa cells. 
H520 cells did not undergo cell death up to 72 h of glucose deprivation and are therefore more 
resistance towards glucose deprivation compared to the other cell lines (Figure 13E). 
Therefore, experiments measuring cytokine release upon glucose deprivation were performed 
at 24 h to exclude cell death involvement. 
To investigate if glucose deprivation induces the release of cytokines, the Proteome Profiler 
Human XL Cytokine Array (R&D System) was performed. This array analysed 105 selected 
human cytokines simultaneously. Therefore, A549 cells were treated for 24 h with 10 % FBS 
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Figure 13 Glucose deprivation induces cell death in lung cancer cells  
A-E) Different cell lines were treated with indicated glucose concentrations and 10 % FBS at 
indicated time points. Cell death was analyzed by PI incorporation and FACS analysis. Data 
represent mean ±SEM (n=3-4). Asterisks denote significant differences between treated cells 
and the control sample in Glc+ (25 mM). 
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in the presence (25 mM) or absence (0 mM) of glucose. The supernatants of three independent 
experiments were collected, combined and analysed according to manufacturer’s instructions.  
 
We found various up- and downregulated cytokines and chemokines involved in various 
cellular processes. Amongst them, we found release of chemokines such as IL-8, 
CCL5/RANTES, CCL20 (MIP-3β) and CCL19, as well as immune cytokines including IL-6, 
IL-2, IL-11, M-CSF and CD40-ligand. Cytokines with alternative functions like LIF, VEGF or 
adiponectin were released as well (Figure 14). This confirms that not only inflammatory ones 
but also cytokines with other functions are secreted from lung cancer cells. Importantly, the 
release of some chemokines like CXCL5 and CCL2 as well as cytokines like IGFBP-2, adipsin, 
angiogenin and PDGF-AA, which have functions in insulin signaling, and angiogenesis were 
downregulated.  
These results indicate, that glucose deprivation does not only induce, but also reduce, the release 
of various cytokines with different biological functions. However, most of the released 
cytokines were identified to be pro-inflammatory. This suggests, that cytokines induced upon 
glucose deprivation may alter the immune landscape in the tumor.  
Figure 14 Proteome Profiler Human XL Cytokine Array of A549 cells  
A549 cells were treated for 24 h with dFBS-free media containing 25 (Glc+) or 0 mM (Glc-) 
glucose. Supernatants of three independent experiments were collected and combined. 
Proteome Profiler Human XL Cytokine Array Kit was performed according to manufacturer 
instructions. Mean densities of membrane spots were analysed by ImageJ and selected proteins 
are shown. Fold induction of each cytokine was calculated versus Glc+.  
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Since there is currently a major interest in inflammatory processes associated with the cancer 
metabolism and patient outcome, the further course of this project focuses on the induction and 
release of inflammatory cytokines, which are associated with immune infiltration in cancer. 
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Figure 15 Glucose deprivation induces immune cytokine and chemokine mRNA 
expression in A549 cells 
A-H) A549 cells were treated for 1, 3, 6, 16 and 24 h with media containing 25 (Glc+) or 0 mM 
(Glc-) glucose. qPCR of CXCL1 (A), CXCL2 (B), CXCL3 (C), IL-8 (D), IL-6 (E), CCL20 (F), 
CCL2 (G), LIF (H), CCL19 (I) and CXCL5 (J) and M-CSF (K) is shown. Fold expression was 
calculated by normalizing to cells treated for 6 h with Glc+. Data represent mean ±SEM 
(n=3-9). Asterisks denote significant differences versus the control samples in Glc+ of each 
time point analysed by two-way ANOVA. 
L) HeLa cells were treated for 8 or 24 h with media containing 25 (Glc+) or 2 mM (Glc-) 
glucose. qPCR for indicated genes is shown. Fold expression was calculated by normalizing to 
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the control sample Glc+ at 8 h. Data represent mean ±SEM (n=3). Asterisks denote significant 
differences between treated cells and samples treated for 8 h with Glc+. 
We validated the induction and release of some of the identified cytokines by ELISA and qPCR 
in A549 and HeLa cells. We confirmed that the mRNA of CXCL2, CXCL3, IL-8, IL-6, CCL20, 
CCL2, LIF and slightly CXCL1 was induced at short time points with a peak at 3 h upon 
glucose deprivation (Figure 15A-H). Cytokine mRNA level returned to basal level within 24 h 
with exception for CXCL2 and IL-6 (Figure 15B,E). We could not confirm an mRNA 
induction of CCL19, CXCL5 and M-CSF upon glucose deprivation in A549 cells 
(Figure15 I-K). We further confirmed mRNA induction of IL-8, IL-6, CXCL1 and TNFα in 
HeLa cells after 24 h of glucose deprivation (Figure 15L). In summary, these results prove that 
glucose deprivation induces the mRNA of inflammatory cytokines upon glucose deprivation. 
We further validated the cytokine release upon glucose deprivation from several cancer cell 
lines of different origin and carcinoma type by ELISA. A549, H460, SW900 and HeLa cells 
released IL-8 at basal level. However, IL-8 release was increased upon glucose deprivation in 
these cell lines, see Figure 16A-D. As a control for IL-8 release, we treated A549 and HeLa 
cells for 24 h with TNFα (10 ng/mL). TNFα induced approximately a 10-fold higher release of 
IL-8 in A549 cells and a 5-fold higher release in HeLa cells compared to glucose deprivation 
(Figure 16E-F).  
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Figure 16 Glucose deprivation induces IL-8 release in cancer cells 
A,E) A549 cells were treated with 25 (Glc+), 0 mM (Glc-) or with TNFα (10 ng/mL) for 24 h 
or as indicated and IL-8 release was measured by ELISA. Data represent mean ±SEM (n=3-4). 
Asterisks denote significance versus the Glc+ control sample for each time point analysed by 
two-way ANOVA. 
B-C) H460 and SW900 cells were treated with 25 mM (Glc+), 0 mM (Glc-) or 2 mM glucose 
between 16 and 48 h (as indicated) and IL-8 release was analysed by ELISA. Data represent 
mean ±SEM (n=3-4). Asterisks denote significance versus the Glc+ control sample for each 
time point analysed by two-way ANOVA.  
D,F) HeLa cells were treated as in A. or for 24 h with TNFα (10 ng/mL) and IL-8 release was 
measured by ELISA. Data represents Mean ±SEM (n=3-4). 
IL-6 was released at basal levels from H460, SW900 and HeLa cells and in accordance with 
IL-8 did glucose deprivation promote the release of IL-6 from A549, H460, SW900 and HeLa 
cells. (Figure 17A-D) 
Regarding CXCL1 we found that A549 and HeLa cells released CXCL1 at basal level, whereas 
secretion was not induced upon glucose deprivation (Figure 18A-B). HeLa cells induced TNFα 
at mRNA level, however TNFα release was not detected by ELISA in HeLa cells (Figure 18B). 
Furthermore, M-CSF and CCL20 release were induced in the protein array however its release 
was not detected by ELISA in A549 cells (Figure 18C-D). 
Figure 17 Glucose deprivation promotes IL-6 release from cancer cells 
A) A549 cells were treated with 25 mM (Glc+) or 0 mM (Glc-) glucose for indicated times and 
ELISA for IL-6 is shown. Data represent mean ±SEM (n=4). Asterisks denote significance 
versus the Glc+ control sample for each time point analysed by two-way ANOVA. 
B-D) H460, SW900 and HeLa cells were treated with 25, 2 or 0 mM glucose for 24 h and IL-6 
release was analysed by ELISA. Data represent mean ±SEM (n=3). Asterisks denote 
significance versus the 25 mM glucose control sample. Data are presented in pg/mg protein. 
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Figure 18 Glucose deprivation does not induce CXCL1, TNFα, M-CSF and CCL20 
release in tested cell lines 
A, C, D) A549 cells were treated for indicated times with 25 (Glc+) or 0 mM (Glc-) glucose 
and ELISA for CXCL1 (n=5) (A), M-CSF (n=6) (C) and CCL20 (n=2) (D) is shown. Data 
represent mean ±SEM. Data are presented in pg/mg protein. 
B) HeLa cells were treated with 25 (Glc+) or 0 (Glc-) mM glucose for 24 h and cytokine release 
was analysed by ELISA for TNFα and CXCL1. Data represent mean ±SEM (n=3-5). Data are 
presented in pg/mg protein. 
We validated cytokine release in H1299 and H520 cells. However, these cells neither released 
IL-8 nor IL-6 upon glucose deprivation in our setting (Figure 19A-D). 
Figure 19 H1299 and H520 cells do not release IL-8 and IL-6 
A-B) H1299 and H520 cell were treated with 0, 2 or 25 mM glucose for indicated time points 
and IL-8 release was measured by ELISA. Data represent mean ±SEM (n=2-3) 
C-D) H1299 and H520 cell were treated with 0, 2 or 25 mM glucose for 24 h and IL-6 release 
was measured by ELISA. Data represent mean ±SEM (n=2). 
In the secreted protein array (Figure 14), we also detected LIF secretion, which was recently 
associated with tumor progression and poor patient survival in several cancers (Pascual-García 
et al., 2019). Therefore, we validated LIF release from several cancer cell lines. We found that 
LIF was secreted in a time and dose dependent manner from the lung cancer cell lines A549, 
H460, SW900 and H1299 cells (Figure 20A-D) but not from HeLa or H520 cells. 
(Figure 20E-F) 
In conclusion, we found that glucose deprivation promotes the induction and release of IL-6, 
IL-8 and LIF at times when cell death was not induced. Within our analysis we could not find 
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a correlation between different carcinoma types (adeno- and squamous carcinoma) and 
cytokines release. Moreover, quantity and cytokine type are cell type dependent.  
Figure 20 Glucose deprivation induces LIF release in cancer cells 
A-E) Cells were treated for indicated times with 25 mM (Glc+), 2 mM or 0 mM (Glc-) glucose 
and LIF release was analysed by ELISA for A549 (A), H460 (B), SW900 (C), H1299 (D) and 
H520 (E) cells. Data represent mean ±SEM (n=4) for A549, (n=4) for H460, (n=3) for SW900, 
(n=5) for H1299 and (n=2) for H520. Asterisks denote significance versus the 25 mM glucose 
control sample of each time point. 
F) HeLa cells were treated for 24 h with Glc+ or Glc- and LIF release was analysed by ELISA. 
Data represent mean ±SEM (n=2).  
7.1.2 IL-8 but not LIF accumulates intracellular in A549 cells upon glucose 
deprivation 
In a next step, we analysed if cytokines are intracellularly stored in A549 cells under normal 
culture conditions and get released upon glucose deprivation, or if cytokines get de novo 
synthesized upon glucose deprivation. First, we analysed IL-8 and LIF protein level in the cell 
lysate and in the supernatant of A549 cells over time and at different glucose concentrations. 
We detected IL-8 in the cell lysate of A549 cells in the presence and absence of glucose, 
however the intracellular IL-8 level was higher in glucose-deprived cells (Figure 21A-B). This 
suggests, that the intracellular IL-8 level is increased in the absence of glucose. We also found 
that intracellular IL-8 level and IL-8 release increased in a dose and time dependent manner, 
meaning that lower glucose level induce higher intracellular IL-8 accumulation and release 
(Figure 21B-C).  
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Figure 21 IL-8 accumulates in the cell lysate of A549 cells upon glucose 
deprivation 
A) A549 cells were treated between 6 and 48 h with 0 mM (Glc-) or 25 mM (Glc+) glucose and 
IL-8 level in the cell lysate were analysed by ELISA. Data represent mean ±SEM (n=3). 
Asterisks denote significant differences between the control sample of each treatment. 
B) A549 cells were treated with Glc- for indicated times and IL-8 was analysed by ELISA in 
the supernatant and in the cell lysate. Data represent mean ±SEM (n=3). Asterisks denote 
significant differences between the control sample at 6 h Glc+ and each treatment. 
C) A549 cells were treated for 24 h at indicated glucose concentrations. IL-8 in cell lysate and 
supernatant was analysed by ELISA. Data represent mean ±SEM (n=3). Asterisks denote 
significant differences between the control sample (25 mM) and each condition. 
We found that LIF release is dose- and time-dependent with the highest secretion at a 
concentration of 0 mM glucose (Figure 22A-B). In contrary to IL-8, we could not detect LIF 
in the presence of glucose (25 mM) intra- or extracellularly (Figure 22A,C). LIF was only 
detectable in the cell lysate after 24 h of glucose deprivation at very low level (Figure 22C). 
Figure 22 LIF is not detectable in the cell lysate of A549 cells. 
A) A549 cells were treated for 16 and 24 h at indicated glucose concentrations and LIF release 
was analysed by ELISA. Data represent mean ±SEM (n=3). Asterisks denote significant 
differences between the sample treated with 25 mM glucose. 
B) A549 cells were treated for indicated times with glucose-free media and LIF was analysed 
by ELISA in the supernatant and the cell lysate. Data represent mean ±SEM (n=2).  
C) A549 cells were treated for 16 and 24 h with indicated doses of glucose and LIF was 
analysed in the cell lysate by ELISA. Data represent mean ±SEM (n=3).  
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7.1.3 Addition of nutrients to glucose-deprived media has differential 
impacts on cytokine release  
Glucose is not exclusively important for energy production, but it is also needed for 
glycosylation of newly synthesized proteins in the ER. Therefore, glucose deprivation leads to 
less energy production as well as to impaired glycosylation in the cell. However, depending on 
the cancer cell type, cells increase the uptake of alternative nutrients to maintain energy 
homeostasis and glycosylation upon glucose deprivation (Chaveroux et al., 2016a). Other 
nutrients include for instance amino acids, fatty acids, lactate as well as glucose derivates such 
as mannose or fructose. These nutrients can be converted into glucose or fuel glycolysis through 
alternative metabolic pathways (Sharma et al., 2014). 
Therefore, we wanted to further understand if the addition of alternative selected nutrients 
reverses the release of cytokines upon glucose deprivation. Hence, we substituted 
glucose-deprived media with nutrients, which are described to substitute for glucose at different 
stages of specific metabolic pathways. These nutrients include: Mannose (Man) and fructose 
(Fru), which fuel the glycolytic pathway, either directly or after conversion to glucose. Methyl-
pyruvate (Me-Pyr) is a mitochondrial substrate for the generation of ATP in cells. Lactate, 
which is a product of anaerobic glycolysis, was recently described to be uptaken and catabolized 
in the Krebs cycle by lung cancer cells (Faubert et al., 2017). N-Acetylglucosamine (GlcNAc), 
which is a product of the hexosamine biosynthetic pathway, can be utilized by cells for N- and 
O-glycosylation. 2-DG, an anti-metabolic drug and inhibitor of glycosylation, has been shown 
to substitute for glucose in cells in certain contexts (Giammarioli et al., 2012; Lee et al., 2018).  
We treated A549 cells for 24 h with glucose free media, which was replenished with one of the 
nutrients described above. First, we measured cell death by FACS and PI-incorporation and 
found that addition of mannose and fructose significantly protected cells from death after 48 h 
of treatment (Figure 23). This suggests, that cells use mannose and fructose to overcome 
glucose deficiency and maintain energy level. Surprisingly, addition of 2-DG slightly protected 
A549 cells from cell death, which was shown before (Lee et al., 2018). However, lactate, 
Me-Pyr and GlcNAc did not protect cells from cell death. (Figure 23) 
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Figure 23 Addition of mannose, fructose and 2-DG protects from glucose 
deprivation induced cell death 
A549 cells were treated for 48 h with indicated concentrations of glucose (Glc), mannose 
(Man), fructose (Fru), N-Acetyl-glucosamine (GlcNAc), methyl-pyruvate (Me-Pyr), lactate 
(Lac) and 2-deoxyglucose (2-DG). Cell death was analysed by PI incorporation and FACS 
analysis. Data represent mean ±SEM (n=4). Asterisks denote significant differences versus the 
0 mM glucose control sample. 
Once we analysed cell death upon addition of alternate nutrients, we also measured the mRNA 
expression of IL-8, CXCL3, CXCL2 and LIF after 6 h, as well as the cytokine release of IL-8 
and LIF after 24 h of glucose deprivation.  
CXCL2 mRNA expression was partially prevented by addition of Man, 2-DG and high doses 
of Me-Pyr (Figure 24A). In contrary, CXCL3 mRNA expression was only prevented by 
addition of high doses of Me-Pyr. Furthermore, low concentrations of 2-DG slightly increased 
and high doses slightly decreased CXCL3 mRNA level, however not significantly. These 
results suggest that cytokine mRNA induction is not regulated in the same manner for all 
cytokines and is dependent on the involvement of distinct metabolic pathways. 
IL-8 mRNA induction and release was prevented by addition of high doses of Me-Pyr to 
glucose-deprived media, similar to the mRNA of CXCL2 and CXCL3 (Figure 24A-C). 
Surprisingly, low doses of 2-DG induced IL-8 mRNA but not its release (Figure 24D). 
Moreover, IL-8 release but not mRNA induction was prevented by Man and and partially Fru. 
This data suggests, that IL-8 mRNA and protein induction are regulated differently, since the 
addition of nutrients have opposing effects on mRNA level and secretion (Figure 24C-D). 
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Regarding LIF we found that mRNA induction upon glucose deprivation was not prevented by 
the addition of any of the tested nutrients, suggesting that LIF mRNA induction is specific to 
the lack of glucose and it cannot be reversed by the addition of alternative substrates for the 
glucose metabolism (Figure 24 E). In contrary, LIF secretion was partially prevented by 
addition of Fru, lactate and high doses of Me-Pyr and completely prevented by addition of Man 
and 2-DG (Figure 24F). 
Figure 24 Mannose reduced IL-8 and LIF release upon glucose deprivation in 
A549 cells 
A,B,C,E) A549 cells were treated for 6 h with indicated concentrations of glucose (Glc), 
mannose (Man), fructose (Fru), N-Acetyl-glucosamine (GlcNAc), methyl-pyruvate (Me-Pyr), 
lactate (Lac) or 2-deoxyglucose (2-DG). qPCR for CXCL2 (A), CXCL3 (B), IL-8 (C) and LIF 
(E) is shown. Data are represented as mean ±SEM (n=3). Asterisks denote significant 
differences versus the control 0 mM glucose sample.  
(D,F) A549 cells were treated for 24 h as described in A. and ELISA for IL-8 (D) and LIF (F) 
is shown. Data are represented as mean ±SEM (n=4). Asterisks denote significant differences 
versus the control 0 mM glucose sample. 
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In conclusion, nutrient addition to glucose-deprived media did not exert the same effect on cell 
death as on cytokine release. This suggests, that these two processes are regulated by 
independent pathways. Moreover, these results demonstrate that the addition of some nutrients 
like Man or Fru can reverse the release of IL-8 and LIF upon glucose deprivation. However, 
the effects on mRNA expression and protein release do not correspond, which is possibly due 
to impaired post translational modifications. Moreover, addition of nutrients to glucose-
deprived media had distinct outcomes on specific cytokines, meaning that cytokines are not 
regulated likewise. In this sense, LIF seems to be regulated at mRNA level in a completely 
different manner compared to the other tested cytokines.  
7.1.4 Glutamine deprivation and anti-metabolic drugs induce cytokines 
The further course of this project will focus on the induction and release of IL-6, IL-8 and LIF, 
due to their importance in lung and other cancer types (Kumari et al., 2016) as well as due to 
their high mRNA induction and release upon glucose deprivation in our model. 
In the previous chapters we proved that glucose deprivation leads to the induction and release 
of cytokines that partially can be reversed by addition of intermediate nutrients of specific 
metabolic pathways. In the following chapter we investigate if glutamine deprivation or total 
starvation as well as treatment with anti-metabolic drugs such as 2-DG and metformin induces 
the same response on cytokine release as glucose deprivation.  
In a first experiment we analysed cell death and we found that none of the conditions described 
before induced cell death within 24 h (Figure 25). Therefore, A549 cells were treated for 24 h 
upon glutamine deprivation and total starvation. Total starvation was mimicked by treating cells 
with Hank’s salt balanced solution (HBSS), a saline buffer containing 5.55 mM glucose.  
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Figure 25 Cell death in A549 cells upon treatment with metabolic drugs and 
starvation 
A549 cells were treated with media containing 25 mM glucose (Glc+), 0 mM glutamine (Gln-
), Hank's Balanced Salt Solution (HBSS), 2-Deoxyglucose (2-DG) or metformin at indicated 
Results-Part II  
80 
 
time points. Cell death was analysed by PI incorporation and FACS analysis. Data represent 
mean ±SEM (n=3). 
We found that IL-6 and IL-8, but not LIF were induced (Figure 26A) and secreted 
(Figure 26B) upon glutamine deprivation. In contrary, HBSS did not induce the release of none 
of the tested cytokines, however the mRNA of IL-8 was partially induced (Figure 26A). These 
results show, that glutamine deprivation but not total starvation promotes cytokine release.  
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Figure 26 Glutamine deprivation induces IL-8 and IL-6 but not LIF mRNA 
expression and release 
A) A549 cells were incubated in 25 mM glucose (Glc+), 0 mM (Gln-) glutamine medium or 
HBSS for 6 h. mRNA expression is shown for IL-8, IL-6 and LIF analysed by qPCR. Values 
were normalized to Glc+ control of each mRNA. Data represent mean ±SEM (n=3). Asterisks 
denote significant differences versus the Glc+ sample of each cytokine. 
B) A549 cells were incubated in Glc+, Gln- medium or HBSS for 24 h. ELISA is shown for 
IL-8, IL-6 and LIF. Data indicate mean ±SEM (n=4). Asterisks denote significant differences 
versus the Glc+ control sample of each cytokine. 
Anti-metabolic drugs, that target glucose or glutamine deprivation are currently under 
investigation in the clinic. Considering that nutrient deprivation induces cytokines, we assumed 
that anti-metabolic drugs could promote the release of cytokines likewise, which could affect 
the efficiency and mode of action of these drugs. 2-DG is a glucose derivate that blocks 
glycolysis and glycosylation in the cell. As a consequence, glucose is not metabolized, and 
glycolysis and protein glycosylation are impaired.  
We found that the mRNA of IL-6 and IL-8 was induced in A549 cells upon treatment with 
2-DG (Figure 27A). Furthermore, IL-8 was release from HeLa and A549 cells but not from 
H460 cells, whereas IL-6 release was induced in all tested cell lines (Figure 27B-C). LIF was 
not induced at mRNA level in A549 cells (Figure 27A) but it was released upon 2-DG treatment 
from all tested cell lines except from HeLa cells in a dose dependent manner (Figure 27D).  
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Figure 27 2-DG induces cytokine release in cancer cells  
A) A549 cells were treated for 6 h with indicated concentrations of 2-deoxyglucose (2-DG). 
mRNA expression for IL-8, IL-6 and LIF was analysed by qPCR. Data represent mean ±SEM 
(n=3-4). Asterisks denote significant differences versus the control (0 mM) sample of each 
cytokine. Data obtained from (Jaime Redondo, Master thesis, 2018) 
B-D) HeLa, A549, H460, SW900, H1299 cells were treated for 24 h as described in A. and 
IL-8 (B), IL-6 (C) and LIF (D) release was analyzed by ELISA. Data represent mean ±SEM 
(n=3-4). Asterisks denote significant differences versus the control (0 mM) sample. 
Metformin, a diabetic drug, interferes with the mitochondria by blocking complex I of the 
respiratory chain. Recently it was shown that metformin affects the growth of lung tumors and 
it is also involved in pro-tumorigenic cytokine production (Levy and Doyen, 2018; Yaniv et al., 
2018). We found that metformin induced the mRNA of IL-8, IL-6 but not LIF in A549 cells 
(Figure 28A). IL-6 and IL-8 release was induced in A549 and H460 but not SW900 cells 
(Figure 28B-C). In contrary, LIF release was not induced by any of the tested cell lines upon 
metformin treatment (Figure 28E). 
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Figure 28 Metformin induces IL-8 and IL-6 release from cancer cells 
A) A549 cells were treated for 6 h with indicated metformin concentrations and mRNA 
expression for IL-8, IL-6 and LIF was analysed by qPCR. Data represent mean ±SEM (n=4). 
Asterisks denote significant differences versus the control (0 mM) sample of each cytokine. 
(Jaime Redondo, Master thesis, 2018) 
(B-E) A549, H460, SW900 and H1299 cells were treated for 24 h as described in A. and IL-8 
(B), IL-6 (C-D) and LIF (E) release was analysed by ELISA. Data represent mean ±SEM (n=3). 
Asterisks denote significant differences versus the control (0 mM) sample.  
To sum it up, we found that glutamine deprivation and treatment with 2-DG and metformin, 
but not total starvation, induces IL-8 and IL-6 in a cell type dependent manner. LIF in contrary, 
was only found to be induced and released upon 2-DG treatment. This suggests that LIF release 
is possibly a specific response to the glucose deprivation or impaired glycosylation, whereas 
IL-6 and IL-8 release is induced by a general interference with the cellular metabolism. 
7.2 The UPR is induced upon glucose deprivation in A549 cells 
In the first result chapter, it was described that cancer cells undergo cell death upon glucose 
deprivation in an UPR dependent manner. However, the UPR is described to be primary a pro-
survival response in order to adapt to extra- or intracellular stresses. In this context, it is 
described that the UPR is induced upon glucose deprivation in cancer cells as that this response 
is involved in cytokine induction upon several stimuli (Iwasaki et al., 2014; Logue et al., 2018; 
Zhang et al., 2013a; Zhu et al., 2017). Therefore, we hypothesized that the UPR is involved in 
cytokine induction upon glucose deprivation in our model. 
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In the first result chapter we found that ATF4 and CHOP are induced upon glucose deprivation 
in HeLa cells. Since the following experiments were performed in A549 cells, we first validated 
if the three branches of the UPR are induced upon glucose deprivation.  
To investigate if the ATF6 arm of the UPR is activated, cells were transfected with an 
ATF6-Flag plasmid and ATF6 cleavage was detected between 6 and 16 h by western blot upon 
glucose deprivation. As a control, cells were treated for 24 h with Dithiothreitol (DTT), a known 
UPR inducer (Figure 29A).  
IRE1 endoribonuclease activity was validated by XBP1 splicing and analysed by PCR. XBP1 
splicing was detected between 3 and 48 h of glucose deprivation (Figure 29B). As a control, 
cells were treated for 24 h with thapsigargin (Tg), a known UPR inducer. This result was further 
validated by qPCR, showing increased XBP1s mRNA level upon 6 h of glucose deprivation 
(Figure 29C). Furthermore, we also showed an induction of IRE1 but not ATF6 at mRNA level 
(Figure 29C-D). RIDD activity was analysed by transfecting A549 cells with a plasmid 
expressing a cytoplasmatic-defective IRE1 mutant (dominant-negative (DN)) (Drogat et al., 
2007; Nguyen et al., 2004) as well as with a plasmid expressing the truncated IRE1 mutant 
variant (*Q780). *Q780 is one of the described somatic mutation (Greenman et al., 2007) in 
the cytosolic domain of IRE1 (Lhomond et al., 2018). Cells were pre-treated for 2 h with 
actinomycin, which blocks gene transcription and afterwards incubated in media without 
glucose. SPARC1 is a known RIDD target (Dejeans et al., 2012) and its mRNA was degraded 
upon treatment with glucose deprivation between 2 and 6 h (WT). However, mRNA 
degradation was prevented when cells were previously transfected with the plasmid expressing 
the DN or mutated *Q780 form of IRE1 (Figure 29E). This proves that glucose deprivation 
promotes RIDD activity in these cells.  
To sum it up, we proved that the ATF6 branch and the IRE1 endoribonuclease activity is fully 
functional in A549 cells upon glucose deprivation.  
Activation of the PERK arm of the UPR was shown by ATF4 and CHOP induction at mRNA 
and protein level starting at 3 h of glucose deprivation (Figure 29F-I). As a control, cells were 
treated for 24 h with Tg. 
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Figure 29 Glucose deprivation activates the UPR in A549 cells  
A) A549 cells were transfected for 24 h with an ATF6-Flag overexpressing plasmid and treated 
for indicated times with 25 mM (+), 0 mM (-) or 1 mM Dithiothreitol (DTT). Representative 
western blot for Flag is shown. UT: not transfected. 
B) A549 cells were treated with 25 mM Glc+ (C), 0 mM (Glc-) or with Tg for indicated times 
and lysed for mRNA extraction. Retro-transcription was performed followed by RT-PCR for 
XBP1. Tg: Thapsigargin (4 µM, 24 h); XBP1u (unspliced) and XBP1s (spliced). 
Representative PCR is shown out of (n=3).  
C) A549 cells were treated for 6 h with Glc+ or Glc- and qPCR analysis for XBP1, XBP1s and 
ATF6 is shown. Data represent mean ±SEM (n=4). Asterisks denote significant differences 
versus the Glc+ control sample. 
(D,F-G) A549 cells were treated as described in C. for indicated times and IRE1 (D), ATF4 (F) 
and CHOP (G) mRNA was analysed by qPCR. Values were normalized versus the 6 h Glc+ 
sample.  
E) A549 cells were transfected for 24 h with plasmids expressing mutated forms of IRE1 
(*Q780, DN) or an empty plasmid (WT). Cells were pretreated for 2 h with actinomycin before 
being incubated in glucose free media for 2, 4 and 6 h. mRNA was extracted and qPCR for 
SPARC1 was performed. Values were normalized versus the control sample time=0 of each 
treatment. 
H-I) A549 cells were treated for indicated time points with Glc+ (labelled as ‘C’), 0 mM (Glc-
) or for 24 h with 4 µM Tg. A representative western blot (n=3) for ATF4 and CHOP is shown. 
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7.2.1 ATF4 mediates IL-8 and IL-6 but not LIF cytokine release  
Some reports demonstrate that the PERK and IRE1 branch of the UPR are involved in cytokine 
release in breast cancer cells and monocytes (Logue et al., 2018; Zhang et al., 2013b). ATF4 
and CHOP as well as the IRE1 arm of the UPR were induced at short time points (3 h) upon 
glucose deprivation, which is in accordance with the cytokine mRNA expression. Therefore, 
we hypothesised that the UPR is involved in cytokine induction. We first investigated if ATF4 
as one of the transcription factors of the PERK branch of the UPR, is involved in the cytokine 
induction upon glucose deprivation.  
Figure 30 ATF4 regulates cytokine mRNA induction  
A-F) A549 cells were transfected for 40 h with non-targeting siRNA (labelled as ‘Control 
siRNA’) or with siRNA against ATF4 (labeled as ‘A#1’ for sequence 1 or ‘A#2’ for sequence 
2) which were treated post transfection for 6 h with media containing 0 mM or 25 mM glucose. 
mRNA expression was analysed by qPCR for CTGF (A), CXCL3 (B), CCL20 (C), CXCL1 
(D), CXCL2 (E) and CCL19 (F). Data are represented as mean ±SEM (n=3-4) Asterisks denote 
significant differences of ATF4-transfected cells versus the control siRNA in each culture 
medium. 
First, we silenced ATF4 using siRNA and analysed the mRNA expression of several cytokines, 
which we proved before to be induced upon glucose deprivation (Figure 15). CTGF, CXCL3, 
CCL20 and CXCL2 (Figure 30A-D) are partially induced by ATF4, whereas CXCL1 and 
CCL19 mRNA was not regulated by ATF4 upon glucose deprivation (Figure 30D-F).  
We further confirmed, that knockdown of ATF4 in HeLa cells (Figure 31A) lead to a reduction 
in IL-8, IL-6 and CXCL1 mRNA expression (Figure 31B-D). 
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Figure 31 ATF4 mediates cytokine induction upon glucose deprivation in HeLa cells 
A) HeLa cells were transfected for 24 h with non-targeting siRNA (labelled as ‘’C" for Control 
siRNA) or siRNA against ATF4 (labelled "A#1" for ATF4 sequence 1). After 24 h cells were 
washed and incubated in 25 (Glc+) or 2 mM (Glc-) glucose. A representative western blot of 
ATF4 is shown.  
B-D). HeLa cells were transfected and treated (24 h) as in A. qPCR for IL-8 (B), IL-6 (C) and 
CXCL1 (D) is shown. Data represent mean ± SEM (n=3). Fold expression was calculated by 
normalizing to the control siRNA in Glc+ conditions or to time=0 (before treatment). Asterisks 
denote significant differences of ATF4-transfected cells versus the control siRNA in each 
culture medium. 
Furthermore, these results were confirmed in A549 cells by silencing ATF4 with two siRNA 
sequences (A#1 and A#2), as shown in Figure 32A, which reduced IL-8 (Figure 32B-C) and 
IL-6 mRNA induction and secretion (Figure 32D-E). However, LIF mRNA expression and 
secretion was not altered (Figure 32F-G), suggesting that ATF4 is not regulating LIF mRNA 
induction or release. 
Figure 32 ATF4 mediates IL-8 and IL-6 but not LIF release 
A) A representative western blot for ATF4 of A549 cells transfected for 40 h with non-targeting 
siRNA (labelled as “C" for Control siRNA) or siRNA against ATF4 (labelled as ‘A#1’ for 
sequence 1 or ‘A#2’ for sequence 2) is shown, which were treated for 24 h with media 
containing 0 mM glucose (Glc-) or  with thapsigargin (4 µM).  
B-G) A549 cells were transfected as described in A. and treated with 25 mM (Glc+) or 0 mM 
(Glc-) glucose for 6 h (B, D, E) or 24 h (C, E, G). qPCR data for CXCL8 (B), IL-6 (D) and LIF 
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(F) were normalized to the control siRNA of Glc+. ELISA is shown for IL-8 (C), IL-6 (E) and 
LIF (G). Data represent mean ±SEM (n=3-5). Asterisks denote significant differences of ATF4-
transfected cells versus the control siRNA in each culture medium.  
In order to investigate which other chemokines are regulated by ATF4, we performed a 
chemokine antibody array, which analyses the secretion of 31 know chemokines. Therefore, 
A549 cells were transfected with control siRNA and siRNA against ATF4 (sequence#1) and 
treated for 24 h in the presence or absence of glucose.  
We found that ATF4 regulated the release of CXCL5 in the presence and absence of glucose in 
this array even the overall release was lower in Glc- than in the presence of glucose 
(Figure 33A-B). We validated these results by qPCR and ELISA and fond that ATF4 regulated 
CXCL5 at mRNA level but not its release (Figure 33C-D). Surprisingly, CCL2 which is a 
chemokine involved in macrophage attraction, is highly secreted at basal levels from A549 
cells, whereas its release was prevented upon glucose deprivation in this array. Surprisingly, 
ATF4 knockdown reversed CCL2 release slightly (Figure 33B). We validated CCL2 mRNA 
expression by qPCR and found that silencing of ATF4 indeed promoted CCL2 mRNA 
induction upon glucose deprivation (Figure 33E). IL-8 release, as proved earlier 
(Figure 32B-C), was regulated by ATF4 in this array (Figure 33B). 
In conclusion we found, that ATF4 is involved in the cytokine regulation upon glucose 
deprivation, however in a cytokine specific manner. With focus on IL-8, IL-6 and LIF we found 
that IL-6 and IL-8 but not LIF are positively regulated by ATF4. 
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Figure 33 ATF4 regulates CXCL5 positively and CCL2 negatively at mRNA 
level. 
A) A549 cells were transfected for 40 h with non-targeting siRNA (labelled as ‘Control siRNA’ 
or C) or with siRNA against ATF4 (labelled as ‘ATF4 siRNA#1’ for sequence 1). Cells were 
treated post transfection for 24 h with media containing 0 mM or 25 mM glucose. Supernatants 
of three independent experiments were collected and combined. Human Chemokine Antibody 
Array was performed according to manufactures instructions. Membranes are shown. 
B) Mean densities of membranes spots in A. were quantified by ImageJ.  
C, E). A549 cells were transfected and treated as in A. and mRNA expression was analysed by 
qPCR after 6 h for CXCL5 (C) and CCL2 (E). Data represent mean ±SEM (n=3-4). Asterisks 
denote significant differences of ATF4-transfected cells versus the control siRNA of each 
culture medium.  
(D) A549 cells were treated and transfected as described in A. and ELISA for CXCL5 is shown. 
Data represent mean ±SEM (n=3). Asterisks denote significant differences of ATF4-transfected 
cells versus the control siRNA in each culture medium. 
7.2.2 The IRE1 branch of the UPR is not involved in IL-8 and LIF 
induction upon glucose deprivation  
Focusing on the IRE1 branch of the UPR, we found that the Inhibitor of the IRE1 RNase activity 
(MKC-8866) reduced XBP1s mRNA level, however it did not regulate the mRNA of IL-8 and 
LIF (Figure 34A). Furthermore, knockdown of IRE1 did not change IL-8 and LIF mRNA 
expression. However, it must be considered that IRE1 knockdown was not very efficient in this 
cell line. (Figure 34B-D) Furthermore, IL-8 but not LIF release was only minorly reduced (not 
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significant) (Figure 34E-F). Therefore, we performed further experiments silencing XBP1, 
which is spliced by IRE1 and functions as a transcription factor of the UPR. 
Figure 34 IRE1 is not involved in IL-8 and LIF regulation upon glucose 
deprivation 
A) A549 cells were pre-treated with the IRE-1 inhibitor MKC-8866 (MKC, 10 μM) for 16 h 
and for another 6 h in combination with media containing 25 mM (Glc+) or 0 mM (Glc-) 
glucose. XBP1s, IL-8 and LIF mRNA was analysed by qPCR. Values are normalized to the 
Glc+ control sample. Data show mean ±SEM (n=3). 
B-D) A549 cells were transfected for 24 h with non-targeting control siRNA (labeled as ‘C’) 
or siRNA for IRE1. qPCR for IRE1 (B), IL-8 (C) and LIF (D) after 6 h treatment with either 
25 mM (Glc+) or 0 mM (Glc-) glucose is shown. Values were normalized to the control siRNA 
in Glc+. Data represent mean ±SEM (n=4). Asterisks denote significant differences of IRE1-
transfected cells versus the control siRNA in each culture medium.  
E-F) A549 cells were transfected and treated for 24 h as described in B. ELISA for IL-8 (E) 
and LIF (F) is shown. Data represent mean ±SEM (n=3). 
Silencing of XBP1 with two siRNA sequences (X#1 and X#2) lead to a reduction of the mRNA 
of XBP1s and Erdj4, which is a known downstream target of XBP1s (Figure 35A-B). However, 
the two sequences had inconsistent effects on Herpud1, which is another known downstream 
target of XBP1s (Figure 35C). We found a similar inconsistent regulation of the two siRNA 
sequences on the mRNA and release of IL-8 and LIF. X#1 reduced IL-8 mRNA and protein 
expression, whereas X#2 had no significant effect on IL-8 induction and release (Figure 35D-
E). Regarding LIF, X#1 induced LIF release, whereas X#2 had controversial effects on mRNA 
and protein release of LIF (Figure 35F-G).  
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To sum it up, our results regarding the role of XBP1 in the induction of cytokines are 
controversial and depending on the siRNA sequence. However, since IRE1 knockdown and its 
RNase inhibitor MKC-8866 did not regulate IL-8 and LIF, neither at mRNA nor at protein 
level, we conclude that the IRE1 arm of the UPR is not involved in cytokines induction.  
 
Figure 35 XBP1 does not regulate IL-8 and LIF upon glucose deprivation 
A-D,F) A549 cells were transfected for 40 h with non-targeting control siRNA (labeled as ‘C’) 
or siRNA for XBP1 (labeled as X#1 for sequence 1and X#2 for sequence 2). Cells were treated 
for 6 h as described in B. and qPCR for XBP1s (A), Erdj4 (B), Herpud1 (C) and IL-8 (D) and 
LIF (F) is shown. Values were normalized to the control siRNA in Glc+. Data represent mean 
±SEM (n=3) for X#1 and (n=4) for X#2. Asterisks denote significant differences of XBP1 
transfected cells versus the control siRNA in each culture medium. 
E,G) A549 cells were transfected as described in A and treated for 24 h with 25 mM (Glc+) or 
0 mM (Glc-). ELISA for IL-8 (E) and LIF (G) is shown. Data represent mean ±SEM (n=3-4). 
Asterisks denote significant differences of XBP1 transfected cells versus the control siRNA in 
each culture medium. 
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7.2.3 ATF6 does not regulate IL-8 induction upon glucose deprivation 
Silencing of ATF6, using siRNA in A549 cells, induced IL-8 and LIF mRNA expression. 
(Figure 36A-C) However, LIF but not IL-8 release is slightly decreased upon ATF6 
knockdown, see Figure 36D-E. Therefore, we conclude that the ATF6 branch of the UPR could 
possibly be involved in the regulation of LIF but not IL-8 upon glucose deprivation. 
Figure 36 ATF6 does not regulate IL-8 upon glucose deprivation 
A-C) A549 cells were transfected for 24 h with non-targeting control siRNA (labelled as ‘C’) 
or siRNA for ATF6. Cells were treated for 6 h with 25 mM (Glc+) or 0 mM (Glc-) glucose and 
qPCR for ATF6 (A), IL-8 (B) and LIF (C) is shown. Data represent mean ±SEM (n=4). 
Asterisks denote significant differences of ATF6-transfected cells versus the control siRNA in 
each culture medium. 
D-E) A549 cells were transfected as in A. and treated with 25 mM (Glc+) or 0 mM (Glc-) 
glucose for 24 h. ELISA for LIF8 (D) and IL-8 (E) are shown. Data represent mean ±SEM 
(n=3). Asterisks denote significant differences of ATF6-transfected cells versus the control 
siRNA in each culture medium. 
We conclude that the IRE1 branch of the UPR is not involved in cytokine induction in our 
model. The ATF6 branch possibly plays a minor role in LIF release. Nevertheless, we proved 
that ATF4 is involved in cytokine induction and release upon glucose deprivation since most 
of the tested cytokines are positively regulated by ATF4.  
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7.2.4 PERK induces LIF release upon glucose deprivation 
ATF4 is induced by the ISR, which is mediated by one of the four kinases PERK, GCN2, PKR 
and HRI. To further test if PERK is involved in cytokine induction, we inhibited PERK with 
two known chemical inhibitors GSK2656157 (GSK) and AMG PERK 44. Both inhibitors lead 
to a partially decreased in ATF4 protein expression (Figure 37A-B).  
Regarding IL-8, the inhibitor GSK2656157 had no effect on IL-8 release (Figure 37C), 
however the inhibitor AMG PERK 44 induced IL-8 release in glucose repleted and depleted 
conditions, see Figure 37D.  
In case of LIF, both inhibitors decreased its release upon glucose deprivation (Figure 37E-F). 
Since we could not show a regulation of LIF by ATF4, this result suggests an ATF4-
independent but PERK-dependent regulation of LIF release. 
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Figure 37 The PERK- Inhibitor GSK2656157 and AMG PERK 44 prevent LIF 
but not IL-8 release upon glucose deprivation  
A) A549 cells were treated for 1 h with GSK2656157 (GSK) at indicated concentrations. 
Afterwards cells were washed and treated with media containing 25 mM (Glc+) or 0 mM (Glc-
) glucose in combination with GSK2656157 at indicated concentrations for 24 h. A 
representative western blot of ATF4 and CHOP is shown (n=3).  
B) A549 cells were treated for 24 h with indicated concentrations of AMG PERK 44 (AMG). 
Western blot of ATF4 and CHOP is shown (n=1).  
C,E) A549 cells were treated as described in A. and cytokine level were measured by ELISA 
for IL-8 (C) and LIF (E) are shown. Data represent mean ±SEM (n=4). Asterisks denote 
significant differences between the control sample of each condition. 
D, F) A549 cells were treated as described in B. and cytokine level measured by ELISA of IL-8 
(D) and LIF (F) are shown. Data represent mean ±SEM of IL-8 (n=4) and LIF (n=3). Asterisks 
denote significant differences between the control sample of each condition. 
Results-Part II 
93 
 
Activation of the ISR results in the phosphorylation of eIF2α, which subsequently leads to the 
specific translation of ATF4. The eIF2α inhibitor ISRIB reverses the effects of eIF2α 
phosphorylation.  
We treated A549 cells, in the presence or absence of glucose in combination with ISRIB for 
24 h and analysed IL-8, IL-6 and LIF release. We found a slight increase in IL-8 release in the 
absence of glucose (Figure 38A), similar to treatment with the AMG PERK 44 inhibitor.  IL-
6 release was not changed upon treatment with ISRIB, as shown in Figure 38B. However, LIF 
release was slightly decreased, which is in coherence with the results of the tested PERK 
inhibitors (Figure 38C).  
Figure 38 ISRIB partially prevents LIF release upon glucose deprivation  
A-C) A549 cells were treated for 24 h with indicated concentrations of ISRIB. ELISA for IL-8 
(A), IL-6 (B) and LIF (C) is shown. Data represent mean ±SEM (n=3). Asterisks denote 
significant differences between the control sample of each condition. 
Altogether, the involvement of PERK in the induction of IL-8 remains unclear since results 
upon treatment with the PERK-inhibitors GSK2656157 and AMG PERK44 remained 
controversial. However, LIF release was partially prevented upon treatment with GSK2656157, 
AMG PERK44 as well as with ISRIB, which suggests a PERK-dependent but ATF4-
independent regulation of LIF. 
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7.3 mTOR signaling is involved in IL-8 but not LIF induction 
The mTOR pathway is the major regulator of protein synthesis and reported to be inactivated 
upon glucose deprivation in an AMPK dependent manner (Gwinn et al., 2008). This allows 
cells to reduce their energy needs based on decreased protein synthesis. We proved that glucose 
deprivation results in mTOR inactivation in A549 cells as shown by pS6 and 4EBP-1 
dephosphorylation (Figure 39). However, in our model multiple repetitions of this experiment 
indicated that AMPK was not phosphorylated upon glucose deprivation in these cells, which 
lack LKB1 expression. As shown in Figure 39, AMPK phosphorylation was lower in cells 
treated without glucose compared to cells grown with glucose. This suggests that mTOR 
inactivation is facilitated in an AMPK-independent manner.  
Previous reports describe an involvement of mTOR inactivation in IL-8 secretion upon 
glutamine deprivation (Shanware et al., 2014). To examine if mTOR inactivation participates 
in cytokine induction in our model, we used two mTOR inhibitor: rapamycin, which blocks 
mTORC1, and Torin1, which blocks mTORC1 and 2. As shown in Figure 40A-B, both 
inhibitors prevent mTOR signaling as shown by dephosphorylation of S6 and 4EBP-1.  
We found that Torin1 but not rapamycin induced IL-8 release in the presence of glucose, 
suggesting that inhibition of both mTOR complexes is essential to promote IL-8 secretion. 
However, treatment with rapamycin and Torin1 in the absence of glucose reduced IL-8 release 
(Figure 40C-D). LIF release was not induced by the two inhibitors in the presence of glucose; 
however, treatment with rapamycin in the absence of glucose slightly reduces LIF release, 
suggesting that mTORC1 is partially involved in LIF release (Figure 40E-F). 
Figure 39 Glucose deprivation inactivates mTOR upon glucose deprivation  
 A549 cells were treated for indicated times with 25 mM (Glc+) or 0 mM (Glc-) glucose. A representative 
western blot is shown for pAMPK, pS6 and 4EBP-1 (n=2) 
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In a nutshell, we found that mTOR inactivation using Torin1 slightly promoted IL-8 but not 
LIF release in the presence of glucose. However, co-treatment of cells with the two mTOR 
inhibitor in the absence of glucose partially prevented IL-8 release. This suggests that upon 
glucose deprivation some mTOR activity remains active that is sufficient to promote IL-8 
release. However, complete inhibition of mTOR signalling by using inhibitors in the absence 
of glucose prevented cytokine release.  
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Figure 40 mTOR partially participates in cytokine release  
A) A549 cells were treated for 24 h with 10 or 100 nM of rapamycin (Rapa) in the presence of 
25 mM (Glc+) or 0 mM (Glc-) glucose. A representative western blot of pS6 and 4EBP-1 is 
shown.  
B) Cells were treated for 24 h with 0.1 or 1 μM Torin1 in the presence of 25 mM (Glc+) or 
0 mM (Glc-) glucose. A representative western blot for pS6 and 4EBP-1 is shown (n=3). 
C-D) A549 cells were treated with rapamycin and Torin1 as described in A and B and IL-8 
release was analysed by ELISA. Data represent mean ±SEM of rapamycin (n=3) and Torin1 
(n=4-5). Asterisks denote significant differences between the control sample of each condition. 
E-F) A549 cells were treated as described in A and B and LIF release was analysed by ELISA. 
Data represent mean ±SEM of rapamycin (n=2) and Torin1 (n=3). Asterisks denote significant 
differences between the control sample of each condition. 
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7.4 The transcription factor p65 mediates IL-8 and IL-6 induction upon 
glucose deprivation 
The NF-κB pathway is known as a major inducer of pro-inflammatory cytokines in several 
settings. The canonical pathway can be induced by several mechanism including among others 
TLRs, cell death receptors or pathogen infection. Moreover, several reports indicate that the 
UPR promotes NF-κB induction (Schmitz et al., 2018). Therefore, we hypothesized that the 
NF-κB pathway, with its major transcription factor p65, is involved in cytokine induction and 
release upon glucose deprivation.  
To prove this, we silenced p65, using siRNA (Figure 41A), and we found that p65 significantly 
reduced CXCL1, IL-6 and IL-8 mRNA expression in HeLa cells (Figure 41B-D).  
 
Moreover, silencing of p65 with two siRNA sequences (p#1 and p#2) in A549 cells 
(Figure 42A) lead to a reduction in IL-8 and IL-6 mRNA expression and release upon glucose 
deprivation (Figure 42B-E). We also confirmed the mRNA regulation by p65 of M-CSF, 
CXCL1 and CXCL2 and CCL20 (Figure 42H-K). However, cytokines like CXCL3, CXCL5 
and CTGF are not regulated by p65 at mRNA level in A549 cells (Figure 42L-N). LIF mRNA 
expression was only reduced with the first siRNA sequence, however none of the two siRNA 
sequences reduced LIF release. (Figure 42F-G) 
Focusing on IL-8, IL-6 and LIF, these results prove that p65 is involved in the mRNA 
expression and protein release of IL-8 and IL-6 but not LIF, in our model.  
Figure 41 p65 regulates cytokine mRNA expression in HeLa cells 
A) HeLa cells were transfected for 24 h with siRNA for p65 (labelled as p#1 for sequence 1) 
and treated for 24 h with 25 mM (Glc+) or 0 mM (Glc-) glucose. A representative western blot 
for p65 is shown. 
B-D) HeLa cells were transfected and treated for 6 h as described in A. qPCR for CXCL1 (B), 
IL-6 (C) and IL-8 (D). Values are normalized versus the control siRNA in Glc+. Results show 
mean ±SEM (n=4) experiments. Asterisks denote significant differences of p65-transfected 
cells versus the control siRNA in each culture medium. 
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Figure 42 p65 regulates IL-8 and IL-6 but not LIF upon glucose deprivation  
A) A549 cells were transfected for 40 h with control non-targeting siRNA (labelled as ‘’C’’) 
and siRNA for p65 (labelled as ‘’p#1’’ for sequence 1 and ‘’p#2’’ for sequence 2). A 
representative western blot of p65 is shown in A. Cells were subsequently treated for 6 h 
(panels B, C, F, H-N) or for 24 h (panels D, E, G and O) with media containing 25 mM (Glc+) 
or 0 mM (Glc-) glucose. qPCR for IL-8 (B), IL-6 (C), LIF (F), MCS-F (H), CXCL1 (I), 
CXCL2 (J), CCL20 (K), CXCL3 (L), CXCL5 (M) and CTGF (N) is shown. Values were 
normalized versus control siRNA in Glc+. IL-8 (D), IL-6 (E), LIF (G) and CXCL5 (O) release 
was analyzed by ELISA after treating cells for 24 h. Results show mean ±SEM (n=3-4). 
Asterisks denote significant differences of p65-transfected cells versus the control siRNA in 
each culture medium.  
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7.5 Functional effects of conditioned media from A549 cells on cancer and 
immune cells 
Tumors are heterogenic and not only composed of cancer cells but also of others such as 
fibroblasts and immune cells. These cells interact continuously via cell-cell interactions within 
the tumor environment. Moreover, the tumor environment is also marked by hostile regions 
with, for instance, high acidity as well as oxygen and nutrient shortage, which results from fast 
tumor growth and poor vascularization. Tumor cells developed adaptive mechanisms in order 
to cope with these environments and maintain tumor progression. Many reports describe that 
cancer cells acquire features that allow them to modify the activity of surrounding cells. For 
instance, cancer cells which lack oxygen secrete cytokines like VEGF that promotes the 
revascularization of the tumor. Moreover, cancer cells also secrete metabolites or exosomes, in 
order to communicate with other cells in the surrounding tissue. But most interestingly, cancer 
cells are able to modify the activity of tumor resident immune cells through the secretion of 
specific immune modulating proteins or metabolites derived from their altered metabolism. 
(O’Sullivan et al., 2019; Wellenstein and De Visser, 2018) 
Keeping this in mind, we proved that cancer cells release cytokines in an environment low in 
nutrients. These released cytokines could promote cell-cell responses between cancer and 
immune cells, favouring tumor progression. To further analyse which possible functions these 
cytokines have in a tumor setting, we analysed cell death and chemotaxis of cancer cells and of 
different immune cell populations, when treated with conditioned media of starved cancer cells.  
For the performance of the following experiments we generated supernatants from A549 cells 
which were treated for 24 h in the presence or absence of glucose and without dFBS. These 
supernatants were concentrated five times and will be designated as ‘conditioned media’ 
(presented with yellow bars) in the further course of this thesis.  
Furthermore, from the supernatant derived from A549 cells, we also generated as second 
fraction, which was washed once with fresh glucose-free media using protein concentrators 
with a permeable membrane (cut-off 3 kDa). This process allowed us to remove metabolites or 
other ´waste products´ of the cell. This fraction only contains the secreted proteins with a size 
≥3 kDa. This fraction will be designated as ´washed conditioned media´ and is presented in 
orange bars in the figures.  
Moreover, when concentrating the supernatants, we also kept the filtrate, which is the 
‘exhausted’ media of the cells, which does not contain proteins but secreted metabolites or other 
waste products of the cell. This fraction is presented in blue bars in the figures. 
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To sum it up, we generated three fractions: The full conditioned media containing secreted 
proteins and waste products (yellow), the washed conditioned media containing only secreted 
proteins (orange) and the filtrate containing only the waste products (blue) of the cell. (see also 
material and methods)  
The following experiments were performed using the three fractions of the conditioned media 
of A549 cells to distinguish between effects of secreted protein, as well as of possible effects 
of secreted metabolites. The detailed preparation is described in chapter 5.9 and shown in 
Figure 43. 
 
  
Figure 43 Scheme for preparation of conditioned media of A549 cells  
1. Cells were treated for 24 h with 25 mM (Glc+) or 0 mM (Glc-) glucose and without dFBS. 
Supernatant (yellow) was 5X concentrated using protein concentrators (cut-off 3 µM) and 
concentrated conditioned media (yellow) and filtrate (blue) was stored.  
2. Supernatant was 20X concentrated and diluted with fresh Glc- medium (orange). Media was 
concentrated again 20X and diluted with fresh Glc- media to a final 5X concentration. For 
experiments, 25 mM glucose was supplemented when indicated. 
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7.5.1 Effects of conditioned media of starved A549 cells on cell death  
First, we investigated the effects of the conditioned media of A549 cells on cell death of other 
A549 cells. Therefore, A549 cells were plated the day before and treated with regular media 
and the three fractions of the conditioned media as described before. Cells undergo cell death 
after 48 h of glucose deprivation when treated with regular glucose free media. There was no 
change in cell death observed when cells were treated with the conditioned media of other 
starved A549 cells (Figure 44A, yellow bars). However, the washed conditioned media, which 
only contained the secreted proteins from glucose-deprived cells (orange bars), slightly 
increased cell death in the absence of glucose (Figure 44B). This suggests that secreted proteins 
from starved A549 cells slightly promote cell death of other A549 cells upon glucose 
deprivation.  
Figure 44 Secreted proteins from starved A549 cells slightly increase cell death upon 
glucose deprivation 
A-B) A549 cells were treated for 48 h with fresh media (white bars) containing 25 mM (+) or 
0 mM (-) glucose or with conditioned media (yellow bars) from other A549 cells. (-/+) 
indicates that 25 mM glucose was added to conditioned media of starved A549 cells. The 
washed conditioned media (orange bars) was substituted with glucose (+) when indicated. Cell 
death was analyzed by PI staining and FACS analysis. Data represent mean ±SEM (n=3) for 
A. and (n=5) for B. Asterisks denote significant differences between Glc- media (white bar) 
and washed conditioned media (orange). 
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To examine weather IL-8 or LIF are mediators of cell death induction, we treated cells with 
recombinant IL-8 or LIF in the presence or absence of glucose. However, neither recombinant 
IL-8 (Figure 45A) nor LIF (Figure 45B) induced cell death. This suggests that extracellular 
IL-8 or LIF does not promote cell death in our model.  
However, the impact of cytokines on cell death could be mediated intracellularly. Therefore, 
A549 cells were transfected with three different sequences of siRNA for IL-8. IL-8 mRNA 
expression and release was reduced upon glucose deprivation when transfected with siRNA 
(Figure 46A-B). Cells were treated for 48 h post transfection in the presence or absence of 
glucose. We observed that two out of three IL-8 siRNA sequences partially protected from cell 
death, as shown in Figure 46C. Furthermore, we knocked down LIF with one siRNA sequence 
and mRNA as well as LIF release was reduced (Figure 46D-E). However, we did not detect an 
effect on cell death upon LIF knockdown (Figure 46F).  
Previously, we described that cancer cells die upon glucose deprivation in an DR5-dependent 
manner. Here, we found that DR5 mRNA expression was slightly decreased upon IL-8 
knockdown (Figure 46G). This could suggest that IL-8 promotes cell death in a DR5-dependent 
manner, however more tests including the analysis of DR5 protein level upon IL-8 knockdown, 
have to be performed. 
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Figure 45 Recombinant IL-8 or LIF do not induce cell death  
A) A549 cells were treated with media containing 25 mM (Glc+) or 0 mM (Glc-) glucose for 
48 h. IL-8 (10 ng/mL) or LIF (10 ng/mL) were added when indicated. Data represent mean 
±SEM IL-8 (n=4) and LIF (n=2).  
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Figure 46 Knockdown of IL-8 protects from cell death upon glucose deprivation  
A, D, G) A549 cells were transfected for 40 h with a non-targeting control siRNA (labelled as 
‘C’) or with siRNA for IL-8 (labelled as IL8#1 for sequence 1, IL8#2 for sequence 2 or IL8#3 
for sequence 3) and for LIF (labelled as LIF#1 for sequence 1). Cells were treated for 6 h with 
media containing 0 mM (Glc-) glucose and mRNA for IL-8 (A), LIF (D) and DR5 (G) was 
analysed by qPCR. Data represent ±SEM (n=3) for IL8#1, (n=3) for IL8#2 and (n=3) for LIF#1. 
Asterisks denote significant differences between the non-targeted siRNA and the targeted 
siRNA in Glc- 
B, E) A549 cells were transfected as in A. and treated for 24 h with media containing 25 mM 
(Glc+) or 0 mM (Glc-) and ELISA for IL-8 (B) and LIF (E) was performed. Data represent 
±SEM (n=4) for IL8#1, (n=3) for IL8#2, (n=2) for IL8#3 and (n=3) for LIF#1. Asterisks denote 
significant differences between the non-targeted siRNA and the targeted siRNA in each 
condition. 
C,F) A549 cells were transfected as in A. and treated for 48 h with Glc+ or Glc- media. Cell 
death was analysed by PI incorporation and FACS analysis. Data represent ±SEM (n=3) for 
IL8#1, (n=3) for IL8#2 and (n=3) for IL8#3 and (n=4) for LIF#1.  
 
7.5.2 Conditioned media of A549 cells promotes the migration of cancer 
cells  
Another previously performed secreted protein array in the group (data not shown) detected 
secreted cytokines involved in extracellular matrix reorganisation, which are associated with 
metastasis. Hence, we suggested that an environment low in nutrients promotes the migration 
of cancer cells through cytokine release and cell-cell communication. 
Effects on the migration of A549 cells were analysed by performing chemotactic assays using 
boyden chambers with a permeable membrane of 8 µM. A549 cells were plated in the upper 
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part of the boyden chamber and the regular control media as well as the conditioned media of 
other A549 cells were plated in the bottom chamber. Cells migrated for 20 h towards the media 
in the bottom chamber.  
We found that A549 cells increased migration towards the conditioned media (yellow bars) of 
other A549 cells. However, no difference was observed between the conditioned media of cells 
cultured in the presence or absence of glucose. On the contrary, cells have the tendency to 
migrate less towards the media of starved A549 cells. This effect was reduced by readding 
25 mM glucose to the conditioned media (-/+) of starved A549 cells. (Figure 47A) This 
tendency was also observed when cells migrated towards the washed fractions of the 
conditioned media (orange bars), suggesting that A549 migrate is stronger in the presence of 
glucose.  
In order to examine if IL-8 or LIF promote migration, A549 cells were allowed to migrate 
towards regular media containing recombinant IL-8 or LIF. In our model we could not show an 
effect of these cytokines on migration (Figure 47B). This suggests that either other secreted 
cytokines or a combination of several cytokines promote migration. 
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Figure 47 Conditioned media of A549 cells induces migration of other A549 cells 
A) A549 cells were plated on top of a boyden insert. Cells were allowed to migrate for 20 h 
towards fresh (white bars) glucose-containing (25 mM, +) or glucose-free medium (0 mM, -), 
or towards conditioned (cond) media (yellow bars) from A549 cells grown in glucose-
containing or glucose-free medium for 24h. (-/+) indicates conditioned, glucose-free medium 
to which 25 mM glucose was added before the experiment. Boyden membranes were stained 
with crystal violet and cells were counted using an inverted microscope (10X) and five pictures 
per condition were taken. Data represent mean ±SEM (n=3). Asterisks donate significant 
differences between the Glc+ control samples (white bar) and each treatment.  
B) A549 cells were plated on top of a boyden insert and were allowed to migrate towards 
glucose-containing media (Glc+) or glucose-free (Glc-) media with the addition if IL-8 (10 nM) 
or LIF (100 ng/mL). Data represent mean ± SEM (n=4).  
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7.5.3 LIF induces IL-8 release in A549 cells in the presence and absence of 
glucose 
In further experiments we investigated if cytokines can induce the secretion of other cytokines 
through paracrine or autocrine cell-cell effects. In this context, several reports indicate that LIF 
induces IL-8 (Tiziana Musso et al., 1995) and IL-6 (Gruss et al., 1992) release in myeloid cells 
and others (Villiger et al., 1993). 
Thus, we treated A549 cells in the presence or absence of glucose with recombinant IL-8 for 
24 h and measured LIF release by ELISA. LIF release was not altered by treatment with 
recombinant IL-8 in A549 cells (Figure 48A). To further validate this finding, cells were 
transfected for 40 h with three IL-8 siRNA sequences (as described before) and cells were 
treated for 24 h upon glucose deprivation. As expected, knockdown of IL-8 had no effect on 
LIF secretion (Figure 48B); Furthermore, we treated cells with recombinant LIF, which indeed 
induced IL-8 release in the presence and absence of glucose (Figure 48C). We also confirmed 
that IL-6 release was increased in the presence of LIF upon glucose deprivation, though not 
significantly (Figure 48D). To further validate this finding, cells were transfected with siRNA 
for LIF (Figure 46D-E) and treated for 24 h upon glucose deprivation. We found that 
knockdown of LIF led to a significant decrease of IL-8 release upon glucose deprivation in 
A549 cells (Figure 48E). In conclusion, we found that LIF induces IL-8 in the presence and 
absence of glucose. 
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Figure 48 Recombinant LIF induces IL-8 release 
A) A549 cells were treated with 25 or 0 mM glucose in the presence or absence of IL-8  
(10 ng/mL). LIF release is shown by ELISA. Data represent mean ± SEM of (n=2).  
B,E) A549 cells were transfected for 40 h with a non-targeting control siRNA (labelled as ‘C’) 
or with siRNA for LIF (labelled as LIF#1 for sequence 1) or for IL-8 (labelled as IL8#1 for 
sequence 1, IL8#2 for sequence 2 or IL8#3 for sequence 3). Cells were treated for 24 h with 
0 mM glucose and ELISA is shown for LIF (B) and IL-8 (E). Data are represented as mean ± 
SEM IL-8 (n=3) and LIF (n=2-4). Asterisks donate significant differences between the control 
sample. 
C-D) A549 cells were treated with 25 or 0 mM glucose in the presence or absence of LIF 
(10 ng/mL). IL-8 (C) and IL-6 (D) release is shown by ELISA. Data represent mean ±SEM 
IL-6 (n=3) and IL-8 (n=6). Asterisks donate significant differences between the Glc+ control 
sample and each treatment. 
7.5.4 Conditioned media of A549 cells induces migration of primary B cells 
and macrophage-like THP-1 cells  
In the previous chapter we showed that secreted cytokines from A549 cells have effects on 
other A549 in terms of cell death, migration and cytokine induction. Hence, we wanted to test 
if the conditioned media of A549 cells also affects the migration of immune cells. Regarding 
that, many studies suggested, that cancer cells have immunosuppressive effects by depleting 
the surrounding tissue of nutrients or by cytokine release. One of the consequences is that some 
immune cells, like T cells, lose their anti-tumor activity (Chang et al., 2015). In addition, it is 
also described that some tumors are marked by an increased infiltration of myeloid cells 
including macrophages and neutrophils, which are associated with poor patient prognosis. 
Hence, we suggested that an environment low in nutrients induces cytokine secretion from 
cancer cells and attracts immune cells from the surrounding tissue.  
In the following chapter, we investigated if different immune cell population migrate towards 
the conditioned media of A549 cells when treated in the presence or absence of glucose. The 
following experiments were performed with macrophage-like THP-1 cells or with primary 
PBMCs and primary neutrophils purified from buffy coats obtained from human blood. We 
analysed the migration of these cells by performing chemotactic assays using boyden chambers 
as described for A549 cells in chapter 7.7. Cells were allowed to migrate between 2 and 20 h 
depending on the cell population (see also material and methods).  
First 500.000 PBMCs were plated on the upper part of a boyden chamber and were allowed to 
migrate for 20 h towards the conditioned media of A549 cells. Afterwards, the conditioned 
media in the bottom chamber, which contained the migrated cells, was collected and cells were 
stained with fluorophore-tagged antibodies for CD3+ (T cells), CD56+ (NK cells) and CD19+ 
(B cells). NKT cells were identified as CD56+ and CD3+ populations. The cell number of 
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migrated cells was quantified by FACS. The percentage of migration was calculated by 
analysing the total amount of PBMCs of each population present in the donor blood sample.  
We found that T cells and NKT cells did not migrate towards the full conditioned media of 
A549 cells (Figure 49A-B). However, NKT cells and T cells had the tendency to migrate 
stronger towards the washed conditioned media of starved A549 cells (orange bars) compared 
to the filtrate (blue bars), independent of glucose availability. Moreover, in accordance with 
NKT cells, NK cells also induced migration towards the washed conditioned media of starved 
A549 cells (Figure 49C).  
This suggests, that secreted proteins from starved cancer cells promote migration, however 
metabolites and the depletion of other nutrients in the filtrate attenuated this effect. 
The strongest migratory effect was obtained for B cells, which migrated significantly stronger 
towards the media of glucose-deprived A549 cells (Figure 49D, yellow bar). Moreover, this 
migration was even stronger towards the washed conditioned media of starved A549 cells 
(orange bars). This again suggests, that metabolites or other factors in the exhausted media 
dampen the migration of cells.  
Figure 49 NK an B cells migrate towards conditioned media of starved A549 
cells 
A-D) Human PBMCs were allowed to migrate for 20 h towards fresh glucose (+)-containing 
(25 mM) or glucose (-)-free medium (white bars), to conditioned (cond) media (yellow bars) 
from A549 cells grown in glucose-containing or glucose-free medium for 24 h, to washed 
conditioned media (orange), and towards the filtrate (blue). Migrated cells were stained for 
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indicated markers and were analysed by FACS. Data represent mean ±SEM (n=5). Asterisks 
denote significant differences between cells migrated towards regular media (Glc+) except for 
A. 
To explore if IL-8 or LIF are involved in the migration of these immune cells, we added 
recombinant IL-8 and LIF in the bottom chamber of the chemotaxis assay and analysed 
migration in the presence and absence of glucose. IL-8 and LIF had no effect on the migration 
of T cells, NKT cells and B cells, see Figure 50A-B, D. However, we found that IL-8, but not 
LIF, slightly induced (not significant) the migration of NK cells in glucose-deprived conditions 
(Figure 50C).  
Figure 50 Recombinant IL-8 and LIF does not induce migration of PBMCs 
A) PBMCs were allowed to migrate for 20 h towards regular media containing 25 or 0 mM 
glucose in combination with recombinant IL-8 (10 nM) or LIF (100 ng/mL). (%) migrated cells 
were analysed by FACS staining with indicated antibodies. Data represent mean ±SEM (n=3) 
Next, we analysed if macrophage-like THP-1 cells migrated towards the conditioned media of  
A549 cells. Therefore, THP-1 cells were differentiated towards their macrophage-like 
phenotype by using PMA. Differentiated THP-1 cells (50.000 cells) were plated on the upper 
part of a boyden chamber and let migrate for 20 h towards the conditioned media of A549 cells. 
We found that THP-1 cells migrated stronger towards the conditioned media of starved A549 
cells compared to conditioned media containing glucose (Figure 51A). Re-adding glucose to 
the conditioned media of starved A549 cells (+/-) did not reverse this effect. This proves that 
migration is due to secreted proteins in the media and not due to the absence of glucose. This 
was further confirmed due to the fact, that the washed conditioned media (orange) of starved 
A549 cells induced the migration, even after re-addition of glucose to the conditioned media, 
see Figure 50B. This proves that secreted proteins are responsible for the migration of THP-1 
cells independently of glucose availability. To examine if IL-8 or LIF promoted migration, we 
added recombinant IL-8 and LIF in the bottom chamber to regular media in the presence or 
absence of glucose. Cells had the tendency (not significant) to migrate stronger towards the 
media containing IL-8 in the presence and absence of glucose and slight towards LIF in the 
absence of glucose. (Figure 50C) 
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Figure 51 Macrophage-like THP-1 cells migrate towards conditioned media of 
starved A549 cells 
A-B) THP-1 cells were differentiated with 100 nM PMA for 24 h and let recover for 48 h. Cells 
were plated on top of a boyden insert and were allowed to migrate for 20 h towards regular 
control media (white bars), conditioned (cond) media of A549 cells (yellow bars), washed 
conditioned media (orange bars) and filtered conditioned media (blue bars). Migrated cells were 
stained on the boyden membrane using crystal violet. Five pictures per membrane were taken 
using an inverted microscope and counted with ImageJ. Fold migration versus control Glc+ 
media is shown. Data represent mean ±SEM A. (n=3), B (n=3-4). Asterisks denote significant 
differences of cells migrated towards regular Glc+ and conditioned media Glc- in A. or as 
indicated. 
C) THP-1 cells were differentiated and plated on top of a boyden insert as described in A. Cells 
migrated towards media with 25 mM (Glc+) or 0 mM (Glc-) substituted with recombinant IL-
8 (10 nM) or LIF (100 ng/mL). Cells were analysed as described in A. Data represent mean 
±SEM (n=3). 
7.5.5 Primary neutrophils migrate towards the conditioned media of 
starved A549 cells 
Lastly, we investigated the effects of the conditioned media of starved A549 cells on the 
migration of neutrophils. First, we performed chemotactic experiments using neutrophil-like 
HL60 cells, which were differentiated towards neutrophils using DMSO and ATRA.  
HL60 cells migrated stronger towards the conditioned media of starved H460 cells but not A549 
cells. (Figure 52A-B) We further validated these experiments by using primary human 
neutrophils isolated from human blood, using dextran sedimentation followed by a percoll 
gradient. Primary neutrophils migrated stronger towards the media of starved A549 cells 
(yellow bars) in comparison to the control media (Figure 52C). Experiments with washed 
conditioned media (orange) confirmed that migration was due to secreted protein from A549 
cells and not due to metabolites in the media, since the filtrate (blue bars) did not induce 
migration.  
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Figure 52 HL60 and primary neutrophils migrate towards conditioned media of 
starved A549 cells 
A-B) HL60 cells were differentiated using 1.25 % DMSO and ATRA and cells migrated 
towards fresh control media (white bars) and conditioned media (yellow bars). Migrated cells 
were counted using a Neubauer chamber. Data represent mean ±SEM (n=3). Asterisks denote 
significant differences of cells migrated towards fresh Glc- media.  
C) Primary neutrophils were extracted from human blood using a percoll gradient and were 
allowed to migrate towards fresh control media (white bars), conditioned media of A549 cells 
(yellow bars), washed conditioned media (orange bars) and filtered conditioned media (blue 
bars) for 2 h. Cells were analysed as described in A. Data represent mean ±SEM (n=4). p-value 
designates significance between the control Glc+ versus the indicated treatment. 
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8. Discussion 
Cells need nutrients like carbohydrates, proteins and fatty acids not only for energy production 
but also for the de novo synthesis of proteins, nucleic acids and lipids for cell growth. Nutrient 
uptake is mediated by transporters embedded in the cell membrane followed by their conversion 
by anabolic and catabolic biochemical reactions. Glucose is one of the major nutrients needed 
for energy generation in form of ATP, as well as for the post translational modification of de 
novo synthesized proteins by glycosylation. Cancer cells are highly dependent on glucose 
compared to untransformed cells due to oncogenic mutations and a rewired metabolism. This 
altered metabolism is characterized by using mainly aerobic glycolysis instead of OXPHOS for 
energy production, which is known as the ‘Warburg effect’ (Hsu and Sabatini, 2008).  
In the last decades, the altered cancer metabolism and its pro-tumorigenic impact on the TME 
arouse larger interest. The TME consists out of heterogenic cell populations, which interact 
among each other through cell-cell responses mediated by secreted cellular factors like 
cytokines or metabolites. Since plenty of discoveries show that tumors are often associated with 
inflammation (Balkwill and Mantovani, 2001; Landskron et al., 2014) many research groups 
investigate the impact of  secreted cytokines and metabolites on intra-tumoral immune cells. 
Tumors that are characterized by immune cell exclusion or inactivation are designated as ‘cold’ 
or immunosuppressed tumors. This phenotype can be facilitated by the upregulation of certain 
immunosuppressive cell surface proteins like PD-L1 or CTL-4, as well as through secretion of 
cytokines by cancer cells. Furthermore, recent reports claim that oncogenic mutations and the 
increased nutrient uptake of cancer cells are accompanied by metabolic competition in the 
surrounding tissue or by the secretion of metabolites such as lactate to promote immune 
suppression in the TME (Chang et al., 2015). On the other hand, myeloid cells like macrophages 
or neutrophils, which are metabolically more resistant, are described to infiltrate tumors and to 
promote its progression through secretion of cytokines like IL-6, TNF and VEGF (Murdoch 
et al., 2008). Therefore, it is suggested that the altered metabolism of cancer cells is associated 
with the immune landscape of the tumor and patient outcome.  
In a tumor, transient nutrient deprivation occurs as a consequence of rapid tumor growth, 
resulting in poor vascularization of the tumor core, or through the application of anti-metabolic 
or anti-angiogenic drugs. In the body, ischemic tissue employed mechanisms that promote 
wound healing and the restoration of the nutrient flux. These mechanisms include angiogenesis 
and inflammation, which have been classically attributed to hypoxia or to necrotic 
inflammatory signals, respectively. Sustained lack of nutrients results in cell death; however, 
since multiple reports show that tumors are often associated with inflammation, we 
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hypothesized that nutrient deprivation promoted the secretion of cytokines with chemotactic 
functions promoting immune cell infiltration in the tumor. 
First, we investigated how cancer cells die upon environments low in glucose and how the UPR 
is involved in this response. Second, we investigated if cells secrete cytokines and chemokines 
upon nutrient deprivation or by the application of anti-metabolic drugs. We further investigated 
the specific signaling pathways that promoted the induction and release of these cytokines. In 
a last step we explored the functional consequences of secreted cytokines on cancer cells 
themselves as well as on immune cells. We focused specifically on IL-6, IL-8 and LIF due to 
their importance in inflammation, tumor progression and patient outcome in the clinic.  
8.1 Glucose deprivation induces ATF4-mediated apoptosis through TRAIL- 
receptor 1 (DR4) and 2 (DR5) 
Sustained ER stress induces a switch from the pro-survival UPR response towards a pro-death 
response. Several reports indicate that the transcription factor ATF4 mediates necrosis (León-
Annicchiarico et al., 2015b) as well as apoptosis (Shin et al., 2015) upon glucose deprivation.  
Moreover, it is reported that the cell death receptors DR4 and DR5 are induced upon ER stress 
stressors, including thapsigargin and 2-DG (Chen et al., 2007; Liu et al., 2009; Yamaguchi and 
Wang, 2004).  
Our results proved that glucose deprivation promotes apoptosis in HeLa cells. Furthermore, 
DR4 and DR5 protein expression was induced in cancer cells and knockdown of the death 
receptors protected from cell death (Figure 10, 53). Several studies before showed that DR5 is 
regulated by CHOP in several cancer cell lines. In our model we could not prove that DR5 is 
regulated by CHOP, however we found that ATF4 knockdown completely prevented DR5 
protein induction (Figure 11). This is supported by other reports that show an UPR-dependent 
but CHOP-independent regulation of DR5 (Martín-Pérez et al., 2012). Furthermore, we found 
that CHOP slightly regulated DR4 protein level, however CHOP knockdown did not protect 
from cell death. Regarding ATF4, we proved that knockdown protected from cell death, which 
is in line with DR5 protein expression. This suggests that cells die in an DR5-dependent manner 
mediated by ATF4. However, within these experiments we could not confirm, if ATF4 directly 
induced DR5 transcriptionally or if its regulation is translationally. Therefore, in further 
experiments the mRNA level of DR5 and DR4 upon silencing of ATF4 and glucose deprivation 
have to be analysed by qPCR.  
Within this project we did not analyse the involvement of the other branches (IRE1 and ATF6) 
of the UPR response in the induction of cell death upon glucose deprivation. Regarding that it 
is described that the IRE1 branch transiently mediates DR5 mRNA decay, which delays the cell 
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death response and allows the cell to recover (Lu et al., 2014). Furthermore, some reports, as 
well as preliminary data from our group, suggest a crosstalk between the three UPR branches. 
Regarding that it is described that the PERK branch enhances IRE1 signaling (Tsuru et al., 
2016) upon treatment with thapsigargin. Possible crosstalk’s between the UPR branches could 
fine tune cell death induction and need to be more profoundly investigated. 
To sum it up, we conclude that sustained glucose deprivation switches the UPR towards a pro-
death response, which induces the upregulation of DR5 and DR4. We proved that DR5 but not 
DR4 induction was mediated by ATF4.  This project was recently published (Iurlaro, Püschel 
et al., 2017). 
 
 
 
Figure 53 Schematic presentation of glucose deprivation induced apoptosis 
Glucose deprivation induces ER stress in cancer cells, which promotes the induction of ATF4 
and CHOP. CHOP slightly regulated DR4 protein level, whereas ATF4 regulated DR5. Cancer 
cells died in a apoptotic DR5-dependent manner mediated by ATF4 upon glucose deprivation. 
Silencing of Noxa and Bim had no effect on cell death induction upon glucose deprivation. 
(Iurlaro, Püschel et al., 2017b) 
 
 
 
Discussion  
114 
 
8.2 Glucose deprivation induces cytokine release 
Several reports show that the UPR induces cytokines in cancer cells (Zhang and Kaufman, 
2008a). Since we demonstrated that the UPR is induced upon glucose deprivation, we 
hypothesized that prior to a cell death inducing response, the UPR promotes cytokine secretion. 
To test that, we performed a secreted protein array using the supernatant of glucose-deprived 
A549 cells under exclusion of cell death. We detected a broad range of secreted proteins 
involved in various cell responses (Figure 12). We detected for instance VEGF, which is a pro-
tumorigenic cytokine associated with angiogenesis. Its release upon glucose deprivation has 
been reported before in monocytes (Satake et al., 1998) and HepG2 cells mediated by ATF4 
(Terashima et al., 2013). We detected other angiogenic cytokines including angiogenin and 
PDGF-AA. That suggests that glucose deprivation induces an angiogenic response, promoting 
the revascularisation of the tumor to restore nutrient flux. However, we did not further validate 
these cytokines by ELISA or qPCR, which should be done, to strengthen this hypothesis. 
Adiponectin, a hormone secreted by adipose tissue, was induced in the protein array. Low level 
of adiponectin have been associated with poor prognosis in leukemia (Aref et al., 2013), in 
colorectal (Xu et al., 2011) and in breast cancer (Macis et al., 2014). This indicates that release 
of adiponectin upon glucose deprivation could promote an anti-tumorigenic response. This is 
further supported by the fact that adiponectin is also associated with AMPK activation and 
mTOR inactivation (Shibata et al., 2005), suggesting that its release lowers the energetic needs 
of the cell. On the other hand, adiponectin is involved in immune escape by blunting the activity 
of dendritic cells (Tan et al., 2014). In conclusion, reports are controversial about the role of 
adiponectin in cancer (Katira et al., 2016). We did not further confirm adiponectin release by 
ELISA, however investigating the role of adiponectin upon glucose deprivation may offer an 
interesting new research field. 
We also detected the release of IL-6 and IL-11 in the protein array of starved A549 cells, which 
are known to promote tumor growth and survival by inducing cell-cell responses. One of the 
pathways activated by these cytokines is the induction of STAT3 signaling in cancer cells, as 
well as in other tumor-intrinsic cell populations, which is associated with tumor progression 
(Huynh et al., 2019). Therefore, the release of IL-6 and IL-11 upon glucose deprivation could 
transmit stress to neighbouring cells in order to escape or to adapt to nutrient shortage. Secreted 
IL-8 and CD14 are involved in tumor growth and inflammation. Regarding CD14 it is 
described, that CD14-high bladder cancer cells are more vascularized and show higher myeloid 
infiltration (Cheah et al., 2015; Hammond et al., 1995).  
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Interestingly, some cytokines like IGFBP-2 or chemokines like CXCL5 and CCL2 were 
downregulated upon glucose deprivation, which could be due to impaired posttranslational 
events such as glycosylation. This assumption is supported by the increased mRNA expression 
of CCL2 upon glucose deprivation, which does not coherent with its secretion (Figure 13,33). 
IGFBP-2 is associated with chemoresistance in esophageal adenocarcinoma (Myers et al., 
2015) and bladder cancer (Zhu et al., 2015). This suggests, that reduced secretion upon glucose 
deprivation could possibly sensitise cancer cells to chemotherapeutic treatment. However, more 
in-depth studies and validation of protein level by ELISA or western blot have to be performed 
to prove this hypothesis. 
In summary, we found several up as well as downregulated cytokines with a broad variety of 
biological functions and impacts on tumor progression. Within this thesis, we did not validate 
all detected cytokines by ELISA or qPCR. However, to completely understand the interplay 
between these cytokines, individual analysis has to be performed in order to clarify their 
regulation and function in tumor settings. 
Focusing on chemokines and cytokines involved in inflammation, we validated some of the 
detected cytokines from the protein array by ELISA. We used several lung cancer cell lines 
from different origin including A549, H1299, H520, SW900 and H460 cells as well as HeLa 
cells. We found IL-8, IL-6 and LIF as major secreted proteins in different cell lines (HeLa, 
A549, H460, SW900), suggesting that this response is conserved between distinct cancer cell 
lines (Figure 16,17,20). IL-8 is described to promote angiogenesis, metastasis and proliferation 
in lung cancer and it is also described as a chemoattractant for neutrophils. High level of 
circulating IL-6 are associated with poor prognosis and an a lower overall survival in NSCLC 
patients (Sunaga et al., 2012). Moreover, IL-6 is well described as an activator of tumor-
associated signaling cascades promoting tumor growth and immune cell infiltration (Johnson 
et al., 2018). In the case of LIF it was just reported, that LIF induces CXCL9 in TAMs and 
impede CD8+ T cell infiltration (Pascual-García et al., 2019) in tumors. Some of the analyzed 
cells showed high basal level of IL-6 or IL-8 (A549, H460, SW900), which is described to be 
mediated by KRAS mutations (Sunaga et al., 2012), promoting tumor growth. 
Considering the important role of these cytokines in tumor progression and tumor-associated 
inflammation, our results suggest that the release of IL-8, IL-6 and LIF upon glucose 
deprivation or upon treatment with anti-metabolic drugs, may worsen patient outcome.  
TNF mRNA was induced in HeLa cells upon glucose deprivation; however, we did not detect 
its release, neither in HeLa nor in A549 cells. A similar outcome was observed for CXCL1, 
which was induced at mRNA level but not its release. This indicates that mRNA induction and 
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cytokine release do not correspond for all cytokines upon glucose deprivation, possibly due to 
impaired posttranslational modifications of some cytokines. Moreover, the peak of mRNA 
induction is at short time points (3 h) and normalizes for some cytokines, like IL-8, within 24 h 
to basal level. Surprisingly, cytokines are still steadily released at late time points upon glucose 
deprivation. This suggests, that cytokines are possibly regulated transcriptionally in a first 
response, however in a long-term response other mechanism take over, which translationally 
regulate cytokine release. Another possibility would be, that cytokines accumulate in the cell, 
as shown for IL-8 but not for LIF (Figure 21,22) after being de novo synthesized at short time 
points upon glucose deprivation. When mRNA level decline to basal level, cytokines can still 
be steadily released. In order to test this hypothesis, Click-iT Assays (Thermo Fisher) have to 
be performed for the time dependent monitoring of de novo cytokine synthesis, as well as 
cytokine secretion. Moreover, sustained glucose deprivation induces cell death receptors such 
as DR5 and DR4 at late time points (data not shown), which are associated with NF-B 
activation. Therefore, other signaling pathway could promote cytokine secretion at later time 
points. 
Recently, it was described that squamous NSCLC cells are more glycolytic and more 
susceptible to glycolytic inhibitors (Goodwin et al., 2017) compared to adenocarcinomas. This 
suggests that these cells secreted higher amounts of cytokines. In our study, we could not find 
a correlation between cytokine release and squamous NSCLC (SW900, H520) or 
adenocarcinoma (A549, H1299, H460) cell lines. Moreover, all tested cell lines released 
distinct amounts and types of cytokines. This indicates that cancer cells secrete their own 
‘cytokine cocktail’, which could be based on oncogenic mutations and the induction of distinct 
downstream (stress) signaling pathways like the UPR or NF-B. In order to predict the secreted 
cytokines upon glucose deprivation by a specific cancer cell line, more detailed analysis of cell 
line specific mutational burden and subsequently induced stress signaling pathways have to be 
performed. Translating this into a clinical setting, the heterogeneity of patients and systemic 
responses have to be considered when developing anti-metabolic drugs. 
H520 cells are more resistance towards glucose deprivation induced cell death (Figure 13). 
Compared to the other tested cell lines, H520 cells did not release any of the tested cytokines. 
It is possible that these cells induce alternative metabolic pathways to bypass glucose 
deprivation, which in turn prevents the induction of stress signaling pathways such as the UPR, 
which mediate cytokine release. This could also be applied to H1299 cells, which only released 
LIF upon glucose deprivation among the tested cytokines. Therefore, further investigations 
have to be performed focusing on the metabolism as well as glucose deprivation induced stress 
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signaling pathways of H520 and H1299 cells compared to A549 cells.  This would deepen the 
knowledge of how glucose deprivation induces cytokines release in a cell type dependant 
manner. Moreover, it would allow to identify new possible targets for anti-metabolic therapies.  
Exosomes are small membrane derived vesicles, secreted from many cancer cells. These 
endocytic membranes are loaded with proteins, micro (mi)RNA or DNA for cell-cell 
communication. Increased exosome secretion from A549 cells upon cisplatin treatment is 
associated with resistance and inflammation (Li et al., 2016) and in cardiomyocytes, glucose 
deprivation promotes the secretion of exosomes (Garcia et al., 2015). Hence, it is likely that 
A549 cells release exosomes upon glucose deprivation loaded with cytokines. To test this, 
supernatants from starved A549 cells have to be prior ultra-centrifuged to remove exosomes. 
Afterwards, supernatants have to be analysed by ELISA in order to test if cytokines are released 
in soluble form or engulfed in exosomes. Moreover, other cellular molecules like DNA or 
miRNA engulfed in these vesicles could be secreted as well. Therefore, a future direction of 
this project could be to test if exosomes are released by glucose deprivation. In case exosomes 
are released, their content and functions in the TME have to be investigated. 
8.3 The impact of nutrient substitution to glucose-deprived media  
We added several intermediate substrates of the glucose metabolism to glucose-deprived media 
to investigate the crucial steps that facilitate cytokine secretion (Figure 24). An overview of 
the results is presented in Figure 54. In some cell lines the induction of the UPR can be 
prevented by the addition of mannose or GlcNAc, which restore glycosylation (Panneerselvam 
and Freeze, 1996), whereas fructose can be converted to glucose or fuel glycolysis through 
alternative pathways (Fan et al., 2017). Mannose and partially fructose reversed the release of 
IL-8 and LIF simultaneously and protected cells from cell death. This suggests that these 
nutrients can replace glucose and prevent that cells undergo starvation. The addition of GlcNAc, 
had only minor effects on cytokine release, which suggests that restoring glycosylation by the 
HBP does not prevent cytokine release. If the UPR is induced due to impaired glycosylation 
but GlcNAc does not resolve glycosylation and cytokine release, it is possible that ATF4 is 
induced in a UPR-independent manner. This is suggested by another group who claim that 
ATF4 is induced in an GCN2-dependent manner due to a secondary loss of amino acids upon 
glucose deprivation (Chaveroux et al., 2016b). To further validate this observation, ATF4 level 
need to be tested upon GlcNAc re-addition and knockdown of PERK and GCN2 upon glucose 
deprivation should be performed. 
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Lactate is described to substitute for glucose by fuelling the TCA cycle in NSCLC cells (Faubert 
et al., 2017). Substituting lactate to glucose-deprived media did not reverse IL-8 release, 
whereas LIF release was partially reduced. This suggests that reduced TCA cycle activity could 
be a cause for LIF release but not for IL-8. However, more experiments should be performed, 
investigating if lactate fuels the TCA cycle in these cells and/or which other effects lactate has 
on the cellular signaling events in A549 cells.  
Methyl-pyruvate, which serves as a mitochondrial substrate, reversed the mRNA expression of 
all tested mRNAs, except for LIF, and also the release of IL-8 and partially LIF. Assuming that 
glucose deprivation promotes ROS production and ATF4 induction, which is suggested by 
some reports (Graham et al., 2012; Kasai et al., 2018), Methyl-pyruvate could function as an 
antioxidant, which is described (Ramos-Ibeas et al., 2017; Wang et al., 2007), preventing ATF4 
induction and cytokine release. Otherwise, methyl-pyruvate could fuel the TCA cycle 
independently of glycolysis and prevent a subsequent ATP drop and stress signalling in the cell. 
Further experiments have to be performed, investigating the energy status and the UPR 
induction upon treatment with Met-Pyr. 
2-DG prevents glycosylation and some reports claim that 2-DG is phosphorylated by the HK 
and accumulates in form of 2-DG-P in the cell, preventing further glucose utilization. In 
contrary, another report describes that 2-DG also inhibits the phosphoglucose-isomerase (GPI), 
which is the enzyme converting G-6-P to be further metabolized by glycolysis. Moreover, this 
report proved that if GPI is blocked, glucose can still be metabolized by the PPP (Ralser et al., 
2008), meaning that the glucose metabolism is still partially functional.  
Addition of 2-DG to glucose free media prevented LIF release, whereas IL-8 release remained 
unchanged. It is possible that upon glucose deprivation some glycosylation remains intact, 
which is sufficient for the highly glycosylated cytokine LIF to be posttranslational modified 
and released. This could be mediated by upregulation of alternative metabolic pathways like 
the HBP, which is described to restore glycosylation in an ATF4 dependent manner in this cell 
line upon glucose deprivation (Chaveroux et al., 2016c). However, combined treatment of 
glucose deprivation with 2-DG could entirely inhibit glycosylation, which in turn prevents de 
novo synthesis of LIF. In contrary, IL-8, which is a non-glycosylated cytokine, keeps on being 
synthesized and released in glucose free media upon 2-DG co-treatment. Another possibility 
would be that LIF trafficking to the cell membrane is affected by additional treatment with 
2-DG, suggesting a distinct secretory pathway for LIF and IL-8 secretion. To further confirm 
this hypothesis, it is necessary to analyse LIF de novo synthesis, trafficking and glycosylation 
status upon cotreatment with glucose deprivation and 2-DG. Furthermore, a more detailed 
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analysis of how glucose deprivation in combination with 2-DG affects glycosylation of other 
cellular proteins would give additional important information. Another hypothesis would be 
that 2-DG and 2-DG-P accumulate in the cell and get detected by glucose level sensors and 
therefore mimic sufficient glucose level, which prevents LIF induction. This would suggest that 
LIF is induced upon glucose sensing mechanism, whereas IL-8 is induced upon consequentially 
upregulated stress signaling pathways upon glucose deprivation. 
Regarding cytokine mRNA level, LIF mRNA expression is not reversed by any of the added 
nutrients, which suggests that LIF mRNA is regulated differently compared to other tested 
cytokines.  
To completely understand how addition of specific nutrients to glucose-deprived culture media 
influences cytokine release, more detailed analysis has to be performed on how these nutrients 
affect intracellular stress signaling pathways, with focus on ATF4 and mTOR induction. 
Furthermore, effects on metabolic outcomes such as ATP levels should be analysed. 
 
 
 
Figure 54 Schematic presentation of glucose metabolism and addition of nutrients in the 
absence of glucose 
Mannose (Man) and fructose (Fru) are uptaken by transporters. Man is converted to F6P, in 
cells that express the phosphomannose isomerase (PMI) only and fuels glycolysis. Man can 
also be converted to GDP-Mannose and restore glycosylation. Fructose fuels glycolysis by its 
conversion to F6P. Methyl-pyruvate (Met-Pyr) fuels the TCA cycle. N-Acetylglucosamine 
(GlcNAc) fuels the HBP and restores glycosylation. 2-deoxyglucose (2-DG) blocks glycolysis 
by blocking the hexokinases (HK) or the glucose-6-P isomerase (GPI) resulting in an ATP drop 
as well as impaired glycosylation mediated by glucose. Metformin blocks complex I of the 
respiratory chain. IL-8: Interleukin-8; LIF: Leukemia inhibitory factor; ✕: no change in 
cytokine release; ↓: Less cytokine release. Orange box: Up- and downregulated cytokine release 
upon substitution of indicated nutrients to glucose-deprived media. 
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8.4 Glutamine deprivation promotes cytokine release 
In our model we found that glutamine deprivation promoted the induction and secretion of IL-6 
and IL-8 but not LIF (Figure 26). Recently it was shown that glutamine deprivation induces 
IL-8 release in a mTOR dependent manner (Shanware et al., 2014) as well as due to ROS 
production (Kim et al., 2014). Moreover, it was reported that glutamine deprivation (Chen et 
al., 2014) as well as glucose deprivation (Chaveroux et al., 2016c) induces ATF4 in a GCN2-
dependent manner. Therefore, IL-8 and IL-6 induction could be mediated by GCN2 and a 
subsequent induction of ATF4 upon glutamine deprivation. This is supported by our finding 
that IL-8 and IL-6 secretion is ATF4 dependent. However, to confirm this hypothesis, further 
analyses have to be done by silencing GCN2 and ATF4 upon glutamine deprivation.  
Since LIF release is ATF4 independent it was expected that glutamine deprivation did not 
induce LIF. This also supports the hypothesis, that LIF release is exclusively glucose dependent, 
possibly induced by specific glucose sensors in the cell. A possible sensing mechanism could 
be the ADP/ATP ratio in the cell. Therefore, it would be interesting to see if replenishing ATP 
to the cell, upon glucose deprivation, reverses LIF release compared to the release of other 
cytokines. This hypothesis is however contradicted by the fact that glucose deprivation does 
not induce AMPK in our model, which is the main sensor for the ADP/ATP ratio in our system. 
Still, there are many other glucose sensors in the cell. Among them is the decrease of the 
NADH/NAD+ ratio or epigenetic regulatory mechanism. These sensing mechanisms could be 
involved in LIF induction and have to be investigated more deeply. 
In our system total starvation, even in the presence of some glucose, did not induce cytokines 
possible due to the absence of growth factors and nutrients which could be essential for cytokine 
synthesis. 
8.5 Anti-metabolic drugs promote cytokine release 
Importantly, we proved that anti-metabolic drugs induced cytokines such as 2-DG, which 
induced IL-6, IL-8 and LIF or metformin, which induced IL-6 and IL-8 but not LIF (Figure 27-
28). Both drugs are associated with ATF4 induction, which could mediate IL-8 and IL-6 release. 
Since we showed that LIF induction is independent of ATF4, release upon 2-DG treatment 
needs to be mediated in a different manner, possibly due to impaired glycosylation or reduced 
ATP level in the cell.  
Metformin blocks mitochondrial respiration and it is also described to induce ROS, which in 
turn could promote ATF4-signaling and cytokine induction (Zeeshan et al., 2016b). An ATF4-
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dependent mechanism of cytokine induction by metformin would also explain why metformin 
did not induce LIF.  
To sum it up, these finding are very important since patient treatment with anti-metabolic drugs 
and subsequent cytokine release and possible inflammatory responses could reverse anti-
tumorigenic effects of these drugs in the clinic and promote resistance or even tumor 
progression. 
8.6 The involvement of ATF4 in cytokine induction upon glucose 
deprivation 
Cancer cells are more resistant towards intra- and extracellular perturbations compared to 
untransformed cells due to the upregulation of adaptive stress responses. Glucose deprivation 
induces the UPR (Palorini et al., 2013) due to possible impaired glycosylation and a subsequent 
accumulation of misfolded proteins in the ER. Since the UPR is a pro-survival response in the 
first place, we hypothesized that ATF4 mediates prior to cell death induction an adaptive 
response to starvation by release of cytokines. These cytokines in turn could affect the TME in 
terms of metabolic rewiring, cell death or immune infiltration. 
We recently reported that ATF4 mediates cell death upon glucose deprivation in HeLa cells 
(Iurlaro, Püschel et al., 2017a). In our current model, ATF4 was induced at short time points 
upon glucose deprivation, which is in accordance with cytokine mRNA induction. Regarding 
that,  ATF4 is linked to IL-6 induction upon metabolic stress in macrophages (Iwasaki et al., 
2014) and human tumor cells (Wang et al., 2012) as well as to VEGF release (Malabanan et al., 
2008). 
We proved that ATF4 mediated the induction and release of IL-6 and IL-8 but not LIF and the 
mRNA induction of several other cytokines upon glucose deprivation (Figure 31,32,55). 
Surprisingly, we found that ATF4 knockdown in the presence of glucose reduced basal IL-8 
release although IL-8 mRNA induction was not altered. This suggests that basal ATF4 level 
could have functions in protein translation independently of transcription. Since we could not 
confirm that ATF4 regulates all cytokines to the same extent, ATF4 cannot be considered as an 
exclusive cytokine regulator. Moreover, we did not evaluate if ATF4 directly induces cytokines 
transcriptionally by binding to their promotor, or if ATF4 is rather a mediator that promotes 
cytokine induction and/or synthesis. Further experiments, including Chromatin 
immunoprecipitation (CHiP), should be performed to strengthen the role of ATF4 in cytokine 
induction. 
Importantly, anti-metabolic drugs including 2-DG and metformin induced ATF4 (Jaime 
Redondo, 2018) and cytokine release in A549 cells. The most studied mode of action of 
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metformin is blocking complex I of the respiratory chain in the mitochondria, which lowers 
ATP production (Owen et al., 2000). Other reports show that metformin induces ATF4 in the 
mouse liver (Kim et al., 2013). Furthermore, metformin induces the PERK arm of the UPR, as 
described in cardiomyocytes (Quentin et al., 2012). 2-DG is a common UPR stressor and 
associated with ATF4 induction (León-Annicchiarico et al., 2015b), suggesting that 2-DG 
promotes IL-8 and IL-6 induction in an ATF4-dependent manner. However, for further 
confirmation, ATF4 knockdown experiments in combination with 2-DG and metformin 
treatment need to be performed to strengthen this hypothesis.  
CHOP, which is also induced upon glucose deprivation in our model, is described to induce 
IL-6 (Hattori et al., 2003). In our model we did not study CHOP involvement, which should be 
done in further experiments. 
In summary, we conclude that ATF4 is involved in the induction and release of IL-6 and IL-8 
but not LIF, either as a mediator or as a transcription factor in A549 and HeLa cells. However, 
not all cytokines are regulated by ATF4, suggesting a cytokine dependent regulation by the 
UPR/ISR, upon glucose deprivation. 
An overview of the involvement of the UPR in IL-8 and LIF regulation is shown in Figure 54. 
 
Figure 55 UPR regulation of IL-8 and LIF upon glucose deprivation 
Glucose deprivation induces the three UPR stress signaling proteins; inositol requiring kinase 
1 (IRE1), the activating transcription factor 6 (ATF6) and the protein kinase RNA-activated 
(PKR)-like endoplasmic reticulum kinase (PERK). PERK and other ISR kinases phosphorylate 
eIF2⍺ and facilitate the induction of the transcription factor ATF4, which promoted the 
induction and release of IL-8 but not LIF. IRE1 promotes the splicing of XBP1. Spliced XBP1 
(XBP1s) is a transcription factor, which did not regulate IL-8 or LIF. Cleaved ATF6 (ATF6N) 
is translocated to the nucleus and functions as a transcription factor. Knockdown of ATF6 
partially reduced LIF but not IL-8 release. 
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8.7 The role of PERK in the regulation of IL-8 and LIF 
In a nutrient deprived setting, ATF4 is described to be induced by one of the ISR kinases PERK 
or GCN2. Focusing on PERK, we used the chemical PERK inhibitor GSK2656157 and AMG 
PERK 44, which both partially reduced ATF4 protein induction upon glucose deprivation. LIF 
release was strongly reduced by GSK2656157 and minor reduced by AMG PERK 44 upon 
glucose deprivation (Figure 37). Previous results excluded ATF4-dependent regulation of LIF, 
suggesting an ATF4-independent but PERK-dependent regulation of LIF. UPR-independent 
functions of PERK include ER-mitochondria tethering at the mitochondria-associated ER 
membrane (MAMS), regulating among others calcium and ROS signaling as well as ER 
morphology (Verfaillie et al., 2012). PERK also induces Nuclear Factor Erythroid (NFE) 2-
Related Factor 2 (NRF2), which regulates the antioxidant response by transcriptionally 
inducing antioxidant enzymes by the antioxidant response element (ARE). In cancer, NRF2 has 
dual roles. On the one hand, it is cytoprotective and prevents tumor initiation through its 
protective effects against metabolic, xenobiotic and oxidative stresses, however hyperactivation 
promotes tumor growth, which is associated with drug resistance (Menegon et al., 2016). 
Moreover, NRF2 is shown to be induced in a PERK dependent manner upon glucose 
deprivation (Cullinan and Diehl, 2004). LIF could be induced by NRF2 due to its involvement 
in many biological processes, which could promote LIF induction. Furthermore, recently it was 
reported that GSK2656157 also inhibits receptor-interacting protein kinase 1 (RIPK1) (Rojas-
Rivera et al., 2017), which is a kinase involved in inflammation, cell death (necroptosis and 
apoptosis) and NF-B induction downstream of the Tumor necrosis factor receptor (TNFR). 
Since the GSK2656157 inhibitor had a major effect on LIF release and AMG PERK 44 only a 
minor, further experiments validating RIPK1 involvement in LIF release upon glucose 
deprivation have to be performed. An overview of the hypothesis is shown in Figure 56. 
Regarding IL-8, the two PERK inhibitors had contradictory effects on its release upon glucose 
deprivation. AMG PERK 44 induced IL-8 release in the presence and absence of glucose, 
whereas GSK2656157 had no effect on IL-8 release (Figure 37).  
Possibly PERK alone, independently of ATF4, could negatively regulate IL-8 release upon 
glucose deprivation. Moreover, RIPK1 is involved in NF-B signaling, which we proved to 
mediate IL-8 release. Furthermore, GSK2656157 inhibits RIPK1 which could balance the 
suppressive effect of PERK on IL-8 release. Therefore, as for LIF, RIPK1 involvement in 
cytokine release upon glucose deprivation of IL-8 has to be further investigated. Moreover, we 
showed that LIF induced IL-8. This suggests that reduced secretion of LIF upon GSK2656157 
treatment consequently also leads to a reduced IL-8 secretion upon treatment with the 
Discussion  
124 
 
GSK2656157 inhibitor, eliminating the inducing effect of PERK inhibition seen upon AMG 
PERK 44 treatment. An overview of the hypothesis is presented in Figure 55. 
 
Figure 56 Regulation of IL-8 and LIF by PERK upon treatment with the 
inhibitor GSK2656157 and AMG PERK 44 
Hypothesis LIF: ATF4 was not involved in LIF induction in the absence (Glc-) of glucose. LIF 
release was reduced by GSK2656157 and minor reduced by AMG PERK 44 treatment upon 
glucose deprivation. (1) GSK2656157 could additionally inhibit RIPK1, which could be an 
inducer of LIF. (2) PERK could ATF4 independently regulate LIF release through induction of 
NRF2 or through a mitochondrial crosstalk. Hypothesis IL8: (1) AMG PERK 44 induced IL-8 
release in the presence of glucose (Glc+). Therefore, basal PERK activity, independent of 
ATF4, could inhibit IL-8 release. In the absence of glucose (Glc-) AMG PERK 44 induced IL-8 
release and GSK2656157 had no effect. (2) AMG PERK 44 could induce IL-8 due to a negative 
regulation of PERK on IL-8 release, independent of ATF4. (3) IL-8 could be regulated by 
RIPK1, which is also inhibited by GSK2656157, and would balance the negative regulation of 
PERK. Hypothesis LIF: (4) GSK2656157 reduced LIF release. If LIF induces IL-8 release upon 
glucose deprivation and LIF release is reduced upon GSK2656157 treatment, IL-8 release 
would be consequentially reduced as well and balance the negative regulation of PERK on IL-8 
release. 
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8.8 The impact of the eIF2 inhibitor ISRIB on cytokine release 
To further investigate the ISR involvement in cytokine release, we focused on eIF2 which is 
phosphorylated by the upstream kinases of the ISR and subsequently leads to the translation of 
ATF4.  
We treated cells with ISRIB, a molecule reversing the phosphorylation of eIF2 upon the 
activation of the ISR (Sidrauski et al., 2013). Recently, it was reported that treatment with the 
inhibitor ISRIB results in a reduced secretion of IL-6 and IL-8 upon glutamine deprivation in a 
breast cancer cell line. This was also supported with a decreased induction of cytokine genes 
dependent on eIF2 phosphorylation (Gameiro and Struhl, 2018).   
Upon treatment with the ISRIB inhibitor in combination with glucose deprivation we found a 
mild reduction of ATF4 protein level (data not shown). However, we found an induction of 
IL-8 release, a small reduction of LIF release and no effect on IL-6 release upon 24 h treatment 
(Figure 38). Therefore, we could not confirm that eIF2-phosphorylation is involved in 
cytokine induction upon glucose deprivation in our model as reported before by Gameiro and 
Struhl. This result suggests that ATF4 could be induced independently of the upstream ISR 
kinases PERK or GCN2. Validating eIF2 phosphorylation in A549 cells upon glucose 
deprivation remained inconclusive, since we already observed basal eIF2 phosphorylation 
(data not shown). A possible explanation could be that ATF4 is induced partially independent 
of phosphorylation of eIF2. Supporting this, a recent publication proved that methionine 
deficiency induced ATF4 independent of the GCN2/peIF2 pathway (Mazor and Stipanuk, 
2016). Moreover, ATF4 can be induced by mTORC1 to induce purine synthesis in cancer cells, 
independent of the cellular stress response and due to growth factors (Ben-Sahra et al., 2016). 
Therefore, either ISRIB contains some unknown off target effects independent of ATF4, or 
ATF4 induction and downstream cytokine release is to some extend induced independent of 
eIF2 phosphorylation. Furthermore, it would also be possibly, that after ISRIB treatment the 
remaining ATF4 induction is sufficient to promote cytokine induction. 
8.9 IL-8 and LIF regulation by the IRE1 and ATF6 branch of the UPR 
Several reports link the IRE1 branch of the UPR to cytokine release and subsequent immune 
infiltration in cancer (Logue et al., 2018; Rubio-Patiño et al., 2018). In our model we could not 
confirm a regulation of IL-8 or LIF by IRE1 knockdown or by treatment with the RNase 
inhibitor MKC-8866 (Figure 34,35). However, knockdown efficiency of IRE1 was weak and 
results of cytokine induction upon treatment with the IRE1 inhibitor MKC–8866 were only 
measured at mRNA level. Since our results showed that mRNA and protein level are not 
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regulated simultaneously, the MKC-8866 inhibitor could still prevent cytokine release, which 
has to be tested in further experiments. However, we investigated if XBP1s, the transcription 
factor of the IRE1 branch of the UPR, mediates IL-8 and LIF release upon glucose deprivation. 
We silenced XBP1 with two different siRNA sequences and their efficiency was verified by 
qPCR. We found reduced mRNA induction for XBP1s, as well as for Erdj4, a known 
downstream target of XBP1s. The results on IL-8 and LIF release upon silencing of XBP1 in 
combination with glucose deprivation remained contradicting. However, considering the results 
of the IRE1 knockdown and the IRE1 RNase Inhibitor MKC-8866, we conclude that the IRE1 
arm of the UPR has no regulatory function in cytokine induction upon glucose deprivation in 
our system.  
We found that ATF6 knockdown induced LIF and IL-8 mRNA expression upon glucose 
deprivation. Though, IL-8 release was not changed, whereas LIF release was slightly reduced. 
This suggests that ATF6 has contradicting effects on mRNA induction and protein synthesis of 
cytokines, induced by glucose deprivation. We conclude that ATF6 only minorly regulated IL-8 
mRNA induction, however we do not exclude a role for ATF6 in LIF induction upon glucose 
deprivation. However, we observed ATF6 cleavage at 6 h of glucose deprivation (Figure 29A) 
whereas LIF is induced at earlier time points. Therefore, we suggest that ATF6 is rather 
involved in the regulation of LIF at later time points, rather than in the initial induction. 
Therefore, further experiments should be performed by using additional siRNA sequences to 
finally conclude the role of ATF6 in LIF release upon glucose deprivation. See also overview 
Figure 55. 
8.10 mTOR involvement in cytokine release 
Protein synthesis is mainly regulated by mTOR signaling and glucose deprivation is known to 
inactivate mTOR in order to attenuate protein synthesis to restore cell homeostasis. 
Furthermore, mTOR inactivation is described to be involved in cytokine induction in immune 
cells (Weichhart et al., 2015).  
Glucose deprivation inactivates mTOR in our model. We also found that IL-8 is induced upon 
glutamine deprivation which, for IL-8, is described to be mediated in an mTOR dependent 
manner (Shanware et al., 2014). To investigate if mTOR signaling is involved in glucose 
deprivation induced IL-8 and LIF release, we used the mTOR inhibitor rapamycin, which 
blocks mTORC1 and Torin1, which blocks mTORC1 and mTORC2.  
In our model we proved that Torin1, but not rapamycin, induced slightly IL-8 release in the 
presence of glucose (Figure 40), suggesting that mTORC2 is involved in IL-8 induction. 
                Discussion 
127 
 
Regarding that it is described, that mTORC2 inhibits PERK in an AKT dependent manner 
(Tenkerian et al., 2015) and  attenuates PERK signaling under oxidative stress (Krishnamoorthy 
et al., 2018). Therefore, mTORC2 inhibition could induce PERK signaling and possibly ATF4 
induction, which could promote IL-8 release. This needs to be further investigated by 
confirming ATF4 induction upon Torin1 treatment in the presence of glucose. Another 
suggestion is that possibly both mTOR complexes or at least mTORC2 have to be inactivated 
to promote IL-8 release in the presence of glucose.  
In the absence of glucose, rapamycin as well as Torin1 reduced IL-8 release. Possibly, upon 
glucose deprivation some mTOR activity remains that is sufficient for IL-8 synthesis. However, 
using mTOR inhibitors, which block mTOR activity more effective, reduced IL-8 release.  
LIF in contrary is not induced by none of the mTOR inhibitors in the presence of glucose, 
suggesting an mTOR-independent regulation of LIF. In the absence of glucose, LIF release was 
only minor and not significantly reduced by rapamycin treatment. Therefore, we assume that 
LIF is regulated independently of mTOR.  
8.11 The role of p65 in cytokine release upon glucose deprivation 
The function of the NF-κB pathway as major cytokine inducer has been studied in many 
systems (Liu et al., 2017). NF-κB is reported to be activated downstream of the UPR by the 
formation of an IRE1-TRAF2 complex, interacting with IKK and resulting in IκB 
phosphorylation and its subsequent degradation, which results in p65 translocation to the 
nucleus. Since we could not prove an IRE1 involvement in cytokine release upon glucose 
deprivation, this is probably not the case in our model. Another UPR-dependent activation of 
the NF-κB pathway is by phosphorylation of eIF2α, which results in global protein synthesis 
attenuation. This reduces IκB protein synthesis and could subsequently lead to p65 translocation 
to the nucleus and cytokine induction.  (Schmitz et al., 2018; Zhang and Kaufman, 2008a). 
Other ways of inducing NF-κB could be mediated by EGFR signaling (Biswas et al., 2002; 
Jiang et al., 2011; Sun and Carpenter, 1998) which is described to be promoted by glucose 
deprivation (Graham et al., 2012) and is also associated with cytokine induction (Bald et al., 
2014). Another possible way of activating NF-κB is through cell death receptors, including 
DR5 and DR4 (Yang et al., 2018) as well as though TNFR (Hayden and Ghosh, 2014). 
Regarding that we found that DR4 and DR5 were induced upon glucose deprivation (Iurlaro et 
al., 2017a) and therefore could participate in cytokine induction. 
We found in HeLa and A549 cells that p65 is involved in the induction and release of IL-8 and 
IL-6 but not LIF (Figure 41,42). Moreover, we also confirmed the regulation of several other 
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cytokines by p65 upon glucose deprivation. This gives p65 an important role in glucose 
deprivation induced cytokine regulation.  
Within this project we did not investigate how NF-B signaling is induced upon glucose 
deprivation. However, NF-B activation and cytokine release could be mediated by DR5, 
which is induced after 8 h upon glucose deprivation in A549 cells (Paula De Scheemaeker, 
Franziska Püschel, Master Thesis, 2017). This could synergistically promote cytokine release 
at late time points. We observed cytokine mRNA regulation of IL-8 and IL-6 at its highest after 
3 h of glucose deprivation, which suggests that NF-kB is activated at short-times in a different 
manner. Either by the UPR, by EGFR or by toll like receptor (TLR) (Kawai and Akira, 2007) 
activation. Furthermore, the literature suggests that NF-B, in cooperation with STAT3, 
induces IL-6 in starved cells (Yoon et al., 2012).  Since it is reported that NF-kB is constitutively 
active in A549 cells (Zou et al., 2014), it would be possible that p65 is already bound to the 
cytokine promotor and gets activated by cofactor binding, by the dissociation of repressor 
proteins or by epigenetic changes upon glucose deprivation. This is supported by our finding 
that knockdown of p65 also reduced basally IL-8 release in the presence of glucose. Some 
reports claim LIF induction by NF-kB, however in our model we could not confirm this result 
concluding that LIF induction is p65-independent upon glucose deprivation in A549 cells.  
In this project, we did not perform a more deepened analysis of NF-kB activation upon glucose 
deprivation, neither in a canonical nor a non-canonical manner. However, our results point out 
that p65 is to a big extend involved in cytokine induction upon glucose deprivation, however 
the detailed regulatory mechanism needs to be further investigated. 
8.12 Functional analysis of conditioned media of starved A549 cells 
We found that nutrient deprivation and metabolic drugs induced cytokines with known 
functions in immunity, including IL-8, IL-6 and LIF. Translating that into a tumor setting, we 
suggested that cytokine release upon low glucose or treatment with metabolic drugs, could 
favour immune cell infiltration. To determine which functions secreted cytokines from starved 
A549 cells convey, we collected supernatants of glucose-deprived cells and applied them to 
other A549 cells as well as immune cells and investigated cell death, cytokine secretion and 
migration.  
8.12.1 Cytokine release and its impact on cell death  
LIF has been associated with promoting apoptosis in mammary epithelial cells (Schere-Levy et 
al., 2003) and IL-8 is described to be anti-apoptotic in prostate and ovarian cancer cells (Singh 
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and Lokeshwar, 2009; Stronach et al., 2015; Wilson et al., 2008) as well as pro-apoptotic by 
upregulation of Bim in neurons (Thirumangalakudi et al., 2007).  
We found that secreted proteins from starved A549 cells slightly increased cell death upon 
glucose deprivation (Figure 44). We also found that silencing of IL-8 but not LIF protected 
from cell death after 48 h of glucose deprivation. 
IL-8 signals through binding to its receptor CXCR1 and CXCR2, which induces several 
downstream signaling pathways in several cancer cell lines including PI3K, Akt, EGFR and 
ERK signaling (Chan et al., 2017; Luppi et al., 2007; Waugh and Wilson, 2008). ERK was 
recently shown to promote glucose deprivation induced cell death (Shin et al., 2015). It would 
be possible that IL-8 promotes ERK activation through paracrine or autocrine effects. 
Knockdown of IL-8 also minorly reduced DR5 mRNA level, which we found to be involved in 
glucose deprivation induced cell death. However, treatment of A549 cells with recombinant 
IL-8 did not promote cell death induction. This suggests that cell death promoting effects of 
IL-8 depend on additional factors, which are present in the conditioned media of starved A549 
cells. Furthermore, IL-8 signaling could be intracellular and receptor independent, rather than 
through extracellular receptor activation.  
LIF is described to be pro-apoptotic, however in our model we could not confirm this finding. 
However, knockdown of LIF by siRNA was not very efficient and experiments should be 
further validated by the generation of LIF knockout cells.  
In conclusion, more experiments have to be performed to elucidate how secreted cytokines 
affect cell death upon glucose deprivation by using cytokine specific neutralising antibodies or 
by the generation of cytokine and cytokine receptor deficient cells. Nevertheless, these finding 
are important and worthy to be followed up for the development of new anti-cancer strategies. 
8.12.2 The role of LIF in cytokine release 
LIF has been reported to induce inflammatory cytokines (MUSSO et al., 1995; Pascual-García 
et al., 2019; Villiger et al., 1993). We silenced LIF by using siRNA and observed a reduction 
of IL-8 mRNA expression and release. Using recombinant LIF, we confirmed the induction of 
IL-8 and slightly IL-6 release in the presence of glucose. The IL-8 release was even higher in 
the absence of glucose, and cotreatment with LIF, compared to glucose deprivation alone 
(Figure 48). We demonstrated before that IL-8 release upon glucose deprivation is mediated 
by ATF4 as well as partially by mTOR inactivation. In these cells we could not confirm that 
recombinant LIF induces ATF4 or inactivates mTOR by western blot (data not shown).  
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Another possible signaling cascades promoting LIF mediated IL-8 release could be STAT3 
signaling, which is described to be induced by LIF receptor binding in several cancers 
(Ohbayashi et al., 2007; Yue et al., 2016) Moreover, NF-B activation, which was shown to 
promote IL-6 induction in monocytes (Gruss et al., 1992). Therefore, it has to be investigated 
if LIF mediates NF-B activation in our system.  
In conclusion, we found that LIF induced IL-8 release in the presence and absence of glucose, 
however the detailed mechanism remains to be investigated. Therefore, more studies have to 
be performed investigating intracellular signaling pathways induced by LIF upon glucose 
deprivation by using LIF deficient cells. 
8.12.3 Conditioned media promotes the migration of cancer cells 
Chemotaxis is an important feature of cancer cells to metastasize, including the migration and 
invasion from the primary tumor site to a distant site (Condeelis et al., 2005; McSherry et al., 
2007).  Metastasis is induced by changes in gene expression, resulting in loss of cell adhesion 
and matrix remodelling, which are only some mechanisms which promote to the mobilisation 
of the cell. Cell migration can be favoured by chemotactic factors including cytokines, 
chemokines or growth factors. Chemical gradients are sensed by the cell and induce several 
signaling cascades, which promote the migration towards a concentration gradient. Sources of 
chemotactic factors within the TME are cancer associated fibroblasts (CAFs) and immune cells 
(Condeelis and Pollard, 2006; Roussos et al., 2011). IL-8 is known to promote metastasis in 
pancreatic  (Shi et al., 1999) and prostate cancer (Inoue et al., 2000) and LIF promotes migration 
in breast cancer cells (Li et al., 2014) 
We found that A549 cells migrate towards the conditioned media of other A549 cells in the 
presence of glucose, which is independent of metabolites or exhaustion of the media 
(Figure 47). In the absence of glucose this effect was slightly diminished: however, re-addition 
of glucose reversed the lower migration. This suggests that secreted factors of cancer cells 
promote migration. However, conditioned media of starved A549 cells did not have a stronger 
effect on migration which is possibly due to the lack of glucose.  
Recombinant IL-8 and LIF alone did not induce migration in these cells, suggesting that either 
other cytokines or the overall secreted cytokine ‘cocktail’ is responsible for migration. 
However, more studies have to be performed by generating IL-8 and LIF knock out cells or by 
applying neutralizing antibodies to clarify their involvement in the migration of A549 cells. 
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8.12.4 Conditioned media of cancer cells promotes the migration of immune 
cells 
Neutrophils dominate the immune cell composition in NSCLC (Kargl, Nature Commun. 2017), 
which is facilitated by secreted chemokines. Moreover, several reports it is described that the 
induction of the UPR in tumor cells mediates immune infiltration (Obacz et al., 2019).  
In our model we identified several released cytokines and chemokines upon glucose 
deprivation, which potentially could promote immune cell infiltration, including IL-8 and LIF. 
We therefore validated chemotactic responses of immune cells, isolated from human blood, 
towards conditioned media of starved A549 cells.  
We could not find a major effect of the complete conditioned media of starved A549 cells on 
the migration of T cells, NKT cells or NK cells (Figure 49). This is possibly due to the 
‘metabolic competition’ between cancer and immune cell described in several reports (Chang 
et al., 2015; Lyssiotis and Kimmelman, 2017). These reports indicate that cancer cells deplete 
their surrounding tissue of nutrients, which attenuates the activity of several immune cell 
population. Focusing on glucose, low level decrease anti-tumor T cell and NK cell functions 
(Ho et al., 2015). Moreover, some reports describe that secreted metabolites from cancer cells, 
such as lactate, impair T cell and NK cell activation and promote their evasion (Li et al., 2014; 
Renner et al., 2017). Regarding that, we found that the washed conditioned media, which is free 
of any secreted metabolites from the cell and only contains secreted proteins had the tendency 
to promote the migration of T, NKT and NK cells in the presence and absence of glucose. This 
suggests, that the exhausted media of cancer cells, containing among others metabolites, 
attenuates the migratory effects of T cells, NKT cells and NK cells towards the conditioned 
media of starved A549 cells. 
In contrary, B cells migrated towards the conditioned media of starved A549 cells and this was 
amplified towards the washed conditioned media. It is described that B cells infiltrate the tumor 
to attenuate the anti-tumor immune response mediated by T-cells (Sarvaria et al., 2017). 
Glucose dependency varies between different stages of B cell differentiation due to metabolic 
reprogramming. For instance, increased glycolysis is associated with antibody production in 
plasma cells (Caro-Maldonado et al., 2014). Furthermore, B cells upregulate glycolytic 
pathways in hypoxic environments to meet their energetic needs (Jellusova et al., 2017). So far, 
the role of B cells in the tumor environment and their metabolic needs are insufficiently 
investigated. However, it is suggested that glucose deprivation of B cells favours differentiation 
with immunosuppressive outcomes (Singer et al., 2018).  
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In our model, B cells seem to be more resistance towards glucose deprivation and therefore 
migrate towards the conditioned media of starved A549 cells. However, we did not analyse the 
differentiation status of the migrated B cells and therefore, we cannot predict a pro- or anti-
tumorigenic role. Nevertheless, based on the literature it is quite likely that B cell migration 
towards the media of starved cancer cells to promote tumor progression. 
As described before, neutrophils, together with macrophages, are the major immune cell 
representatives in many tumor types, promoting tumor progression and growth. Performance 
of chemotactic assays using primary neutrophils purified from human blood and THP-1 cells, 
which were differentiated towards macrophage-like cells using PMA, confirmed that these cells 
migrated preferentially towards the conditioned media of starved A549 cells (Figure 51,52). 
Further analysis revealed that migration was due to the secreted cytokines of starved A549 cells, 
and not due to the exhausted media. Neutrophils were first classified as glycolytic coupled to 
glucose dependency (Maianski et al., 2004). However, just recently it was reported that a subset 
of immature neutrophils uses mitochondrial fatty acid oxidation to circumvent low nutrients 
supply and to generate NADPH in order to maintain ROS secretion, which subsequently 
attenuates T cell function (Rice et al., 2018). Furthermore, hypoxia was shown to promote the 
anti-inflammatory effects of TAMs in tumors (LaGory and Giaccia, 2016). This suggests that 
neutrophils and macrophages are more resistance towards environments low in glucose, which 
allow them to maintain their cellular functions and migrate towards secreted chemokines from 
starved cancer cells.  
Focusing on IL-8 and LIF as potential chemotactic factors, we observed a tendency of 
recombinant IL-8 and LIF for attracting THP-1 cells. However, more precise experiments have 
to be performed by knockout out IL-8 and/or LIF or by using neutralizing antibodies to validate 
the role of these cytokines in the migration of neutrophils and macrophage-like THP-1 cells. 
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9. Conclusion and future directions 
Within this thesis it was demonstrated that nutrient deprivation as well as the application of 
anti-metabolic drugs mediated the release of pro-inflammatory cytokines from cancer cells. 
This finding is very important, since the application of anti-metabolic or anti-angiogenic drugs, 
could cause inflammatory responses in a tumor setting and worsen patient outcome. Regarding 
the composition of released cytokines upon glucose deprivation we suggest a cell type 
dependency, possibly depending on mutational load and metabolic phenotypes. However, the 
majority of identified cytokines in the tested cell lines were associated with tumor progression 
and poor patient outcome.  
Moreover, we also suggest that this finding could be an evolutionary conserved response and 
non-cancerous body tissue could also promote the release of cytokines upon glucose 
deprivation. Physiological conditions in which nutrient limitation occurs in the body tissue 
include for instance trauma, vessel occlusion followed by stroke and other pathologies, which 
are associated with transient ischemia. Importantly, these scenarios are associated with 
inflammation that is up to date related to hypoxia or necrosis, promoting wound healing.  
We demonstrated in this project, that nutrient deprivation alone causes cytokine release and the 
migration of immune cells, which could promote tumor progression as well as wound healing. 
Regarding the intracellular regulation we found that most of the tested cytokines, with focus on 
IL-8 and IL-6, are regulated in an UPR-dependent manner, mediated by ATF4. We also 
confirmed that p65, a transcription factor of the NF-B pathway, is next to ATF4 the major 
inducer of the tested cytokines and could be either induced downstream of the UPR or in an 
independent manner. Within this project we did not demonstrate how glucose deprivation 
induced the NF-B pathway. Due to its complexity, the exploration of NF-B activation upon 
glucose deprivation is a follow-up project in the group. 
Regarding LIF, we could not identify the detailed regulatory mechanism that caused its release 
upon glucose deprivation. Investigations including the UPR, NF-B and mTOR pathway only 
show minor regulatory roles. This suggests that LIF induction is possibly independent of 
classically induced stress signaling pathways upon glucose deprivation and leads to the 
temporary conclusion that LIF is induced by glucose sensing mechanisms in a short response 
rather than by stress signaling pathway. This is supported by the finding that LIF has a major 
role in inducing cytokines such as IL-8 and IL-6 upon glucose deprivation. This finding is 
important, since targeting LIF alone could already be sufficient to suppress glucose deprivation 
induced cytokine release, which could be a new therapeutic target for anti-cancer therapies. Up 
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to date, the further investigation of LIF regulation upon glucose deprivation is another follow-
up project in the lab.  
In general, we conclude that not all cytokines are regulated in the same manner and depending 
on the cell and cytokine type more investigations have to be performed in order to make 
predictions for the release of specific cytokines. Moreover, within this project we did not 
investigate whether the overall impact of these cytokines is pro- or anti-tumorigenic and how 
this affects tumor progression or patient survival. 
The most important finding is that cytokines, released upon glucose deprivation, promoted the 
migration of primary B cells and neutrophils as well as of macrophage-like THP-1 cells, which 
are associated with immune suppressive functions and poor patient survival. These finding were 
not translated in an animal model or in a clinical setting so far. However, it is highly 
recommended to perform in vivo studies, including a mouse model with an inducible knockout 
of glucose metabolism related genes to mimic glucose deprivation, independent of hypoxia. 
Moreover, the model should be syngeneic to monitor immune cell infiltration. This would give 
deeper insights whether cytokines released by glucose deprivation promote a pro- or anti-
tumorigenic immune response and how this affects the overall survival of the patient. A 
schematic overview of the conclusion is presented in Figure 56. 
A future clinical direction would be to treat patients with anti-metabolic or anti-angiogenic 
drugs in combination with neutralizing antibodies for specific cytokines, which could increase 
the efficiency of the anti-metabolic drugs in the clinic through the modulation of the immune 
response in the tumor.  
To sum it up, these finding offer a completely new understanding of how inflammatory 
responses may be initiated in a tumor and this knowledge opens up new therapeutically targets 
and therapies for the cure of cancer.  
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Figure 56 Schematic overview of the conclusion 
Middle: We found that glucose deprivation and the application of anti-metabolic drugs 
promotes the release of inflammatory cytokines from cancer cells. Secreted factors promoted 
the attraction of macrophage-like THP-1 cells as well as of primary neutrophils and B cells 
purified from human blood. Left: Glucose and glutamine deprivation as well as 2-DG and 
metformin treatment promoted the release of IL-8 and IL-6 in several cancer cell lines. We 
found that ATF4, promoted IL-8 and IL-6 release. We also found that the major regulator of 
IL-8 and IL-6 release was p65. Right: Glucose deprivation and 2-DG treatment promoted LIF 
release from several cancer cell lines. We also found that LIF promoted the release of IL-8 in 
the presence and absence of glucose. ATF6 and PERK slightly regulated LIF release.
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Glucose Deprivation Induces ATF4-
Mediated Apoptosis through TRAIL
Death Receptors
Raffaella Iurlaro,a Franziska Püschel,a Clara Lucía León-Annicchiarico,a
Hazel O’Connor,b Seamus J. Martin,b Daniel Palou-Gramón,a Estefanía Lucendo,a
Cristina Muñoz-Pinedoa
Cell Death Regulation Group, Molecular Mechanisms and Experimental Therapy in Oncology Program,
Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spaina; Molecular Cell
Biology Laboratory, Department of Genetics, The Smurfit Institute, Trinity College, Dublin, Irelandb
ABSTRACT Metabolic stress occurs frequently in tumors and in normal tissues un-
dergoing transient ischemia. Nutrient deprivation triggers, among many potential
cell death-inducing pathways, an endoplasmic reticulum (ER) stress response with
the induction of the integrated stress response transcription factor ATF4. However,
how this results in cell death remains unknown. Here we show that glucose depriva-
tion triggered ER stress and induced the unfolded protein response transcription factors
ATF4 and CHOP. This was associated with the nontranscriptional accumulation of TRAIL
receptor 1 (TRAIL-R1) (DR4) and with the ATF4-mediated, CHOP-independent induction
of TRAIL-R2 (DR5), suggesting that cell death in this context may involve death receptor
signaling. Consistent with this, the ablation of TRAIL-R1, TRAIL-R2, FADD, Bid, and
caspase-8 attenuated cell death, although the downregulation of TRAIL did not, sug-
gesting ligand-independent activation of TRAIL receptors. These data indicate that
stress triggered by glucose deprivation promotes the ATF4-dependent upregulation
of TRAIL-R2/DR5 and TRAIL receptor-mediated cell death.
KEYWORDS apoptosis, ATF4, cancer metabolism, glucose, TRAIL
Glucose is an essential nutrient for mammalian cells. In particular, cancer cellsdisplay glucose avidity and are more sensitive to cell death by starvation than
nontransformed cells. This predisposition to cell death has been associated with the
hyperactivation of oncogenes and the inactivation of tumor suppressors, most of which
regulate glucose uptake and utilization (1–3).
Cell death induced by glucose deprivation is thought to occur in the nutrient-
deprived necrotic core and is the desirable outcome of novel anticancer therapies that
target glucose metabolism (4). However, the cell death pathways engaged by glucose
deprivation remain unclear. Some reports indicate that glucose deprivation leads to
energy stress or endoplasmic reticulum (ER) stress that can cause necrosis of mouse
embryonic fibroblasts or rhabdomyosarcoma (5, 6). In other cell types, particularly
hematopoietic tumor cells, glucose deprivation leads to mitochondrial apoptosis, which
is mediated by Bcl-2 family proteins (7–9). In cells that are incapable of undergoing
apoptosis through the mitochondrial pathway, such as Bax-Bak-deficient mouse em-
bryonic fibroblasts (MEFs), glucose deprivation stimulates caspase-8-mediated apopto-
sis instead (10).
The signaling pathways that promote cell death in response to starvation are a
subject of debate. It was thought that the loss of ATP and mTOR inactivation were the
cause of cell death induced by starvation. However, it was recently shown that cell
death caused by the loss of specific nutrients is a highly regulated process that depends
on active signaling pathways. In response to glutamine depletion or the inhibition of
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glutaminolysis, the transcription factor ATF4 is induced by a mechanism involving its
selective translation, and it leads to the induction of proapoptotic Bcl-2 family proteins
(11). This transcription factor is part of the integrated stress response (ISR) engaged in
the response to viral infection or amino acid depletion and of the unfolded protein
response (UPR) activated in response to ER stress. In response to glucose deprivation or
inhibition of glucose metabolism with 2-deoxyglucose, ATF4 has also been shown to be
induced, and it regulates the mitochondrial apoptotic pathway (12, 13). Here we show
that ATF4 is required for apoptosis induced by glucose deprivation in cells in which
caspase-8 is the apoptosis-initiating caspase. Glucose deprivation induces the TRAIL
receptors DR4 and DR5. TRAIL receptor 2 (TRAIL-R2)/DR5 is regulated by ATF4 in this
context, and both receptors mediate cell death, with TRAIL receptor 2 being quanti-
tatively more important.
RESULTS
Glucose deprivation induces apoptosis and endoplasmic reticulum stress in
human tumor cells. Human tumor cell lines have been shown to die either by necrosis
or by apoptosis upon glucose deprivation. We show here that in HeLa cells, glucose
withdrawal resulted in poly(ADP-ribose) polymerase (PARP) and caspase-3 cleavage
after 48 and 72 h of treatment that was prevented by cotreatment with the caspase
inhibitor Q-VD (Fig. 1A), indicating that cell death is apoptosis. Moreover, HeLa cells
were protected by cotreatment with the pancaspase inhibitors Q-VD and Z-VAD but not
with Y-VAD, an inhibitor of caspase-1, indicating that cell death is due to apoptotic and
not inflammatory caspases (Fig. 1B). To test whether these cells died through mito-
chondrial apoptosis, we subjected HeLa cells overexpressing Bcl-xL (14) to glucose
deprivation and observed that they also died in a caspase-dependent manner, al-
though they were partially protected, and thus, the kinetics were slower (Fig. 1C and D).
These cells were completely protected from tumor necrosis factor (TNF), which kills
HeLa cells in a mitochondrion-dependent manner. Additionally, we subjected HCT116
cells and their Bax-Bak-deficient counterparts to glucose deprivation and observed that
they died with different kinetics, but in both cases, they were significantly protected by
cotreatment with Q-VD (Fig. 1E to G). In all cell lines, a necrotic component was
observed at later time points. Since HeLa cells do not express RIPK3 (15), this compo-
nent is probably not necroptotic. However, we employed inhibitors of RIPK1 and RIPK3
in HCT116 cells and their Bax-Bak-deficient counterparts and observed that these
inhibitors do not confer protection from cell death when incubated in the presence or
absence of the caspase inhibitor Q-VD (Fig. 1F and G). Similarly, HeLa cells were not
protected by using necrostatin-1 (Fig. 1H). Indeed, this compound was slightly toxic at
high concentrations and longer times, possibly as an inhibitor of the tryptophan-
catabolizing enzyme IDO (indoleamine-pyrrole 2,3-dioxygenase) (Fig. 1F to H) (16). All
these data suggested that glucose deprivation activates apoptosis partially indepen-
dently of the mitochondrial apoptotic pathway, together with nonnecroptotic necrosis.
We and others have shown that the transcription factor ATF4 plays a role in cell
death induced by the deprivation of glucose or glutamine (6, 11, 17) or by treatment
with the nonmetabolizable glucose analog 2-deoxyglucose (12). ATF4 is central to the
integrated stress response and the unfolded protein response induced, among other
stimuli, upon ER stress. Glucose is required to provide glycosylation precursors, and its
absence disturbs the ER and Golgi apparatus (18). Additionally, glucose deprivation
may cause a secondary loss of amino acids, which is known to activate the ISR, which
is mediated by the uncharged tRNA-activated kinase GCN2. As shown in Fig. 2A and B,
glucose deprivation induces ATF4, its downstream effector CHOP, and ER stress, as
measured by the induction of the chaperone GRP78/Bip and splicing of the mRNA of
XBP1, a target of the ER stress sensor IRE1. This suggests that the ISR/UPR may
participate in cell death, as previously observed for other cell lines (19).
Glucose deprivation regulates levels of TRAIL receptors. Stimuli that promote
endoplasmic reticulum stress, such as tunicamycin and thapsigargin, can induce apop-
totic cell death through the mitochondrial pathway. However, they have also been
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FIG 1 Glucose deprivation induces apoptosis and necrosis in human tumor cell lines. (A) HeLa cells were plated at 20% confluence
in 60-mm dishes, and 24 h later, they were incubated with (Glc) or without (Glc) glucose for the indicated times in the presence
of DMSO (Q-VD) or Q-VD (Q-VD). Western blotting of caspase-3 and PARP is shown. (B) HeLa cells were incubated in the
presence or absence of glucose plus DMSO, Y-VAD, Q-VD, or Z-VAD and collected to determine PI incorporation by FACS analysis
at the indicated time points. The averages and SEM of data from at least three experiments are shown. (C and D) HeLa and
HeLa-Bcl-xL cells were plated at 20% confluence in 12-well plates, and 24 h later, they were incubated without glucose for 24, 48,
(Continued on next page)
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shown to induce TRAIL receptors and to be sensitized to TRAIL (20). Intriguingly, some
TRAIL receptors can mediate ER stress-induced cell death in a manner independent of
death receptor-death ligand interactions (21–23). Since glucose deprivation induced
ATF4 and CHOP, the latter of which has been linked to TRAIL receptor transcription (24),
we examined the levels of TRAIL receptors upon treatment without glucose. Figure 2C
shows that glucose deprivation strongly induced the accumulation of the TRAIL
receptors DR4/TRAIL-R1 and DR5/TRAIL-R2. Next, we analyzed their mRNA levels.
Quantitative PCR (qPCR) analysis indicated that mRNA levels of DR4 did not change
upon glucose withdrawal at any time examined, with the exception of later time points
at which DR4 mRNA levels are reduced (Fig. 2D). In contrast, the accumulation of DR5
may involve its transcriptional upregulation at short times (Fig. 2E), although by 24 h
of glucose deprivation, DR5 mRNA levels returned to control levels, while the protein
levels continued to increase. DR5 was previously shown to be localized mainly in
intracellular membranes upon treatment with ER-stressing drugs (22), although an
increase in plasma membrane translocation was also detected (25). We analyzed DR5
localization in cells grown without glucose and observed that the majority of DR5
detected after treatment accumulated in the Golgi apparatus and did not colocalize
with mitochondria or the endoplasmic reticulum protein calnexin (see Fig. 6F and G
and data not shown). However, we also observed some accumulation in the plasma
membrane (see Fig. 6F and G).
Altogether, these data indicated that glucose deprivation regulates the expression
of TRAIL receptors, possibly via ER stress-dependent pathways and most likely in a
posttranscriptional manner.
Caspase-8, FADD, and Bid mediate apoptosis induced by glucose deprivation.
Caspase-8 is the apical caspase in the death receptor pathway, which cleaves and
activates executioner caspases directly or indirectly upon death receptor ligation. Death
receptors activate caspase-8 through the recruitment of adapter molecules to a death-
inducing signaling complex (DISC) to which this protease is recruited. Previously, we
showed that Bax-Bak-deficient MEFs subjected to glucose deprivation die in a caspase-
8-dependent manner that could bypass the mitochondrial pathway (10). To test
whether caspase-8 was involved in the apoptosis of HeLa cells, we silenced caspase-8
using small interfering RNA (siRNA), and we detected a significant reduction of cell
death under glucose deprivation (10) (Fig. 3A and B). siRNA against this protease
revealed that caspase-8 also participated in the apoptosis of Bcl-xL-overexpressing
HeLa cells (Fig. 3C). Moreover, the apoptosis of Bax-Bak-deficient HCT116 cells was also
dependent on caspase-8, although the amount of protection conferred by the siRNA
was small, consistent with the small amount of protection conferred by caspase
inhibitors (Fig. 1D and 3D and E). All these data suggest that glucose deprivation
induces caspase-8-dependent apoptosis in diverse human tumor lines with either an
intact or a deficient mitochondrial pathway.
The fact that HeLa cells overexpressing Bcl-xL died slower suggested that the
mitochondria could participate in apoptosis in these cells through the cleavage of Bid
by caspase-8. Indeed, silencing of Bid in HeLa cells partially prevented cell death (Fig.
3F and G). In contrast, levels of BH3-only proteins such as Bim and Noxa, previously
FIG 1 Legend (Continued)
and 72 h or with TNF plus cycloheximide for 24 h and subjected to Western blotting (C) or collected to determine PI incorporation
by FACS (D). The averages and SEM of data from at least three experiments are shown. (E) HCT116 cells were incubated in the
presence or absence of glucose plus DMSO, Q-VD, necrostatin-1 (40 or 100 M), and/or a RIPK3 inhibitor (1 or 3 M) as indicated
and collected for an LDH test at 24 h. The averages and SEM of data from three experiments are shown. (F) Bax/Bak/ HCT116
cells were plated at 20% confluence in 60-mm dishes, and 24 h later, they were incubated without glucose in the presence or
absence of Q-VD and collected to determine PI incorporation by FACS analysis at the indicated time points. The averages and SEM
of data from three experiments are shown. (G) Bax/Bak/ HCT116 cells were incubated in the presence or absence of glucose
plus DMSO, Q-VD, necrostatin-1 (40 or 100 M), and/or a RIPK3 inhibitor (1 or 3 M) as indicated and collected for an LDH test
at 72 h. The averages and SEM of data from at least three experiments are shown. (H) HeLa cells were incubated in the absence
of glucose plus DMSO, Q-VD, or necrostatin-1 or a combination of Q-VD and necrostatin-1 (1 or 3 M) and collected for PI analysis
by FACS analysis at the indicated time points. The averages and SEM of data from at least three experiments are shown. *, P 
0.05; **, P  0.01; ***, P  0.001.
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linked to apoptosis induced by ER stress or by starvation (reviewed in reference 21),
were increased with treatment (Fig. 4A and B), but they did not participate in cell death,
as revealed by siRNA (Fig. 4C to F).
Caspase-8 is usually activated upon its dimerization in intracellular or membrane
DISCs through recruitment by the adapter molecule FADD in response to the interac-
tion of death ligands with death receptors. We previously analyzed the role of these
interactions in cell death induced by glucose deprivation in Bax-Bak-deficient MEFs and
could not detect any role of death ligand-receptor interactions (10). For this reason, we
analyzed two unconventional platforms to activate caspase-8: the ripoptosome and
p62. The ripoptosome is nucleated by the kinase RIPK1 and is formed upon the
inhibition and degradation of cellular inhibitor of apoptosis proteins (cIAP) (26, 27). We
observed that glucose deprivation promoted the disappearance of cIAP1, cIAP2, and
X-linked inhibitor of apoptosis protein (XIAP) (Fig. 5A). This, however, did not lead to a
FIG 2 Glucose deprivation induces ER stress and TRAIL receptors. (A) HeLa cells were incubated with
glucose and/or Q-VD (Q-VD) or DMSO (Q-VD) as indicated for 24, 48, and 72 h and collected for Western
blotting of GRP78, ATF4, and CHOP. (B) HeLa cells were treated with thapsigargin (Tg) for 24 h or incubated
in the presence () or absence () of glucose for the indicated times and collected for reverse
transcription-PCR analysis of unspliced and spliced XBP1. (C) HeLa cells were incubated with glucose and/or
Q-VD (Q-VD) or DMSO (Q-VD) as shown for the indicated times and then collected for Western blotting
of DR4 (TRAIL-R1) and DR5 (TRAIL-R2). (D and E) HeLa cells were incubated with or without glucose for the
times shown and collected for qPCR analysis. DR4 mRNA levels relative to the values for the housekeeping
gene and time zero (T0) are reported in panel B. DR5 mRNA levels relative to the values for the
housekeeping gene and time zero (T0) are reported in panel C. The averages and SEM of data from at least
three experiments are shown. (F and G) HeLa cells were plated for immunofluorescence, and 24 h later, they
were incubated with or without glucose for 24 h before performing confocal analysis of DR5 and GM130
(F) or calnexin (G) localization. *, P  0.05; **, P  0.01; N.S., not significant.
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detectable interaction of RIPK1 and caspase-8 in the absence (Fig. 5B) or presence (data
not shown) of caspase inhibitors. Moreover, the downregulation of RIPK1 did not
prevent cell death induced by glucose deprivation (Fig. 5C and D). Caspase-8 has been
shown to interact with the autophagosomal proteins LC3 and p62 upon several stimuli,
with p62 contributing to its aggregation and activation (21, 28, 29). We previously
described the accumulation of p62 upon glucose deprivation due to an inactivation of
autophagic flux (30) (Fig. 5E and F, input). We observed that caspase-8 coimmunopre-
cipitated with p62 upon glucose deprivation (Fig. 5E and F), However, there was no
measurable translocation of caspase-8 to p62 spots (aggresomes) (Fig. 5G and H), and
similar to what we previously observed in Bax-Bak-deficient MEFs (30), p62 knockdown
did not prevent glucose deprivation-induced cell death (Fig. 5I and J).
In order to examine the role of FADD, we performed colocalization analysis of
caspase-8 and FADD by immunostaining under normal and glucose-deprived condi-
tions (Fig. 6A and B). We detected a basal interaction of the two proteins, but no
changes were observed after glucose removal. In order to clarify the role of FADD in
cell death induced by glucose deprivation, we employed siRNA to target this
protein (Fig. 6C) and observed that its downregulation protected from glucose
deprivation to the same extent that it protected from cross-linking the Fas receptor
with an antibody (Fig. 6D). Moreover, the elimination of FADD by using clustered
regularly interspaced short palindromic repeats (CRISPR) prevented cell death by
glucose deprivation (Fig. 6E and F).
ATF4 and TRAIL receptors mediate apoptosis upon glucose deprivation. It has
been reported that ER stressors induce DR4 and DR5 through the transcription factor
CHOP, which is itself a transcriptional target of ATF4 (24, 31). We thus investigated a
role for the ATF4/CHOP axis in apoptosis induced by glucose deprivation and in the
FIG 3 Human cell lines die in a caspase-8- and Bid-dependent manner under glucose deprivation. (A to C) HeLa cells (A and B) and HeLa-Bcl-xL cells (C) were
plated at 50% confluence in 6-well plates, and 5 h later, they were transfected with caspase-8 or control siRNA. At 24 h posttransfection, cells were treated
without glucose for 24 and 48 h and collected to determine PI incorporation by FACS analysis. The averages and SEM of data from three experiments are shown.
Western blotting of control and caspase-8 siRNA-transfected HeLa cells treated without glucose for the indicated times is shown in panel B. (D and E) Bax/Bak/
HCT116 cells were plated at 50% confluence in 6-well plates, and 5 h later, they were transfected with caspase-8 siRNA or control siRNA. At 24 h posttransfection,
cells were incubated without glucose for 72 and 96 h and collected to determine PI incorporation by FACS analysis. The averages and SEM of data from three
experiments are shown. Western blotting of cells transfected with control or caspase-8 siRNAs is shown in panel E. (F and G) HeLa cells were plated at 50%
confluence in 6-well plates, and 5 h later, they were transfected with Bid (1) and Bid (2) siRNAs or the control siRNA. At 24 h posttransfection, cells were treated
without glucose for 24, 48, and 72 h and collected to determine PI incorporation by FACS analysis. The averages and SEM of data from three experiments are
shown. Western blotting of cells transfected with control, Bid (1), or Bid (2) siRNAs and treated without glucose for the indicated times is shown in panel G.
*, P  0.05; **, P  0.01; ***, P  0.001.
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accumulation of death receptors. ATF4 downregulation with siRNA strongly reduced
cell death, as described by other models of starvation (Fig. 7A and B). Its downregu-
lation also prevented DR5 accumulation although not DR4 expression (Fig. 7C). We
analyzed the role of CHOP and observed that different siRNAs partially protected from
cell death (Fig. 7D and E). Different from a number of studies that reported the
induction of DR5 mediated by CHOP in response to other stimuli, siRNA against CHOP
did not prevent DR5 induction induced by glucose deprivation (Fig. 7F). However, a
modest reduction of the accumulation of DR4 was observed. Because the amount of
protection from cell death conferred by siRNA was very small, we generated cells
lacking CHOP via CRISPR knockout (Fig. 7G and H). These cells showed no protection
from cell death, which indicates that cell death is mediated by ATF4 but is independent
of CHOP.
We subsequently analyzed the role of TRAIL death receptors in apoptosis induced by
glucose deprivation. siRNAs against DR5 protected from cell death, although protection
was not uniform, and their strength depended on the sequence employed (Fig. 8A and
B). Up to five bands corresponding to different isoforms of DR5 (long and short) and
possibly their unglycosylated counterparts were detected upon glucose deprivation
(Fig. 8B). It was previously shown that DR5-mediated cell death in response to thapsi-
gargin is dependent on the long isoform of DR5 (22). We observed that siRNA against
the short isoform (DR5S) did not prevent the death of HeLa cells subjected to glucose
deprivation (Fig. 6A and B). In contrast, sequences that downregulated the long isoform
(DR5L) were effective in protecting HeLa and HeLa-Bcl-xL cells from apoptosis, corre-
lating with their efficiency in suppressing DR5L expression (Fig. 8A to C). In order to
FIG 4 Noxa and Bim are dispensable for glucose deprivation-induced cell death of HeLa cells. (A and B)
HeLa cells were incubated in the presence () or absence (Glc) of glucose for the indicated times and
collected for Western blotting of Bim (A) and Noxa (B). (C and D) HeLa cells were transfected with control
siRNA or siRNAs against Bim, incubated for 24 and 48 h without glucose, and collected for Western
blotting of Bim (C) or FACS analysis (D). (E and F) HeLa cells were transfected with siRNA against Noxa,
incubated for the indicated times without glucose, and collected for FACS analysis (E) and Western blot
analysis (F). N.S., not significant.
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verify the results obtained by using siRNA, we generated cells deficient in DR5, and we
observed protection from cell death (Fig. 8D). DR5 downregulation also prevented the
death of HCT116 and Bax-Bak-deficient HCT116 cells, and in these cells, the downregu-
lation of the short isoform of DR5 was also effective (Fig. 8E to H).
Since we also observed an upregulation of DR4, we employed siRNAs against this
TRAIL receptor and observed that they produced a small but significant reduction of
cell death in HeLa cells (Fig. 9A and B). The deletion of DR4 via CRISPR significantly
protected HeLa cells from glucose deprivation (Fig. 9C). We also observed that the
combination of DR4 and DR5 siRNAs conferred better protection from glucose depri-
vation than did the single siRNAs (P  0.04 for DR4 versus the combination; P  0.01
for DR5 versus the combination) (Fig. 9D and E). However, the double combination of
FIG 5 RIPK1 and p62 are not involved in cell death under glucose deprivation. (A) HeLa cells were plated at 20% confluence in 60-mm dishes,
and 24 h later, they were incubated without glucose for 24, 48, and 72 h and collected for Western blot analysis of cIAPs and XIAP. (B) HeLa cells
were plated at 20% confluence in 100-mm dishes, and 24 h later, they were incubated with or without glucose for 24 h before performing
immunoprecipitation of caspase-8 or GST as a control. Western blots of caspase-8 and RIPK1 are shown. (C) Western blot analysis of
glucose-deprived cells transfected with control () or RIPK1 () siRNA and incubated without glucose for the times shown. (D) HeLa cells were
plated at 50% confluence in 6-well plates, and 5 h later, they were transfected with 50 nM RIPK1 siRNAs or the control siRNA. Twenty-four hours
after transfection, cells were incubated without glucose for 24 and 48 h and collected for PI analysis by FACS analysis. The averages and SEM of
data from three experiments are shown. (E and F) HeLa cells were plated at 20% confluence in 100-mm dishes, and 24 h later, they were incubated
with glucose (), without glucose or Q-VD (), or without glucose but with 10 M Q-VD (-Q) for 24 h before immunoprecipitation of caspase-8
(E) or p62 (F) was performed. Western blot analyses of caspase-8 and p62 are shown. (G and H) HeLa cells were plated for immunofluorescence
analysis, and they were treated with or without glucose for 24 h. Representative confocal microscopy images of caspase-8 and p62 (H) and data
from colocalization analysis using ImageJ software (G) are shown. The graph shows the averages and the standard deviations of data from four
independent experiments. (I and J) HeLa cells were transfected with 50 nM p62 (1) and p62 (2) siRNAs and the control siRNA. At 24 h
posttransfection, cells were incubated without glucose for 24 and 48 h and collected to determine PI incorporation by FACS analysis. Western
blotting of p62 is shown in panel I. The averages and SEM of data from three experiments are shown in panel J. Differences between siRNAs were
not statistically significant.
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CRISPR-deleted DR4 and DR5 did not provide significantly better protection than did
DR5 alone (Fig. 9F and G).
DR5 has been shown to play a role in cell death induced by other stimuli that induce
ER stress: thapsigargin and the GRP78-depleting bacterial agent subtilase cytotoxin AB
(22, 23). Moreover, the authors of that study reported that TRAIL receptor-mediated cell
death occurred in a manner independent of the ligand TRAIL upon treatment with ER
inducers. We tested whether TRAIL participated in cell death induced by glucose
deprivation in these cells. In agreement with our previous results in which a blockade
of death receptor-ligand interactions did not prevent cell death by glucose deprivation
in MEFs (10), the downregulation of TRAIL using two different siRNA oligonucleotides
did not prevent cell death (Fig. 10A and B).
DISCUSSION
This study places the integrated stress response and ER stress-associated factor ATF4
as a central player in apoptosis induced by glucose deprivation. ATF4 is one of the small
subsets of proteins induced under conditions of general translational repression upon
the phosphorylation of the translation initiation factor eIF2. At least two kinases are
responsible for eIF2 phosphorylation upon glucose deprivation: PERK and GCN2 (19,
32). PERK participates in the unfolded protein response and is activated by endoplasmic
reticulum stress, an event that occurs when the glucose level is low, probably due to
the accumulation of misfolded, unglycosylated proteins. GCN2 is activated in the ISR by
amino acid loss (11). The role of these responses and the subsequent translational arrest
is to restore homeostasis; however, eIF2 phosphorylation and ATF4 induction also
induce cell death if damage is not repaired. The role of ATF4 in apoptosis induced by
“classical” ER stressors has been widely documented, although it is unclear which
proteins mediate cell death in this context, and it may depend on the cell type or the
FIG 6 FADD is involved in cell death under glucose deprivation. (A and B) HeLa cells were plated for immunofluorescence, and 24 h later, they
were incubated with (Glc) or without (Glc) glucose for 24 h. Confocal microscope pictures of colocalization of caspase-8 with FADD (A) and
quantification by using ImageJ software (B) are reported. The graph shows the averages and the standard deviations of data from four
independent experiments. (C and D) HeLa cells were transfected with control, FADD (1), or FADD (2) siRNA. At 48 h posttransfection, cells were
incubated without glucose for 24 and 48 h or with an anti-Fas antibody for 48 h and collected for Western blotting (D) and for determining PI
incorporation by FACS analysis (C). The averages and SEM of data from at least three experiments are shown. (E and F) HeLa cells knocked out
for FADD (clones 1 and 2) and their controls were subjected to glucose deprivation for the indicated times and subjected to Western blot analysis
(F) or determination of the number of dead cells under a microscope (E). Data show the averages and SEM of results from three independent
experiments. **, P  0.01; ***, P  0.001.
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coactivation of other pathways (21). Only recently has this protein emerged as a crucial
regulator of metabolic sensing and also as a cell death effector upon amino acid
depletion (11, 17).
We previously reported that ATF4 participates in mitochondrial apoptosis induced
by the glucose analog 2-deoxyglucose, which works as an ER stressor (12). In addition,
it was recently shown that ATF4 participates in the induction of apoptosis in response
to glucose deprivation in HEK293 cells (13) and in the necrosis of rhabdomyosarcoma
cells deprived of glucose (6). However, in these studies, the mechanism of cell death
was not elucidated. Shin et al. reported a role for the BH3-only protein Bid downstream
of ATF4 (13). Our data indicate that Bid, Bax, and Bak participate in the transduction of
FIG 7 ATF4 and CHOP. (A to C) HeLa cells were transfected with ATF4 siRNAs or the control siRNA. At 24 h posttransfection,
cells were incubated without glucose for 24, 48, and 72 h and collected to determine PI incorporation by FACS analysis (C).
The averages and SEM of data from four to seven experiments under each condition are shown. Western blots of ATF4, DR5,
and DR4 in cells transfected with control, ATF4 (1), and ATF (2) siRNAs are shown in panels B and C. (D to F) HeLa cells were
transfected with CHOP siRNAs and the control siRNA. At 24 h posttransfection, cells were incubated without glucose for 24,
48, and 72 h and collected to determine PI incorporation by FACS analysis (D). The averages and SEM of data from at least three
experiments are shown. Western blots of CHOP, DR5, and DR4 in cells transfected with control or CHOP siRNAs are shown in
panels E and F. (G and H) HeLa cells knocked out for CHOP (clones 1 and 2) and their controls were subjected to glucose
deprivation for the indicated times and subjected to Western blot analysis after treatment with 10 g/ml brefeldin A or
determination of the number dead cells under a microscope. Data show averages and SEM of results from three independent
experiments. **, P  0.01; ***, P  0.001; N.S., not significant.
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cell death signals from caspase-8 to mitochondria, although apoptosis also occurred in
Bcl-xL-overexpressing or Bax-Bak-deficient cells. Cell death in response to ER stressors,
including glucose deprivation and inhibitors of glycolysis, is generally thought to be
mediated through the transcriptional activation of the mitochondrial pathway of
apoptosis by CHOP downstream of ATF4. Indeed, CHOP induces Bim in response to the
glycolytic inhibitor 2-deoxyglucose (33). CHOP is not only important for the activation
of the mitochondrial pathway but is also the ER stress-associated transcription factor
that mediates TRAIL receptor induction in several cell lines upon ER stress (22–24, 31).
However, ER stress-dependent, CHOP-independent upregulation of DR5 has also been
documented (20). In the present study, and in contrast to other reports, CHOP did not
play a role in the induction of DR5, although participation in DR4 accumulation upon
glucose deprivation was observed. However, the mRNA levels of DR4 do not change
after the treatment, which suggests that the regulation of this receptor is achieved
mostly at the posttranscriptional level. In contrast, we observed the transcriptional
induction of DR5 at early time points of glucose removal and a strong accumulation of
the protein at later time points, which could be prevented by ATF4 but not CHOP
silencing. These data suggest that ATF4 might directly regulate the expression of DR5,
independently of CHOP, possibly at both the transcriptional and posttranscriptional
levels (Fig. 10).
Downstream of death receptors, glucose deprivation has been described to reduce
FLIP levels, thus leading to sensitization to TRAIL, although FLIP downregulation does
not occur in all cell types (34, 35). We describe here an unequivocal role of FADD as a
mediator of apoptosis induced by glucose deprivation, while the FADD- and caspase-
8-interacting protein RIPK1 did not play any role in cell death, nor did p62, which we
have previously shown accumulates upon glucose deprivation in these cells and can
regulate caspase-8 activation downstream of TRAIL receptors (28, 30). A possible role of
TRADD and other adapter molecules remains to be tested.
FIG 8 DR5 siRNAs protect from death induced by glucose deprivation. (A and B) HeLa cells were transfected with DR5L (1), DR5L (2), DR5S, DR5 (Tot), or the
control siRNA. At 24 h posttransfection, cells were incubated without glucose for 24 and 48 h and collected to determine PI incorporation by FACS analysis (A)
or Western blot analysis of DR5 48 h after treatment (B). The averages and SEM of data from at least three experiments are shown. (C) HeLa-Bcl-xL cells were
transfected with DR5L (1), DR5L (2), DR5S, or the control siRNA. At 24 h posttransfection, cells were incubated without glucose for 24 and 48 h and collected
to determine PI incorporation by FACS analysis. The averages and SEM of data from at least three experiments are shown. (D) Control HeLa cells and cells
deficient in DR5 (KO1 and KO2) were incubated without glucose for the indicated times, and the number of dead cells was determined with a microscope.
Shown are averages and SEM of data from three independent experiments. Western blotting for the expression of DR5 is shown in Fig. 9F. (E and F) HCT116
cells were transfected with DR5L (1), DR5L (2), DR5S, DR5 (Tot), or the control siRNA. At 24 h posttransfection, the cells were incubated without glucose for 24
h and collected for an LDH test. The averages and SEM of data from four experiments are shown. Western blotting of DR5 after 24 h of treatment is shown
in panel F. (G and H) Bax/Bak/ HCT116 cells were transfected with DR5L (1), DR5L (2), DR5S, DR5 (Tot), or the control siRNA. At 24 h posttransfection, cells
were incubated without glucose for 72 h and collected for an LDH test. The averages and SEM of data from four experiments are shown. Western blotting of
DR5 in Bax/Bak/ HCT116 cells 72 h after treatment is shown in panel H. *, P  0.05; **, P  0.01; ***, P  0.001; N.S., not significant.
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DR5 has been shown in several reports to play a role in cell death induced by other
stimuli that induce ER stress, most notably thapsigargin (22–24). The role of DR4 is less
established, although it has also been documented (31). The precise mechanism that
activates these receptors upon glucose deprivation remains to be determined. In the
case of “classical” ER stressors such as tunicamycin and thapsigargin, death mediated by
DR5 could not be blocked by using siRNA against TRAIL or incubating cells in the
presence of an extracellular, soluble form of TRAIL receptors (22, 23). Here we show that
the downregulation of TRAIL to undetectable levels did not prevent cell death by
glucose deprivation. This suggests that these receptors are activated through ligand-
independent, intracellular aggregation. In fact, it is known that the overexpression of
death receptors can induce their activation (36). This aggregation could possibly occur
in membranes of the secretory pathway, such as those of the Golgi apparatus, although
this remains to be proven, and the mechanism remains to be identified. Glucose is
required not only for energy production but also as a substrate for the posttranscrip-
tional modification of proteins. It is possible that the lack of glucose modifies trafficking
through secretory pathways, which, together with the modification of glycosylation
patterns of the receptors themselves, may promote ligand-independent associations.
MATERIALS AND METHODS
Cell culture and treatments. HeLa cells from the ATCC and Bax/Bak/ simian virus 40 (SV40)-
transformed MEFs (37) were cultured in pyruvate-free high-glucose (25 mM) DMEM (Dulbecco’s modified
Eagle’s medium; Gibco Life Technologies, Waltham, MA). HCT116 cells and Bax/Bak/ HCT116 cells
FIG 9 DR4 is involved in cell death under glucose deprivation. (A and B) HeLa cells were transfected with DR4 (1), DR4 (2), or the control siRNA. At 24 h
posttransfection, cells were incubated without glucose for 24 and 48 h and collected to determine PI incorporation by FACS analysis. The averages and SEM
of data from at least three experiments are shown in panel A. Western blotting of cells treated for 48 h without glucose and transfected with control, DR4 (1),
or DR4 (2) siRNA is shown in panel B. (C) Control HeLa cells and cells deficient in DR4 (KO1 and KO2) were incubated without glucose for the indicated times,
and the dead cells were counted under a microscope. Shown are averages and SEM of data from three independent experiments. Western blotting is shown
in panel F. (D) HeLa cells were transfected with DR4 (1), DR5L (1), or control siRNA (50 nM) or the combination of DR4 (1) plus DR5L (1) siRNAs at 100 nM as
a control. At 24 h posttransfection, cells were incubated without glucose for 24 and 48 h and collected to determine PI incorporation by FACS analysis. The
averages and SEM of data from at least three experiments are shown. Numbers indicate the average protection (percent) conferred by each siRNA or siRNA
combination versus its control. (E) Western blotting of DR5 and DR4 in HeLa cells 48 h after treatment. (F) Western blotting of knockout cells (DR4, DR5, and
DR4-DR5 double knockout) generated as described in Materials and Methods. (G) Control HeLa cells and cells doubly deficient in DR4 and DR5 (KO1 and KO2)
were incubated without glucose for the indicated times, and the dead cells were counted under a microscope. Shown are averages and SEM of data from three
independent experiments and include DR5 data from Fig. 8D for comparison. Western blotting is shown in panel F. *, P  0.05; **, P  0.01; ***, P  0.001.
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(provided by M. Rehm, Royal College of Surgeons Ireland) were cultured in RPMI medium supplemented
with 10% FBS (fetal bovine serum; Invitrogen, Carlsbad, CA), 200 mg/ml of penicillin (Invitrogen), 100
mg/ml of streptomycin (Invitrogen), and 2 mM glutamine (Invitrogen). Cells were maintained at 37°C in
a 5% CO2 atmosphere and split 3 times per week by using a 0.05% trypsin–EDTA solution (Invitrogen).
For glucose deprivation treatment, cells were plated at a concentration of 150,000 cells/ml in 6-well
plates or 60-mm dishes (BD) and treated 24 h later, when they reached a concentration of 500,000
cells/ml, corresponding to 80% confluence. Cells were washed twice with FBS-free, pyruvate-free,
glucose-free DMEM (Gibco Life Technologies) and then treated with this medium supplemented with 200
mg/ml penicillin, 100 mg/ml streptomycin, freshly added 2 mM glutamine, and 10% dialyzed FBS. The
same procedure was used for treating Bax/Bak/ HCT116 cells by using glucose-free RPMI medium
(Gibco Life Technologies). Q-VD-OPH (apeXbio, Houston, TX) and Ac-Y-VAD-cmk (Sigma-Aldrich, St. Louis,
MO) were used at 10 M, Z-VAD-fmk (apeXbio) was used at 20 M, and all components were added at
the moment of treatment. The same amount of dimethyl sulfoxide (DMSO) was added to control wells.
TNF- (Peprotech, Le-Perray-en-Yvelines, France) was used at 10 ng/ml in combination with 10 M
cycloheximide. Necrostatin-1 (catalog number BML-AP309-0020; Enzo, Farmingdale, NY) was used at 40
and 100 M, while a RIPK3 inhibitor (GSK’872; Calbiochem, Darmstadt, Germany) was used at 1 and 3 M.
Fas human-activating CH11 antibody (Millipore, Darmstadt, Germany) was used at 50 ng/ml. Thapsi-
gargin (Sigma-Aldrich) was used at 300 ng/ml.
siRNA transfection. HeLa and Bax/Bak/ HCT116 cells were plated into 6-well plates at a conflu-
ence of 50% and transfected 5 h later. A transfecting solution containing 50 nM each siRNA and 1 l/ml
Dharmafect1 (Fisher-Thermo Scientific, Waltham, MA) was incubated for 30 min in DMEM without serum
and antibiotics and then added to the cells that had previously been incubated in DMEM without
FIG 10 TRAIL does not participate in cell death. HeLa cells were transfected with 50 nM TRAIL siRNAs or the
control siRNA. At 24 h posttransfection, cells were incubated with or without glucose for 24 and 48 h. (A)
Averages and SEM of data from three experiments to determine PI incorporation by FACS analysis. (B)
Western blotting of cells incubated for 24 h or 48 h without glucose or for 24 h with glucose and transfected
with control, TRAIL (1), or TRAIL (2) siRNA. (C) Summary of pathways leading to cell death of glucose-
deprived HeLa cells.
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antibiotics. Cells were maintained in transfection medium for 24 h or 48 h in the case of FADD siRNAs
before treatments were performed. Control sequences were a nontargeting sequence (5=-UAAGGCUAU
GAGAGAUAC-3=) and an On-Target control (Dharmacon, Lafayette, CO). siRNA sequences were 5=-GCC
UAGGUCUCUUAGAUGA-3= for ATF4 (1), 5=-CCAGAUCAUUCCUUUAGUUUA-3= for ATF4 (2), 5=-
GAAGACAUCAUCCGGAAUA-3= for Bid (1), 5=-CAGGGATGAGTGCATCACAAA-3= for Bid (2), 5=-GCACCCAU
GAGUUGUGACA-3= for Bim (1), 5=-GACCGAGAAGGUAGACAAUUG-3= for Bim (2), Dharmacon On-Target
Plus siRNA pools of 4 oligonucleotides for caspase-8 in HCT116 cells, 5=-GGAGCUGCUCUUCCGAAUU-3=
for caspase-8 in HeLa cells, 5=-AAGAACCAGCAGAGGUCACAA-3= for CHOP (1), 5=-GCCTGGTATGAGGAC
CTGC for CHOP(2), 5=-CACCAAUGCUUCCAACAAU-3= for DR4 (1), 5=-AACGAGAUUCUGAGCAACGCA-3= for
DR4 (2), 5=-GACCCUUGUGCUCGUUGUC-3= for DR5 (Tot), 5=-CCUGUUCUCUCUCAGGCAUUU-3= for DR5L
(1), 5=-UGUGCUUUGUACCUGAUUCUU-3= for DR5L (2), 5=-UAUGAUGCCUGAUUCUUUGUG-3= for DR5S,
5=-GAUUGGAGAAGGCUGGCUC-3= for FADD (1), 5=-GAACUCAAGCUGCGUUUAU-3= for FADD (2), 5=-GGU
GCACGUUUCAUCAAUU-3= for Noxa (1), 5=-GCTACTCAACTCAGGAGATTT-3= for Noxa (2), 5=-GAUCUGCG
AUGGCUGCAAUUU-3= for p62 (1), 5=-GCAUUGAAGUUGAUAUCGAU-3= for p62 (2), an On-Target Plus
siRNA pool of 4 oligonucleotides for RIPK1, 5=-AACGAGCUGAAGCAGAUGCAG-3= for TRAIL (1), and
5=-UUGUUUGUCGUUCUUUGUGUU-3= for TRAIL (2).
Generation of knockout cell lines via CRISPR-Cas9. HeLa cells (105 cells/well in 6-well plates) were
transfected with 1 g plasmid plentiCas9-BLAST (Addgene plasmid 52962) by using GenJet, followed 24
h later by selection with blasticidin (6 mg/ml) for 7 days. Blasticidin-resistant cells were then seeded as
single cells into 96-well plates. After 3 to 4 weeks, colonies derived from single clones were screened for
Cas9 expression by immunoblotting. Targeted single guide RNAs (sgRNAs) were designed with the help
of the Broad Institute sgRNA design tool (http://portals.broadinstitute.org/gpp/public/analysis-tools/
sgrna-design) and cloned into pLentiguidePuro (Addgene plasmid 52963). HeLa cells stably expressing
Cas9, generated as described above, were transfected with plasmids containing sgRNAs of interest by
using GenJet and selected with 250 ng/ml puromycin for 7 days. Puromycin-resistant cells were seeded
as single colonies into 96-well plates. After 3 to 4 weeks, colonies derived from single clones were
screened for the expression of proteins of interest by immunoblotting. Sequences are GCGGGGAGGAT
TGAACCACG for DR4 sgRNA 1, AAGTGTGGGGCTCTTCCGCG for DR4 sgRNA 2, CCAGGACCCAGGGAGG
CGCG for DR5 sgRNA 1, CCTAGCTCCCCAGCAGAGAG for DR5 sgRNA 2, GAGGCATAGGAACTTGAGCT for
FADD sgRNA 1, GCTCCAGCAGCATGGAGAAG for FADD sgRNA 2, CCAGCTGGACAGTGTCCCGA for CHOP
sgRNA 1, and AGCACATCTGCAGGATAATG for CHOP sgRNA 2. Controls used for experiments were cells
transfected with the empty vector and subjected to the same procedures.
Cell death analysis. Cell death analysis was performed quantifying propidium iodide (PI) incorpo-
ration by fluorescence-activated cell sorter (FACS) analysis. After treatment, adherent cells and dead cells
in suspension were collected by trypsinization and centrifuged at 450  g for 7 min. The cells were then
resuspended in a final volume of 300 l of phosphate-buffered saline (PBS) plus 0.5 g/ml of PI and
analyzed by using a Gallios flow cytometer (Beckman Coulter). Quantification was done by using FlowJo
software version 7.6.4. A lactate dehydrogenase (LDH) test (Promega, Fitchburg, WI) was also used to
measure cell death. After treatment, 50 l of conditioned medium was resuspended in reactive solution
and incubated for 30 min at 37°C in a 96-well plate. The absorbance at 490 nm was acquired by using
a BioTek PowerWave XS microplate spectrophotometer. Cell death of knockout (CRISPR) cell lines was
analyzed by counting dead cells under an inverted microscope. A total of 150 cells per well and 3 wells
per condition were counted.
Immunoprecipitation. After treatment, cells were collected by using immunoprecipitation (IP)
buffer (20 mM Tris-HCl [pH 7.5], 137 mM NaCl, 1% Triton X-100, 2 mM EDTA [pH 8]) containing protease
inhibitors (Roche, Basel, Switzerland), lysed on ice for 20 min, sonicated, and quantified by using a
bicinchoninic acid (BCA) colorimetric kit (Pierce-Thermo Scientific, Waltham, MA) according to the
manufacturer’s instructions. The Pure Proteome protein G magnetic bead system (Millipore) was used for
immunoprecipitation. Twenty-five microliters of magnetic beads under each condition was blocked by
incubation with IP buffer including 1% bovine serum albumin (BSA) for 1 h at 4°C under rotation. The
beads were then incubated with 1 g of primary antibodies for 3 to 4 h at 4°C under rotation. This
solution was replaced with 1,200 g of lysates in 1 ml of IP buffer supplemented with protease inhibitors
(Roche), and the mixture was incubated overnight at 4°C under rotation. Beads were then washed 3 to
4 times with IP buffer, and proteins were eluted with IP buffer plus 2% SDS and then incubated with
Laemmli buffer (with freshly added 2-mercaptoethanol) and warmed at 95°C for 10 min before being
loaded onto an SDS-PAGE gel. Inputs were total lysates and represent 5% of the immunoprecipitated
fraction. Primary antibodies used for IP were anti-human caspase-8 p18 (C-20; Santa Cruz, Dallas, TX) and
anti-p62 (catalog number BML-PW9860; Enzo, Farmingdale, NY). Anti-glutathione S-transferase (anti-GST)
(rabbit IgG) and anti-green fluorescent protein (anti-GFP) (mouse IgG), used as isotype controls, were
obtained from Rockland (Limerick, PA). Horseradish peroxidase (HRP)-conjugated Clean-Blot IP detection
reagent (Thermo Scientific) was used as a secondary antibody for Western blotting of p62.
Western blotting. After treatments, cells were collected by trypsinization, mixed with floating cells,
washed with PBS, and centrifuged at 500  g. The pellet was resuspended in radioimmunoprecipitation
assay (RIPA) buffer (Thermo Scientific) supplemented with protease inhibitors (Roche) and phosphatase
inhibitors (Roche). The lysates were then sonicated and quantified by using BCA. Forty micrograms of
proteins under each condition was prepared in a 40-l final volume of 4 Laemmli buffer (63 mM
Tris-HCl, 10% glycerol, 2% SDS, 0.01% bromophenol blue, 5% 2-mercaptoethanol) and warmed at 95°C
for 10 min. The proteins were loaded onto an SDS-PAGE gel (Mini-protean; Bio-Rad, Hercules, CA) and run
at 120 V for 1 h 30 min. The proteins were then transferred to an Immobilon-FL polyvinylidene difluoride
(PVDF) membrane (Merck Chemicals, Darmstadt, Germany) using the Trans-Blot SD (Bio-Rad) semidry
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system for 1 h at 200 mA. The transfer of the proteins was checked by Ponceau S staining (Sigma-Aldrich).
Membranes were blocked with 5% nonfat dry milk in Tween–Tris-buffered saline (TBS) (TTBS) or in
Odyssey blocking solution (Li-Cor Biosciences, Lincoln, NE) for 1 h at room temperature. The membranes
were then incubated with primary antibodies generally diluted 1:1,000 in blocking solution for 1 to 2 h
at room temperature or overnight at 4°C with agitation. The next day, the membranes were incubated
with HRP-conjugated secondary antibodies diluted 1:5,000 in blocking buffer or with fluorescent
secondary antibodies diluted 1:15,000 in a 1:1 solution of TBS-Odyssey blocking buffer for 1 h at room
temperature. After 3 washes in TTBS, the membranes were developed with an enhanced chemilumi-
nescence (ECL) reaction using a freshly prepared ECL reagent (Promega) or with the Odyssey infrared
imaging system. Primary antibodies were antibodies to actin (C-4; ICN), ATF4 (C-20; Santa Cruz), Bid
(catalog number 2002; Cell Signaling, Beverly, MA), cIAP1 (catalog number B75-1; Pharmingen, San
Diego, CA), cIAP2 (catalog number AF8171; R&D, Minneapolis, MN), caspase-3 (catalog number 9662S;
Cell Signaling), caspase-8 p18 (C-20; Santa Cruz), CHOP (catalog number F-168; Santa Cruz), DR4 (catalog
number B-N28 [Diaclone, Besançon, France] or D9S1R [Cell Signaling]) for the data shown in Fig. 9F, DR5
(catalog number D4E9; Cell Signaling), FADD (catalog number H-10 [Santa Cruz] or 610400 [BD Trans-
duction Laboratories]) for the data shown in Fig. 6F, GRP78 (N-20; Santa Cruz), PARP (catalog number
9542S; Cell Signaling), p62 (catalog number BML-PW9860; Enzo), RIPK1 (catalog number C38; Pharmin-
gen), and TRAIL/TNFSF10 (catalog number 55B709.3; Novus Bio). HRP-conjugated secondary antibodies
were anti-rabbit and anti-mouse antibodies from Zymax and anti-goat antibody from Rockland. Second-
ary anti-mouse, anti-rabbit, or anti-goat antibodies (IRDye 800CW donkey anti-rabbit, IRDye 680LT
donkey anti-mouse, and IRDye 680CW donkey anti-goat antibodies) were obtained from Li-Cor Biosci-
ences.
Immunocytochemistry. Cells were plated in 12-well plates (BD) on 12-mm round sterile coverslips
precoated with a 0.1% poly-L-lysine solution (Sigma) at 37°C. Twenty-four hours later, cells were treated
at a confluence of 70 to 80% without glucose for 24 h. Cells were then fixed with a PBS–4%
paraformaldehyde solution (Merck) for 20 min at room temperature. Cells were washed 3 times with PBS
for 5 min each and then incubated with blocking buffer (0.05% Triton, 3% BSA in PBS) for 1 h, with
shaking, at room temperature. The cells were then incubated with primary antibodies diluted 1:200 in
blocking buffer at 4°C overnight in a humid covered dish. The coverslips were washed 3 times with PBS
for 5 min each and incubated for 1 h with secondary antibodies diluted 1:400 in blocking buffer at room
temperature. Cells were then washed 3 times with PBS and once with 4=,6-diamidino-2-phenylindole
(DAPI) diluted 1:10,000 in PBS for 10 min at room temperature. The coverslips were then mounted by
using 3 l of Vectashield solution (Vector Laboratories, Burlingame, CA) and allowed to dry for at least
1 day. Photographs at different zooms were acquired by using the Suite Advanced Fluorescence software
application (2.6.0.7266; LAS AF) using a Leica TSC SP5 spectral confocal microscope with an HCX PLAPO
lambda blue 63, 1.4-numerical-aperture objective. Colocalization analysis was done by using the
colocalization plug-in of Fiji/Image J software, measuring three images per experiment (80 cells). The
graphs show the averages and the standard deviations of data from at least three independent
experiments. Primary antibodies used for immunocytochemistry were anticalnexin (catalog number
AF18; Abcam), anti-human caspase-8 (C-20; Santa Cruz), anti-DR5 (catalog number D4E9; Cell Signaling),
anti-FADD (catalog number H-181; Santa Cruz), anti-GM130 (catalog number 35; BD Pharmingen), and
anti-p62 (catalog number BML-PW9860; Enzo). Secondary antibodies were rabbit Alexa Fluor 568 (Life
Technologies, Waltham, MA)-conjugated, mouse Alexa Fluor 647 (Life Technologies)-conjugated, and
goat Alexa Fluor 488 (Life Technologies)-conjugated antibodies.
qPCR analysis. Cells were collected at room temperature by trypsinization, washed once with PBS,
and centrifuged for 5 min at 300  g. RNA was extracted from the pellets by using the RNeasy minikit
(Qiagen, Valencia, CA) according to the manufacturer’s instructions. One microgram of RNA under each
condition was retrotranscribed to cDNA by using the High-Capacity cDNA reverse transcription kit from
Applied Biosystems (Waltham, MA). qPCR analysis was performed by using LightCycler 480 SYBR green
I Master solution (Roche) starting with 10 ng of cDNA per reaction mixture. Amplification was performed
with a LightCycler 96-well plate (Roche) by using the following protocol: a preincubation step of 1 cycle
at 95°C, amplification for 45 cycles at 95°C (primer-dependent temperature) and 72°C, a melting curve of
1 cycle at 95°C, 65°C, and 97°C; and cooling for 1 cycle at 40°C. The primers used for analyses were
hTRAIL-R1 (DR4) (forward primer GCTGTGCTGATTGTCTGTTG and reverse primer TCGTTGTGAGCATTGTC
CTC) and hTRAIL-R2 (DR5) (forward primer TGAGACCTTTCAGCTTCTGC and reverse primer ATCGTGAGT
ATCTTGCAGCC). The housekeeping gene used for analysis was the RPL32 gene (forward primer AACG
TCAAGGAGCTGGAAG and reverse primer GGGTTGGTGACTCTGATGG). Results were further normalized to
the values for control treatment.
RT-PCR analysis of spliced XBP1. Total RNA was isolated by using the RNeasy minikit (Qiagen)
according to the manufacturer’s instructions. One microgram of RNA under each condition was retro-
transcribed at cDNA by using the High-Capacity cDNA reverse transcription (RT) kit from Applied
Biosystems. Amplification was performed with a 2720 thermal cycler (Applied Biosystems, Waltham, MA)
by using the following protocol: 95°C for 5 min, 95°C for 1 min, 55°C for 1 min, and 72°C for 1 min for
34 cycles and 72°C for 1 min, 72°C for 5 min, and 16°C to the end. The primers used for analysis were
forward primer TTACGAGAGAAAACTCATGGCC and reverse primer GGGTCCAAGTTGTCCAGAATGC. PCR
products were analyzed on an 8% acrylamide gel.
Statistics. Error bars represent the standard errors of the means (SEM). The significance of data was
measured by using two-tailed, paired Student’s t test. Significant differences are marked as indicated in
the figure legends.
TRAIL Receptors Mediate Apoptosis by Starvation Molecular and Cellular Biology
May 2017 Volume 37 Issue 10 e00479-16 mcb.asm.org 15
 o
n
 February 13, 2018 by IRIS
http://m
cb.asm
.org/
D
ow
nloaded from
 
ACKNOWLEDGMENTS
We acknowledge Alfredo Caro, Inna Lavrik, Abelardo López Rivas, Víctor Yuste,
Andreas Villunger, C. Ruiz de Almodóvar, Giulio Donati, Christian Hellwig, and Markus
Rehm for discussions. We acknowledge Juan Huertas-Martínez, Dídac Domínguez-
Villanueva, and Carmen Casal Moreno for technical assistance.
We acknowledge the funding agencies CERCA, FEDER (A Way To Achieve Europe),
ISCIII (PI13-00139), and MINECO (BFU2016-78154-R). The Martin laboratory is supported
by an investigator award from Science Foundation Ireland (14/IA/2622). This project has
received funding from the European Union’s Horizon 2020 research and innovation
program under Marie Sklodowska-Curie grant agreement no. 675448.
We declare no conflict of interest.
REFERENCES
1. Choo AY, Kim SG, Vander Heiden MG, Mahoney SJ, Vu H, Yoon S-O,
Cantley LC, Blenis J. 2010. Glucose addiction of TSC null cells is caused
by failed mTORC1-dependent balancing of metabolic demand with
supply. Mol Cell 38:487–499. https://doi.org/10.1016/j.molcel.2010.05
.007.
2. DeBerardinis RJ, Sayed N, Ditsworth D, Thompson CB. 2008. Brick by
brick: metabolism and tumor cell growth. Curr Opin Genet Dev 18:
54–61. https://doi.org/10.1016/j.gde.2008.02.003.
3. Iurlaro R, León-Annicchiarico CL, Munoz-Pinedo C. 2014. Regulation of
cancer metabolism by oncogenes and tumor suppressors. Methods Enzy-
mol 542:59–80. https://doi.org/10.1016/B978-0-12-416618-9.00003-0.
4. El Mjiyad N, Caro-Maldonado A, Ramirez-Peinado S, Munoz-Pinedo C.
2011. Sugar-free approaches to cancer cell killing. Oncogene 30:
253–264. https://doi.org/10.1038/onc.2010.466.
5. Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G,
Mukherjee C, Shi Y, Gélinas C, Fan Y, Nelson DA, Jin S, White E. 2006.
Autophagy promotes tumor cell survival and restricts necrosis, inflam-
mation, and tumorigenesis. Cancer Cell 10:51–64. https://doi.org/10
.1016/j.ccr.2006.06.001.
6. Leon-Annicchiarico CL, Ramirez-Peinado S, Dominguez-Villanueva D,
Gonsberg A, Lampidis TJ, Munoz-Pinedo C. 2015. ATF4 mediates necrosis
induced by glucose deprivation and apoptosis induced by
2-deoxyglucose in the same cells. FEBS J 282:3647–3658. https://doi.org/
10.1111/febs.13369.
7. Caro-Maldonado A, Munoz-Pinedo C. 2011. Dying for something to eat:
how cells respond to starvation. Open Cell Signal J 3:42–51. https://doi
.org/10.2174/1876390101103010042.
8. Lowman XH, McDonnell MA, Kosloske A, Odumade OA, Jenness C, Karim
CB, Jemmerson R, Kelekar A. 2010. The proapoptotic function of Noxa in
human leukemia cells is regulated by the kinase Cdk5 and by glucose.
Mol Cell 40:823–833. https://doi.org/10.1016/j.molcel.2010.11.035.
9. Zhao Y, Coloff JL, Ferguson EC, Jacobs SR, Cui K, Rathmell JC. 2008.
Glucose metabolism attenuates p53 and puma-dependent cell death
upon growth factor deprivation. J Biol Chem 283:36344–36353. https://
doi.org/10.1074/jbc.M803580200.
10. Caro-Maldonado A, Tait SWG, Ramirez-Peinado S, Ricci JE, Fabregat I,
Green DR, Munoz-Pinedo C. 2010. Glucose deprivation induces an atyp-
ical form of apoptosis mediated by caspase-8 in Bax-, Bak-deficient cells.
Cell Death Differ 17:1335–1344. https://doi.org/10.1038/cdd.2010.21.
11. Qing G, Li B, Vu A, Skuli N, Walton ZE, Liu X, Mayes PA, Wise DR,
Thompson CB, Maris JM, Hogarty MD, Simon MC. 2012. ATF4 regulates
MYC-mediated neuroblastoma cell death upon glutamine deprivation.
Cancer Cell 22:631–644. https://doi.org/10.1016/j.ccr.2012.09.021.
12. Ramírez-Peinado S, Alcázar-Limones F, Lagares-Tena L, El Mjiyad N,
Caro-Maldonado A, Tirado OM, Muñoz-Pinedo C. 2011. 2-Deoxyglucose
induces noxa-dependent apoptosis in alveolar rhabdomyosarcoma. Can-
cer Res 71:6796–6806. https://doi.org/10.1158/0008-5472.CAN-11-0759.
13. Shin S, Buel GR, Wolgamott L, Plas DR, Asara JM, Blenis J, Yoon SO. 2015.
ERK2 mediates metabolic stress response to regulate cell fate. Mol Cell
59:382–398. https://doi.org/10.1016/j.molcel.2015.06.020.
14. Llambi F, Moldoveanu T, Tait SW, Bouchier-Hayes L, Temirov J, McCor-
mick LL, Dillon CP, Green DR. 2011. A unified model of mammalian BCL-2
protein family interactions at the mitochondria. Mol Cell 44:517–531.
https://doi.org/10.1016/j.molcel.2011.10.001.
15. He S, Wang L, Miao L, Wang T, Du F, Zhao L, Wang X. 2009. Receptor
interacting protein kinase-3 determines cellular necrotic response to
TNF-alpha. Cell 137:1100–1111. https://doi.org/10.1016/j.cell.2009.05
.021.
16. Vandenabeele P, Grootjans S, Callewaert N, Takahashi N. 2013.
Necrostatin-1 blocks both RIPK1 and IDO: consequences for the study of
cell death in experimental disease models. Cell Death Differ 20:185–187.
https://doi.org/10.1038/cdd.2012.151.
17. Zhang J, Fan J, Venneti S, Cross JR, Takagi T, Bhinder B, Djaballah H,
Kanai M, Cheng EH, Judkins AR, Pawel B, Baggs J, Cherry S, Rabinowitz
JD, Thompson CB. 2014. Asparagine plays a critical role in regulating
cellular adaptation to glutamine depletion. Mol Cell 56:205–218. https://
doi.org/10.1016/j.molcel.2014.08.018.
18. Palorini R, Cammarata FP, Balestrieri C, Monestiroli A, Vasso M, Gelfi C,
Alberghina L, Chiaradonna F. 2013. Glucose starvation induces cell death
in K-ras-transformed cells by interfering with the hexosamine biosyn-
thesis pathway and activating the unfolded protein response. Cell Death
Dis 4:e732. https://doi.org/10.1038/cddis.2013.257.
19. Muaddi H, Majumder M, Peidis P, Papadakis AI, Holcik M, Scheuner D,
Kaufman RJ, Hatzoglou M, Koromilas AE. 2010. Phosphorylation of
eIF2alpha at serine 51 is an important determinant of cell survival and
adaptation to glucose deficiency. Mol Biol Cell 21:3220–3231. https://
doi.org/10.1091/mbc.E10-01-0023.
20. Martin-Perez R, Niwa M, Lopez-Rivas A. 2012. ER stress sensitizes cells to
TRAIL through down-regulation of FLIP and Mcl-1 and PERK-dependent
up-regulation of TRAIL-R2. Apoptosis 17:349–363. https://doi.org/10
.1007/s10495-011-0673-2.
21. Iurlaro R, Munoz-Pinedo C. 2016. Cell death induced by endoplasmic
reticulum stress. FEBS J 283:2640–2652. https://doi.org/10.1111/febs
.13598.
22. Lu M, Lawrence DA, Marsters S, Acosta-Alvear D, Kimmig P, Mendez AS,
Paton AW, Paton JC, Walter P, Ashkenazi A. 2014. Opposing unfolded-
protein-response signals converge on death receptor 5 to control apop-
tosis. Science 345:98–101. https://doi.org/10.1126/science.1254312.
23. Martin-Perez R, Palacios C, Yerbes R, Cano-Gonzalez A, Iglesias-Serret D,
Gil J, Reginato MJ, Lopez-Rivas A. 2014. Activated ERBB2/HER2 licenses
sensitivity to apoptosis upon endoplasmic reticulum stress through a
PERK-dependent pathway. Cancer Res 74:1766–1777. https://doi.org/10
.1158/0008-5472.CAN-13-1747.
24. Yamaguchi H, Wang HG. 2004. CHOP is involved in endoplasmic retic-
ulum stress-induced apoptosis by enhancing DR5 expression in human
carcinoma cells. J Biol Chem 279:45495–45502. https://doi.org/10.1074/
jbc.M406933200.
25. Jiang CC, Chen LH, Gillespie S, Kiejda KA, Mhaidat N, Wang YF, Thorne R,
Zhang XD, Hersey P. 2007. Tunicamycin sensitizes human melanoma
cells to tumor necrosis factor-related apoptosis-inducing ligand-induced
apoptosis by up-regulation of TRAIL-R2 via the unfolded protein re-
sponse. Cancer Res 67:5880–5888. https://doi.org/10.1158/0008-5472
.CAN-07-0213.
26. Feoktistova M, Geserick P, Kellert B, Dimitrova DP, Langlais C, Hupe M,
Cain K, MacFarlane M, Hacker G, Leverkus M. 2011. cIAPs block ripopto-
some formation, a RIP1/caspase-8 containing intracellular cell death
complex differentially regulated by cFLIP isoforms. Mol Cell 43:449–463.
https://doi.org/10.1016/j.molcel.2011.06.011.
27. Tenev T, Bianchi K, Darding M, Broemer M, Langlais C, Wallberg F,
Zachariou A, Lopez J, MacFarlane M, Cain K, Meier P. 2011. The ripop-
Iurlaro et al. Molecular and Cellular Biology
May 2017 Volume 37 Issue 10 e00479-16 mcb.asm.org 16
 o
n
 February 13, 2018 by IRIS
http://m
cb.asm
.org/
D
ow
nloaded from
 
tosome, a signaling platform that assembles in response to genotoxic
stress and loss of IAPs. Mol Cell 43:432–448. https://doi.org/10.1016/j
.molcel.2011.06.006.
28. Jin Z, Li Y, Pitti R, Lawrence D, Pham VC, Lill JR, Ashkenazi A. 2009.
Cullin3-based polyubiquitination and p62-dependent aggregation of
caspase-8 mediate extrinsic apoptosis signaling. Cell 137:721–735.
https://doi.org/10.1016/j.cell.2009.03.015.
29. Pan JA, Ullman E, Dou Z, Zong WX. 2011. Inhibition of protein degradation
induces apoptosis through a microtubule-associated protein 1 light chain
3-mediated activation of caspase-8 at intracellular membranes. Mol Cell Biol
31:3158–3170. https://doi.org/10.1128/MCB.05460-11.
30. Ramírez-Peinado S, León-Annicchiarico CL, Galindo-Moreno J, Iurlaro R,
Caro-Maldonado A, Prehn JHM, Ryan KM, Muñoz-Pinedo C. 2013. Glu-
cose starved cells do not engage in pro-survival autophagy. J Biol Chem
288:30387–30398. https://doi.org/10.1074/jbc.M113.490581.
31. Li T, Su L, Lei Y, Liu X, Zhang Y, Liu X. 2015. DDIT3 and KAT2A proteins
regulate TNFRSF10A and TNFRSF10B expression in endoplasmic reticu-
lum stress-mediated apoptosis in human lung cancer cells. J Biol Chem
290:11108–11118. https://doi.org/10.1074/jbc.M115.645333.
32. Ye J, Kumanova M, Hart LS, Sloane K, Zhang H, De Panis DN,
Bobrovnikova-Marjon E, Diehl JA, Ron D, Koumenis C. 2010. The GCN2-
ATF4 pathway is critical for tumour cell survival and proliferation in
response to nutrient deprivation. EMBO J 29:2082–2096. https://doi.org/
10.1038/emboj.2010.81.
33. Zagorodna O, Martin SM, Rutkowski DT, Kuwana T, Spitz DR, Knudson
CM. 2012. 2-Deoxyglucose-induced toxicity is regulated by Bcl-2 family
members and is enhanced by antagonizing Bcl-2 in lymphoma cell lines.
Oncogene 31:2738–2749. https://doi.org/10.1038/onc.2011.454.
34. Munoz-Pinedo C, Ruiz-Ruiz C, Ruiz de Almodovar C, Palacios C, Lopez-
Rivas A. 2003. Inhibition of glucose metabolism sensitizes tumor cells to
death receptor-triggered apoptosis through enhancement of death-
inducing signaling complex formation and apical procaspase-8 process-
ing. J Biol Chem 278:12759 –12768. https://doi.org/10.1074/jbc
.M212392200.
35. Nam SY, Amoscato AA, Lee YJ. 2002. Low glucose-enhanced TRAIL
cytotoxicity is mediated through the ceramide-Akt-FLIP pathway. Onco-
gene 21:337–346. https://doi.org/10.1038/sj.onc.1205068.
36. Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL, Lenardo MJ. 2000. A
domain in TNF receptors that mediates ligand-independent receptor
assembly and signaling. Science 288:2351–2354. https://doi.org/10
.1126/science.288.5475.2351.
37. Wei MC, Zong W-X, Cheng EHY, Lindsten T, Panoutsakopoulou V, Ross AJ,
Roth KA, MacGregor GR, Thompson CB, Korsmeyer SJ. 2001. Proapoptotic
BAX and BAK: a requisite gateway to mitochondrial dysfunction and death.
Science 292:727–730. https://doi.org/10.1126/science.1059108.
TRAIL Receptors Mediate Apoptosis by Starvation Molecular and Cellular Biology
May 2017 Volume 37 Issue 10 e00479-16 mcb.asm.org 17
 o
n
 February 13, 2018 by IRIS
http://m
cb.asm
.org/
D
ow
nloaded from
 
REVIEW ARTICLE
Endoplasmic reticulum stress signalling – from basic
mechanisms to clinical applications
Aitor Almanza1, Antonio Carlesso2, Chetan Chintha1, Stuart Creedican3, Dimitrios Doultsinos4,5,
Brian Leuzzi1, Andreia Luıs6, Nicole McCarthy7, Luigi Montibeller8, Sanket More9, Alexandra
Papaioannou4,5, Franziska P€uschel10, Maria Livia Sassano9, Josip Skoko11, Patrizia Agostinis9,
Jackie de Belleroche8, Leif A. Eriksson2, Simone Fulda7, Adrienne M. Gorman1 , Sandra Healy1,
Andrey Kozlov6, Cristina Mu~noz-Pinedo10 , Markus Rehm11, Eric Chevet4,5 and Afshin Samali1
1 Apoptosis Research Centre, National University of Ireland, Galway, Ireland
2 Department of Chemistry and Molecular Biology, University of Gothenburg, G€oteborg, Sweden
3 Randox Teoranta, Dungloe, County Donegal, Ireland
4 INSERM U1242, University of Rennes, France
5 Centre de Lutte Contre le Cancer Eugene Marquis, Rennes, France
6 Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, AUVA Research Centre, Vienna, Austria
7 Institute for Experimental Cancer Research in Paediatrics, Goethe-University, Frankfurt, Germany
8 Neurogenetics Group, Division of Brain Sciences, Faculty of Medicine, Imperial College London, UK
9 Department Cellular and Molecular Medicine, Laboratory of Cell Death and Therapy, KU Leuven, Belgium
10 Cell Death Regulation Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
11 Institute of Cell Biology and Immunology, University of Stuttgart, Germany
Keywords
endoplasmic reticulum; proteostasis;
signalling pathway; stress
Correspondence
E. Chevet, INSERM U1242, Centre de Lutte
Contre le Cancer Eugene Marquis, Avenue
de la bataille Flandres Dunkerque, 35042
Rennes, France
The endoplasmic reticulum (ER) is a membranous intracellular organelle
and the first compartment of the secretory pathway. As such, the ER con-
tributes to the production and folding of approximately one-third of cellu-
lar proteins, and is thus inextricably linked to the maintenance of cellular
homeostasis and the fine balance between health and disease. Specific ER
stress signalling pathways, collectively known as the unfolded protein
response (UPR), are required for maintaining ER homeostasis. The UPR
is triggered when ER protein folding capacity is overwhelmed by cellular
Abbreviations
4-PBA, 4-phenylbutyric acid; ALS, amyotrophic lateral sclerosis; ATF4, activating transcription factor 4; ATF6f, cytosolic domain of ATF6;
ATF6a, activating transcription factor 6 a; ATF6b, activating transcription factor 6 b; BBF2H7, cAMP responsive element-binding protein 3
like 2; BiP, binding immunoglobulin protein (gene GRP78); bZIP, basic-leucine zipper; CHOP, CAAT/enhancer-binding protein (C/EBP)
homologous protein; CRCL, chaperone-rich cell lysate; CREB3L3, cAMP responsive element-binding protein 3 like 3; CREB, cAMP response
element-binding protein; eIF2B, eukaryotic translation initiation factor 2B; eIF2a, eukaryotic translation initiation factor 2a; ERAD, ER-
associated protein degradation; ER, endoplasmic reticulum; ERN1, endoplasmic reticulum to nucleus signalling 1; ERN2, endoplasmic
reticulum to nucleus signalling 2; ERO-1, ER oxidoreductin 1; ERa, oestrogen receptor a; GADD34, growth arrest and DNA-damage-
inducible 34; GRP78, glucose-regulated protein 78; GSH, glutathione; IBD, inflammatory bowel disease; IRE1a, inositol-requiring enzyme 1
a; IRE1b, inositol-requiring enzyme 1 b; LUMAN, cAMP responsive element-binding protein 3 or CREB3; MAM, mitochondria-associated
membrane; MBTPS1, membrane bound transcription factor peptidase, site 1; MBTPS2, membrane bound transcription factor peptidase, site
2; MDM1/SNX13, mitochondrial distribution and morphology 1/sorting nexin 13; mTOR, mammalian target of rapamycin; N-ATF6, N-terminal
portion of ATF6 or ATF6f; NF-Y, nuclear transcription factor Y; NGLY1, N-glycanase; NPR, NADPH-P450 reductase; OASIS, cAMP
responsive element-binding protein 3 like 1; ORAI1, calcium release-activated calcium channel protein 1; PDI, protein disulfide isomerase;
p-eIF2a, phospho-eIF2a; PERK, protein kinase RNA-like (PKR-like) endoplasmic reticulum kinase; PKR, protein kinase RNA-activated; PM,
plasma membrane; PP1, protein phosphatase type 1; qPCR, quantitative polymerase chain reaction; RER, rough endoplasmic reticulum;
RIDD, regulated IRE1-dependent decay; ROS, reactive oxygen species; SEC22b, vesicle-trafficking protein SEC22b; SERCA, sarco/
endoplasmic reticulum ATPase Ca2+-ATPase; SER, smooth endoplasmic reticulum; TAD, transcriptional activation domain; TRAF2, tumour
necrosis factor receptor-associated factor 2; TUDCA, tauroursodeoxycholic acid; UDCA, ursodeoxycholic acid; UPR, unfolded protein
response; WT, wild-type; XBP1s, spliced isoform of XBP1; XBP1u, unspliced isoform of XBP1; XBP1, X-box binding protein 1.
1The FEBS Journal (2018) ª 2018 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
Fax: +33 (0)299253164
Tel: +33 (0)223237258
E-mail: eric.chevet@inserm.fr
A. Samali, Apoptosis Research Centre,
Biomedical Sciences, NUI Galway, Dangan,
Galway, Ireland
Fax: +353 91 494596
Tel: +353 91 492440
E-mail: afshin.samali@nuigalway.ie
Aitor Almanza, Antonio Carlesso, Chetan
Chintha, Stuart Creedican, Dimitrios
Doultsinos, Brian Leuzzi, Andreia Luıs,
Nicole McCarthy, Luigi Montibeller, Sanket
More, Alexandra Papaioannou, Franziska
P€uschel, Maria Livia Sassano and Josip
Skoko contributed equally to this work and
are listed in alphabetical order.
(Received 18 March 2018, revised 24 June
2018, accepted 18 July 2018)
doi:10.1111/febs.14608
demand and the UPR initially aims to restore ER homeostasis and normal
cellular functions. However, if this fails, then the UPR triggers cell death.
In this review, we provide a UPR signalling-centric view of ER functions,
from the ER’s discovery to the latest advancements in the understanding
of ER and UPR biology. Our review provides a synthesis of intracellular
ER signalling revolving around proteostasis and the UPR, its impact on
other organelles and cellular behaviour, its multifaceted and dynamic
response to stress and its role in physiology, before finally exploring the
potential exploitation of this knowledge to tackle unresolved biological
questions and address unmet biomedical needs. Thus, we provide an inte-
grated and global view of existing literature on ER signalling pathways
and their use for therapeutic purposes.
Introduction
The endoplasmic reticulum (ER) is a cellular orga-
nelle that was first visualized in chicken fibroblast-like
cells using electron microscopy and was described as
a ‘delicate lace-work extending throughout the cyto-
plasm’ [1]. Its current name was coined almost
10 years later by Porter in 1954 [2]. The ER appears
as a membranous network of elongated tubules and
flattened discs that span a great area of the cyto-
plasm [3]. This membrane encloses the ER lumen and
allows for the transfer of molecules to and from the
cytoplasm.
ER structure
The ER is classically divided into the rough ER
(RER) and smooth ER (SER), depending on the pres-
ence or absence of ribosomes on the cytosolic face of
the membrane respectively. The SER and RER can
exist either as interconnected or spatially separated
compartments [4]. More recently, a novel classification
was proposed based on membrane structure rather
than appearance. According to this classification, the
ER comprises the nuclear envelope, sheet-like cisternae
and a polygonal array of tubules connected by three-
way junctions [5]. A striking difference between these
ER structures is the curvature of the membrane,
whereby ER tubules possess a high membrane curva-
ture compared to the sheets of the nuclear envelope
and cisternae. The ER occupies an extensive cell-type-
specific footprint within the cell and is in contact with
many other intracellular organelles. It forms physical
contact sites with mitochondria named mitochondria-
associated membranes (MAMs), which play a crucial
role in Ca2+ homeostasis [6]. It also comes in contact
with the plasma membrane (PM), an interaction regu-
lated by proteins like stromal interaction molecule 1 in
the ER and calcium release-activated calcium channel
protein 1 in the PM which are controlled by Ca2+
levels [7]. Vesicle-trafficking protein SEC22b (SEC22b)
and vesicle-associated membrane protein 7 are also
involved in the stabilization of ER-PM contacts and
PM expansion [8]. The ER also interacts with endo-
somes [9] and is tethered by StAR-related lipid transfer
protein 3 and StAR-related lipid transfer protein 3
[10], which also contribute to cholesterol maintenance
in endosomes [11]. Interestingly, an ER interaction
with the endolysosomal system, mediated by the mito-
chondrial distribution and morphology 1/sorting nexin
13 (MDM1/SNX13) complex [12], suggests ER
involvement in autophagy. Indeed, a specialized ER
structure called the omegasome forms contact sites
with the phagophore, which elongates and becomes a
mature autophagosome [13,14] (Fig. 1). In this way,
the ER on its own or in coordination with other cell
2 The FEBS Journal (2018) ª 2018 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
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organelles exerts its multifaceted roles in the function-
ality of the cell as it is discussed in the next sections.
ER functions
The ER is involved in many different cellular func-
tions. It acts as a protein synthesis factory, contributes
to the storage and regulation of calcium, to the synthe-
sis and storage of lipids, and to glucose metabolism
[3]. These diverse functions indicate a pivotal role for
the ER as a dynamic ‘nutrient sensing’ organelle that
coordinates energetic fluctuations with metabolic
reprogramming responses, regulating metabolism and
cell fate decisions (Fig. 1).
Protein folding and quality control
The ER is involved in secretory and transmembrane
protein synthesis, folding, maturation, quality control
and degradation, and ensures that only properly folded
proteins are delivered to their site of action [15]. About
30% of all proteins are cotranslationally targeted to the
ER [16] where they are exposed to an environment
abundant in chaperones and foldases that facilitate their
folding, assembly and post-translational modification
before they are exported from the ER [16]. Protein pro-
cessing within the ER includes signal sequence cleavage,
N-linked glycosylation, formation, isomerization or
reduction of disulfide bonds [catalysed by protein disul-
fide isomerases (PDIs), oxidoreductases], isomerization
of proline or lipid conjugation, all of which ultimately
result in a properly folded conformation [16–19]. Mis-
folded proteins are potentially detrimental to cell func-
tion and are therefore tightly controlled. Although
protein misfolding takes place continually, it can be
exacerbated during adverse intrinsic and environmental
conditions. The ER has developed quality control sys-
tems to ensure that there are additional opportunities to
correct misfolded proteins or, if terminally misfolded, to
be disposed of by the cell. Terminally misfolded secre-
tory proteins are eliminated by a process called ER-
associated degradation (ERAD) [20]. Proteins are first
recognized by an ER resident luminal and transmem-
brane protein machinery, then retrotranslocated into
Fig. 1. ER molecular machines and contact sites with other organelles. The ER is primarily subdivided into the SER and RER, with the latter
characterized by the presence of ribosomes at its cytosolic surface. Alternatively, the ER has been recently classified into the nuclear
envelope, ER sheet-like cisternae and tubular ER (panel 1). The ER forms multiple membrane contact sites with other organelles, including
the endosomes and lysosomes (through STARD3, STARD3NL, Mdm1; panel 2), the mitochondria (through Mfn-2, Sig-1R, PERK; panel 3),
and the PM (through ORAI1, STIM1, Sec22b, VAMP7; panel 4) with various functional implications. The ER plays instrumental roles in
secretory and transmembrane protein folding and quality control, protein and lipid trafficking, lipid metabolism, and Ca2+ homeostasis, all of
these processes being mediated by a diverse series of ER resident proteins (schematically depicted in panels 1 and 5).
3The FEBS Journal (2018) ª 2018 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
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the cytosol by a channel named dislocon [21] and the
cytosolic AAA+ ATPase p97 [22], deglycosylated by N-
glycanase (NGLY1; [23]) and targeted for degradation
via the ubiquitin–proteasome pathway [20,24,25]
(Fig. 1).
Lipid synthesis
The ER also plays essential roles in membrane produc-
tion, lipid droplet/vesicle formation and fat accumula-
tion for energy storage. Lipid synthesis is localized at
membrane interfaces and organelle contact sites, and
the lipid droplets/vesicles are exported in a regulated
fashion. The ER dynamically changes its membrane
structure to adapt to the changing cellular lipid con-
centrations. The ER contains the sterol regulatory ele-
ment-binding protein family of cholesterol sensors
ensuring cholesterol homeostasis [26]. This compart-
ment also hosts enzymes catalysing the synthesis of cell
membrane lipid components, namely sterols, sphin-
golipids and phospholipids [27]. The synthesis of those
lipids from fatty acyl-CoA and diacylglycerols takes
place at the ER membrane [28], which also hosts 3-
hydroxy-3-methyl-glutaryl-coenzyme A reductase, the
rate-limiting enzyme of the mevalonate/isoprenoid
pathway that produces sterol and isoprenoid precur-
sors [29]. Precursors made by ER membrane-localized
enzymes are subsequently converted into structural
lipids, sterols, steroid hormones, bile acids, dolichols,
prenyl donors and a myriad of isoprenoid species with
key functions for cell metabolism. Interestingly,
MAMs have been identified as a privileged site of sph-
ingolipid synthesis [30] (Fig. 1).
ER export
Most of the proteins and lipids synthesized in the ER
must be transported to other cellular structures,
which occurs mostly through the secretory pathway.
To maintain the constant anabolic flux, export needs
to be tightly regulated, and defects in secretion can
lead to serious structural and functional consequences
for the ER. Central to this export process is the gen-
eration of ER COPII transport vesicles, named after
the family of proteins that shapes and coats them
[31]. In addition to COPII vesicle transport, several
other mechanisms of lipid export have been
described. A variety of lipids can be transported by
nonvesicular mechanisms; for example, large lipopro-
tein cargo has been shown to be exported out of the
ER in another type of vesicle termed prechylomicron
transport vesicles [32] or to accumulate in lipid dro-
plets (Fig. 1).
Ca2+ homeostasis
Ca2+ is involved as a secondary messenger in many
intracellular and extracellular signalling networks,
playing an essential role in gene expression, protein
synthesis and trafficking, cell proliferation, differentia-
tion, metabolism or apoptosis [33]. ER, as the main
cellular compartment for Ca2+ storage, plays a pivotal
role in the regulation of Ca2+ levels and reciprocally
many ER functions are controlled in a Ca2+-depen-
dent way, thereby regulating the calcium homeostasis
of the whole cell [34]. Consequently, both ER and
cytosolic Ca2+ concentrations need to be highly spa-
tiotemporally regulated in order for the ER to main-
tain a much increased physiological intraluminal Ca2+
concentration and oxidizing redox potential than the
cytoplasm. To modulate these levels, the ER employs
a number of mechanisms that control Ca2+ concentra-
tion on both sides of the membrane: (a) ER membrane
ATP-dependent Ca2+ pumps for cytosol-to-lumen
transport; (b) ER luminal Ca2+-binding chaperones
for sequestering free Ca2+; and (c) ER membrane
channels for the regulated release of Ca2+ into the
cytosol. These mechanisms are facilitated by a tight
communication between the ER and other organelles,
such as the PM and the mitochondria, thereby sup-
porting the cell needs.
Traditionally thought as a site of protein synthesis,
recent evidence has established the involvement of the
ER in many different cellular functions: from novel
roles in lipid metabolism to connections with
cytoskeletal structures or roles in cytoplasmic stream-
ing, our view of the ER keeps rapidly expanding, plac-
ing it increasingly as a key organelle governing the
whole cellular metabolism.
Perturbing ER functions
Conditions that disrupt ER homeostasis create a cellu-
lar state commonly referred to as ‘ER stress’. The cel-
lular response to ER stress involves the activation of
adaptive mechanisms to overcome stress and restore
ER homeostasis. This response is dependent on the
perturbing agent/condition and the intensity/duration
of the stress [35].
Intrinsic ER perturbations
Cell autonomous mechanisms can lead to ER pertur-
bation and examples of this can be seen in several dis-
eases, including cancer, neurodegenerative diseases and
diabetes. The hallmarks of cancer such as genetic
instability and mutations [36] can result in constitutive
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activation of ER stress response pathways leading to
cell growth, proliferation, differentiation and migra-
tion. In addition, the uncontrolled, rapid growth of
cancer cells requires high protein production rates with
a consequent impact on ER systems [37]. Many can-
cers have a high mutation load which results in an
intrinsically higher level of ER stress. For example,
melanoma has the highest mutation burden of any
cancer and the sheer numbers of mutated proteins are
a source of intrinsically higher ER stress levels. In
chronic myeloid leukaemia, the fusion protein pro-
duced the Philadelphia chromosome, BCR-ABL1, is a
constitutively active oncoprotein that enhances cell
proliferation and interferes with Ca2+-dependent
apoptotic response [38]. In addition, mutation-driven
ER stress can also induce senescence that contributes
to chemoresistance [39]. ER stress has also been linked
to several neurodegenerative diseases. For example,
mutations in the ER resident vesicle-associated mem-
brane protein-associated protein B in familial amy-
otrophic lateral sclerosis (ALS) are linked to induction
of motor neuron death mediated by the alteration of
ER stress signalling [40,41]. On the other hand, secre-
tory cells such as pancreatic b cells have a highly
developed ER to manage insulin production and
release in response to increases in blood glucose. The
C96Y insulin variant leads to its impaired biogenesis
and ER accumulation in the Akita mouse. As the ER
cannot cope with the mutation induced stress, beta
cells die and type 1 diabetes develops [42,43]. Insulin
mutation-related ER stress was also reported in neona-
tal diabetes [44,45].
Extrinsic perturbations
Microenvironmental stress
In tumours, the ER stress observed in rapidly prolifer-
ating cells is compounded by the fact that increased
proliferation eventually depletes the microenvironment
of nutrients and oxygen, causing local microenviron-
mental stress and resulting in hypoxia, starvation and
acidosis, all of which cause ER stress and perturb pro-
tein, and possibly lipid synthesis [46]. Nutrient depri-
vation, and particularly glucose starvation, at least in
part, promotes ER stress by impairing glycosylation.
Exposure to ER stressors
Several small molecules that induce ER stress through
a variety of mechanisms have been identified [47,48].
Stressors such as tunicamycin [49,50], or 2-deoxyglu-
cose [51] target the N-linked glycosylation of proteins,
whereas dithiothreitol inhibits protein disulfide bond
formation[52]. Alternatively, Brefeldin A impairs ER-
to-Golgi trafficking, thus causing a rapid and reversi-
ble inhibition of protein secretion [53]. Targeting the
Sarco/ER Ca2+-ATPase (SERCA) with compounds,
such as thapsigargin and cyclopiazonic acid [54,55],
induces ER stress by reducing ER Ca2+ concentration
and impairing protein folding capacity.
Exposure to enhancers of ER homeostasis
Conversely, other molecules have been found that can
alleviate ER stress. These include small molecules, pep-
tides and proteostasis regulators. The frequently used
4-phenylbutyric acid (4-PBA) reduces the accumulation
of misfolded proteins in the ER [56]. Tauroursodeoxy-
cholic acid (TUDCA) is an endogenous bile acid able
to resolve ER stress in islet cells [57]. TUDCA is the
taurine conjugate of ursodeoxycholic acid (UDCA), an
FDA-approved drug for primary biliary cirrhosis that
is also able to alleviate ER stress [58]. The precise
mode of action of such proteostasis modulators still
remains elusive.
Temperature
Body temperature is crucial for the viability of meta-
zoans; normal mammalian physiological temperatures
are 36–37 °C. Deviations from this range can disrupt
cellular homeostasis causing protein denaturation and/
or aggregation [59]. Moreover, an acute increase in
temperature, known as heat shock, causes the frag-
mentation of both ER and Golgi [59]. Heat precondi-
tioning at mildly elevated temperatures (up to 40 °C)
in mammalian cellular and animal models has been
shown to lead to the development of thermotolerance,
which is associated with an increase in the expression
of several heat shock proteins and ER stress markers
[60,61]. In addition, moderate hypothermia (28 °C)
induces mild ER stress in human pluripotent stem
cells, the activation of which may be sufficient to pro-
tect against severe stress through an effect known as
ER hormesis [62,63].
Reactive oxygen species production and other
perturbations
Several external agents can induce intracellular reactive
oxygen species (ROS) production, and when ROS pro-
duction exceeds the antioxidant capacity oxidative
stress negatively affects protein synthesis and ER
homeostasis [64]. ROS, including free radicals, are gen-
erated by the UPR-regulated oxidative folding
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machinery in the ER [65] and in the mitochondria [66].
In this context, increased mitochondrial respiration
and biogenesis promotes survival during ER stress
through a reduction of ROS [67]. The ER provides an
oxidizing environment to facilitate disulfide bond for-
mation and this process is believed to contribute to as
much as 25% of the overall ROS generated [68,69].
The interconnection between the ER and ROS is medi-
ated by signalling pathways which involve glutathione
(GSH)/glutathione disulfide, NADPH oxidase 4,
NADPH-P450 reductase, Ca2+, ER oxidoreductin 1
(ERO1) and PDI [70]. The latter, in particular, has
been found upregulated in the central nervous system
of Alzheimer’s disease patients thus highlighting the
relevance of these pathways in neurodegenerative dis-
ease [71]. Overall, from the sections above it is appar-
ent that directly or indirectly impaired ER function
contributes to disease development and treatment
resistance.
ER stress consequences
In response to ER stress, cells trigger an adaptive sig-
nalling pathway called the unfolded protein response
(UPR), which acts to help cells to cope with the stress
by attenuating protein synthesis, clearing the unfolded/
misfolded proteins and increasing the capacity of the
ER to fold proteins.
The UPR
The UPR is a cellular stress response originating in the
ER and is predominantly controlled by three major sen-
sors: inositol requiring enzyme 1 (IRE1), protein kinase
RNA-activated (PKR)-like ER kinase (PERK) and
activating transcription factor 6 (ATF6). The ER lumi-
nal domains of all three ER stress sensors are normally
bound by the ER resident chaperone, heat shock pro-
tein A5 [heat shock protein family A (Hsp70) member
5, also known as glucose-regulated protein 78 (GRP78)
and binding immunoglobulin protein (gene GRP78)
(BiP)], keeping them in an inactive state [72,73]. Accu-
mulating misfolded proteins in the ER lumen engage
BiP thus releasing the three sensors. A FRET UPR
induction assay, developed to quantify the association
and dissociation of the IRE1 luminal domain from BiP
upon ER stress [74], demonstrated that the ER luminal
co-chaperone ERdj4/DNAJB9 represses IRE1 by pro-
moting a complex between BiP and the luminal stress-
sensing domain of IRE1a [75]. Moreover, it has
recently been reported that another ER luminal chaper-
one, Hsp47, displaces BiP from the IRE1 UPRosome
to promote its oligomerization [76]. Once released from
BiP, IRE1 and PERK homodimerize or oligomerize
and trans-autophosphorylate to activate their down-
stream pathways [72]. In contrast, BiP dissociation
from AFT6 reveals an ER export motif [73] which facil-
itates its translocation to the Golgi apparatus [77]. This
‘competition model’ of UPR activation assumes that
BiP acts as a negative regulator of UPR signalling.
However, other BiP-dependent or independent models
have been proposed (reviewed in [78]; Fig. 2).
IRE1 signalling
In humans, there are two paralogues of IRE1 (IRE1a
and b), encoded by endoplasmic reticulum to nucleus
signalling 1 and 2 (ERN1 and ERN2), respectively
[79–81]. Both human IRE1 isoforms share significant
sequence homology (39%) [20]. IRE1a (referred to
IRE1 hereafter) is ubiquitously expressed; however,
inositol-requiring enzyme 1 b (IRE1b) expression is
restricted mainly to the gastrointestinal tract and the
pulmonary mucosal epithelium [82,83]. Ern1 knockout
(KO) in mice is embryonic lethal due to growth retar-
dation and defects in liver organogenesis and placen-
tal development [84] while Ern2 KO mice develop
colitis of increased severity and shorter latency [82]
but are otherwise histologically indistinguishable from
the Ern2WT mice. BiP dissociation, caused by accu-
mulating unfolded proteins, triggers IRE1 oligomer-
ization and activation of its cytosolic kinase domain.
The oligomers position in close proximity, in a face-
to-face orientation, enabling trans-autophosphoryla-
tion. This face-to-face configuration is adopted by
both human and murine IRE1 [85,86]. Phosphoryla-
tion in the activation loop of the kinase domain,
specifically at Ser724, Ser726 and Ser729, is not only
necessary to activate its cytosolic RNase domain [87]
but is also required to initiate recruitment of tumour
necrosis factor receptor-associated factor 2 (TRAF2)
and JNK pathway signalling [88]. The IRE1 cytosolic
domain, which is highly homologous with RNase L
[89], induces a selective cleavage of dual stem loops
within the X-box binding protein 1 (XBP1) mRNA
[79,90,91]. Therefore, IRE1, in a spliceosome indepen-
dent-manner, but together with the tRNA ligase
RNA 20,30-cyclic phosphate and 50-OH ligase [92–97],
catalyses the splicing of a 26 nucleotide intron from
human XBP1 mRNA to produce spliced isoform of
XBP1 (XBP1s) [90,91]. XBP1s is a basic leucine zip-
per (bZIP) transcription factor [98–100] and the
unspliced isoform of XBP1 (XBP1u) is unable to acti-
vate gene expression due to lack of a transactivation
domain [91]. The N-terminal region of XBP1u con-
tains a basic region and a leucine zipper domain
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involved in dimerization and DNA binding
[91,98,100,101]. The XBP1u C-terminal region con-
tains a P (proline), E (glutamic acid), S (serine) and
T (threonine) motif which destabilizes proteins (ubiq-
uitin-dependent proteolysis) and contributes to its
short half-life [98,101–103]. The N-terminal region
Fig. 2. Signalling the UPR and downstream pathways. The 3ER stress sensors (PERK, IRE1, ATF6) upon release from BiP, PDIA5, 6 initiate
signalling cascades through transcription factor production (ATF4, XBP1s, ATF6f) and associated processes such as RIDD, NFjB activation
and ERAD to address the misfolded protein load on the ER. By modulating transcriptional output and translational demand the UPR
attempts to re-establish ER protein folding homeostasis and promote cell survival. If ER stress cannot be resolved then mechanisms are
triggered to promote cell death.
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also contains two other domains: a hydrophobic
region that targets XBP1u to the ER membrane and
a domain that promotes efficient XBP1 splicing [104–
106] and cleavage [103] by pausing XBP1 translation.
IRE1-mediated splicing of XBP1 mRNA results in an
open reading frame-shift inducing the expression of a
transcriptionally active and BP1s [90,91,101]. XBP1u
has been reported to negatively regulate XBP1s tran-
scriptional activity as well as to promote the recruit-
ment of its own mRNA to the ER membrane
through the partial translation of its N-terminal
region [107,108]. XBP1s directs the transcription of a
wide range of targets including the expression of
chaperones, foldases and components of the ERAD
pathway, in order to relieve ER stress and restore
homeostasis [109,110]. However, XBP1s can also par-
ticipate in the regulation of numerous metabolic path-
ways such as lipid biosynthesis [111–113], glucose
metabolism [114–118], insulin signalling [117,119,120],
redox metabolism [121], DNA repair [122] and it
influences cell fate including cell survival [123], cell
differentiation [124–128] and development [126,129–
131]. Although there is strong evidence pointing to a
key role for XBP1 in multiple cellular functions, the
exact mechanisms by which XBP1 mediates gene
transactivation are still elusive. Indeed, in addition to
the known interaction of the XBP1s transactivation
domain with RNA polymerase II, other mechanisms
could exist. For example, XBP1 can physically inter-
act with many other transcription factors such as AP-
1 transcription factor subunit [132], oestrogen recep-
tor a (ERa) [133], GLI-family zinc finger 1 [134],
SSX family member 4 [134], forkhead box O1 [114],
ATF6 [135], cAMP response element-binding protein
(CREB)/ATF [135] and hypoxia inducible factor 1
alpha subunit [136] (Fig. 2).
The RNase activity of IRE1 can also efficiently tar-
get other transcripts through a mechanism called regu-
lated IRE1-dependent decay (RIDD) [137]. Analysis of
the in vitro RNase activity of wild-type (WT) vs
mutant IRE1 led to the discovery of a broad range of
other IRE1 substrates [138,139] and, interestingly, it
was noted that IRE1 can also degrade its own mRNA
[140]. RIDD is a conserved mechanism in eukaryotes
[137,141–145] by which IRE1 cleaves transcripts con-
taining the consensus sequence (CUGCAG) accompa-
nied by a stem-loop structure [142,146]. The cleaved
RNA fragments are subsequently rapidly degraded by
cellular exoribonucleases [141,147]. RIDD is required
for the maintenance of ER homeostasis by reducing
ER client protein load through mRNA degradation
[137,141,142]. Recently, it has been proposed that
there is basal activity of RIDD [138] which increases
progressively with the severity of ER stress. However,
this hypothesis needs further experimental validation.
Interestingly, IRE1b was found to selectively induce
translational repression through the 28S ribosomal
RNA cleavage [81] demonstrating that IRE1a and
IRE1b display differential activities [148]. Characteriz-
ing RIDD activity, particularly in vivo, has proven dif-
ficult due to the complex challenge of separating the
RIDD activity from the XBP1 splicing activity of
IRE1. In addition, basal RIDD can only target specific
mRNA substrates, as full activation and subsequent
targeting of further transcripts requires strong ER
stress stimuli (Fig. 2).
PERK signalling
PERK was identified in rat pancreatic islets as a ser-
ine/threonine kinase and, similar to PKR, heme regu-
lated initiation factor 2 alpha kinase and general
control nonderepressible 2, can phosphorylate eIF2a
[149,150]. PERK is ubiquitously expressed in the body
[149] and has an ER luminal domain as well as a cyto-
plasmic kinase domain [150]. BiP detachment from the
ER luminal domain leads to oligomerization [72],
trans-autophosphorylation and activation of PERK
[151]. Active PERK phosphorylates eIF2a on serine 51
[150]. eIF2a is a subunit of the eIF2 heterotrimer
[152,153] which regulates the first step of protein syn-
thesis initiation by promoting the binding of the initia-
tor tRNA to 40S ribosomal subunits [154]. However,
eIF2a phosphorylation by PERK inhibits eukaryotic
translation initiation factor 2B (eIF2B) activity and
thereby downregulates protein synthesis [155]. Block-
ing translation during ER stress consequently reduces
the protein load on the ER folding machinery [156].
Remarkably, some transcripts are translated more
efficiently during PERK-dependent global repression
of translation initiation. The ubiquitously expressed
activating transcription factor 4 (ATF4) [157], whose
transcript contains short upstream open reading
frames (uORFs) [158], is normally inefficiently trans-
lated from the protein-coding AUG [159]. However,
attenuation of translation from uORFs shifts transla-
tion initiation towards the protein coding AUG,
resulting in more efficient synthesis of ATF4 [158].
ATF4 can then bind to the C/EBP-ATF site in the
promoter of CAAT/enhancer-binding protein (C/EBP)
homologous protein (CHOP)/GADD153 [160] and
induce its expression [158]. ATF4 and CHOP directly
induce genes involved in protein synthesis and the
UPR [161], but conditions under which ATF4 and
CHOP increase protein synthesis can result in ATP
depletion, oxidative stress and cell death [162]. eIF2a
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phosphorylation (p-eIF2a) can also directly enhance
the translation of CHOP [163,164] and other proteins
involved in the ER stress response, as reviewed in
[165]. For example, growth arrest and DNA-damage-
inducible 34 (GADD34) [166,167] is positively regu-
lated by eIF2a phosphorylation [168] and likewise
transcriptionally induced by ATF4 [169] and CHOP
[170]. Interestingly, GADD34 interacts with the cat-
alytic subunit of type 1 protein serine/threonine phos-
phatase (PP1) [171], which dephosphorylates eIF2a
thereby creating a negative feedback loop that antago-
nizes p-eIF2a-dependent translation inhibition and
restores protein synthesis [169,170,172]. The transla-
tional arrest induced by p-eIF2a reduces protein load
in ER lumen and conserves nutrients, while ATF4 dri-
ven expression of adaptive genes involved in amino
acid transport and metabolism, protection from oxida-
tive stress, protein homeostasis and autophagy
together help the cell to cope with ER stress [173,174].
However, sustained stress changes the adaptive
response to a prodeath response and ultimately, the
phosphorylation status of eIF2a appears to codeter-
mine the balance between prosurvival or prodeath sig-
nalling [175,176]. This is accomplished by the above
mentioned delayed feedback through which the inter-
play of GADD34, ATF4 and CHOP results in the
activation of genes involved in cell death, cell-cycle
arrest and senescence [177–180] (Fig. 2).
ATF6 signalling
The transcription factor ATF6, which belongs to an
extensive family of leucine zipper proteins [8], is encoded
in humans by two different genes: ATF6A for ATF6a
[181] and ATF6B for ATF6b [153]. After its activation
in the ER and export to the Golgi, it is cleaved by the
two Golgi-resident proteases membrane bound tran-
scription factor peptidase, site 1 (MBTPS1) and
MBTPS1, releasing a fragment of ~ 400 amino acids
corresponding to ATF6 cytosolic N-terminal portion
(ATF6f). ATF6f comprises a transcriptional activation
domain (TAD), a bZIP domain, a DNA-binding
domain and nuclear localization signals. In the nucleus,
ATF6f induces UPR gene expression [73,182]. Although
the two ATF6 paralogs share high homology [153],
ATF6b is a very poor activator of UPR genes due to the
absence of eight important amino acids in the TAD
domain [157]. Indeed, it rather seems to function as an
inhibitor by forming heterodimers with ATF6a [10,158].
Interestingly, ATF6 can modulate gene expression by
interacting with other bZIPs, such as CREB [159],
cAMP responsive element-binding protein 3 like 3
(CREB3L3) [160], sterol regulatory element-binding
transcription factor 2 [161] and XBP1 [71], and various
other transcription factors such as serum response fac-
tor [181], components of the nuclear transcription factor
Y (NF-Y) complex [159,162,163], yin yang 1 [163,164]
and general transcription factor I [165]. Converging
with IRE1 and PERK signalling cascades, ATF6 can
also induce the expression of XBP1 and CHOP to
enhance UPR signalling [30,166,167]. However, ATF6
is not the only ER-resident bZIP transcription factor.
At least five other tissue-specific bZIPs, named Luman,
cAMP responsive element-binding protein 3 like 1
(OASIS), cAMP responsive element-binding protein 3
like 2 (BBF2H7), CREB3L3 and CREB, reviewed in
[183], are involved in ER stress signalling (Fig. 2), high-
lighting the regulatory complexity this branch of the ER
stress response is subjected to at the organismal level.
Noncoding RNAs
Noncoding RNAs are connected to the three UPR sen-
sors with effects on both physiological and pathological
conditions [184]. These RNA species mostly include
microRNAs (miRNAs) and also long noncoding RNAs
(lncRNAs). This additional level of regulation works in
fact in a bidirectional manner. This means that either
the UPR sensors themselves or their downstream com-
ponents can also modulate their expression levels. A
certain number of miRNAs have been so far recognized
to regulate IRE1, which in turn regulates miRNAs
through XBP1s at a transcriptional level and through
RIDD activity via degradation. One miRNA regulates
PERK expression, while this in turn regulates miRNAs
through its downstream targets. ATF6 is also modu-
lated by miRNAs, but only one miRNA has been
found under its direct effect. Upstream of IRE1, PERK
and ATF6, the BiP chaperone is also regulated by miR-
NAs but does not control any. In addition to miRNAs,
lncRNAs exhibit a similar role regarding the regulation
of UPR factors and vice versa. Their levels change in
accordance to the cell stress status and depending on
the pathophysiological context lead to distinct cell
fates. This interconnection between noncoding RNAs
and the UPR may contribute to a more complex net-
work but at the same time reveals the existence of fine-
tuning mechanisms governing ER stress responses and
their effects in cell homeostasis (described in [184]).
Proximal impact of UPR activation
Transcriptional programmes
Each branch of the UPR pathway culminates in tran-
scriptional regulation and, together the UPR’s major
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transcription factors, ATF6f, XBP1s and ATF4, stim-
ulate many adaptive responses to restore ER function
and maintain cell survival [35]. They regulate genes
encoding ER chaperones, ERAD factors, amino acid
transport and metabolism proteins, phospholipid
biosynthesis enzymes, and numerous others [185]. In
particular, the IRE1–XBP1 pathway is involved in the
induction of ER chaperones and capacity control of
ERAD [186] as well as promoting cytoprotection [187]
and cleaving miRNAs that regulate the cell death-
inducing caspases [188]. ATF6f translocates to the
nucleus where it activate genes involved in protein
folding, processing, and degradation [185]. ATF4, acti-
vated downstream of PERK and p-eIF2a, increases
the transcription of many genes that promote survival
under ER stress. Some of these prosurvival genes
include genes that are involved in redox balance,
amino acid metabolism, protein folding and autophagy
[189].
Translational programmes
Translation is directly impacted by UPR activation
under ER stress conditions, particularly by PERK as
described above. It also affects the expression of sev-
eral miRNAs, which may further contribute to transla-
tion attenuation or protein synthesis [35]. It has been
shown that ER stress can regulate the execution phase
of apoptosis by causing the transient induction of inhi-
bitor of apoptosis proteins (IAPs). Several papers have
reported that cIAP1, cIAP2 and XIAP are induced by
ER stress, and that this induction is important for cell
survival, as it delays the onset of caspase activation
and apoptosis. PERK induction of cIAPs and the
transient activity of PI3K–AKT signalling suggest that
PERK not only allows adaptation to ER stress, but it
also actively inhibits the ER stress-induced apoptotic
programme [190].
Protein degradation
There are two main protein degradation pathways
activated by components of the UPR following ER
stress: ubiquitin–proteasome-mediated degradation via
ERAD and lysosome-mediated protein degradation via
autophagy. ERAD is responsible for removing mis-
folded proteins from the ER and several genes
involved in ERAD are upregulated by ATF6f and
XBP1s [185]. ERAD involves the retrotranslocation of
misfolded proteins from the ER into the cytosol where
they are degraded by the proteasome (see above) [187].
When accumulation of misfolded proteins overwhelms
ERAD, autophagy is induced as a secondary response
to limit protein build-up [187,191]. Autophagy is a
pathway involved in the degradation of bulk compo-
nents such as cellular macromolecules and organelles.
It involves target recognition and selectivity, sequester-
ing targets within autophagosomes, followed by the
fusion of the autophagosome with the lysosome, where
targets are then degraded by lysosomal hydrolases
[187,192]. The direct link between ER stress and
autophagy has been established in both Saccha-
romyces cerevisiae and mammalian cells, where autop-
hagy plays a solely cytoprotective role. The PERK
(eIF2a) and IRE1 (TRAF2/JNK) branches of the
UPR have been implicated in ER stress-induced
autophagy in mammalian systems to avoid accumula-
tion of lethal disease-associated protein variants [192].
IRE1–JNK signalling activates Beclin 1, a key player
and regulator of autophagy, via the phosphorylation
of Bcl-2 and the subsequent dissociation from Beclin
1. This then leads to the activation of ATG proteins
required for the formation of the autophagolysosome
[193]. Overall, these mechanisms decrease the build-up
of improperly folded proteins in the ER thus allowing
adaptive and repair mechanisms to re-establish home-
ostasis. As the amounts of improperly folded proteins
decrease, the UPR switches off. However, the molecu-
lar details of UPR attenuation still remain to be fur-
ther elucidated.
Overall, the three mechanisms describe above
decrease the build-up of proteins in the ER which
allows adaptive and repair mechanisms to re-establish
homeostasis. As the amounts of improperly folded
proteins decrease, the UPR switches off. However, the
molecular details of UPR attenuation remain to be
further elucidated.
Regulation of MAMs
Mitochondria-associated membranes (MAMs), which
are mainly responsible for Ca2+ homeostasis mainte-
nance as well as lipid transport, mediate the interaction
between the ER and mitochondria thereby controlling
mitochondrial metabolism and apoptosis [194]. MAMs
contain many proteins and transporters which mediate
mitochondrial clustering and fusion, such as the dyna-
min-like GTPase mitofusin-2 (MFN2) [195]. MFN2
interacts with PERK, serving as an upstream modula-
tor and thereby regulating mitochondrial morphology
and function as well as the induction of apoptosis
[196]. Furthermore, the cytosolic domain of PERK
serves as an ER-mitochondria tether, thus facilitating
ROS-induced cell death [197].The sigma 1 receptor
(Sig-1R) is located in the MAMs and forms a complex
with BiP. Recent studies show that S1R stabilizes IRE1
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at the MAMs upon ER stress, promoting its dimeriza-
tion and conformational change, and prolonging the
activation of the IRE1–XBP1 signalling pathway
through its long-lasting endoribonuclease activity. Fur-
thermore, mitochondria-derived ROS stimulates IRE1
activation at MAMs [198]. Another MAM component
is Bax-inhibitor-1 (BI-1), regulating mitochondrial
Ca2+ uptake and apoptosis. BI-1 is a negative regula-
tor of IRE1-XBP1 signalling and in BI-1 deficient cells
there is IRE1 hyperactivation and increased levels of
its downstream targets [199]. Apoptosis activation by
the UPR results in mitochondrial membrane permeabi-
lization, with the resulting Ca2+ transfer potentially
triggering mitochondrial cytochrome c release [200].
Less well understood are the interactions of the mito-
chondria with the ER during sublethal ER stress. The
latter results in more ER-mitochondria contacts than
lethal levels of ER stress, allowing for transfer of Ca2+
and enhancement of ATP production through
increased mitochondrial metabolism [201] (Fig. 1).
These evidences demonstrate the importance of the
ER-mitochondria communication in regulating the ER
homeostasis and in coordinating the cellular response
to ER stress, thereby restoring cellular homeostatic
condition or leading towards cell death.
Redox homeostasis
Oxidative stress can be induced through several mech-
anisms and is critically controlled by the UPR. PERK
activity helps to maintain redox homeostasis through
phosphorylation of NRF2 which functions as a tran-
scription factor for the antioxidant response [202].
ATF4 also regulates redox control and has been
shown to protect fibroblasts and hepatocytes from
oxidative stress [173], as well as ensuring that there is
an adequate supply of amino acids for protein and
GSH biosynthesis [203]. However, in neurons and
HEK293 cells ATF4 was shown to induce cell death in
response to oxidative stress while CHOP was reported
to induce ERO1-a, resulting in ER Ca2+ release and
apoptosis in macrophages [204]. Direct interactions of
PDIs with ER stress sensors, protein S-nitrosylation
and ER Ca2+ efflux that is promoted by ROS con-
tribute to redox homeostasis and by extension to the
balance between prosurvival and prodeath UPR sig-
nalling [205]. As such, these signalling loops are para-
mount to normal cellular function.
Global metabolic impact of the UPR
It was recently shown that the UPR and mitochon-
drial proteotoxic stress signalling pathways converge
on ATF4 to induce the expression of cytoprotective
genes [174]. Another pathway regulating energy meta-
bolism is the nutrient-sensing mammalian target of
rapamycin (mTOR) signalling hub. mTOR is associ-
ated with the UPR through crosstalk with regulatory
pathways (reviewed in [206]), and mTOR inhibitors
such as rapamycin lead to the activation of PERK
signalling, thus favouring cell viability [207]. PERK
can also regulate the PI3K–AKT–mTORC1 axis
through the activation of AKT. Furthermore, it was
observed that mTORC2 plays a role in the inhibition
of PERK through AKT activation [208]. Altogether
these data suggest that crosstalk between mTOR and
the UPR is complex and occurs through multiple
pathways.
Lipid metabolism
The UPR can also be activated by deregulated lipid
metabolism. In this regard, the UPR has been shown
to be activated in cholesterol-loaded macrophages
resulting in increased CHOP signalling and apoptosis
[209]. Notably, chronic ER stress leads to insulin
resistance and diabetes in obesity. This is caused by
alterations in lipid composition which lead to inhibi-
tion of SERCA activity and hence ER stress [210].
On the other hand, the UPR is involved in systemic
metabolic regulation. Disturbance of ER homeostasis
in the liver is involved in hepatic inflammation,
steatosis and nonalcoholic fatty liver disease [211].
The PERK–eIF2a pathway has been reported to reg-
ulate lipogenesis and hepatic steatosis. Compromising
eIF2a phosphorylation in mice by overexpression of
GADD34 results in reduced hepatosteatosis upon
high-fat diet [212]. ATF4 the downstream effector of
PERK–eIF2a pathway has also been suggested to
regulate lipid metabolism in hepatocytes in response
to nutritional stimuli by regulating expression of
genes involved in fatty acid and lipid production
[213,214]. Furthermore, it has been demonstrated that
the IRE1–XBP1–PDI axis links ER homeostasis with
VLDL production which plays an important role in
dyslipidaemia [215]. In addition, XBP1 is required for
the normal hepatic fatty acid synthesis and it was
shown that selective XBP1 deletion in mice resulted
in marked hypocholesterolaemia and hypotriglyceri-
daemia [216]. These studies suggest that ER stress
and the UPR are involved in lipid metabolism.
Relieving ER stress ameliorates the disease state asso-
ciated with lipid metabolism alterations, suggesting
that targeting ER stress might serve as a therapeutic
strategy for treating diseases associated with lipid
accumulation.
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Glucose metabolism
It has been suggested that in the liver the PERK–
eIF2a pathway is responsible for disruption of insulin
signalling caused by intermittent hypoxia, though
IRE1–JNK pathways may still play a role [217]. Adi-
ponectin is widely regarded as a marker of functional
glucose metabolism and as a suppressor of metabolic
dysfunctions. In hypoxic and ER-stressed adipocytes,
reduced adiponectin mRNA levels are observed due
to negative regulation by CHOP [218,219]. In b-cells,
it was shown that IRE1 is involved in insulin biosyn-
thesis after transient high glucose levels. However,
chronic exposure to high glucose leads to full UPR
induction and insulin downregulation[220]. IRE1 sig-
nalling was shown to be involved in insulin resistance
and obesity through JNK activation. In hepatocytes,
IRE1-dependent JNK activation leads (a) to insulin
receptor substrate 1 (IRS1) tyrosine phosphorylation
(pY896) decrease and (b) to AKT activation leading
to an increase of IRS1 phosphorylation (pS307), con-
sequently blocking insulin signalling. A role for
XBP1 in the pancreas was demonstrated by the fact
that b-cell-specific XBP1 mutant mice show hypergly-
caemia and glucose intolerance due to decreased
insulin release of b-cells [221]. ER stress-induced acti-
vation of ATF6 in rat pancreatic beta cells exposed
to high glucose, impairs insulin gene expression and
glucose-stimulated insulin secretion. Interestingly,
knocking down expression of orphan nuclear receptor
short heterodimer partner (SHP) previously reported
to be involved in beta cell dysfunction by downregu-
lating expression of PDX-1 and RIPE3b1/MafA
partly mitigated this effect. However, it remains
unclear how ATF6 induces expression of SHP and
whether ATF6 alone can directly regulate the expres-
sion of insulin, PDX-1 and RIPE3b1/MafA [222]. It
has been suggested that physiological impact of ER
stress with respect to glucose metabolism depends
upon the availability of glucose. Indeed acute glucose
availability in beta cells leads to concerted efforts of
each branch of UPR to supply insulin, while chronic
glucose stimulation leads to depletion of insulin pro-
duction and beta cell mass due to apoptosis. More-
over, chronic fasting conditions in mice have shown
that XBP1s directly activates the promoter of the
master regulator of starvation response, PPARa
demonstrating a further link between the UPR and
glucose and lipid metabolism [223]. Acquiring further
knowledge on link between UPR and metabolic sen-
sor mechanisms will significantly expand the possibil-
ity of gaining beneficial metabolic output. Taken
together this indicates that the UPR arms are critical
for the cell to regulate metabolism through regulating
mTOR signalling, lipid homeostasis as well as insulin
signalling.
Downstream impact of UPR activation
The activation of UPR leads to the modulation of
many cellular pathways, thereby influencing prosur-
vival mechanisms as well as processes such as prolifer-
ation, differentiation, metabolism and cell death.
UPR-associated cell death
Following prolonged activation of the UPR, the cellu-
lar response switches from prosurvival to prodeath.
Several types of cell death, including apoptosis, necro-
sis/necroptosis and autophagic cell death, can be
induced following ER stress.
Apoptosis
Unresolved ER stress can lead to the activation of
either the intrinsic (mitochondrial) or extrinsic [death
receptor (DR)] pathways of apoptosis. Both pathways
trigger activation of caspase proteases that dismantle
the cell, and all of the three branches of the UPR are
involved in apoptosis. In the extrinsic pathway, the
activation of DRs on the PM leads to the recruitment
of caspases to the DRs and their proximity-induced
trans-autoactivation. Intrinsic apoptosis involves the
release of cytochrome c (along with other proapoptotic
factors) from the mitochondria, which promotes the
formation of a cytosolic protein complex to activate a
caspase cascade. This release is controlled by pro- and
antiapoptotic members of the BCL-2 protein family.
In particular, the BH3-only members of the family
including PUMA, NOXA and BIM are pivotal com-
ponents of ER stress-induced apoptosis [224], and cells
deficient in BH3-only proteins are protected against
ER stress-induced cell death [190]. ER stress leads to
transcriptional upregulation of these proapoptotic
molecules resulting in cytochrome c release. Both the
IRE1 and PERK arms of the UPR have been linked
to induction of apoptosis during ER stress. In particu-
lar, CHOP, a transcription factor that is downstream
of PERK, and a direct target of ATF4, has been
implicated in the regulation of apoptosis during ER
stress. As discussed in section PERK signalling
CHOP-induced expression of GADD34 promotes
dephosphorylation of p-eIF2a reversing translational
inhibition and allowing transcription of genes includ-
ing apoptosis-related genes [172]. CHOP activates
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transcription of BIM and PUMA, while it represses
transcription of certain antiapoptotic BCL-2 family
members such as MCL-1 [225]. In addition, the ATF4/
CHOP pathway can increase the expression of other
proapoptotic genes, such as TRAIL-R1/DR4 and
TRAIL-R2/DR5 which promote extrinsic apoptosis
[180]. Apart from CHOP, p53 is also involved in the
direct transcriptional upregulation of BH3‑ only pro-
teins during ER stress. However, the link between p53
activation and ER stress is unclear [226].
Although IRE1–XBP1s signalling is mainly prosur-
vival, IRE1 can promote apoptosis. Activated IRE1
can interact directly with TRAF2, leading to the acti-
vation of apoptosis signal-regulating kinase 1 (ASK1)
and its downstream targets c-Jun NH2-terminal kinase
(JNK) and p38 MAPK [227,228]. Phosphorylation by
JNK has been reported to regulate several BCL-2 fam-
ily members, including the activation of proapoptotic
BID and BIM, and inhibition of antiapoptotic BCL-2,
BCL-XL and MCL-1 [229,230]. In addition, p38
MAPK phosphorylates and activates CHOP, which
increases expression of BIM and DR5, thereby pro-
moting apoptosis [231,232]. In fact, cell death induc-
tion in HeLa cells overexpressing CHOP is dependent
on its phosphorylation by p38 MAPK [233]. Interest-
ingly, it was proposed that ER stress and MAPK sig-
nalling act in a positive feed-forward relationship, as
ER stress induces MAPK signalling which in turn
increases ER stress [234]. IRE1 signalling may also
contribute to apoptosis induction through prolonged
RIDD activity which degrades the mRNA of protein
folding mediators [142].
Interestingly, recent studies indicate a role for miR-
NAs in the induction of apoptosis following prolonged
ER stress. For example, miRNA29a which is induced
during ER stress via ATF4 results in the downregula-
tion of antiapoptotic Bcl-2 family protein Mcl-1, and
thus promotes apoptosis [235]. miRNA7 has also been
linked with ER stress-induced apoptosis, where IRE1
reduces miRNA7 levels which results in the stability of
a membrane-spanning RING finger protein, RNF183.
RNF183 has an E3 ligase domain that then causes the
ubiquitination and subsequent degradation of the anti-
apoptotic member of the BCL-2 family BCL-XL. Fol-
lowing prolonged ER stress, increased expression of
RNF183 via IRE1 leads to increased apoptosis [236].
In the last decade, it also became clear that ER
stress can profoundly modify the immunological con-
sequences of apoptotic cell death. Accumulating
in vitro and in vivo evidence have highlighted that the
activation of the PERK arm of ER stress evoked in
response to selected of anticancer therapies (including
anthracyclines, oxaliplatin, radiation and
photodynamic therapy (reviewed in [237]), drives a
danger signalling module resulting in the surface expo-
sure of the ER luminal chaperone calreticulin and the
exodus of other danger-associated molecular patterns,
eliciting immunogenic cell death (reviewed in [238]).
Necroptosis
Necroptosis, a programmed form of cell death, is
dependent on the activation of receptor-interacting
protein kinase 1 (RIPK1), RIPK3 and mixed lineage
kinase domain-like (MLKL) protein and has been
linked to ER stress. In an in vivo mouse model of
spinal cord injury, there is induction of necroptosis and
ER stress, with localization of MLKL and RIPK3 on
the ER in necroptotic microglia/macrophages suggest-
ing a link between necroptosis and ER stress in these
cells [239]. Necroptosis is frequently activated down-
stream of TNFR1 when apoptosis is blocked [240].
This has been linked to ER stress-induced necroptosis
whereby tunicamycin kills L929 murine fibrosarcoma
cells by caspase-independent, death ligand-independent,
TNFR1-mediated necroptosis [241].
Autophagic cell death
Endoplasmic reticulum stress has also been connected
to autophagic cell death. Autophagy not only pro-
motes cell survival, but can also mediate nonapoptotic
cell death under experimental conditions when apopto-
sis is blocked, or in response to treatments that specifi-
cally trigger caspase-independent autophagic cell death
[192]. IRE1a mediated TRAF2 and ASK1 recruitment,
and subsequent JNK activation mediates autophagy.
JNK-mediated phosphorylation of BCL-2 releases
Beclin-1 (while XBP1s also transcriptionally upregu-
lates its expression), which interacts with the ULK1
complex to promote vesicle nucleation that leads to
the formation of the autophagosome [242]. Activated
PERK can induce autophagy through ATF4 by induc-
ing vesicle elongation while Ca2+ release from the ER
lumen through the IP3R can relieve mTOR inhibition
on the ULK1 complex [187].
UPR-associated morphological changes
Endoplasmic reticulum stress causes morphological
changes in cellular models. Experiments to date have
largely focused on the morphologies associated with
apoptotic and autophagic cell death resulting from
UPR activation. UPR-regulated flattening and round-
ing of cells, indicative of cell death, has been observed
in many model systems, with traditional caspase-
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dependent apoptosis being responsible [200,243–248].
These morphological changes can be reversed by phys-
iological and pharmacological ER stress relief
[247,249]. Both IRE1 and PERK arms of the UPR
have been implicated in the observed changes
[193,243,244,247,249–251]. As described above, pro-
grammed cell death and its associated morphological
changes have become a focal and much researched
outcome of the use of UPR-inducing cytotoxic agents.
An intensively studied consequence of ER stress is
the epithelial to mesenchymal transition (EMT) and its
role in cancer invasion and metastasis. EMT is an
essential component of tissue repair following wound-
ing, allowing for the migration of new healthy cells
into any lesions that have occurred. Morphological
changes indicative of EMT have been observed in mul-
tiple cell models under physiologically relevant stress
(e.g. hypoxia) and pharmacological induction of ER
stress [252–255]. The IRE1–XBP1 pathway has been
reported to negatively regulate the traditional epithelial
marker E-cadherin, while positively regulating the mes-
enchymal marker N-cadherin in models of colorectal,
breast and pulmonary fibrosis [254,256,257]. Breast
cancer and pulmonary fibrosis models showed an
IRE1–XBP1-dependent regulation of mesenchymal
promoting transcription factor SNAIL that is responsi-
ble for EMT [254,256]. Human mammary epithelial
cells undergo EMT in response to PERK activation,
and PERK-mediated phosphorylation of eIF2a is
required for invasion and metastasis [258]. Other ER
stress-regulated pathways have been proposed to act in
the EMT in cellular models, including autophagy and
activation of c-SRC kinase in tubular epithelial cells
[259] and the compensatory activation of the NRF-2/
HO-1 antioxidative stress response pathway in HT-29
and DLD-1 colon cancer cells [252]. Therefore, UPR
signalling pathways appear to induce morphological
changes indicative of EMT. These data have generated
interest in the field of cancer research where the phar-
macological inhibition of UPR components might be
used to reduce tumour invasiveness and metastasis.
Hormone production
The tissues and cells of the endocrine system responsi-
ble for hormone production and extracellular sig-
nalling often have a high protein load, resulting in ER
stress and activation of the UPR. OASIS (CREB3L1)
and ATF6a have been shown to regulate arginine
vasopressin (AVP), a potent vasoconstrictor, in murine
and rat models [260,261]. Upon dehydration or salt
loading in rat models, cleaved active OASIS is
observed binding the AVP promoter region, directly
upregulating protein expression [260]. In ATF6/
murine models subjected to intermittent water depriva-
tion, similar downstream effects were observed, but
signalling pathways were not investigated [261]. ER
stress-inducing agents palmitate and oxysterol 27-
hydroxycholesterol both result in a reduction in leptin
(a long-term mediator of energy balance) expression
and extracellular concentrations. This has been attribu-
ted, by using ChIP analysis and siRNA knockdowns,
to the fact that the PERK downstream target CHOP
negatively regulates C/EBPa, transcriptionally down-
regulating its translation and release [262,263]. UPR
activation has been implicated in the hypothalamic
and brown adipose tissue response to thyroid hormone
triiodothyronine (T3). Elevated T3 levels induce the
UPR downstream of AMPK in the ventromedial
nucleus of the hypothalamus, resulting in decreased
ceramide levels. JNK1 KO revealed that it acts down-
stream of this AMPK-dependent activation, possibly
as a target of IRE1 but to our knowledge no studies
have yet confirmed this [264]. In response to ER stress
in hepatocytes, CREBH is exported from the ER and
cleaved in the Golgi apparatus. The CREBH cytosolic
fragment binds to the promoter region of hepcidin and
transcriptionally upregulates its production [265].
These examples of UPR-regulated hormone produc-
tion and release give scope for further investigation
into the longer term, system wide effects of UPR sig-
nalling outside of the current focuses on cytotoxicity
and acute diseases.
Physiological ER stress signalling
It has been established that ER stress signalling is
important in interorganelle and intercellular interac-
tions. It therefore comes as no surprise that it forms a
significant network of interactions upon which normal
physiology is based. This is not only the case in
humans, but is also conserved throughout species and
has been an important fact in the design of experimen-
tal model organisms to further study ER stress sig-
nalling and it role in physiology and disease.
Embryology and development
The UPR as the major conduit of ER stress regulation
has been extensively studied in developmental biology
in the majority of organisms commonly used in transla-
tional research. The use of multiple models has been
important in discerning the variable ER stress signalling
between species, as demonstrated by the discovery that
protein quality control in mammals is critically depen-
dent on ATF6 while the major player in
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Caenorhabditis elegans and Drosophila melanogaster is
IRE1 [182,266]. Mammalian and other embryos
implanted in vitro or naturally, undergo a multitude of
physical, biochemical and cellular stresses involving epi-
genetic changes as well as a disproportional increase in
protein synthesis load that affect cell differentiation,
proliferation and growth.[267]. In zebrafish, transgenic
models have been generated to monitor XBP1 splicing
during development and implantation, showing that
maternal XBP1s is active in oocytes, fertilized eggs and
early stage embryos, presenting a potential model for
study of the impact of water pollutants on embryogene-
sis [268]. It was recently shown that in medaka fish the
JNK and RIDD pathways are dispensable for growth,
with development solely dependent on the XBP1 arm
of IRE1 signalling, thereby supporting the hypothesis
that XBP1 and RIDD may be differentially utilized in
development and homeostasis [269]. In C. elegans it has
been postulated that the IRE1-XBP1 axis as well as the
PERK pathway are responsible for the maintenance of
cellular homeostasis during larval development [270].
Pronephros formation was shown to be BiP dependent
in Xenopus embryos, where BiP morpholino knock-
down not only blocked pronephros formation but also
attenuated retinoic acid signalling, impacting markers
such as the Lim homeobox protein [271]. In early
mouse development, it was shown that the BiP pro-
moter is activated in both the trophoectoderm and
inner cell mass at embryonic day 3.5 and that absence
of BiP leads to proliferative defects and inner cell mass
apoptosis, suggesting it is necessary for embryonic cell
growth and pluripotent cell survival [272]. Furthermore,
mouse studies revealed that ER stress proteins such as
BiP, GRP94, calreticulin and PDIA3 were downregu-
lated in adult neural tissues compared to embryonic
ones, suggesting a pivotal role for ER stress signalling
in the development of neural tissues such as the brain
and retina [273]. Beyond the nervous system, ER stress
signalling impairment has repeatedly shown mouse
embryonic lethality and, in particular in the hepatocel-
lular system, multiple studies have demonstrated that
IRE1 and XBP1 signalling defects lead to fetal liver
hypoplasia, intrauterine anaemia and early antenatal
pancreatic dysfunction [274]. The UPR is intrinsically
linked to the mouse embryonic morula–blastocyst tran-
sition [275] and this, in combination with evidence that
there is an immediate postnatal downregulation of BiP,
shows that there is an important role for the UPR both
in early and late gestation [276]. Taking all this evidence
into consideration, it is apparent that the correct inte-
gration of signals both intracellularly and between the
developing oocyte, follicular environment and support-
ing cumulus cells is absolutely essential for embryonic
development, making ER stress signalling a key regula-
tor in the earliest stages of life in all organisms [277].
Growth and differentiation
Many cell types experience a high protein load during
various stages of differentiation and maturation, result-
ing in ER stress. In several cases, morphological
changes required for the final function of the cell would
not be possible without transient activation of the
UPR’s cytoprotective mechanisms. Deletion of PERK
in murine models results in loss of pancreatic b cell
architecture but not in cell death, and was accompa-
nied by an increase in b cell proliferation. This mor-
phological change results in a diabetes mellitus-like
pathology and is not a result of increased cell death as
previously proposed [278]. Various haematopoietic lin-
eages require the activation of the UPR in order to sur-
vive ER stress resulting from production of
immunoglobulins and lysosomal compartments in
order to reach maturity [279–281]. One physiological
function that is indispensable for survival is the innate
immune response, and cell differentiation is at its epi-
centre. The conversion of B lymphocytes to highly
secretory plasma cells is accompanied by a huge expan-
sion of the ER compartment, and genetic alterations to
induce immunoglobulin production are good examples
of the necessity of ER signalling in normal physiology
[123]. This is supported by a study that suggests the
UPR, and the PERK pathway in particular, govern the
integrity of the haematopoietic stem-cell pool during
stress to prevent loss of function [282]. The ability of
skin fibroblasts to produce collagens and matrix metal-
loproteinases (proteins increased at wound sites), along
with their ability to differentiate into myofibroblasts,
provides another example where physiological ER
stress may drive morphological cellular transition [283].
Although not yet fully characterized, the RIDD path-
way has been linked to a multitude of physiological
processes including lysosomal degradation and xenobi-
otic metabolism through cytochrome P450 regulation
[284]. At the same time, substrates of regulated
intramembrane proteolysis such as CREBH are
involved in normal physiological processes such as glu-
coneogenesis [284]. Another substrate of regulated
intramembrane proteolysis, OASIS, is involved in mul-
tiple stages of bone homeostasis and development.
Mice lacking OASIS present with severe osteopenia,
which is compounded by the fact that the gene for type
1 collagen is an OASIS target [285]. Moreover, osteo-
blast OASIS expression is controlled by factors essen-
tial to osteogenesis (BMP2), pointing to a PERK-
eIF2a-ATF4 pathway upregulation during osteoblast
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differentiation, where ATF4 restores deficiencies of
PERK null osteoblasts all the while impacting apopto-
sis for bone remodelling [251,286]. Furthermore, a link
between osteoblast differentiation and hypoxia has
been established, with decreased vascularization shown
in OASIS null mice pointing towards a potential role
of ER stress in angiogenesis during bone development
[287]. This signalling cascade does not only restrict
itself to the normal physiology of bone but also modu-
lates UPR signalling in astrocytes and is responsible
for the terminal, early to mature, goblet cell differentia-
tion in the large intestine [288–290].
Metabolism
The ER is a site of significant metabolic regulation.
The UPR plays a major role in the regulation of gly-
colysis and it was recently shown that IRE1 mediates
a metabolic decrease upon glucose shortage in neu-
rons, suggesting an important role for the UPR as an
adaptive response mechanism in relation to energy
metabolism [291]. Moreover, mTOR signalling adjusts
global protein synthesis, which is a highly energy con-
suming process, and thereby regulates energy metabo-
lism (reviewed in [292]).
Lipid homeostasis
The ER is heavily involved in lipid homeostasis. Char-
acteristically, hepatocytes are enriched in SER, because
in addition to protein synthesis, these cells also synthe-
size bile acids, cholesterol and phospholipids. XBP1
ablation in murine liver results in hypolipidaemia due
to feedback activation of IRE1 caused by the lack of
XBP1. Activated IRE1 induces the degradation of
mRNAs of a cohort of lipid metabolism genes via
RIDD, demonstrating the critical role of IRE1–XBP1
signalling in lipid metabolism and suggesting that tar-
geting XBP1 may be a viable approach to the treat-
ment of dyslipidaemias [113]. It was also reported that
in hepatocyte-specific IRE1-null mice, XBP1 is
involved in very low-density lipoprotein synthesis and
secretion [215]. Interestingly, ATF6 has also been
shown to have a role in adipogenesis by inducing adi-
pogenic genes and lipid accumulation [293].
Glucose metabolism
The UPR is also involved in regulating glucose meta-
bolism. Initial murine studies suggested the PERK–
eIF2a arm was responsible for impaired insulin sig-
nalling due to knock out effects on beta cells during
development. Further studies have since shown that
IRE1 RIDD activity is responsible for a reduction in
the mRNA of proinsulin processing proteins, including
INS1, PC1 and SYP. These effects can be observed in
cases of XBP1 deficiency and in cases of extensive
UPR activation, highlighting the divergent effects of
IRE1 RNase activity [119,221,294].
Amino acid metabolism
The UPR is also described to be involved in amino
acid metabolism. It was recently described that ATF4
mediates increased amino acid uptake upon glutamine
deprivation [295]. Furthermore, a low protein diet
leads to the upregulation of cytokines mediated by
IRE1 and RIG1 which results in an anticancer
immune response in tumours [296]. In summary, these
findings show the importance of the various UPR
arms in cell metabolism and energy homeostasis with
effects not only on the cell itself but also on the whole
cellular environment.
Pharmacological targeting of the UPR
Several small molecules have been reported to modu-
late (activate or inhibit) one or more arms of the
UPR. Importantly, these molecules have shown
promising beneficial effects in diverse human diseases
(Table 1). X-ray cocrystal structures are now available
for IRE1 and PERK with several endogenous or
exogenous ligands. The understanding of how small
molecules bind to the active sites and modulate the
function of IRE1 and PERK will have a profound
impact on the structure-based drug discovery of novel
UPR modulators. Available X-ray structures, in addi-
tion to mutagenesis analysis of critical amino acids
[297], have revealed a variety of unexpected allosteric
binding sites on IRE1 [297–299].
Pharmacological modulators of IRE1
IRE1 signalling information along with CHOP/Gal4-
Luc cells and UPRE-Luc engineered cells were used to
screen large chemical libraries in high throughput
screening assays for discovery of pathway-selective
modulators of IRE1 [300].
IRE1 ATP-binding site
IRE1 modulators have been discovered primarily by
traditional drug discovery methods, identifying inhibi-
tors specific to the kinase or RNase domain (Table 1).
The IRE1 kinase modulators were used as tools to
understand the allosteric relationship between the
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kinase and RNase domains [301,302]. Kinase inhibi-
tors can be broadly classed as (a) ATP-competitive
inhibitors that inhibit the kinase domain and activate
the RNase domain and (b) ATP-competitive inhibitors
that inhibit the kinase domain and inactivate RNase
(kinase inhibiting RNase attenuators – KIRAs). Avail-
able IRE1 crystal structures reveal a possible mecha-
nism of RNase activation by conformational changes
that occur in the kinase domain when transitioning
from a monomeric to an active dimeric state. Type I
IRE1 kinase inhibitors include APY29 [303] and suni-
tinib [304], which target the ATP-binding site and
inhibit the phosphorylation but stabilize the active
form of the kinase domain. An active kinase confor-
mation is seen in human apo dP-IRE1* (PDB 5HGI),
as a back-to-back dimer. Notably, the DFG motif
(Asp711-Phe712-Gly713) faces into the active site
(DFG-in), with helix-aC-in conformation. In contrast,
human IRE1 bound to KIRA compound 33 (PDB:
4U6R) shows an inactive kinase conformation, with
DFG-in and helix-aC-out conformation. The inactive
conformation is incompatible with back-to-back dimer
formation due to the displaced helix-aC [301]. Imida-
zopyrazine-based inhibitors and other KIRAs
Table 1. Different modulators that target the UPR-transducer protein pathways. Molecule name, respective molecular target and brief
description with the associated reference are provided (ND: not determined).
UPR Arm Name Target Brief description Reference
PERK GSK2656157 PERK Kinase In preclinical stage for multiple myeloma
and pancreatic cancer
[314,364]
Salubrinal GADD34/PP1c Inhibition of eIF2a dephosphorylation [365–367]
In ALS, it increases lifespan of mutant
superoxide dismutase 1 transgenic mice
In Parkinson’s disease, it increases neuronal
survival of a-synuclein transgenic mice
ISRIB eIF2b Decreased ATF4 expression [322]
Guanabenz GADD34/PP1c Inhibitor of eIF2a phosphatase, [368]
Sephin1 GADD34 (PP1c) Inhibitor of eIF2a phosphatase [369]
IRE1 Salicylaldimines IRE1 RNase IRE1aRNase active-site inhibitor [305]
STF-083010 IRE1 RNase IRE1a RNase active-site inhibitor [308]
In preclinical stage for multiple myeloma treatment
MKC-3946 IRE1 RNase IRE1a RNase active-site inhibitor [307,370]
In preclinical stage for multiple myeloma treatment
4l8c IRE1 RNase IRE1a RNase active-site inhibitor [306]
In preclinical stage for multiple myeloma treatment
APY29 IRE1 Kinase IRE1a kinase active-site inhibitor [303]
Sunitinib IRE1 Kinase IRE1a kinase active-site inhibitor [85,304]
FDA approved for renal cell carcinoma
It acts on multiple kinases
KIRA IRE1 Kinase IRE1a kinase active-site inhibitor [371]
Toyocamycin IRE1 RNase IRE1a RNase active-site inhibitor [309,372]
In preclinical stage for various cancers treatment
3-ethoxy-5,6-
dibromosalicylal-
dehyde
IRE1 RNase IRE1a RNase active site inhibitor [305]
Apigenin Proteasome Increase of IRE1a nuclease activity in model [373]
FIRE peptide IRE1 Kinase Modulation IRE1 oligomerization in vitro, [85]
Xbp1 mRNA cleavage in vitro, in cell culture
and in vivo (Caenorhabditis elegans)
ATF6 Apigenin ATF6 Upregulation of ATF6 expression [373]
Baicalein ATF6 Upregulation of ATF6 expression [374]
Ceapin ND Inhibitor of ATF6 [323]
Kaempferol ATF6 Downregulation of ATF6 expression [375]
Melatonin ATF6 Inhibitor of ATF6 [325]
Compound 147 ATF6 Activator of ATF6 [376]
Compound 263 ATF6 Activator of ATF6 [376]
16F16 PDI Inhibitor of PDI [377]
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allosterically inhibit the RNase activity of phosphory-
lated IRE1 by possibly displacing helix-aC from an
active conformation to an inactive conformation [301].
IRE1 RNase-binding site
IRE1 RNase inhibitors include salicylaldehydes [305]
4l8C [306], MKC-946 [307], STF-83010 [308], toy-
ocamycin [309] and hydroxyl-aryl-aldehydes [86]. The
reported cocrystal structures of murine IRE1a with
salicyaldehyde-based inhibitor show that Lys 907 is
involved in Schiff base arrangement (PDB code: 4PL3
[86]). Lys 907 is a crucial residue present within the
hydrophobic pocket of the IRE1 RNase catalytic site
[310]. Quercetin is reported to activate IRE1 through a
site distinct from the nucleotide-binding site (crystal
structure PDB 3LJ0), increasing the population of
IRE1 dimers in vitro [299]. A recent in silico study
identified the anthracycline antibiotic doxorubicin as
an inhibitor of the IRE1-XBP1 axis [311]. Covalent
binders are very efficient in the sense that they com-
pletely block the proteins to which they bind, but this
can also have several drawbacks [312]. Noncovalent
kinase and allosteric modulators in general inhibit
competitively and are thus less efficient, but can at the
same time be extremely useful in obtaining new
insights for developing selective and potent modulators
of IRE1a-XBP1 signalling (Table 1).
Other IRE1 modulators
Peptides derived from the kinase domain of human
IRE1 promote oligomerization in vitro, enhancing
XBP1 mRNA cleavage activity in vitro and in vivo
[85]. However, although peptide-based modulators
have limited clinical application [313] (Table 1) peptide
mimetics may prove more useful. These are different
aspects that can be exploited to develop selective IRE1
modulators. Despite significant progress in understand-
ing IRE1 signalling and in the development of modu-
lators of IRE1 activity, several questions still remain
to be answered to fully control IRE1 activity and sig-
nalling outcomes, including how to selectively target
the XBP1 and RIDD arms of IRE1 signalling.
Pharmacological modulators of PERK
Through biochemical screening of exclusive library col-
lections and structure-based lead optimization, GSK
discovered PERK inhibitors GSK2606414 and
GSK2656157 [314]. These potent PERK inhibitors can
be orally administered [314], reducing tumour growth
in mouse xenograft models [314,315]. GSK2606414
was also the first oral small molecule to prevent neu-
rodegeneration in vivo in prion-diseased mice, with
GSK2606414 reducing the levels of p-PERK and p-
eIF2a and restoring protein synthesis rates [316].
Despite the promising selectivity profile, pharmacologi-
cal inhibition of PERK in mice caused damage to exo-
crine cells and pancreatic beta cells, a similar
phenotype to that observed in PERK/ mice [317].
Furthermore, GSK2606414 and GSK2656157 were
found recently to inhibit RIPK1 at nanomolar concen-
trations [318]. To overcome the b-cell toxicity, small
molecules modulating the eIF2a pathway without
directly inhibiting PERK were examined. Integrated
stress response inhibitor (ISRIB) is the first small
molecule described to bind and activate guanine
nucleotide exchange factor eIF2B [319,320]. Unlike
GSK inhibitors, ISRIB did not show any pancreatic
toxicity [321]. Interestingly, ISRIB increased learning
and memory in WT mice [322] (Table 1).
ATF6 modulators
The identification of small molecules that modulate
ATF6 has been challenging due to lack of potentially
druggable binding sites and unavailability of the pro-
tein crystal structure. Recently, Walter and colleagues
identified selective inhibitors of ATF6 signalling, the
small molecules Ceapins, using a high throughput
cell-based screen [323]. Ceapins do not affect the
IRE1 and PERK arms of the UPR. Ceapins are
chemically classed as pyrazole amides and extensive
biochemical and cell biology evidence show that they
trap ATF6 in the ER and thus prevent its transloca-
tion to the Golgi upon stress [324]. Ceapins sensitize
cells to ER stress without affecting unstressed cells
and hence have potential to be developed within the
framework of a therapeutic strategy to induce cell
death in cancer cells. A recent study identified mela-
tonin as an ATF6 inhibitor, leading to enhanced liver
cancer cell apoptosis through decreased COX-2
expression [325]. The activation of ATF6 depends on
a redox process involving PDIs suggesting that PDI
inhibitors such as PACMA31 [326], RB-11-ca [327],
P1 [327] and 16F16 [328] may be able to modulate
ATF6 activation. Additionally, the serine protease
inhibitor 4-(2-aminoethyl) benzenesulfonyl fluoride is
reported to prevent ER stress-induced cleavage of
ATF6 [329] (Table 1). Albeit the above developments
hold strong promise for the future, very little is
known to date about specific binding sites, which
together with the lack of a crystal structure and
insufficient templates to enable homology modelling,
rational drug design targeting ATF6 remains a
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challenge. Availability of an ATF6 crystal structure is
in this sense the key aspect, as this will provide ato-
mistic level understanding of interactions and mecha-
nism of action, and enable in silico based rational
design of ATF6 modulators.
The UPR in the clinic
In this section, we review recent preclinical and clinical
studies in which UPR components were used as dis-
ease biomarkers or as therapeutic targets (Fig. 3). As
already described in section Perturbing ER functions
molecules have been designed to modulate ER stress
by inducing the UPR (Brefeldin A, DTT), inhibiting
SERCA Ca2+ ATPases (thapsigargin) or preventing
the generation of glycoproteins, and hence, the induc-
tion of ER stress through calcium imbalance or mis-
folded protein accumulation. They were touted as
potential antitumour therapies as they could poten-
tially induce tumour cell death through ER stress over-
activation. However, none of these compounds were
used in the clinic due to their lack of specificity and
high toxicity. It has been reported though that a pro-
drug analogue of thapsigargin, mipsagargin, did dis-
play acceptable tolerability and favourable
pharmacokinetic profiles in patients with solid tumours
[330]. On the other hand, section 6 describes molecules
that inhibit the various arms of the UPR.
UPR biomarkers
Changes in UPR and ER stress markers in blood or
tissue biopsy samples can be indicative of disease state
and could be/are utilized as valuable biomarkers for
different human pathologies. For instance, BiP has
strong immunological reactivity when released into the
extracellular environment [331], and in 1993, it was the
first ER stress protein associated with the pathogenesis
of osteogenesis imperfecta [332]. Since then, further
evidence suggests overexpression of BiP in several
human diseases (reviewed in [333]). The UPR tran-
scription factors can also be seen as potential biomark-
ers of various diseases. ATF4 is upregulated and
contributes to progression and metastasis in patients
with oesophageal squamous cell carcinoma [334]. Simi-
larly, XBP1 overexpression is linked to progressive
clinical stages and degree of tumour malignancy in
osteosarcoma [335]. In contrast, IRE1–XBP1 downreg-
ulation can differentiate germinal centre B cell-like
lymphoma from other diffuse large B-cell lymphoma
subtypes and contributes to tumour growth [336].
Moreover, XBP1 is genetically linked to inflammatory
bowel disease (IBD) [337]. Using cohorts of IBD
patients to test the association of 20 SNPs across the
XBP1 gene region, it was found that three SNPs
rs5997391, rs5762795 and rs35873774 are associated
with disease, thus linking cell-specific ER stress
changes with the induction of organ-specific inflamma-
tion. Quantitative changes in ER stress chaperones in
the CSF have been proposed as possible biomarkers to
monitor the progression of neurodegenerative diseases
such as ALS [338,339]. Finally, the mesencephalic
astrocyte-derived neurotrophic factor (MANF) can be
used as a urine biomarker for ER stress-related kidney
diseases [340]. MANF localizes in the ER lumen and
is secreted in response to ER stress in several cell
types. Similarly, angiogenin was identified as an ER
stress responsive biomarker found in the urine of
patients with kidney damage [341]. Thus, noninvasive
ER stress-related biomarkers can be used to stratify
disease risk and disease development (Fig. 3).
ER stress and UPR-based therapies
Beyond their use as biomarkers, ER stress signalling
components also represent relevant therapeutic targets.
BiP was recently recognized as a universal therapeutic
target for human diseases such as cancer and bacte-
rial/viral infections [333]. Antibodies targeting BiP
exhibited antitumoural activity and enhanced radiation
efficacy in non-small-cell lung cancer and glioblastoma
multiforme in mouse xenograft models [342]. It was
also shown that short-term systemic treatment with a
monoclonal antibody against BiP suppressed AKT
activation and increased apoptosis in mice with
endometrial adenocarcinoma [343]. Moreover, the ER-
resident GRP94 is being evaluated as a therapeutic
target because of its ability to associate with cellular
peptides irrespective of size or sequence [344]. Preclini-
cal studies have linked GRP94 expression to cancer
progression in multiple myeloma, hepatocellular carci-
noma, breast cancer and colon cancer. Finally, this
protein has been identified as a strong modulator of
the immune system that could be used in anticancer
immunotherapy [345].
ER stress-induced transcription factors can also rep-
resent relevant targets. Thus, XBP1s has been one of
the main targets for drug discovery and gene therapy
[346]. Elimination of XBP1 improves hepatosteatosis,
liver damage and hypercholesterolaemia in animal
models. As such direct targeting of IRE1 or XBP1 can
be a possible strategy to treat dyslipidaemias [113]. In
cancer, toyocamycin was shown to inhibit the constitu-
tive activation of XBP1s expression in multiple mye-
loma cells as well as in patient primary samples [309].
Despite being the least studied UPR arm, there are
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instances that ATF6 can be a specific clinical target.
The activation of ATF6 but not IRE1 or PERK has
been linked with airway remodelling in a mouse model
of asthma [347]. Additionally, these studies showed
that expression of orosomucoid-like 3 (ORMDL3) reg-
ulates ATF6 expression and airway remodelling
through ATF6 target genes such as SERCA2b,
TGFb1, ADAM8 and MMP9 (Fig. 3, Table 2).
Fig. 3. UPR disease biomarkers and therapeutic targets. Schematic representation of the UPR signalling pathway as defined in Fig. 2 and
annotated with the relevance to disease of each component. The colour code indicates the type of disease (cancer: orange; metabolic
disease: red; degenerative disease: blue; infectious disease: green; inflammatory disease: pink) and the lines indicate the role as biomarker
(continuous line) or therapeutic target (dashed line).
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ER stress targets are also strong candidates for
immunotherapy and vaccines development, a good
example of which is the production of chaperone pro-
tein-based cancer vaccines termed chaperone-rich cell
lysate (CRCL) [348]. The CRCL are purified from
tumour tissue or recombinantly produced and applied
as vaccines against murine and canine cancers or infec-
tious diseases. Advantages of CRCL vaccines include
small quantities and easily obtained starting materials
[349]. Furthermore, DNA vaccination with gp96-pep-
tide fusion proteins showed increased resistance
against the intracellular bacterial pathogen Listeria
monocytogenes in a mouse model [350]. To improve
the efficacy of gp96 vaccines, gp96 was pooled with
CpG in combination with anti-B7H1 or anti–inter-
leukin-10 monoclonal antibodies to treat mice with
large tumours [351]. The heterogeneous or allogeneic
gp96 vaccines protected mice from tumour challenge
and re-challenge. In addition to its role as a molecular
chaperone, GRP94 was likewise identified as a peptide
carrier for T-cell immunization [352]. However, the
immunological application of GRP94 derived from its
peptide binding capacity was not further investigated
(Fig. 3, Table 2). The activation of ER stress has been
reported as well in different critical care diseases mod-
els, such as sepsis [331,332], liver, heart, brain and kid-
ney ischaemia [353–359] and haemorrhagic shock
[334,335]. But, the pathophysiological impact of ER
stress activation in these conditions severely lacks
characterization. Multiple factors such as inflamma-
tion, hypoxia present in sepsis and shock can induce
ER stress but its effects are ambivalent. It has been
shown that induction of ER stress is cytoprotective
[353,354], and that proteostasis promotors/disruptors
such as 4-PBA [336] or TUDCA [337] can be used to
improve disease outcome. The increase of CHOP in
renal tissue was reported to inhibit inflammatory
response in and provide protection against kidney
injury [336]. Moreover, the activation of PERK seems
to facilitate survival of lipopolysaccharide-treated car-
diomyocytes by promoting autophagy [338]. Addition-
ally, the activation of ATF6 before ischaemia reduced
myocardial tissue damage during ischaemia/reperfusion
(I/R) injury [339]. Furthermore, induction of BiP in
cardiomyocytes stimulated AKT signalling and pro-
tected against oxidative stress, conferring cellular I/R
damage protection [340]. In contrast, inhibition of ER
stress was indicated to limit cellular damage in
Table 2. ER stress-centred clinical trials. A range of clinical entities in endocrinology, oncology and paediatrics have been targeted through
clinical trials. This table presents such trials detailing the trial targeted, interventional agent investigated and national authority carrying out
the investigation.
Trial Disease Intervention Country
Role of ER stress in the pathophysiology
of type 2 diabetes
• Diabetes mellitus, type 2 No intervention France
ER stress and resistance to treatments
in Ph-negative myeloproliferative neoplasms
• Polycythemia vera
• Essential thrombocythemia
Biological: RNA sample
of total leucocytes
before start of treatment
France
Effect of ER stress on metabolic function • Insulin resistance
• Diabetes
• Obesity
Drug: TUDCA United States
Other: placebo
Drug: sodium phenylbutyrate
ER stress in chronic respiratory diseases • Chronic airway disorders
• Lung cancer
Observational South Korea
TUDCA for protease-inhibitor associated
insulin resistance
• HIV-related insulin resistance
• Protease inhibitor-related Insulin
resistance
Drug: TUDCA United States
Other: placebo tablet
ER stress in NAFLD • Obesity
• NAFLD
Drug: methyl-D9-choline United States
TUDCA in new-onset type 1 diabetes • Type 1 diabetes Drug: TUDCA United States
Drug: Sugar Pill (placebo)
Effects of Liraglutide on ER stress in
obese patients with type 2 diabetes
• Type 2 diabetes Drug: liraglutide United States
A clinical trial of dantrolene sodium in
paediatric and adult patients with
wolfram syndrome
• Wolfram syndrome
• Diabetes mellitus
• optic nerve atrophy
• Ataxia
Drug: dantrolene sodium United States
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pathologies such as hepatic I/R [341]. This contradic-
tion may be due to interference between UPR and
inflammatory pathways. CHOP-/- mice were reported
to have more prominent increase in NF-kB activation
and further upregulation of proinflammatory genes
(CXCL-1, MIP-2, IL-6) [342]. Interestingly, inhibition
of IRE1-NF-kB by resveratrol protected against sep-
sis-induced kidney failure [343]. In this light, the mod-
ulation of specific UPR branches is promising
approach for therapy of critical care diseases.
As discussed above, understanding and characteriz-
ing the UPR has provided several potential targets to
develop new therapeutics for various diseases, with an
encouraging increase in the number of clinical trials
based on ER stress pathway targets or associated
drugs. Several of these trials [ClinicalTrials.gov, Euro-
pean Clinical Trials Database and the ISRCTN reg-
istry] have focused on diabetes mellitus. A trial testing
TUDCA and 4-PBA for the treatment of high lipid
levels or insulin resistance was conducted by the
Washington University School of Medicine; however,
although this study was completed in 2014, the find-
ings are not available yet. The results from the first
completed human trial using BiP for rheumatoid
arthritis are described in Box 1. We can anticipate that
clinical trials to test ER stress targeting drugs in sev-
eral other diseases will shortly ensue.
Concluding remarks
The ER has evolved in our knowledge from a key
player in proteostasis and the secretory pathway to a
cornerstone of metabolic functions. Such wealth of
information has allowed the identification of numerous
mechanisms for fine-tuning ER signalling, as well as
motivated the need for their better characterization
towards relevant health-related applications. This drive
to further ER knowledge has also led to the identifica-
tion of emerging roles for the ER in physiology and
disease. In particular, it appears an indispensable tool
for cellular communication that reaches beyond the
intracellular space. The concept of transmissible ER
stress illustrates the far-reaching control that ER sig-
nalling exerts in interorgan communication affecting
disease pathogenesis and normal physiology [360,361].
Our increasing knowledge of ER signalling mecha-
nisms presents opportunities to exploit the resulting
applications on multiple fronts, including bioengineer-
ing and health, concepts that may routinely overlap.
For example, boosting ER protein production capacity
may be applied to cell engineering to increase biologic
therapy production. This will drive down costs of bio-
logics, helping demand to be met and leading to more
widely available medications, thus having a significant
effect on public health. Population-wide consequences
of ER modulation may not be restricted to the pro-
duction of biologic therapies as its applications could
also contribute to bioengineering approaches for crop
or livestock improvement.
A thorough understanding of the ER stress response
and its role in physiology and pathophysiology can be
applied to develop new ER stress targeted therapies
and stratifying patients into cohorts suitable for ER-
targeted therapies. Considering the enormity of attri-
tion rates of novel therapeutic discovery in an ever-
tightening financial climate, there is an urgent need for
new therapeutic targets as well as precision tools that
target and guide innovation to specific patient pools.
ER stress signalling may provide such tools. Not only
is it central to life itself but it is involved in a wide
array of clinical presentations. Moreover, its effect on
heterogeneous presentations within the same diseases
makes it an attractive target for translational precision
medicine. Of course, when undertaking medical
research or trying to solve a biomolecular functional
mystery one cannot look past the logistical aspect of
the task ahead. The conserved metazoan nature of ER
stress signalling combined with the emergence of high
throughput and in silico strategies supplies researchers
with a wealth of tools to study pathophysiology, from
structure to function in multiple in vivo and in vitro
models, producing robust results to be put forward for
clinical scrutiny while all the while observing both the
safeguards of the declaration of Helsinki and ethics on
animal experimentation. Our deeper understanding of
the ER and its major homeostatic regulator, the UPR
response, is introducing an individualized molecular
Box 1. First-in-human trial
Intravenous infusion of GRP78/BiP is safe in patients
In 2006, Brownlie et al. [362] reported that the prophy-
lactic or therapeutic parenteral delivery of BiP amelio-
rates clinical and histological signs of inflammatory
arthritis in mice. Ten years later, the first human clinical
trial using intravenous BiP demonstrated that GRP78/
BiP is safe in patients with active rheumatoid arthritis
and some patients had clinical and biological improve-
ments [363]. In phase I/IIA RAGULA trial, 42 patients
were screened, and 24 were randomized to receive either
BiP or placebo. The study showed that after a single
intravenous infusion, BiP may induce remission lasting
up to 3 months in rheumatoid arthritis patients.
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approach to health management at a preventative,
diagnostic and therapeutic level and, uncovering the
genetic architecture underlying the ER stress response
could significantly influence future therapeutic strate-
gies in patients.
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Chapter 12
Measuring the Activation of Cell Death Pathways upon
Inhibition of Metabolism
Franziska Pu¨schel and Cristina Mun˜oz-Pinedo
Abstract
Nutrient starvation or inhibition of cellular metabolism can induce cancer cell death. This can be measured
by a variety of methods. We describe here four simple methods to measure cell death in culture by using
microscopy, western blot, and flow cytometry. We also provide tools to differentiate between different
forms of cell death like apoptosis and necrosis by using chemical inhibitors.
Key words Cell death, Necrosis, Apoptosis, Necroptosis
1 Introduction
Inhibition of Cancer Metabolism Promotes Cell Death: Cancer cells
demand a high level of energy and metabolites to maintain high
proliferation rates through increased glucose uptake and increased
metabolic activity. Energy andmetabolites can be provided through
extracellular nutrients like glucose, amino acids or lipids, as well as
through intracellular recycling pathways like autophagy or lyso-
somal and proteasomal degradation [1]. Upon transient nutrient
deprivation, cancer cells are frequently able to resolve metabolic
stress. However, sustained stress or treatment with drugs that
inhibit metabolism leads to permanent cell cycle arrest or induction
of cell death [2].
Cell Death: Cell death occurs in different forms classified by
their morphology and biochemical criteria. The two main forms are
designated as apoptosis and necrosis. The traditional view indicates
that apoptosis is an autonomous, programmed cell death form
whereas the latter is a passive process induced through cell injuries
by external factors. However, some forms of non-apoptotic cell
death like necroptosis, pyroptosis, and ferroptosis are regulated by
signaling pathways [3]. Necrosis is morphologically characterized
through cell swelling and the rupture of the plasma membrane,
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which involves the liberation of cytoplasmic contents. The hall-
marks of apoptosis are the detachment, rounding, and shrinking
of the cell accompanied by chromatin condensation. In cell cul-
tures, shrunk cells and apoptotic bodies accumulate; the latter
consist out of cytoplasm containing a high content of organelles
as well as nuclear fragments. In animals, the apoptotic bodies are
recycled by being phagocytized by macrophages that degrade
them. These morphological changes are visible under the micro-
scope (Fig. 1).
The cellular mechanism of apoptosis is different from other
forms of cell death because it involves activation and cleavage of
caspases, which are in an inactive form as pro-caspases present in the
cell. Upon activation they auto-cleave and activate further down-
stream caspases, which cleave numerous substrates that lead to
morphological changes. Morphological criteria are useful to count
dead cells; however, they are not recommended to distinguish
apoptosis from other forms of cell death as inhibition of metabo-
lism may change cellular morphology and cause detachment of
cells.
Microscopical analysis of cell death allows a quantitative analy-
sis by taking photographs at an inverted microscope, as well as by
staining with Trypan Blue Solution. These methods provide an easy
and quick approach with little expenses. A more precise and repro-
ducible method is the cell death analysis by Flow Cytometry or
Fluorescence-Activated Cell Sorting (FACS) and the use of fluores-
cent markers. These methods allow quantitative as well as qualita-
tive analysis of cell death since different cell death forms can be
distinguished through co-treatment with drugs inhibiting specific
cell death forms as well as through specific staining methods.
Fig. 1 Dead A549 cells. Cells were incubated for 48 h in DMEM with 25 mM or 0 mM glucose. Arrows show
dying or dead cells. To verify that cells are dying via apoptosis, the use of inhibitors is recommended rather
than morphology-based assays
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Compared to the microscope, FACS is more costly and results
could be affected due to a longer cell processing.
Drugs that can inhibit cell death are pan-caspase inhibitors like
Q-VD-OPH (QVD) and Z-VAD-fmk (Z-VAD) (which block apo-
ptosis), or Ac-Y-VAD-cmk (Y-VAD), the caspase-1 inhibitor that
inhibits pyroptosis. Necroptosis is a specific form of necrosis
mediated by RIP kinases and the pore-forming protein MLKL,
and can be prevented by using Necrostatin-1 (Nec-1) or RIPK3
inhibitors (GSK872) [3] (Fig. 2). Other forms of cell death like
ferroptosis and mitochondrial permeability transition-mediated can
be prevented by ferrostatins and cyclosporin A, respectively.
The different approaches summarized in Fig. 3 will be
described in the following chapter. Methods widely used to mea-
sure proliferation like MTT-like assays are based on metabolic
measurements. We strongly advise against the use of these tools
to analyze cell death, especially when the stimulus used to induce
cell death disturbs metabolic parameters.
2 Materials
Prior to the start of the experiments all the reagents have to be
cooled down or warmed up to room temperature except it is
indicated differently. Antibodies and drugs were prepared accord-
ing to the manufacturer’s instructions.
Fig. 2 Inhibitors targeting cell death machineries. Cell death receptor activation leads to the formation of the
necrosome which induces necroptosis. GSK872 inhibits RIPK3 whereas Nec-1 blocks RIPK1. Formation of the
DISC (Death Inducing Signaling Complex) leads to activation of caspases and induces apoptosis. Z-VAD and
QVD are caspase inhibitors
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2.1 Cell Culture 1. Fetal bovine serum (FBS).
2. Phosphate-buffered saline (PBS).
3. Dialysing membrane (MWCO 7000).
4. Syringe filter (0.22 μm).
5. DMEM: pyruvate-free, 25 mM Glucose, supplemented with
2 mM L-glutamine.
6. DMEM: pyruvate-free, 0 mM Glucose, supplemented with
2 mM L-glutamine.
2.2 Drugs 1. 2-Deoxyglucose (2-DG).
2. Q-VD-OPH (Q-VD).
3. Z-VAD-fmk (Z-VAD).
4. Ac-Y-VAD-cmk (Y-VAD).
5. Necrostatin-1 (Nec-1).
6. GSK 872 (RIPK3 inhibitor).
7. Trypan Blue Solution.
8. Inverted Microscope.
9. Neubauer cell counting chamber.
10. Software ImageJ.
Cell Death
Apoptosis ↔ Necrosis
Protein Quantification
ÿ Protein extraction
ÿ Western blotting
ÿ Caspase-3, -8
ÿ Substrates: PARP
Microscopy
ÿ Cell counting
ÿ Trypan Blue staining
FACS
ÿ PI staining
Cell death inhibitors
Apoptosis: Q-VD-OPH, Z-
VAD-fmk
Necrosis : Necrostatin-1, 
RIPK3 inhibitor
Fig. 3 Overview of methods for cell death analysis: Cell death can be classified into two main routines:
apoptosis and necrosis, which can be blocked by specific inhibitors. The detection can be facilitated through
FACS, microscopy, or protein cleavage quantification
166 Franziska Pu¨schel and Cristina Mun˜oz-Pinedo
2.3 Materials
for Western Blot
Analysis
2.3.1 Reagents
1. Phosphate-Buffered Saline (PBS).
2. Trypsin-EDTA (0.05%).
3. RIPA buffer: 25 mmol/L Tris–HCl (pH 7.6), 150 mM NaCl,
1% NP-40, 1% sodium deoxycholate, 0.1% SDS supplemented
with protease inhibitors and phosphatase inhibitors.
4. 4 Laemmli buffer: 63 mM Tris–HCl; 10% glycerol; 2% SDS;
0.01% bromophenol blue; 5% β-mercaptoethanol.
5. BCA Protein Assay.
6. SDS-PAGE Running buffer: 0.025 M Tris–HCl, 0.192 M gly-
cine, 0,1% SDS.
7. Western blot Transfer buffer: 0.025 M Tris–HCL 0.192 M
glycine, 20% methanol.
8. Tris-buffered saline containing 0.05% Tween-20 (TBST):
0.01 M Tris–HCl, 0.15 NaCl.
9. Nitrocellulose membrane.
10. Ponceau S. staining.
11. Odyssey blocking solution.
2.3.2 Antibodies Primary: Caspase-3, Caspase-8, PARP.
Secondary: Rabbit Alexa Fluor 568, Mouse Alexa Fluor 647.
2.4 Materials
for FACS
1. Phosphate-buffered saline (PBS).
2. Trypsin-EDTA (0.05%).
3. Propidium Iodide.
4. Gallios Flow Cytometer Beckman Coulter.
5. Software Flow Jo.
3 Methods
3.1 Dialyzing FBS 1. Inactivate FBS by heating up to 57 C for 30 min. Allow it to
cool down to room temperature.
2. Warm up the dialyzing membrane to 60 C for 30 min in a
water bath or wash as recommended by the manufacturer.
3. Close the membrane with a knot or an appropriate clip at
one side and add 100 mL of inactivated FBS in the pipe.
Close the other end of the pipe with a further knot or clip (see
Note 1).
4. Wash the pipe twice for one hour in 1 L PBS at 4 C while
stirring. Afterward, wash another time with PBS overnight at
4 C, stirring.
5. Filtrate dialyzed FBS (dFBS) sterile using a 0.22 μmsyringe filter.
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3.2 Glucose
Deprivation
1. Plate A549 cells (300,000 cells/well) in a 6-well plate in
pyruvate-free DMEM containing 25 mM glucose, 10% FBS
and supplemented with 2 mM L-glutamine.
2. Treat cells at a confluence of 80% 24 h after plating (see
Note 2). Wash cells twice with pyruvate-free DMEM without
glucose to remove remaining glucose.
3. Add 2mL of pyruvate-free DMEMwithout glucose containing
10% FBS and supplement with 2 mM L-glutamine and incubate
for up to 72 h at 37 C in the incubator. Long term experi-
ments would require plating the cells at low concentrations to
avoid overgrowth in the controls. Alternatively, a low-density
control culture should be used in parallel.
3.3 Treatment
with Metabolic Drugs
1. Plate cells as described above and treat them 24 h after plating
with 2-DG (see Note 3) in pyruvate-free DMEM containing
25 mM glucose, 10% FBS and supplemented with 2 mM L-
glutamine.
2. Analyze cell death up to 72 h post-treatment with methods
indicated below.
3.4 Treatment
with Cell Death
Inhibiting Drugs
1. Plate and treat cells upon glucose deprivation as described
above.
2. Add the inhibitor of interest at the same time point as the
glucose deprivation treatment. If cell death is fast (less than
12 h), the inhibitors can be preincubated for 1 h.
3. Use Q-VD at a concentration of 10 μM and Z-VAD at 20 μM.
4. Use Nec-1 at 40 and 100 μM and the GSK 872 at a concentra-
tion of 1 and 3 μM (see Note 4).
5. Analyze cell death between 48 and 72 h after treatment with
methods indicated below.
3.5 Cell Death
Analysis by
Microscopy
Cell death is detectable through different approaches (Fig. 3). The
easiest and fastest method to detect cell death in a cell population is
by using the microscope. Dying cells are clearly distinguishable
from healthy cells through their morphology which is characterized
by the appearance of apoptotic bodies, rounding, detachment, and
loss of refringent appearance (Fig. 1). Furthermore, counting dead
cells by microscopic examination is the more precise method to
analyze cell death in adherent cell cultures. The reason is cells do
not have to be harvested and cell death induced by the protocol is
excluded. Additional staining of cells with Trypan Blue Solution
after trypsinization dyes dead cells blue and cell death can be
quantified by counting total and dead cells with a Neubauer cell
counting chamber. Use positive controls for cell death induction
(see Note 5).
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1. Plate cells in 6-well plates the day before treatment and let
them grow to 80% confluence (described above).
2. Treat cells (described above) and take at least three pictures of
different areas of the culture plate.
3. Use ImageJ software or count detached cells manually and
calculate the corresponding percentage.
Alternatively, or in parallel, use Trypan Blue Staining:
4. Transfer the supernatant to a tube.
5. Wash attached cells with PBS. Incubate attached cells for 5 min
with 500 μL Trypsin-EDTA (0.05%) and resuspend cells in
1 mL of DMEM (pyruvate-free, 10% FBS, supplemented with
2 mM L-glutamine).
6. Combine supernatant and trypsinized cells and centrifuge for
5 min at 450 rcf and room temperature.
7. Resuspend cell pellet in 1 mL DMEM containing 10% FBS,
25 mM glucose and supplement with 2 mM L-glutamine.
8. Dilute 10 μL of cell suspension in 10 μL of Trypan Blue
Solution and use a Neubauer cell counting chamber according
to the manufacturer’s instructions. If needed, adjust cell num-
ber by diluting cell suspension.
9. Total cell number and blue stained cells are counted and per-
centage of cell death is calculated.
3.6 Cell Death
Analysis by Western
Blot of Caspases or
Caspase Substrates
Another approach is to analyze caspase cleavage through perfor-
mance of western blots and further quantification of the protein
expression of pro-caspase 3 or 8 and their cleaved forms as well as
by detecting the cleaved form of the caspase substrate Poly
(ADP-ribose) polymerase (PARP).
Before starting the experiment prepare complete RIPA lysis
buffer by adding protease and phosphatase inhibitors according
to the manufacturer’s instructions.
1. Treat and harvest cells as described above.Wash once with PBS.
2. Resuspend cell pellet in 30 μL RIPA buffer completed with
protease and phosphatase inhibitors.
3. Sonicate cell lysate to guarantee complete cell membrane rup-
ture and DNA disruption.
4. Quantify protein concentration by BCA or Bradford Protein
Assay according to the manufacturer’s instructions.
5. Heat samples containing 40 μg of protein in a final volume of
40 μL in 4 Laemmli Buffer up to 95 C for 10 min.
6. Load samples on a 12% SDS gel (10% recommended for PARP)
and add 500 mL of Running buffer.
7. Run SDS PAGE at 120 V for 1.5 h.
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8. Transfer proteins to nitrocellulose membrane using Transfer
buffer.
9. Check quantitative protein transfer by incubating membrane
for 2 min with Ponceau S. Staining.
10. Remove dye by washing several times for 5 min with TBST.
Repeat until dye is completely removed.
11. Block membrane in 5% milk and TBST for 1 h at room
temperature.
12. Incubate with primary antibody diluted 1:1000 in Blocking
buffer overnight at 4 C while shaking.
13. Wash membranes 3 times for 5 min with TBST.
14. Incubate with fluorescent secondary antibodies diluted
1:15,000 with TBST and 5% milk for 1–2 h at room tempera-
ture in agitation.
15. Wash membranes 3 times for 10 min with TBST and develop
them using the Odyssey Infrared Imaging System (Fig. 4) (see
Note 6).
3.7 Cell Death
Analysis by FACS
Another possibility to measure quantitative cell death is to detect
membrane alterations like the phosphatidylserine translocation
which can be detected by Annexin-V binding, as described else-
where [4] Alternatively, using propidium iodide (PI) would allow
cell death measurement thanks to its ability to intercalate in the
DNA of dying cells. The resulting emission can be detected
25 kDa
20 kDa
15 kDa
37 kDa
25 mM 0 mM 25 mM 0 mM
Q-VD
Pro-caspase 3 
Cleaved caspase 3 (p17)
Cleaved caspase 8 (p18)
100 kDa
75 kDa
50 kDa
Pro-caspase 8
PARP
glucose
cleaved PARP
Fig. 4 Schematic representation of western blot for Caspase-8, -3 and its
substrate PARP. Cells were incubated for 48 h in DMEM with 25 mM or 0 mM
glucose. Right lanes, cells incubated in the presence of Q-VD 20 μM
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through a photodetector between 550 and 700 nm at the
fluorescence-activated cell sorter (FACS). Since PI can only cross
the permeable membranes of dead cells, quantification can be done
through measuring total cell count and PI positive cells. This form
of cell death analysis is very accurate, reproducible and allows
detecting even small amounts of dead cells.
1. Treat cells as described above.
2. Wash cells once with PBS and trypsinize with 500 μL of 0.05%
of Trypsin-EDTA.
3. Combine supernatant and cell suspension in a FACS tube and
centrifuge for 7 min at 450 rcf at room temperature.
4. Discard the supernatant and resuspend cell pellet in 300 μL of
PBS containing 0.5 μg/mL PI.
5. Measure cell death after 10 min incubation using the Gallios
Flow Cytometer Beckman Coulter.
6. Analyze data using FlowJo (Fig. 5).
7. Plot data side scattered (SS-A) versus foward scattered (FS-A)
and gate the total cell population excluding cell debris (parti-
cles approximately 10 times smaller than untreated cells)
(Fig. 5a). Apply the gate to all samples.
8. Plot FS-A versus FL3-A (red-channel) and measure dead cells
(Fig. 5b). Apply for all samples.
Fig. 5 Flow Jo analysis of cell death by PI staining. (a) Total cell population presented as SS-A versus FS-A. (b)
FS-A is plotted versus FL-3 and dead cell population is gated
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4 Notes
1. Avoid bubbles to guarantee a complete dialysis.
2. Keep the cell concentration consistent. Starvation can induce
very different cell numbers when cells are grown at high or low
density.
3. 2-DG concentrations for treatment range between 2 and
10 mM depending on the cell line.
4. Effective inhibitor concentrations can vary between different
cell lines.
5. Use positive controls when measuring cell death. Classical
apoptotic inducers are serum removal and most chemothera-
peutic drugs. Classical necrotic inducers are freeze-thaw and
high H2O2 (between 33 and 66 μM) [5].
6. Other bands may appear due to internal caspase cleavage.
Depending on the stimulus, QVD may not protect fully from
the production of the small fragment of caspase-3 and other
bands accumulate instead at 19–20 kDa apparent molecular
weight.
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Spotlight
In the Hunger
Games, the Winner
Takes Everything
Franziska Püschel1 and
Cristina Muñoz-Pinedo1,*,@
Entosis is an atypical form of cell
death that occurs when a cell
engulfs and kills another cell. A
recent article by Overholtzer and
colleagues indicates that glucose
deprivation promotes entosis.
AMP-activated protein kinase
(AMPK) activation in the loser cells
triggers their engulfment and elim-
ination by winner cells, which
endure starvation.
Cells in our bodies are constantly dying
and being replaced by new cells. The
best understood form of regulated cell
death is apoptosis. However, other
forms of cell death are pathologically
and physiologically relevant in certain
contexts. In some cases, cell death is
actively engaged from within the cell,
which senses that it is damaged or aged.
These subroutines of cell death include
the mitochondrial apoptotic pathway and
can be called suicide. In other cases,
cells die when they are attacked by the
immune system that senses that they are
infected, and are, thus, usually,
‘murdered’. This includes granzyme-
and death-receptor-mediated apopto-
sis, and perforin-mediated necrosis.
However, other intriguing and under-
studied cell death routines involve the
killing of living cells that are selected
and phagocytosed by professional phag-
ocytes (phagoptosis, [1]) or by a neigh-
boring epithelial cell (entosis). These
forms of cell death could be labeled as
‘cannibalism’.
Entosis is a particularly intriguing process
by which a perfectly viable living cell is
eaten and killed by an epithelial cell [2].
Entotic structures are detected in human
carcinomas, and this observation sug-
gested that entosis could represent a
form of competition between cancer cells.
This competition involves a winner and a
loser cell, and the winner status has been
shown to be conferred by oncogenes
such as KRas [3]. The winner versus loser
status is dictated by mechanical deform-
ability, with the loser cell being stiffer and
becoming entrapped by the softer cell
that engulfs it.
In a recent article, Hamann et al. exam-
ined whether the frequency of entotic
events in culture could be enhanced by
starvation [4]. The group had previously
shown that during entosis, recovery of
amino acids from entotic corpses contrib-
utes to nutrient balance [5]. However,
amino acid deprivation did not promote
entosis. In contrast, the authors now
show that glucose deprivation greatly
increased the number of entotic events.
Moreover, the time between engulfment
and death of the internalized cells was
reduced under glucose deprivation.
Glucose deprivation has been shown to
induce cell death in several manners, and
in many cases simultaneously. Indeed, in
the culture conditions employed by
Hamann et al. [4], some MCF-7 cells died
by apoptosis or necrosis along with ento-
sis. However, inhibition of entosis by
deleting E-cadherin, which had been
shown to mediate this process, reduced
the total number of dead cells. Deletion of
E-cadherin or inhibition of rho-associated
protein kinase (ROCK) also increased the
percent of necrotic versus apoptotic cells,
which suggests interplay between necro-
sis and entosis. As shown before for
spontaneous entosis, LC3, which is
involved in autophagy and in phagocyto-
sis of corpses, decorated entotic vesicles.
Another similarity with autophagy was
that silencing ATG5, a protein involved
in autophagy vesicle formation, reduced
the number of engulfed cells that could
not escape and underwent cell death.
Although the effects of silencing ATG5
on the percent cell death in the whole
population were not addressed, this rein-
forces the notion that macroautophagy
does not promote survival of glucose-
deprived cells [6]. Interestingly, however,
entosis did support proliferation of the
winner cells. Moreover, entosis promoted
multinucleation and aneuploidy in the
population (Figure 1), suggesting that
starvation can promote aneuploidy by
inducing entosis, and thus contribute to
tumor promotion.
Perhaps the most intriguing finding is
what determines whether a cell eats or
gets eaten. The authors investigated
AMPK, the ATP/AMP sensor, and found
that the cells that activate it are the ones
that turn ‘stiffer’ and get eaten as a con-
sequence [4]. In fact, activation of AMPK
is sufficient to enhance the frequency of
entosis in the presence of glucose. The
question remains whether, under glucose
deprivation, the cells that activate AMPK
are more stressed; perhaps because of
the cell cycle stage that they are in – or
whether both populations, winners and
losers, undergo the same levels of ener-
getic stress but stochastically activate
AMPK differentially. Even clonal cell pop-
ulations in culture are heterogeneous, and
in this case, detecting energy failure is
lethal.
Several questions arise regarding the
evolution and consequences of entosis
in this context. Why does AMPK activa-
tion promote entosis: is this somehow
linked to phagocytosis? It should be men-
tioned that AMPK is an evolutionarily con-
served signal of infection: numerous
publications link AMPK activation to viral
infection, while AMPK is activated via
transforming growth factor b-activated
kinase 1 (TAK1) downstream of immune
cytokines [7]. This suggests that detec-
tion of loss of ATP could be evolutionarily
linked to detection of infection, and to
immune function, and perhaps it is a sig-
nal that promotes phagocytosis by neigh-
boring cells. Follow-up questions in the
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context of entosis include: does AMPK
promote exposure and/or secretion of
‘eat me’ signals? Which classical eat
me signals are associated with entosis?
How is AMPK linked to the mechanical
changes involved in entosis? The recent
finding that AMPK participates in
mechanotransduction should help clarify
mechanistic details [8].
Metabolic stress, and particularly, glu-
cose starvation, has been shown to pro-
mote several different forms of cell death,
ranging from necrosis to atypical
necroptosis or mitochondrial apoptosis,
and more recently, death-receptor-medi-
ated apoptosis [9,10]. We should now
add cannibalism to the list of typical
and atypical cell death subroutines
engaged by lack of nutrients.
1Cell Death Regulation Group, Oncobell Program,
Bellvitge Biomedical Research Institute (IDIBELL),
Barcelona, Spain
@Twitter: @apoptosislab
*Correspondence: cmunoz@idibell.cat (C. Muñoz-Pinedo).
http://dx.doi.org/10.1016/j.tibs.2017.08.004
References
1. Brown, G.C. and Neher, J.J. (2012) Eaten alive! Cell death
by primary phagocytosis: ‘phagoptosis’. Trends Biochem.
Sci. 37, 325–332
2. Overholtzer, M. et al. (2007) A Nonapoptotic cell death
process, entosis, that occurs by cell-in-cell invasion. Cell
131, 966–979
3. Sun, Q. et al. (2012) Competition between human cells by
entosis. Cell Res. 24, 1299–1310
4. Hamann, J.C. et al. (2017) Entosis is induced by glucose
starvation. Cell Rep. 20, 201–210
5. Krajcovic, M. et al. (2013) mTOR regulates phagosome
and entotic vacuole fission. Mol. Biol. Cell 24, 3736–3745
6. Ramirez-Peinado, S. et al. (2013) Glucose-starved cells do
not engage in prosurvival autophagy. J. Biol. Chem. 288,
30387–30398
7. Hardie, D.G. (2011) AMP-activated protein kinase: an
energy sensor that regulates all aspects of cell function.
Genes Dev. 25, 1895–1908
8. Bays, J.L. et al. (2017) Linking E-cadherin mechanotrans-
duction to cell metabolism through force-mediated activa-
tion of AMPK. Nat. Cell Biol. 19, 724–731
9. Ding, B. et al. (2016) Sestrin2 is induced by glucose
starvation via the unfolded protein response and protects
cells from non-canonical necroptotic cell death. Sci. Rep.
6, 22538
10. Iurlaro, R. et al. (2017) Glucose deprivation induces ATF4-
mediated apoptosis through TRAIL death receptors. Mol.
Cell Biol. 37, e00479–16
Proli ferao n Mulnu clea on
Glucose starvaon
Winn er
(deformabl e)
Loser
(s ff)
Rac1
AMPK
E-Cadh erin
Figure 1. Glucose Starvation Promotes Entosis Mediated by AMPK Induction. Metabolic stress
induced by glucose starvation results in induction of entosis. This is mediated by activation of the energy sensor
AMPK in the loser cells accompanied by a stiffer cell phenotype. In contrast, winner cells show a more
deformable phenotype after glucose starvation. Entosis is facilitated by ROCK signaling and can be blocked by
Rac1 induction. Subsequent engulfment of loser cells supports winner cells with nutrients promoting multi-
nucleation, proliferation and survival. AMPK, AMP-activated protein kinase; ROCK, rho-associated protein
kinase.
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